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Abstract 
 
The research described in this thesis utilised novel extraction phases and 
analytical approaches in order to develop new methods for the separation and 
determination of important pharmaceuticals in complex biological matrices. 
The project employed bioanalytical chemistry to solve real-world biological and 
clinical problems.  
The first project involved the development and validation of an 
analytical protocol for the extraction, separation and determination of 
rifampicin and efavirenz in HIV-positive patients. The protocol was developed 
to support the hypothesis that ‘concomitant treatment with rifampicin-
containing anti-tuberculosis (TB) therapy and the anti- HIV therapy, efavirenz, 
results in a decreased rifampicin half life’. The emphasis in this work was the 
determination of both drugs simultaneously in one sample in a simple, rapid and 
cost effective assay. This was achieved using solid phase extraction and LC-UV 
analysis. The main challenge was developing a low cost assay to detect the 
drugs within a clinically relevant concentration range using standard 
chromatography equipment in order to make it applicable to resource-limited 
settings, in particular in areas where there are high incidences of HIV 
infections, such as sub-Saharan Africa, Eastern Europe and Asia. Successful 
development of a LC-UV method preceded by SPE obtained satisfactory results 
fit for this purpose and was employed to measure drug levels in HIV-positive 
patients. Using a Zorbax SB-Phenyl reverse-phase analytical column, good 
separation and detection of the drugs was attained within a 10 minute run time. 
Intra- and inter-assay precision RSD values were found to be less than 15% at 
the concentrations examined (0.1-20 μg/mL). The LOQ was found to be 0.1 
μg/mL for each agent and the assay was found to generate a linear response up 
to 20 μg/mL. Drug levels were measurable and significant differences in 
circulating rifampicin levels were found among the patients. 
 Having completed the above, a second analytical protocol was 
developed to support evaluation of an emerging hypothesis that ‘cutting a 
scopolamine transdermal patch in half will reduce the side effects associated 
with the medication while still having effective protection from motion 
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sickness’. The validated assay utilised solid-phase extraction coupled to LC-
MS to sensitively and accurately estimate the serum drug concentrations 
evident in subjects who participated in a pilot study undertaken as part of this 
project. The main challenge met here was developing a fast, isocratic method 
capable of determining the extremely low concentrations of scopolamine in 
serum post patch and half patch application. As the circulating level of 
scopolamine, especially when only half a patch is applied, is very low, 
enormous challenges had to be overcome to couple extraction and analysis 
methods and push them to their very limits to reliably and reproducibly 
measure the levels of drug encountered. This was accomplished by coupling 
SPE and LC-MS methods to detect the drug at pg/mL levels in blood. Using an 
Agilent Zorbax SB-Phenyl column, intra- and inter-assay precision RSD values 
were found to be less than 15% at the concentrations examined (10-200 
pg/mL). The assay LOQ was 10 pg/mL with a linear response up to 200 
pg/mL. Successful determination of scopolamine levels in circulating blood 
levels of patients administered the transdermal patch, both full and cut in half 
was achieved. It was found cutting the patch significantly impacted on the 
anticipated pharmacokinetics of the drug. 
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Chapter 1 
 
General introduction to quantitation of pharmaceutical 
levels in biological samples 
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1.1 Research objectives and relevance of work 
 
1.1.1 Introduction and research aims 
 
Analytical methods for finished products, raw materials, or active 
pharmaceutical ingredients have their own development and validation 
challenges. However, bioanalytical methods, especially in support of 
pharmacokinetic studies, are among the most challenging to develop and 
validate (FDA, 2001). The complexity of the sample matrices, the trace levels 
of drug and metabolites usually encountered, and even the complexity of the 
instrumentation used for the analyses, combine to present a huge challenge to 
analysts (FDA, 2001). 
Many components in biological matrices influence the result of an 
analysis and affect assay sensitivity and reproducibility (Chiu et al., 2010). 
Matrix components present in biological samples can disturb the response of the 
analyte of interest which can lead to inaccurate quantitation (Burgess, 2000). 
Careful assessment of matrix effects and judicial use of the appropriate sample 
preparation coupled with adequate chromatography and detection is essential 
for successful method development and validation. 
 
The main objectives of this work were to: 
 
• Develop and validate a novel, fast and simple LC-UV method for the 
quantitative determination of efavirenz and rifampicin in plasma 
employing SPE. 
• Develop and validate a novel, sensitive LC-MS method for the 
quantitative determination of scopolamine in serum employing SPE. 
 
 While each project had their own requirements, overall, it was hoped to 
keep the assays relatively simple, recoveries of the relevant drugs high and to 
make the procedure easy to follow such that technology transfer to a hospital, 
research lab or even into a field clinic could later be achieved.  
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 Work for the first project of the thesis was carried out in Dublin City 
University (DCU) School of Chemical Sciences and in the National Institute for 
Cellular Biotechnology in collaboration with the National Centre for Sensor 
Research (NCSR). Work for the second project of the thesis was carried out in 
the Space Life Sciences Laboratory (SLSL), Kennedy Space Centre, Florida, 
and in the National Institute for Cellular Biotechnology. 
 
1.2 Analytical separation and extraction techniques 
 
1.2.1 Separation techniques 
  
There are a number of techniques used for the separation of drugs from 
biological matrices for analytical purposes. Some of the most widely used are 
based on chromatography. Chromatography encompasses a diverse group of 
methods that are utilised for the separation of closely related components of 
mixtures. Chromatography is a physical method of separation in which the 
components to be separated are distributed between two phases, one of which is 
stationary (the stationary phase), while the other (the mobile phase) moves in a 
definite direction over the stationary phase (Ardrey, 2003b). The phases are 
chosen such that components of the sample have differing affinities for each 
phase.  
The most commonly employed separation technique for bioanalysis is 
high performance liquid chromatography (HPLC), also known simply as LC. 
The method is popular because it is non-destructive, has very broad 
applicability and may be applied to thermally labile compounds (unlike GC); it 
is also a very sensitive technique since it can incorporate a wide choice of 
detection methods. With the use of post-column derivatisation methods to 
improve selectivity and detection limits, HPLC can easily be extended to trace 
determination of compounds that do not usually provide adequate detector 
response. The wide applicability of HPLC as a separation method makes it a 
valuable separation tool in many scientific and pharmaceutical fields. HPLC is 
an important tool for the analysis of pharmaceutical drugs, for drug monitoring 
and for quality assurance. 
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1.2.2 Theory of liquid chromatography 
 
1.2.2.1 Capacity factor 
 
The time taken for an analyte to elute from a chromatographic column with a 
particular mobile phase is termed its retention time tR. Since this will vary with 
several factors, including, column length and mobile phase flow rate, it is more 
useful to use the capacity factor, k' (Dong, 2006a). This relates the retention 
time of an analyte to the time taken by an unretained compound, i.e. one which 
passes through the column without interacting with the stationary phase, to 
elute from the column under identical conditions (t0) (Ardrey, 2003b). The 
capacity factor, k', (sometimes called the retention factor) is an essential factor 
in the retention mechanism of analytes. The retention factor for analyte A is 
defined as a measure of the affinity that an analyte has for the stationary phase 
(See Eqn. 1.1 and Figure 1.1) 
 
k'A = tR – t0 / t0      Eqn 1.1 
where: tR: analyte retention time (min) 
t0: time taken for the mobile phase to pass through the column      
(min) 
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Figure 1.1: Schematic of a typical HPLC chromatogram  
Ideally, the capacity factor for an analyte is between two and five. A 
retention factor less than two indicates the analyte has eluted too quickly and is 
too close to the void volume so accurate determination of the retention time is 
difficult. When an analytes retention factor is more than five, the analyte has 
eluted too slowly so the run time may be excessively long. The k' value can be 
altered by modifying the mobile phase composition or pore size of the column 
(Hooper, 1992). 
1.2.2.2 Separation efficiency 
 
Separation efficiency is a measure of the sharpness of peaks eluting from a 
specific column. The column efficiency is measured either in terms of the plate 
height (H), the efficiency of the column per unit length, or the plate number 
(N), i.e. the number of plates for the column (Ardrey, 2003b). The plate model 
supposes that the chromatographic column contains a large number of separate 
layers, called theoretical plates. Separate equilibrations of the sample between 
the stationary and mobile phase occur in these "plates". The analyte moves 
down the column by transfer of equilibrated mobile phase from one plate to the 
next (Dong, 2006a). The number of theoretical plates that a real column 
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possesses can be found by examining a chromatographic peak after elution, see 
Eqn. 1.2.  
                                                                      
                                                                                                                                  Eqn. 1.2
where:    w1/2: Peak width at half-height 
The number of theoretical plates is proportional to the column length. 
The height equivalent to theoretical plate HETP also describes the efficiency of 
a given column for unit length of column. See Eqn 1.3 (Dong, 2006a). The 
higher the number of theoretical plates in a column, N, the better and the lower 
the plate height the better. 
HETP = L / N    Eqn. 1.3 
where:    L: Length of the column 
The concept of theoretical plates was first introduced by Martin and 
Synge (Martin et al., 1941); however, Van Deemter (van Deemter et al., 1956) 
developed a more realistic theory which takes into account the diffusion effects 
of mass transfer and migration through a packed bed, with the resulting peak 
shape being affected by the rate of elution (Hooper, 1992). See Eqn. 1.4 for the 
Van Deemter equation for plate height. 
 
 
 Eqn. 1.4 
 
where:   u: Average velocity of the mobile phase  
  A: Eddy diffusion  
  B: Longitudinal diffusion  
  C: Resistance to mass transfer  
 
The mobile phase moves through the column which is packed with 
stationary phase. Eddy diffusion is caused by the movement of molecules from 
the same analyte, which migrate through the stationary phase at random. This 
N    = 
5.55 tR 2 
w 1/2 2 
HETP = A + B   u + C u
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will cause broadening of the solute band, because different paths are of different 
lengths (Braithwaite et al., 1996). 
Longitudinal diffusion occurs due to the concentration of analyte being 
less at the edges of the band than at the centre. Analyte diffuses out from the 
centre to the edges causing broadening. If the velocity of the mobile phase is 
high then the analyte spends less time on the column, which decreases the 
effects of longitudinal diffusion (Braithwaite et al., 1996). 
The last parameter is due to the amount of time an analyte takes to 
equilibrate between the stationary and mobile phase. If the velocity of the 
mobile phase is high, and the analyte has a strong affinity for the stationary 
phase, then the analyte in the mobile phase will move ahead of the analyte in 
the stationary phase (Braithwaite et al., 1996). The band of analyte is broadened. 
The higher the velocity of mobile phase, the worse the broadening becomes. 
 
1.2.2.3 Selectivity factor  
The selectivity factor, α, of a chromatographic separation describes the 
separation of two species (A and B) on the column and is the ratio of their 
capacity factors (Ardrey, 2003b), see Eqn. 1.5. 
   
       
  Eqn. 1.5  
 
It is a measure of the band proximity of two adjacent analyte bands. 
Selectivity is a measurement of the difference in interactions of two analytes 
with the mobile and stationary phases, and therefore the difference in retention 
times. The factor is identified with the selectivity of a chromatographic system, 
i.e., the ability of the system to provide different retention times for two specific 
analytes. Selectivity factor is always greater than one (Dong, 2006b). As with 
capacity, the selectivity of a column is determined by the column packing 
material and the eluents used. 
 
 
α   =
k 'B 
k 'A 
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1.2.2.4 Resolution 
 
Arguably the most important concept in HPLC chromatography is resolution 
(R), which is dependent on all the factors listed above. R is calculated as the 
difference in retention time of two analytes divided by the average width of the 
two peaks at the baseline. The most important goal of the chromatographer is 
to achieve adequate resolution between all peaks in the chromatogram in a 
reasonable amount of time (Ardrey, 2003b). The resolution, R is calculated 
using Eqn. 1.6. 
 
 
 Eqn. 1.6 
 
where:  W: the baseline peak width of the components 
 
For quantitative analysis, baseline resolution is achieved when R=1.5.  It 
is useful to relate the resolution to the number of plates in the column, the 
selectivity factor and the retention factors of the two solutes as per Eqn. 1.7;  
 
 
 
 
       Eqn. 1.7 
 
To obtain high resolution, the three terms must be maximised. The 
optimum parameter with which to control resolution is α; however, this is 
primarily achieved by changing the stationary phase. Resolution is also 
proportional to the square root on N and to k'. It may be improved by increasing 
these parameters; however, these can lead to long analysis times and increased 
band broadening.  
The degree of resolution between two chromatographic peaks is 
dependent upon three factors. The first term, efficiency can be varied with flow 
rate and column length. This term reflects how much dispersion takes place 
within a chromatographic peak. The second term, selectivity, illustrates how 
R  = 
2 (tR2 - tR1)
W1 + W2 
R   = 
√N 
(
α  - 1
)     ( 
1 + k'B 
) 
4 α k'B 
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well the chromatographic system chosen can distinguish between sample 
components. 
 Selectivity is dependent upon stationary phase selection, mobile phase 
selection and column temperature, among others. The final term is related to the 
capacity factor and is primarily influenced by mobile phase composition (Dong, 
2006b). 
 
1.2.3 Modes of separation in HPLC 
 
There are various modes of operation of HPLC.   The mechanism of interaction 
of the solutes with the stationary phases determines the classification of the 
mode of liquid chromatography.   Almost any type of solute mixture can be 
separated by HPLC because of the wide range of stationary phases available. 
There are many different modes of LC including size exclusion, ion-exchange, 
normal and reversed phase. Table 1.1 summarises the variety of modes of liquid 
chromatography, of which Reversed Phase stands out as the most widely used 
mode in HPLC. 
Mode Normal Phase Reversed Phase Ion exchange 
Size 
Exclusion 
Stationary 
Phases 
chemistry 
Polar-
hydrophilic 
Non-polar-
lipophilic Ion-bonding 
Sieving by 
size 
Typical 
Stationary 
Phases 
Silica, Alumina
Alkylated 
silica, mostly 
C18 
Ionic 
functional 
groups on 
silica or 
polymer 
Gel type 
polymers 
Typical 
mobile 
phase 
Hexane; 
isopropanol; 
methylene 
chloride 
Water; 
methanol; 
acetonitrile; 
buffers; ion 
pairing agents 
Water; 
buffers; acid; 
base 
Two modes: 
aqueous and 
non-aqueous
Typical 
solutes Fatty and oily 
Almost all 
organic 
compounds 
Any ion-
charged 
compounds 
Polymers: 
synthetic or 
biological 
 
Table 1.1: Summary of the different modes of operation of HPLC 
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1.2.3.1 Size exclusion LC 
 
Size exclusion chromatography (SEC) is a useful technique for separating 
components with a significant difference in molecular weight. The solutes are 
separated on the basis of size, with the larger ones eluting first. Stationary 
phases contain pores through which compounds are able to diffuse to a certain 
extent (Rouessac et al., 2007). SEC is of particular value in characterising 
polymer mixtures and in separating biological macro molecules such as 
peptides and proteins (Steehler, 2003). 
 
1.2.3.2 Ion exchange LC 
 
Ion-exchange chromatography is used to separate mixtures of ionic solutes such 
as inorganic cations and anions, amino acids and proteins (Steehler, 2003). The 
packing material possesses charge bearing functional groups, which are capable 
of exchanging with ionic analytes in the mobile phase. The functional groups 
employed are permanently bonded ionic groups associated with counterions of 
the opposite charge. Separation occurs as a result of interaction between the 
charged solute and the oppositely charged, solid stationary phase (Rimmer, 
2011). There are two modes of Ion exchange chromatography, anion exchange 
chromatography in which the packing material is a strongly basic quaternary 
ammonium group, and cation exchange chromatography where the packing 
material is a strongly acidic sulphonic acid group. Both of these functional 
groups are totally dissociated, i.e., their exchange properties are independent of 
pH. There are also exchangers that possess weakly acidic and basic functional 
groups, such as carboxylate and tertiary amine groups. In this instance, the 
retention mechanism of analyte ions is dependent upon the pH of the mobile 
phase (Rimmer, 2011). 
Ion exchange chromatography has a wide range of applications 
including the analysis of amino acids on a cation exchanger to the simultaneous 
separation of inorganic anions and cations using anion and cation exchange 
columns in tandem (Rimmer, 2011). 
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1.2.3.3 Normal phase LC 
 
In normal phase chromatography, separation occurs through the interaction of 
analytes with a polar stationary phase (usually a cyano or amino bonded 
stationary phase) and a less polar mobile phase, such as hexane and heptane 
(Rimmer, 2011). Analytes are retained on the column based upon their polarity; 
the more polar the analyte, the more it will be retained on the column. Its main 
application is for the separation of very hydrophobic compounds that would 
take too long to elute in reversed phase chromatography. Normal phase 
chromatography is best suited to the analysis of compounds that are soluble in 
non-polar solvents (Rouessac et al., 2007). 
 
1.2.3.4 Reversed phase LC 
 
Reversed phase liquid chromatography is considered as the method of choice 
for the analysis of pharmaceutical compounds for several reasons, such as its 
compatibility with aqueous and organic solutions as well as with different 
detection systems, high consistency and repeatability and the fact that the vast 
majority of drugs are lipophilic or have some lipophilic moieties and will 
necessitate organic-based separation strategies. The separation mechanism in 
reversed phase chromatography depends on the hydrophobic binding interaction 
between the solute molecule in the mobile phase and the immobilised 
hydrophobic ligand, i.e. the stationary phase (Braithwaite et al., 1996). The 
solute molecules partition (i.e. an equilibrium is established) between the 
mobile phase and the stationary phase. The distribution of the solute between 
the two phases depends on the binding properties of the medium, the 
hydrophobicity of the solute and the composition of the mobile phase (Smith, 
1995). In summary, the more polar the compound, the more time it will spend 
in the polar mobile phase and will hence flow through the system quickly. The 
more non-polar the compound, the more time it will spend interacting with the 
stationary phase and will hence be retained on the column for a longer period of 
time and elute later. 
The stationary phase in the reversed phase chromatographic columns is 
a hydrophobic support that is consisted mainly of porous particles of silica gel 
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in various shapes (spherical or irregular) at various diameters (1.8, 3, 5, 7, 10 
mm etc.) at various pore sizes (such as 60, 100, 120, 300 Å).  The surface of 
these particles is covered with various chemical entities, such as various 
hydrocarbons (C1, C6, C4, C8, C18, etc.) (Rouessac et al., 2007). There are 
also hydrophobic polymeric supports that are used as stationary phases when 
there is an extreme pH in the mobile phase.  In most methods used currently to 
separate medicinal materials, C18 columns are used. 
When the samples contain solutes of ionisable functional groups, such 
as amines, carboxyls, phosphates, phosphonates, sulfates and sulfonates, it is 
possible to control their ionisation degree with the help of buffers in the mobile 
phase.  As a rule, the change of an ionisable molecule to an ion makes it more 
polar and less available to the stationary phase.  In most of the traditional silica-
gel based stationary phases it is not possible to increase the mobile phase’s pH 
above 8 due to hydrolysis of the silica gel (Rimmer, 2011). 
 
1.2.4 Detection techniques 
 
The detector is the part of the chromatographic system that responds to the 
presence of the solutes in the mobile phase. In HPLC there are a number of 
different detectors used today including refractive index, UV/Vis, Mass 
Spectrometry and Fluorescence. Less common but important detectors are 
conductivity and Evaporative light scattering. See Table 1.2 for a brief 
comparison of advantages and limitations of some of the most common 
detection techniques used with HPLC today. 
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Advantages Limitations 
UV/Vis detection 
Easy to use 
 
Reliable 
 
Relatively inexpensive 
 
Solvent gradient compatible 
 
Non-destructive to sample 
 
Relatively sensitive 
 
Specific 
 
Poor response if compound doesn’t 
have a good chromophore 
 
Solvents limited by UV cutoff 
 
Only detects compounds that absorb 
UV or visible radiation 
 
Detection based on extinction 
coefficient 
 
Baseline drift with gradients at low 
wavelength 
 
Solvent front interference at low 
wavelength 
Fluorescence detection 
Very sensitive  
 
Generally insensitive to flow and 
temperature changes  
 
 
Very selective  
 
Limited linearity 
 
Complicated to use –understanding of 
chemical and instrument variables 
essential 
 
Must degas well- chemicals like oxygen 
may quench fluorescence 
 
Not many compounds naturally 
fluoresce 
 
Derivatisation complicates method 
Refractive index detection 
Universal nature of the detector 
response 
 
Good linear dynamic range - ~4 
orders of magnitude 
 
Easy to operate 
Poor sensitivity 
 
Very sensitive to temperature and 
pressure fluctuations 
 
Slow to equilibrate 
 
Cannot be used with solvent gradients 
 
Baseline instability due to temperature 
change 
 
Solvent front interference 
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Mass spectrometry detection 
Very  sensitive 
 
Very selective 
 
Provides structural information 
Purchase price is very high 
 
Complicated operation 
 
Frequent maintenance needed 
 
Table 1.2: Summary of advantages and limitations of the most commonly used 
detectors used in HPLC 
 
1.2.4.1 UV-Vis spectrometry detection 
 
UV-Vis spectroscopy examines the electronic transitions of molecules as they 
absorb light in the UV and visible regions of the electromagnetic spectrum 
(Settle, 1997). UV–Vis is a relatively easy method that delivers fast results in a 
non-destructive format where sample remnants can be collected after the 
detector for further analysis by other applications. Molecular moieties likely to 
absorb light in the 200 to 800 nm region of the electromagnetic spectrum 
generally contain pi-electron functions and heteroatoms possessing non-
bonding valence-shell electron pairs  e.g. all olefins, all aromatics and  
compounds,  for  example, containing > C = O, > C = S, – N = N – groups. 
Such light absorbing groups are known as chromophores (Settle, 1997). Any 
species with an extended system of alternating double and single bonds will 
absorb UV light, and anything with colour absorbs visible light, making UV-
Vis spectroscopy applicable to a broad variety of samples (Rouessac et al., 
2007). The UV-Vis spectra have broad features that are of restricted use for 
sample identification but are extremely useful for quantitative measurements. 
The concentration of an analyte in solution is determined by measuring the 
absorbance at a particular wavelength, usually at a wavelength where 
absorbance is greatest.  
Radiation absorbance depends on the radiation wavelength and the 
functional groups of the chemical compound. Electromagnetic field depending 
on its energy (frequency) can interact with electrons causing their excitation and 
transfer up to a higher energy level, or it can excite molecular bonds causing the 
vibration or rotation of their functional group. The intensity of the beam with 
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the energy corresponding to the possible transitions will decrease while it is 
passing through the flow-cell. Absorbance is the logarithm of the ratio of the 
intensities of the incident light (I0) and the transmitted light (I). It is related 
according to the Beer-Lambert Law to the molar absorptivity (molar extinction 
coefficient, ε), the thickness of the substance (i.e., the path length of the cell, b) 
and the molar concentration of the substance (c) as per Eqn. 1.8 (Rimmer, 
2011). 
A = log (I0/I) = εbc           Eqn. 1.8 
The molar extinction coefficient (ε) corresponds to the absorbance for a 
molar concentration of the substance with a path length of 1 cm. Molar  
absorptivity is dependent on the wavelength and chromatographic conditions, 
(solvent, pH and temperature). It is a constant at a specified wavelength. 
UV detectors can be used with gradient elution providing the solvents 
do not absorb significantly over the wavelength range that is being used for 
detection.  In  reversed  phase  chromatography,  the  solvents  usually 
employed are water, methanol, acetonitrile and tetrahydrofuran (THF), all of 
which are relatively transparent to UV light  over the  total  wavelength  range 
normally used by UV detectors (Rimmer, 2011). In normal phase operation 
more care is needed in solvent selection as many solvents that might be 
appropriate as the chromatographic phase system are likely to absorb UV light 
very strongly. The n-paraffins, methylene dichloride, aliphatic alcohols and 
THF are useful solvents that are fairly transparent in the UV and can be used 
with normal distribution systems (e.g. a polar stationary phase such as silica 
gel). 
Fixed wavelength detectors are detectors which do not allow change to 
the wavelength of the radiation measured whereas variable wavelength 
detectors are detectors which allow selection of the operating wavelength. 
Monitoring of different wavelengths during a run (one at a time) is possible 
using a variable wavelength detector (Rimmer, 2011). With a Photo Diode 
Array (PDA) detector, a single wavelength, a variety of wavelengths or the 
entire spectrum from the whole photodiode array of the column eluent can be 
monitored in real time. This often permits identification of compounds as well 
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as quantitation and is an extremely useful method development tool (Rimmer, 
2011). Many organic compounds have characteristic spectra in the UV which 
can be used to help identify the substance passing though the sensor cell. Thus, 
when a given substance is eluted through the sensor cell, all the outputs from 
the array can be acquired and the result used to construct an absorption 
spectrum that can be compared with standard and/or library spectra for 
identification purposes. Alternatively, by selecting the appropriate diode, the 
wavelength of the light at which there is maximum absorption can be 
selectively monitored to provide maximum detector sensitivity for that 
substance.   
 
1.2.4.2 Mass spectrometry detection 
 
Mass spectrometry (MS) combined with the separation power of 
chromatography has revolutionised the way chemical analysis is done today. 
Liquid chromatography - mass spectrometry (LC-MS) is an extremely versatile 
instrumental technique. With a selection of LC–MS interfaces now available, a 
wide range of analytes, from low molecular-weight drugs and metabolites 
(<1000 Da) to high-molecular-weight biopolymers (>100 000 Da), may be 
studied (Chen et al., 2006). The mass spectrometer provides the most definitive 
identification of all of the HPLC detectors. It allows for the molecular weight of 
the analyte to be determined and with certain mass spectrometers, the structure 
can be elucidated also. Also the high selectivity of the mass spectrometer often 
provides identification capability on chromatographically unresolved or 
partially resolved components. This selectivity allows the use of isotopically 
labelled analytes as internal standards and this, coupled with high sensitivity, 
allows very accurate and precise quantitative determinations to be carried out 
(Ardrey, 2003b). 
The equipment comprises a chromatograph, attached via a suitable 
interface, to a mass spectrometer. As MS measures the mass to charge (m/z) 
ratio of ions, most molecules which can be ionised will be suitable for this 
detector, hence the detector is considered to be a ‘universal’ one. The MS 
obtains information regarding molecular weight and the compound’s chemical 
20 
 
structure. Components eluting from the chromatographic column are introduced 
to the mass spectrometer by means of a specialised ion source (See Figure 1.2). 
 
 
 
Figure 1.2: A schematic of the principle components of a MS 
 
Interfacing the two techniques is not straightforward as the solutes 
leaving an LC column are dissolved in mobile phase at atmospheric pressure, 
whereas the MS is set up to detect gas phase ions in vacuum (Ardrey, 2003a). 
To ease this transition from the liquid to the gas phase, a number of ion source 
interfaces have been developed. 
 
1.2.4.2.1 Sample ionisation 
 
The use of Atmospheric Pressure Ionisation (API) techniques allow positive or 
negative ions to be created and detected. API offers a soft ionisation approach 
resulting in little or no analyte fragmentation. A typical API spectrum contains 
only the protonated (positive ion mode) or deprotonated (negative ion mode) 
molecular ion (Westman-Brinkmalm et al., 2008). The detected ion peaks are 
generally created through addition or subtraction of a proton adducts of analyte 
ions of other types such as sodium or potassium can be seen in some 
circumstances (in positive mode) (Hoffmann, Stroobant 2007). MS spectra 
provide valuable molecular weight information of singly and multiply charged 
ions and identification of the charge state of each peak in the charge-state 
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envelope of a given compound. Software can be used to deconvolute multiply 
charged mass spectral data of mixtures of proteins and other biopolymers.  
The API source can operate using electrospray, nanospray or 
atmospheric pressure chemical ionisation (APCI) techniques. The vast majority 
of LC–MS analyses currently in use employ either electrospray ionisation (ESI) 
or APCI, both which are soft ionisation techniques (Ardrey 2003c). See Figure 
1.3 for a broad summary of the general analyte analysis applications of APCI 
and ESI ionisation techniques. 
 
 
 
Figure 1.3: Illustration of the applications of different ionisation techniques 
 
 In electrospray ionisation (ESI) the analyte is introduced to the source at 
slow flow rates, typically of the order of 0.5 mL/min. The analyte solution flow 
passes through the electrospray needle that has a high potential difference (with 
respect to the counter electrode) applied to it (typically in the range from 2.5 to 
4 kV) – see Figure 1.4 (Westman-Brinkmalm et al., 2008). This forces the 
spraying of charged droplets from the needle with a surface charge of the same 
polarity to the charge on the needle. The droplets are repelled from the needle 
towards the source sampling cone on the counter electrode. As the droplets pass 
through the space between the needle tip and the cone, solvent evaporation also 
occurs, generally augmented by a flow of inert gas. As the solvent evaporation 
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occurs, the droplet shrinks until it reaches the point that the surface tension can 
no longer sustain the charge (the Rayleigh limit) at which point a ‘Coulombic 
explosion’ occurs and the droplet is ripped apart. This produces smaller droplets 
that can repeat the process as well as naked charged analyte molecules. These 
charged analyte molecules can be singly or multiply charged (Hoffmann et al., 
2007). This is a very soft method of ionisation as very little residual energy is 
retained by the analyte upon ionisation.  
In summary, ESI converts the liquid molecules that elute from the LC 
into charged gaseous analytes by evaporating the LC solvent and charging the 
analytes and then pulling the ions into the mass analyser by keeping the 
capillary at a high voltage of opposite charge and at high vacuum. The only 
disadvantage of the technique is that very little (usually none) fragmentation is 
produced directly although this may be overcome through the use of tandem 
mass spectrometric techniques such as MS/MS or MSn. This ionisation 
technique is very suitable for the analysis of polar, thermally labile molecules 
such as drugs, DNA, RNA, sugars, peptides and proteins (Westman-Brinkmalm, 
2008). 
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Figure 1.4: Adapted schematic of electrospray ionisation (Gates, 2004)
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Nanospray ionisation (NSI) is essentially ESI operating at very low 
liquid flow rates of 100 nL/min to several μL/min in static or dynamic modes. It 
is most compatible with capillary LC separations. 
Atmospheric pressure chemical ionisation (APCI) vaporises the sample 
solution at high temperatures up to 600 °C. Application of a high electrical 
potential produces reagent ion plasma, mainly from the solvent vapour. The 
sample vapour is formed by ion-molecule reactions with the reagent ions in the 
plasma. APCI accommodates liquid flows of 100 μL/min to 2 mL/min and is 
generally employed for larger, poorly ionisable, hydrophobic molecules 
(Westman-Brinkmalm et al., 2008). 
 
1.2.4.2.2 Mass analysers 
 
A mass analyser measures gas phase molecules with respect to their mass-to-
charge ratio (m/z), where the charge is produced by the addition or loss of a 
proton(s), cation(s), anions(s) or electron(s) (Westman-Brinkmalm et al., 2008). 
The addition of charge allows the molecules to be affected by electric fields 
thus allowing its mass measurement. There are a number of types of mass 
analysers available and choice depends on the information required from the 
ionised analytes.  
Quadrupole mass analysers have been important in mass analysis for 
many decades because they are relatively inexpensive, rugged, and have been 
implemented in a wide variety of instrumental configurations including triple 
quadrupole instruments which can do MS/MS experiments. A quadrupole mass 
analyser consists of four parallel rods that have fixed DC and alternating RF 
potentials applied to them (see Figure 1.5) (Westman-Brinkmalm et al., 2008). 
Ions produced in the source are focussed and passed along the middle of the 
quadrupoles. Motion of these ions will depend on the electric fields so that only 
ions of a particular mass to charge ratio (m/z) will have a stable trajectory and 
thus pass through to the detector (Chen et al., 2006). Varying the RF brings 
ions of different m/z into focus on the detector and thus builds up a mass 
spectrum.
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Figure 1.5: Adapted schematic of a Quadrupole Mass Analyser (Gates, 2009) 
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 Quadrupoles can also be placed in tandem to enable them to perform 
fragmentation studies - the most common set-up is the triple quadrupole (QQQ) 
(Yost et al., 1978) mass spectrometer which enables basic ion fragmentation 
studies (tandem mass spectrometry MS/MS) to be performed. These 
instruments are particularly sensitive in selected ion monitoring modes and 
hence ideal for trace analysis and pharmacokinetic applications.  
 In a triple quadrupole, the sample enters the ion source and is usually 
fragmented by either an electron impact or chemical ionisation process. The 
first quadrupole acts as a filter for the ion of interest; the various charged ions 
are separated in the usual way and then pass into the second quadrupole section 
sometimes called the collision cell. This one acts as a collision chamber for the 
MS/MS to form the product ions of interest (Hoffmann et al., 2007). 
 
Figure 1.6: Schematic of the Triple Quadrupole Mass Spectrometer 
 
 These product ions are then passed into the third quadrupole which 
functions as a second analyser to detect the aforementioned ions for 
quantitation. The second analyser segregates the product ions into their 
individual masses, which are detected by the sensor, producing the mass 
spectrum (originally from ions of one mass only). In this way, the exclusive 
mass spectrum of a particular molecular or product ion can be obtained from 
the myriad of ions that may be produced from the sample in the first analyser. 
A diagram of a triple Quadrupole Mass Spectrometer is shown in Figure 1.6. 
MS QQQ is an extremely powerful analytical system that can handle 
exceedingly complex mixtures and very involved molecular structures. The 
system has more than adequate resolving power and is valuable for structure 
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elucidation. The combination of the triple quadrupole mass spectrometer with a 
separation technique such as a gas chromatograph or a liquid chromatograph is 
probably one of the most powerful analytical tools available to the 
contemporary chemist.  
 Ion traps (which are normally quadrupole ion traps) are popular because 
they are relatively inexpensive, rugged, and provide MSn capabilities that 
enhance selectivity and qualitative analysis. The trap confines the motion of 
ions in three, rather than two dimensions (Westman-Brinkmalm et al., 2008). 
Ions are generated outside of the mass analyser in most commercial LC-MS 
systems, mainly by the ion source and hence sent into the trap.  The quadrupole 
ion-trap consists of a ring electrode with further electrodes, the end-cap 
electrodes, above and below this. In contrast to the quadrupole, described 
above, ions, after introduction into the ion-trap, follow a stable (but complex) 
trajectory, i.e. are trapped, until an RF voltage is applied to the ring electrode. 
Ions of a particular m/z then become unstable and are directed toward the 
detector. By varying the RF voltage in a systematic way, a complete mass 
spectrum may be obtained. Again, this is a low-resolution device, capable of 
fast scanning and tolerant of relatively high operating pressures (Ardrey, 
2003c). 
The trap can carry out a number of experiments on the trapped ions such 
as isolation and fragmentation, before their release and detection (Westman-
Brinkmalm et al., 2008). While ion traps can be used for quantitation, they are 
most useful for structural elucidation of novel compounds. This analyser is 
being widely employed for applications in drug discovery and combinatorial 
chemistry. An ion trap performs tandem mass spectrometry in time as opposed 
to space for the triple quadropole (Hoffmann et al., 2007). Tandem in time 
instruments perform the steps of precursor ion selection, ion activation and 
acquisition of fragment ion spectra in the very same place. Ion traps have 
limited dynamic range due to space charge affects. If too many ions are 
accumulated in the trap their charges repel each other having a detrimental 
affect on instrument resolution and quantitative analysis (Hoffmann et al., 
2007). 
The Time-of-flight (TOF) analyser is the simplest type of mass analyser. 
TOF systems require a pulsed ion source, a flight tube and an ion detector. This 
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system relies on the fact that if all of the ions produced in the source of a mass 
spectrometer, by whatever technique, are given the same kinetic energy then the 
velocity of each will be inversely proportional to the square root of its mass. As 
a consequence, the time taken for them to traverse a field-free region (the flight 
tube of the mass spectrometer) will be related in the same way to the m/z of the 
ion (Westman-Brinkmalm et al., 2008). A complete mass spectrum is obtained 
simply by allowing sufficient time for all of the ions of interest to reach the 
detector. The operation of this type of device is fundamentally different to those 
described previously in which ions of one m/z ratio at a time enter the mass 
analyser. By varying the conditions in the mass analyser, e.g. magnetic field, 
quadrupole field, etc., ions of different m/z values are brought to the detector 
and a corresponding mass spectrum obtained. In the time-of-flight instrument, it 
is essential that ions of all m/z ratios present in the source are transferred, 
simultaneously and instantaneously, into the mass analyser at a known time so 
that their times of flight, and thus their m/z ratios, may be determined accurately. 
Were ions to be introduced continuously it would be impossible to determine 
exactly when each began its passage through the flight tube and therefore to 
calculate its m/z ratio. A complete mass spectrum at a specific time is therefore 
obtained and when this has been recorded, a matter of milliseconds later, a 
further set of ions can be transferred from the source. 
This is sometimes referred to as a ‘pulsed’ source. Fast scanning, only 
limited by the time it takes the heaviest ion to travel from the source to the 
detector, is possible and any distortion of ion intensity brought about by 
changes in analyte concentration during the scanning process is removed 
(Ardrey, 2003c). 
 The mass of an ion is related to the time it takes that ion to travel 
through the flight tube to the detector. Recently developed TOF systems have 
demonstrated high sensitivity and high resolution. Another attribute of TOF is 
the ‘scan speed’ benefits. Because TOF scan times for complete mass spectra 
are so fast, chromatographic techniques that separate complex mixtures in short 
intervals can be interfaced with this technique. The other great advantage of 
TOF is the virtually unlimited mass range when sampling in the time domain 
(Hoffmann et al., 2007). 
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1.2.4.2.3 Modes of detection 
 
Typically the mass spectrometer is set to scan a specific mass range.  This mass 
scan can be wide as in the full scan analysis or can be very narrow as in selected 
ion monitoring.  A single mass scan can take anywhere from 10 ms to 1 s 
depending on the type of scan.  Many scans are acquired during an LC-MS 
analysis.  LC-MS data is represented by adding up the ion current in the 
individual mass scans and plotting the ‘total’ ion current as an intensity against 
time (Hoffmann et al., 2007). Different modes of acquiring LC-MS data  are 
available including full scan acquisition resulting in the typical total ion current 
plot, selected ion monitoring and selected reaction monitoring or multiple 
reaction monitoring. Selected reaction monitoring and multiple reaction 
monitoring are essentially identical techniques from different manufacturers. 
The total ion current (TIC) is a plot of the total number of ions in each 
MS scan plotted as an intensity point against time.  In the TIC plot, ions of 
every mass over the chosen range are plotted. As many compounds have the 
same m/z it can be difficult finding the compound of interest. A specific mass 
can later be selectively extracted but sensitivity is not as good as the next 
technique of selected ion monitoring. TIC plots are often overlaid onto UV or 
other plots and this can give useful information about the compounds being 
studied. 
With selected ion monitoring (SIM) the mass spectrometer is set to scan 
over a very small mass range, typically one mass unit. This is obviously most 
useful when the actual mass is known. Compounds with the selected mass only 
are detected and plotted. However, some compounds have the same mass and in 
ESI where there are multiply charged species the likelihood is high for 
compounds to have the same m/z value.  As the mass spectrometer can dwell for 
a longer time over a smaller mass range, this makes SIM more sensitive that 
TIC. 
Selected reaction monitoring (SRM) is the most common method used 
for performing mass spectrometric quantitation. SRM creates a unique fragment 
(product) ion that can be monitored and quantified in the midst of complicated 
matrices, thus enabling more confirmatory identification. SRM plots usually 
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contain only a single peak rendering it ideal for sensitive and specific 
quantitation.  
 
1.2.4.2.4 Limitations of MS analysis 
 
Analysing biological fluids is one on the most difficult tasks faced by an 
analytical chemist. Most challenging are interferences from matrices and 
decomposition products combined with low concentrations of target analytes. 
Matrix components present in biological samples can affect the response of the 
analyte of interest and can lead to inaccurate quantitation. The primary matrix 
effect associated with LC-MS/MS methods is ion suppression or enhancement 
caused by the co-eluting matrix components. Matrix effects occur when 
molecules co-eluting with the compound/s of interest alter the ionisation 
efficiency of the electrospray interface. 
  This phenomenon was first described by Tang and Kebarle (Tang et al., 
1993) who showed that electrospray responses of organic bases decreased as the 
concentrations of other organic bases were increased. The exact mechanism of 
matrix effects is unknown, but it probably originates from the competition 
between an analyte and the coeluting, undetected matrix components (Taylor, 
2005). King et al., 2000, have shown through a series of experiments that 
matrix effects are the result of competition between nonvolatile matrix 
components and analyte ions for access to the droplet surface for transfer to the 
gas phase. Although they conclude that the exact mechanism of the alteration of 
analyte release into the gas phase by these nonvolatile components is unclear. 
They postulate “…a likely list of effects relating to the attractive force holding 
the drop together and keeping smaller droplets from forming should account for 
a large proportion of the ionisation suppression observed with electrospray 
ionisation”. Depending on the environment in which the ionisation and ion 
evaporation processes take place, this competition may effectively decrease 
(commonly known as ion suppression) or increase (ion enhancement) the 
efficiency of formation of the desired analyte ions present at the same 
concentrations in the interface. Thus the efficiency of analyte ions to form is 
very much dependent on the matrix entering the electrospray ion source 
(Taylor, 2005). 
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Matrix effects are also compound dependent. Bonfiglio et al., 1999, 
reported that the chemical nature of a compound has a significant effect on the 
degree of matrix effects. In a study of four compounds of different polarities 
under the same mass spectrometric conditions, the most polar was found to 
have the largest ion suppression and the least polar was affected less by ion 
suppression. These findings of differential matrix effects have important 
ramifications particularly when selecting a suitable internal standard for 
quantification purposes.  
The possible origins of ion suppression are multiple. The main problem 
source commonly reported is the presence of endogenous substances, i.e. 
organic or inorganic molecules present in the sample and that are retrieved in 
the final extract. Among this first group of ion suppressor agents, can be 
included ionic species (inorganic electrolytes, salts), highly polar compounds 
(phenols, pigments), and various organic molecules including carbohydrates, 
amines, urea, lipids, peptides, analogous compounds or metabolites with a 
chemical structure close to the target analyte one. Finally, a wide range of 
molecules can lead to ion suppression especially when they are present in high 
concentration in the extract and eluted in the same retention window than the 
analyte of interest (Antignac et al., 2005). A second problem source, usually 
less described, is due to the presence of exogenous substances, i.e. molecules 
not present in the sample but coming from various external sources during the 
sample preparation. Among this second group of ion suppressor agents, can be 
included plastic and polymer residues (Mei et al., 2003), phthalates, detergent 
degradation products (alkylphenols), ion pairing reagents (Gustavsson et al., 
2001, Chaimbault et al., 1999, Chaimbault et al., 2000) , proton-exchanges 
promoting agents such as organic acids (Chaimbault et al., 2000, Keever et al.,  
1998, Roberts et al., 1998), calibration products, buffers, or material released by 
the solid phase extraction, LC or GC stationary phases. 
Many components in biological matrices influence the result of an 
analysis, affecting assay sensitivity and reproducibility. Improved matrix 
management becomes critical as requirements for higher assay sensitivity and 
increased process throughput become more demanding (Chiu et al., 2010). 
When ion suppression occurs, the sensitivity and lower limit of quantification 
of a method may be adversely affected (Buhrman et al., 1996). 
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1.2.5 Sample preparation techniques 
 
Prior to LC analysis, biological samples must be ‘cleaned up’. This involves 
isolating the drug to be analysed from its matrix with reliable recovery. Three 
sample preparation techniques are commonly used to extract analytes out of 
biological matrices: protein precipitation, supported liquid extraction or liquid-
liquid extraction and solid phase extraction. Among the three, protein 
precipitation was the most used sample preparation approach in early drug 
discovery due to a lesser amount of method development time required which 
resulted in fast data turnaround time. However, realistically choosing which 
extraction approach is best is compound dependent. Analysis of highly 
hydrophilic molecules in biological matrices presents challenges due to low 
extraction recovery from biological matrices.  
 
1.2.5.1 Liquid-liquid extraction 
 
Classical liquid-liquid extraction (LLE) is one of the simplest techniques used 
in the preparation of biological fluids such as urine, plasma and blood. Also 
known as solvent extraction or partitioning, LLE is a method of separating 
compounds from each other based on their relative solubilities in two different 
immiscible liquids, usually water and an organic solvent (Steehler, 2004). It 
involves transfer of a substance from one liquid phase into another liquid phase. 
The sample solution is mixed thoroughly with an immiscible solvent in which 
the target analyte is preferentially soluble. The mixing process creates a large 
interfacial area between the two liquids to facilitate efficient mass transfer of 
the target analytes from the sample into the extractant. The two phases are 
allowed to separate, or are separated by centrifugation, and the extractant is 
removed for analysis. If the drug of interest has preferential solubility for a 
hydrophobic environment, it will be successfully extracted from the aqueous 
phase by an organic solvent leaving behind the endogenous compounds such as 
proteins and lipids etc. For biological fluids, a water-immiscible solvent such as 
ethyl acetate or chloroform is generally employed (Steehler, 2003). 
The success of LLE depends upon the difference in solubility of a 
compound in various solvents. A judicious choice of solvent leads to clean 
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extracts although the technique is not applicable to hydrophilic analytes. For 
example, with LLE, the majority of phospholipids stay in the aqueous layer 
when using tert-butyl methyl ether (t-BME) as an extraction solvent regardless 
if the plasma pH is adjusted or not. Phospholipids are major components that 
stay in the extracts and elute late in the columns. It may not affect polar 
compounds as much as they do for late eluting analytes. However, the lipids 
require high organic composition in the LC gradient to clean them out of the LC 
column, otherwise it will accumulate inside the column and leading to column 
deterioration with poor peak shape or retention shifts. By switching to a more 
polar organic extraction solvent, such as ethyl acetate, more lipids will 
participate into the organic layer. LLE is preferred by many practicing scientists 
due to its speed and simplicity compared with solid-phase extraction and 
protein precipitation, although its green credentials are questionable.  
 
1.2.5.2 Protein precipitation 
 
Protein precipitation (PP) is a well-established sample preparation technique for 
the removal of unwanted proteins from biological fluid samples. In a PP 
procedure a solvent (often an equal or higher volume (e.g. 1:3) of acetonitrile 
(or sometimes methanol) or strong acid or base are added to the biological 
sample which causes proteins and other biological material to precipitate out of 
solution. The sample is mixed and centrifuged, resulting in the formation of a 
protein pellet and its corresponding supernatant. The supernatant, now 
containing the analyte of interest, is transferred, dried, reconstitiuted, or directly 
injected into a LC column (Bakhtiar et al., 2006). This procedure is easily 
amenable to automation and is applicable to a host of structurally diverse group 
of small analytes. While PP is fast, easy to apply, and applicable to a broad 
class of small molecules, it also suffers from several disadvantages. PP lacks 
specificity and selectivity that SPE and LLE can offer. Consequently, 
significant matrix effects and ion suppression can be observed due to the 
presence of other endogenous molecules that compete with the analyte(s) 
during ionisation. PP contributes to the sample extracts a fair amount of 
phospholipids that concentrate during the dry down and reconstitution step. In 
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addition, compounds that are highly bound to the protein can yield low sample 
recovery in the PP procedure (Bakhtiar et al., 2006). 
 
1.2.5.3 Solid phase extraction 
 
Over the last twenty years, solid phase extraction (SPE) has become the most 
powerful technique available for rapid and selective sample preparation prior to 
analytical chromatography. Various SPE procedures are used due to the 
abundance of different retention mechanisms available to retain the desired 
analytes, and extract them out of bio-matrices. Often this involves time 
consuming method development, not suitable for quick turnaround of samples.  
SPE is one of the most effective and most versatile methods of sample 
preparation. SPE is a chromatographic technique used to prepare samples for 
subsequent analysis by removing interfering substances that may be present. 
Problems associated with LLE such as incomplete phase separations, less-than-
quantitative recoveries as much of the target analyte is typically lost during the 
extraction process, use of expensive, breakable specialty glassware, and 
disposal of large quantities of organic solvents can be prevented using SPE 
which is a more efficient clean up method yielding quantitative extractions that 
are easy to perform. SPE is rapid, can be automated and solvent use and lab 
time are reduced (Arendale, 1986). SPE switches sample matrices to a form 
more compatible with chromatographic analyses, has more efficient use of all 
of the analyte present for increased sensitivity, removes interferences to 
simplify chromatography and improve quantitation and also protects the 
analytical column from contaminants. 
Common SPE methods use a solid phase, typically in a disposable 
cartridge, and a liquid solvent to isolate one, or one type, of analyte from a 
solution. SPE can be used to isolate analytes of interest from a wide variety of 
matrices, including complex ones such as urine, blood, water samples, 
beverages, soil and even animal tissue. There are three approaches in which 
SPE is used to separate compounds of interest from impurities.  
In the classic mode, selective extraction, the separating ability of SPE is 
based on the preferential affinity of desired solutes in a liquid, mobile phase for 
a solid, stationary phase through which the sample is passed. For interference 
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laden samples (e.g., biological fluids), samples are generally diluted with buffer. 
When dealing with ionisable compounds pH manipulation is important.  A 
compound’s ionisation state can drastically change its retention and elution 
characteristics on a given SPE sorbent. Mobile phase pH should be selected so 
that it is at least ± 2 pH units from the analyte’s pKa. This assures that the 
analytes are either 100% ionised or 100% non-ionised and should help control 
run to run reproducibility.  At high pH, acidic compounds are ionised and are 
much more hydrophilic than under ion suppression conditions.   
The first step involves conditioning and equilibrating the SPE cartridge. 
Conditioning wets or activates the bonded phases to ensure consistent 
interaction between the analyte and the sorbent functional groups. Reversed-
phase sorbents are often conditioned with a water miscible solvent such as 
methanol or acetonitrile (Steehler, 2004). Equilibration introduces a solution 
similar to the sample load in terms of solvent strength and pH in order to 
maximize retention. Buffer or water are good choices for reversed-phase 
equilibration (see Figure 1.7). 
The second step involves loading the diluted sample at a consistent and 
reduced flow rate of ~1-2 drops/second to ensure optimal retention. Impurities 
and irrelevant substances in the sample are then washed away while the analyte 
of interest is retained on the stationary phase. A wash step is necessary to elute 
interferences without prematurely eluting compounds of interest. 5-20% 
methanol in water or sample pre-treatment buffer is typical for wash solvents 
(Steehler, 2004). 
Analytes that are retained on the stationary phase are then eluted from 
the cartridge with an appropriate solvent. The hydrophobic interactions between 
the analyte and sorbent functional groups are interrupted with an organic 
solvent or solvent combination of sufficient non-polar character (Steehler, 
2004). Example elution solvents are methanol or acetonitrile. It is often 
necessary to evaporate and reconstitute the SPE eluate in mobile phase prior to 
LC analysis.  
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Figure 1.7: Schematic showing the four main steps in a typical SPE procedure 
 
The second mode is selective washing which involves the compounds of 
interest and the impurities being retained on the SPE packing when the sample 
passes through. The impurities are rinsed through with wash solutions that are 
strong enough to remove them, but weak enough to leave the compounds of 
interest behind. Finally, selective elution works by eluting the adsorbed 
compounds of interest in a solvent that leaves the strongly retained impurities 
behind. 
SPE cartridges are commercially available with a variety of different 
stationary phases, but most are based on a bonded silica material that is 
derivatised with a specific functional group. Some of these functional groups 
include hydrocarbon chains of variable length (for reversed phase SPE), 
quaternary ammonium or amino groups (for anion exchange), and sulfonic acid 
or carboxyl groups (for cation exchange) (Steehler, 2004). 
 Reversed phase SPE separates analytes based on their polarity. In a 
reversed phase SPE cartridge compounds of mid to low polarity are retained 
due to their hydrophobicity and attraction to the stationary phase. Separation is 
achieved using a polar or moderately polar sample matrix and a nonpolar 
stationary phase (LoBrutto et al., 2006). Materials for reversed phase SPE 
include alkyl- and aryl-bonded silicas (LC-18, LC-8, LC-4, and LC-Ph) 
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whereby the hydrophilic silanol groups at the surface of the raw silica packing 
are chemically modified with hydrophobic alkyl or aryl functional groups by 
reaction with the corresponding silanes (Steehler, 2004). Retention of organic 
analytes from polar solutions onto these materials is due primarily to the 
attractive forces between the carbon-hydrogen bonds in the analyte and the 
functional groups on the silica surface. These nonpolar-nonpolar attractive 
forces are commonly called van der Waals forces, or dispersion forces 
(Kazakevich et al., 2006). The analyte can be eluted by washing the cartridge 
with a non-polar solvent, which disrupts the interaction of the analyte and the 
stationary phase. Reversed-phase SPE is considered the least selective retention 
mechanism when compared to normal-phase or ion-exchange SPE. In other 
words, it may be difficult for a reversed-phase method or bonded-chemistry to 
differentiate between molecules that are structurally similar. However, because 
reversed-phase will retain most molecules with any hydrophobic character, it is 
very useful for extracting analytes that are very diverse in structure within the 
same sample (LoBrutto et al., 2006). 
Normal phase SPE typically involves a polar analyte, a mid- to nonpolar 
matrix (e.g. acetone, chlorinated solvents, and hexane), and a polar stationary 
phase. Polar-functionalized bonded silicas (e.g. LC-CN, LC-NH2, and LC-
Diol), and polar adsorption media (LC-Si, LC-Florisil and LC-Alumina) 
typically are used under normal phase conditions (Kazakevich et al., 2006). 
Retention of an analyte is primarily due to interactions between polar functional 
groups of the analyte and polar groups on the sorbent surface. These include 
hydrogen bonding, pi-pi interactions, dipole-dipole interactions, and dipole-
induced dipole interactions, among others. A compound adsorbed by these 
mechanisms is eluted by passing a solvent that disrupts the binding mechanism 
- usually a solvent that is more polar than the sample’s original matrix.  
Ion exchange sorbents separate analytes based on electrostatic 
interactions between the analyte of interest and the positively charged groups on 
the stationary phase. For ion exchange to occur, both the stationary phase and 
sample must be at a pH where both are charged to encourage interaction. Anion 
exchange sorbents are derivatised with positively charged functional groups that 
interact with and retain negatively charged anions, such as acids. Strong anion 
exchange sorbents contain quaternary ammonium groups that have a permanent 
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positive charge in aqueous solutions, and weak anion exchange sorbents use 
amine groups which are charged when the pH is below about 9. To elute the 
analyte from either the strong or weak sorbent, the stationary phase is washed 
with a solvent that neutralises the charge of either the analyte, the stationary 
phase, or both. Once the charge is neutralised, the analyte will elute from the 
cartridge. Cation exchange sorbents are derivatised with functional groups that 
interact and retain positively charged cations, such as bases. Strong cation 
exchange sorbents contain aliphatic sulfonic acid groups that are always 
negatively charged in aqueous solution, and weak cation exchange sorbents 
contain aliphatic carboxylic acids, which are charged when the pH is above 
about 5. To elute the analyte from either the strong or weak sorbent, the 
stationary phase is washed with a solvent that neutralises ionic interaction 
between the analyte and the stationary phase. Once the interaction between 
analyte and stationary phase is neutralised, the analyte will elute from the 
cartridge. 
Solutions used in SPE procedures can have a very broad pH range. 
Silica-based packings, such as those used in HPLC columns, usually have a 
stable pH range of 2 to 7.5. At pH levels above and below this range, the 
bonded phase can be hydrolyzed and cleaved off the silica surface, or the silica 
itself can dissolve. In SPE, however, the solutions usually are in contact with 
the sorbent for short periods of time. The fact that SPE cartridges are 
disposable, and are meant to be used only once, allows one to use any pH to 
optimise retention or elution of analytes.  
For reversed phase SPE procedures on bonded silicas, the pH of the 
conditioning solution and sample should be adjusted for optimum analyte 
retention. If the compound of interest is acidic or basic a pH at which the 
compound is not charged is used. Retention of neutral compounds (no acidic or 
basic functional groups) usually is not affected by pH. In normal phase SPE 
procedures on bonded silicas or adsorption media, pH is usually not an issue, 
because the solvents used in these processes are typically nonpolar organic 
solvents, rather than water. Retention in ion exchange SPE procedures depends 
heavily on the pH of the sample and the conditioning solutions. For retention of 
the analyte, the pH of the sample must be one at which the analyte and the 
functional groups on the silica surface are charged oppositely. In order for 
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electrostatic retention to occur, both analyte and sorbent functional groups must 
be in their ionised form. This is done through strict pH control of the sample 
matrix. For basic analytes, the pH should be adjusted to at least 2 pH units 
below the molecule’s pKa. For acidic analytes, the pH should be adjusted to at 
least 2 pH units above the molecule’s pKa. To elute, the opposite is true. By 
adjusting the pH of the eluant to at least two pH units above or below the 
analytes’ and/or sorbent’s pKa, one can effectively neutralize one or both 
functional groups disrupting the electrostatic 
The stationary phase in SPE is packed into a syringe-shaped cartridge, a 
disc or a 96 well plate, which can be mounted on a commercially available 
extraction manifold. A typical SPE manifold can accommodate 12 or 24 SPE 
cartridges so that many samples can be processed simultaneously. Many SPE 
manifolds are equipped with a vacuum port which speeds up the extraction 
process by pulling the liquid sample through the stationary phase at a set speed. 
A sample tube rack inside the manifold collects the samples as they are eluted 
off the cartridges. 
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Figure 1.8: Photograph of a typical SPE manifold (above) which can 
accommodate 12 SPE cartridges and a 96 well sample processing manifold 
(below) 
 
Reliable, high throughput sample preparation techniques are essential in 
today’s bioanalytical laboratory. A 96 well sample processing manifold 
increases productivity by allowing the processing of up to 96 samples 
simultaneously. These manifolds can process SPE, LLE or PP plates hence 
minimising method development time and enhancing throughput. Figure 1.8 
shows a typical SPE manifold accommodating 12 SPE cartridges and a 96 well 
sample processing manifold. Both types of manifold were used for work in this 
thesis. 
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1.2.6 Validation of analytical methods 
 
Before a procedure can provide useful analytical information, it is necessary to 
demonstrate that it is capable of providing acceptable results. Several articles 
have been published on the requirements of method validation for analytical 
methods (Kanarek, 2005, Krause, 2005). Validation is an evaluation of whether 
the precision and accuracy obtained by following the procedure are appropriate 
for the problem. In addition, validation ensures that the written procedure has 
sufficient detail so that different analysts or laboratories following the same 
procedure obtain comparable results (Goldsmith, 2000). Bioanalytical method 
validation includes all of the procedures that demonstrate that a particular 
method used for quantitative measurement of analytes in a given biological 
matrix, such as blood, plasma, serum, or urine, is reliable and reproducible for 
the intended use.  
Due to the nature of the sample, bioanalytical methods are more 
complex and more difficult to validate than methods used for quality control or 
quality assurance of drug products. This is because bioanalytical methods 
include more complex matrices, a large variety of possible interferences from 
metabolites, and typically low sample volumes (Garofolo, 2004). In addition, 
bioanalytical data needs to be accurate and reliable because they are used for 
critical applications including the calculation of pharmacokinetic parameters 
that are critical to the review of the performance of a drug or a formulation. 
Therefore, bioanalytical methods need to be thoroughly validated.  
The objective of analytical method validation is to ensure that every 
future measurement in routine analysis will be close enough to the unknown 
true value for the content of the analyte in the sample (González et al., 2007). 
There are various guidelines for validation of analytical assays such as those 
published by the FDA, Institute of Validation, EU and those laid down at the 
Washington Conference of 1990 to name a few (Clarke, 1994, Taverniers et al., 
2004, Shah et al., 1992).  
Precision, accuracy, sensitivity, linearity and range, recovery and 
stability are the most important parameters during a validation. Where possible, 
intra-day precision (repeatability) and inter-day precision (intermediate 
precision), accuracy, sensitivity, limits of detection and quantitation (LOD and 
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LOQ), linearity and range, recovery and stability to freeze-thaw cycles are 
tested. After developing a method with desired attributes, the method is 
validated to establish that it will continue to provide accurate, precise, and 
reproducible data during study-sample analysis (FDA, 2001). Results from 
method validation can be used to judge the quality, reliability and consistency 
of analytical results; it is an integral part of any good analytical practice. 
Analytical methods need to be validated or revalidated before their introduction 
into routine use, whenever the conditions change for which the method has been 
validated (e.g., an instrument with different characteristics or samples with a 
different matrix) and whenever the method is changed and the change is outside 
the original scope of the method. 
 
1.2.6.1 Accuracy 
 
Accuracy is a measure of the closeness of test results obtained by a method to 
the true value (Goldsmith, 2000). Accuracy indicates the deviation between the 
mean value found and the true value. It is determined by applying the method to 
samples to which known amounts of analyte have been added. These should be 
analysed against standard and blank solutions to ensure that no interference 
exists. The accuracy is then calculated from the test results as a percentage of 
the analyte recovered by the assay.  
Errors in measurement can be divided into two general categories: 
systematic errors and random errors. Systematic errors result from sources that 
can be traced to the methodology, the instrument or the operator, and affect 
both the accuracy and the precision of the measurement. Random errors only 
affect the precision, and are difficult to eliminate, because they are the result of 
random fluctuations in the measured signal, due to noise and other factors 
(Garofolo, 2004). Whilst systematic errors are proportional to the sum of 
individual contributions, random errors are proportional to the root of the sum 
of the squares of the individual contributions (Garofolo, 2004). Thus, the 
precision of the entire procedure is often dominated by the random errors of the 
most imprecise step. 
Accuracy in this thesis was expressed as % error i.e. [the absolute 
difference between calculated concentration and nominal concentration] / 
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nominal concentration × 100. Analytical methods may be divided into three 
groups based on the magnitude of their relative errors. When an experimental 
result is within 1% of the correct result, the analytical method is highly 
accurate. Methods resulting in relative errors between 1% and 5% are 
moderately accurate, but methods of low accuracy produce relative errors 
greater than 5%. The magnitude of a method’s relative error depends on how 
accurately the signal is measured and the ease of handling the sample without 
loss or contamination (Goldsmith, 2000). 
 
1.2.6.2 Precision 
 
The precision of an analytical method is the degree of agreement among 
individual test results obtained when the method is applied to multiple sampling 
of a homogenous sample (Goldsmith, 2000). The closer the agreement between 
individual analyses, the more precise the results. Precision is a measure of the 
reproducibility of the whole analytical method (including sampling, sample 
preparation and analysis) under normal operating circumstances.  
Accuracy is generally the more important characteristic of quantitative 
data to be assessed, although consistency, as measured by precision, is of 
particular concern in some circumstances (Steehler, 2003). Precision is a 
measure of the spread of data about a central value and may be expressed as the 
range, the standard deviation, or the variance. Intra-day and inter-day precision 
in this thesis was determined by calculating RSD (relative standard deviation) 
values. RSD was expressed as [deviation from the mean]/mean 
concentration × 100. 
Precision is commonly divided into two categories: repeatability and 
reproducibility. Repeatability is the precision obtained when all measurements 
are made by the same analyst during a single period of laboratory work, using 
the same solutions and equipment. Reproducibility, on the other hand, is the 
precision obtained under any other set of conditions, including that between 
analysts, or between laboratory sessions for a single analyst (Garofolo, 2004). 
Since reproducibility includes additional sources of variability, the 
reproducibility of an analysis can be no better than its repeatability. Errors 
affecting the distribution of measurements around a central value are called 
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indeterminate and are characterised by a random variation in both magnitude 
and direction. Indeterminate errors can be traced to several sources, including 
the collection of samples, the manipulation of samples during the analysis, and 
the making of measurements.  
 
1.2.6.3 Sensitivity  
 
The ability to demonstrate that two samples have different amounts of analyte is 
an essential part of many analyses. A method’s sensitivity is a measure of its 
ability to establish that such differences are significant. Sensitivity is often 
confused with a method’s detection limit. The detection limit is the smallest 
amount of analyte that can be determined with confidence. The detection limit, 
therefore, is a statistical parameter. Sensitivity is the change in signal per unit 
change in the amount of analyte (Goldsmith, 2000). 
 Limit of detection is the lowest concentration in a sample that can be 
detected, but not necessarily accurately quantitated, under the stated 
experimental conditions. The limit of detection is important for impurity tests 
and the assays of dosages containing low drug levels and placebos. The limit of 
detection is generally quoted as the concentration yielding a signal-to-noise 
ratio of 3:1 (Garofolo, 2004). Since the limit of detection is dependent on the 
signal-to-noise ratio; it can be improved by enhancing the analyte signal and 
reducing the detector noise. Noise is the width of the baseline created by 
background fluctuations such as the detector electronics, pump oscillations 
and/or a dirty column or the baseline signal in the absence of the analyte. The 
signal (i.e. peak height) can be increased by selecting the optimum monitoring 
wavelength, increasing the injection volume or mass (below signal or column 
saturation), increasing the peak sharpness with high efficiency columns and by 
optimising the mobile phase. For absorbance detectors, longer path lengths in 
the flow cell enhances sensitivity though often to the detriment of post column 
dispersion. Noise can be reduced by using high sensitivity detectors with low 
noise and drift characteristics, slower detector response time, mobile phases 
with low absorbance and pumps with low pulsation. Limit of quantitation is the 
lowest concentration of analyte in a sample that can be determined with 
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acceptable precision and accuracy. It is quoted as the concentration yielding a 
signal-to-noise ratio of 10:1 (Garofolo, 2004). 
 
1.2.6.4 Linearity and range 
 
The linearity of an analytical procedure is its ability (within a given range) to 
obtain test results that are directly proportional to the concentration (amount) of 
analyte in the sample (Lee, 2004). The range of an analytical procedure is the 
interval between the upper and lower concentrations (amounts) of analytes in 
the sample (including these concentrations) for which it has been demonstrated 
that the analytical procedure has a suitable level of precision, accuracy, and 
linearity (Lee, 2004). To determine linearity and range of an assay a calibration 
curve needs to be prepared over the range of concentrations appropriate to the 
assay and the regression coefficient determined.  
 
1.2.6.5 Recovery  
 
The recovery is a measure of the efficiency of the method in detecting all the 
analyte of interest present in the original sample. It is more important that 
recovery is constant within the calibration range and is hence evaluated close to 
the extremes of the calibration range and at an intermediate concentration 
(Braggio et al., 1996). The percentage of drug recovered from the biological 
samples was determined by comparing the integrated areas of extracted samples 
spiked before extraction with the response of extracted blank matrix samples 
spiked just before HPLC assay. This is performed rather than a comparison with 
pure unextracted standards in order to compensate any effect the matrix may 
have in the signal response (Peters et al., 2007). Most authors agree, that the 
value for recovery is not important, as long as the data for LOD, precision and 
accuracy (bias) are acceptable (Bressolle et al., 1996, Causon et al., 1997, 
Dadgar et al., 1995, Hartmann et al., 1998, Karnes et al., 1991, Shah et al., 
2000). 
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1.2.6.6    Stability  
 
It is extremely important to perform a stability study of the analyte in biological 
fluids in order to obtain information concerning the conditions and times of 
sample storage so that sample integrity before assay is assured (Braggio et al., 
1996). Chemical compounds can decompose prior to chromatographic 
investigations, for example, during the preparation of the sample solutions, 
extraction, cleanup, phase transfer or storage of prepared vials (in refrigerators 
or in an automatic sampler). Method development should investigate the 
stability of the analytes and standards under these circumstances (Bretnall et al., 
2011). 
Drug stability in a biological fluid is a function of the storage 
conditions, the chemical properties of the drug, the matrix, and the container 
system.  Stability procedures should evaluate the stability of the analytes during 
sample collection and handling, after long-term (frozen at the intended storage 
temperature) and short-term (bench top, room temperature) storage, and after 
going through freeze and thaw cycles and the analytical process.  The procedure 
should also include an evaluation of analyte stability in stock solution.  
Conditions used in stability experiments should reflect situations likely to be 
encountered during actual sample handling, storage and analysis (Peters et al., 
1998). Stability of analytes during the whole analytical procedure is a 
prerequisite for reliable quantification. 
 
1.3 Conclusions 
 
From this introductory chapter, the underlying theories of the different 
separation techniques along with the various modes of detection and sample 
preparation methods were outlined and discussed. Due to its wide applicability, 
high performance liquid chromatography is the most commonly employed 
separation technique in many scientific and pharmaceutical fields. HPLC is a 
very sensitive technique seeing as it can incorporate a wide choice of detection 
methods such as UV/Vis, fluorescence and mass spectrometry, all of which 
have been successfully applied to the analysis of a wide range of samples.  
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The aim of this thesis was the development of chromatographic 
methodologies for the analysis of different therapeutic drugs in biological 
matrices under challenging conditions representative of the extremes of real 
world analytical problems. As previously discussed, one of the most difficult 
tasks faced by the analytical chemist is in the analysis of biological fluids. 
Analytical methods for pharmaceutical formulations are far less challenging to 
develop and validate than bioanalytical methods, especially in support of 
pharmacokinetic studies. Problems encountered with interferences from sample 
matrices, decomposition products and low levels of drug and metabolites 
proved the most challenging to overcome in this work. Careful assessment of 
matrix effects and judicial use of the sample preparation methods coupled with 
adequate chromatography and detection proved critical to the overall success of 
the methods developed herein. 
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Chapter 2 
 
Simultaneous determination of efavirenz, rifampicin and its 
main metabolite desacetyl rifampicin levels in human 
plasma 
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2.1 Scope of research 
 
The objective of this work was to develop a method for the simultaneous 
determination of efavirenz (Efv) and rifampicin (Rif) and its metabolite, desacetyl 
rifampicin (dRif), from human plasma. Appropriate treatment of microbial illness 
represents a significant pharmaceutical challenge.  Nowhere more so than in the 
management of HIV infection, where patients often present with concurrent 
tuberculosis infection, thereby necessitating combination drug treatment.  We 
developed a collaboration with Dr Patrick Mallon in the Mater Hospital who 
routinely treats concurrently HIV and TB positive patients.  An international 
collaboration involving the Mater group hypothesise that the pharmacokinetics of 
Rif are adversely affected when a patient is administered both drugs at the same 
time. A clinical study termed the SPhEAR study (Study on the Pharmacokinetics 
of Efavirenz And Rifampicin) was initiated with the objective of determining the 
effect of HIV infection and exposure to antiretroviral therapy on the 
pharmacokinetics of Rif in patients treated for Mycobacterium tuberculosis 
infection. Examination of this hypothesis would necessitate developing a new 
method capable of convenient, rapid and cost effective quantitation of two 
unrelated pharmaceuticals the antiviral agent Efv, the anti-TB agent, Rif and its 
primary metabolite (dRif) and we sought to provide just such a technique. 
 
2.2 Introduction 
 
2.2.1 HIV and its treatment 
 
The human immunodeficiency virus (HIV) pandemic is a complex mix of diverse 
epidemics within and between countries and regions of the world (Simon et al., 
2006). It represents a global problem, estimated to affect over 40 million people 
with infection rates increasing by nearly five million per year (WHO, 2006). The 
HIV retrovirus, if left untreated, leads to acquired immunodeficiency syndrome 
(AIDS). HIV infection occurs through the transfer of blood, semen, vaginal fluid 
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or breast milk. The four major routes of transmission are unprotected sexual 
intercourse, contaminated needles, transmission from mother (if infected) to her 
baby at birth and through breast milk. 
 HIV primarily infects vital cells such as helper T cells, macrophages and 
dendritic cells in the human immune system. It is estimated that AIDS has killed 
more than 25 million people since it was first recognised in 1981. It is also 
estimated that 0.6% of the worlds living population is infected with HIV. To date, 
there is no cure or vaccine for HIV or AIDS. Avoiding exposure to the virus is the 
only know method of prevention.  
 Antiretroviral treatment has transformed AIDS from an inevitably fatal 
condition to a largely chronic, manageable disease (Simon et al., 2006). Highly 
active antiretroviral therapy (HAART) is the current treatment for HIV infection. 
HAART does not cure the patient but it does allow stabilisation of the patient’s 
symptoms and reduction of viremia. Current HAART options are combinations of 
at least three drugs belonging to at least two classes of anti-retroviral agents. These 
classes include nucleoside analogue reverse transcriptase inhibitors, protease 
inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTI). Efv is 
used as part of HAART for the treatment of HIV type 1 - see Figure 2.1 for 
structure. Efv belongs to the non-nucleoside reverse transcriptase inhibitors group. 
It works by interrupting the replication of new HIV particles in already infected 
cells (Rezk et al., 2004). 
  Efv does this by preventing the reverse transcriptase enzyme from 
properly functioning. This enzyme functions to change the RNA of the virus so 
that it becomes DNA.  Once this occurs, the material which encodes HIV will be 
inserted into the genetic code of the infected cell.  
 The recommended dose for Efv is 600 mg daily (some recommend a 
higher dose of 800 mg daily when used with Rif), usually dosed at night and as the 
agents do not cure the disease, Efv treatment for HIV will need to be given 
continuously or with treatment “holidays” for the remainder of the patient’s life.  
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Figure 2.1: Chemical structures of (a) Efv and (b) Rif (R = OCOCH3) and dRif (R 
= OH) 
 
2.2.2 TB and its treatment 
 
Tuberculosis (TB) is an infection caused by mycobacteria, mainly Mycobacterium 
tuberculosis (Allanson et al., 2007). TB most commonly attacks the lungs (as 
pulmonary TB) but can also affect the central nervous system, the lymphatic 
system, the circulatory system, bones, joints and even the skin. Among infectious 
(a) 
(b) 
 
 
R 
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diseases, TB is globally the leading cause of death, killing around three million 
people each year (Zumla et al., 1999). There are approximately eight million new 
cases each year worldwide, almost all of them preventable or treatable (Allanson 
et al., 2007). When people suffering from active pulmonary TB cough, sneeze, 
speak, kiss, or spit, they expel infectious aerosol droplets, known as bacilli. 
Currently one-third of the world's population is infected with the TB bacillus 
(Allanson et al., 2007).  However, TB bacilli-infected people will not necessarily 
become sick with the disease. TB bacilli are protected with a thick waxy coat and 
the immune system may form a fibrous granuloma around a site of infection 
limiting growth hence, the disease can lie dormant for years. However, the 
chances of becoming sick are increased when a person’s immune system is 
weakened. TB is significantly more common in deprived city areas, among the 
homeless, alcoholics, older people and patients with HIV/AIDS.  
 Treatment for TB uses antibiotics to kill the bacteria. Rif is an important 
first line drug prescribed throughout TB therapy, often as part of fixed dose 
combination tablets, which may also contain isoniazid and pyrazinamide 
(Allanson et al., 2007). Rif has both early bactericidal activity and, more 
importantly, sterilising activity against Mycobacterium tuberculosis. See Figure 
2.1 for structure. Rif exerts its anti-TB activity by targeting the bacterial DNA 
dependant RNA polymerase of both intracellular and extracellular Mycobacterium 
tuberculosis (Hartkoorn et al., 2007). The ability to kill Mycobacterium 
tuberculosis is related to the concentration of drug to which the bacterium is 
exposed (Balbão et al.,  2010). 
  The recommended dose for Rif is 600 mg daily, which can be dosed at any 
time of the day (usually in the morning). The duration of treatment depends on the 
type of TB - standard is six months for pulmonary TB and 9-12 months for 
extrapulmonary TB. WHO recommends a 6-month regimen comprising Rif,  
isoniazid, pyrazinamide, ethambutol which are given together for the first 2 
months followed by Rif and isoniazid therapy for the next 4 months. Rif is mainly 
eliminated in the bile and then reabsorbed, hence, enterohepatic circulation 
ensues. During this time the drug is progressively deacylated into its 
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microbiologically active metabolite, 25-desacetyl rifampicin which is less 
absorbable as compared to the parent drug (Panchagnula et al., 1999). 
 
2.2.3 Combination treatment 
 
In the decades preceding 1980, rates of TB declined globally. After the appearance 
of HIV, however, rates in many countries increased markedly and now, the two 
epidemics are catastrophically intertwined (Myers et al., 2008). TB is a leading 
cause of death among people who are HIV-positive. There are an estimated 11.5 
million people co-infected with HIV and TB (Sehu et al., 2008). A patient who is 
HIV-positive and infected with TB bacilli is many times more likely to become 
sick with TB than someone infected with TB bacilli who is HIV-negative. Current 
guidelines recommend treatment of TB and HIV co-infection with antiretroviral 
combinations containing NNRTI’s (WHO, 2006).  Of the two NNRTI drugs 
currently available, Efv is preferred as it is dosed once daily and is less 
hepatotoxic than the alternative. 
  How HIV infection alters Rif pharmacokinetics and any additional effects 
of introducing antiretroviral therapy have not been closely studied. In particular, 
the optimal dose of Rif for use in HIV-infected patients treated with Efv-
containing antiretroviral regimens has not been determined. If Rif levels were 
significantly affected by either HIV infection itself or concomitant exposure to 
Efv therapy then this may limit the effectiveness of Rif in TB therapy and increase 
the risk of development of multi-drug resistant TB, an increasing cause of 
morbidity and mortality in resource limited settings with evidence of spread 
within these populations (Gandhi et al., 2006) and the potential for spread to other 
countries, including Western Europe (Brennan-Benson, 2005). 
 Concurrent treatment of HIV and TB is complicated by drug interactions 
between Rif and antiretrovirals (Ramachandran et al., 2006) and it has been 
hypothesised that the pharmacokinetics of Rif are adversely affected when a 
patient is administered both drugs at the same time. In order to study whether the 
pharmacokinetics of Rif are adversely affected when a patient is also administered 
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Efv, a clinical study termed the SPhEAR study was initiated at the Mater Hospital, 
Dublin which required an analytical method capable of extraction, separation and 
determination of Efv and Rif (and also Rif’s metabolite dRif) simultaneously in 
plasma. 
 
2.2.4 Physiochemical properties of efavirenz and rifampicin 
 
Efv, a white to slightly pink crystalline powder, is a polar, slightly basic anti-HIV 
drug. It has a molecular weight of 315.7 g/mol (D’Avolio et al., 2010)  and a pKa 
of 10.2. It is practically insoluble in water but soluble in lower alcohols. The 
aqueous solubility increases as the pH increases above 9.0, consistent with the loss 
of the proton on the amine of the carbamate.  
 Rif, a red/orange powder has a molecular weight of 822.94 g/mol. Rif has 
two pKa values since it is a zwitterion – the pKa at 1.7 relates to the 4-hydroxy 
moiety and the pKa at 7.9 relates to the 3-piperazine nitrogen (Balbão et al.,  
2010).  It is very slightly soluble in water, freely soluble in chloroform and DMSO 
and soluble in ethyl acetate, methanol and tetrahydrofuran. Solubility in aqueous 
solutions is increased at acidic pH.   
 
2.2.5 Sample extraction/clean-up procedures for efavirenz and rifampicin 
 
In order to routinely determine drug concentrations in plasma, it is necessary to 
have an accurate, precise and selective analytical method, requiring a small 
sample volume complemented by rapid sample processing methods. The three 
main sample extraction techniques employed to extract drugs from biological 
fluids are liquid liquid extraction (LLE), protein precipitation (PP) and solid phase 
extraction (SPE). All three approaches have been used in the reported methods for 
Efv and Rif analysis as shown in Tables 2.1 and 2.2. 
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2.2.5.1 Sample extraction/clean-up procedures for efavirenz  
 
Efv has been successfully isolated from plasma using LLE, PP and SPE. LLE is 
by far the more popular mode of extraction for Efv. See Table 2.1. However, a 
number of these methods require large sample volumes of 0.5 mL or higher 
(Lakshmi Sailaja et al., 2007, Dailly et al.,  2004, Matthews et al., 2002, Proust et 
al., 2000), and LLE is a labour-intensive method which often does not lend itself 
easily to automation. Also recoveries vary between 78 and 101% (Lakshmi Sailaja 
et al., 2007, Dailly et al., 2004, Proust et al., 2000, Weller, 2007, Rouzes et al., 
2004). Matthews et al., 2002, and Ramachandran et al., 2006, both employed LLE 
and obtained recoveries between 89 and 101%. Matthews used a mixture of 
dichloromethane and hexane to extract Efv from 0.5 mL plasma. The procedure 
involved a number of steps and a large quantity of extraction solvent (8 mL) but 
analyte recovery was high, greater than 89% at all points on the standard curve. 
Ramachandran used ethyl acetate for the extraction in a much simpler procedure 
which involved 0.25 mL plasma and also preconcentrated the sample by a factor 
of five. The average recovery of Efv from plasma using this extraction procedure 
was 101%. 
 PP has also been successful for Efv’s extraction. In comparison to LLE the 
sample volumes required are much lower, in the region of 50 – 100 μL (D’Avolio 
et al,. 2010, Mogatle et al., 2009, Kappelhoff et al.,  2003, Volosov et al., 2002) 
and in one case 250 μL (Veldkamp et al., 1999) and the recoveries obtained are 
high (85 – 110%).  Veldkamp et al., 1999, utilised PP to extract Efv from plasma. 
Precipitation was achieved by mixing 0.25 mL plasma with acetonitrile. Recovery 
of Efv was 106%. Efv has also been extracted from serum using PP. Dogan-Topal 
et al., 2007, achieved excellent recovery of Efv (99.9-100.3%) but the method 
required a 1 mL serum volume for the extraction.  
 All reported SPE methods for the extraction of Efv from plasma require 
plasma volumes of 500 μL or higher (Matthews et al., 2002, Notari et al., 2006, 
Rezk et al., 2004, Rezk et al., 2002) and up to 1 mL in Rentsch's et al., 2003, case. 
The only SPE method which required a smaller sample volume was Sarasa-
63 
 
Nacenta et al., 2001, with 300 μL plasma. However, recovery was much lower 
than the other SPE methods at 83% in comparison to greater than 90% in all the 
other SPE methods reported. Sarasa-Nacenta et al., 2001, developed an SPE 
method for the determination of Efv in human plasma. SPE was performed using 
Oasis SPE cartridges (30 mg) which were conditioned with methanol and water, 
loaded with 0.3 mL plasma followed by a water aliquot and then washed with 
50% aqueous methanol. Efv was eluted with methanol, dried down and 
reconstituted with 0.1 mL of mobile phase, preconcentraing the sample by a factor 
of three.  
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Reference Analytes Matrix Extraction mode 
Extraction 
recoveries 
(%) 
Detection 
Approx 
retention 
time 
(min)
LOQ/ 
LOD Column 
Sample 
vol. 
(μL) 
          
(D’Avolio et 
al., 2010) 
Efv and 
other 
drugs 
Dried 
plasma spots 
on glass 
filter 
n/a >85.0 MS ~16.9 31.2 
ng/mL 
LOQ 
Atlantis T3 
C18 
Not 
stated 
(Martin et al., 
2009) 
Efv and 
other 
drugs 
Human 
plasma 
PP & on-
line SPE 
75-98 MS 1.9 100 
ng/mL 
LOQ 
LUNA 
Phenyl 
Hexyl 
Not 
stated 
(Mogatle et al., 
2009) 
Efv Human 
plasma 
PP 92.7-94.1 UV ~8 200 
ng/mL 
LLOQ
LUNA C18 100
(D’Avolio et 
al., 2007) 
Efv and 
other 
drugs 
Human 
plasma 
PP 93-110 MS 16.7 31.2 
ng/mL 
LOQ 
Atlantis 
dC-18 
50
(Dogan-Topal 
et al., 2007) 
Efv and 
other 
drugs 
Human 
serum 
PP 99.9-100.3 UV 11.6 8.96 
ng/mL 
LOQ 
Spherisorb 1000
(Lakshmi 
Sailaja et al., 
2007) 
Efv Human 
plasma 
LLE >78.0 UV 6.5 200 
ng/mL
Zorbax C18 1000
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(Weller et al., 
2007) 
Efv and 
other 
drugs 
Human 
plasma 
LLE 83.6-84.4 UV 15 50 
ng/mL
Octyl C8 200
(Choi et al., 
2007) 
Efv and 
other 
drugs 
Human 
plasma 
LLE >89.0 UV 23.7 10 
ng/mL 
LLOQ
Zorbax C18 200
(Ramachandran 
et al., 2006) 
Efv Human 
plasma 
LLE 101 UV 6.2 50 
ng/mL
Lichrospher 
C18 
250
(Notari et al., 
2006) 
Efv and 
other 
drugs 
Human 
plasma 
SPE 89.7-121.5 UV 28.4 100 
ng/mL
C18 
Symmetry 
600
(Rezk et al., 
2004) 
Efv and 
other 
drugs 
Human 
plasma 
SPE >90.0 UV 24.9 10 
ng/mL
Zorbax C18 550
(Rouzes et al., 
2004) 
Efv and 
other 
drugs 
Human 
peripheral 
blood 
mononuclear 
cells 
LLE 88.6 MS 8.3 2 ng/3 
x 
10^6 
cells 
X-Terra 
MS C18 
Not 
stated 
(Dailly et al., 
2004) 
Efv and 
other 
drugs 
Human 
plasma 
LLE 80 UV 16.1 100 
ng/mL
Symmetry 
C18 
1000
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(Kappelhoff et 
al., 2003) 
Efv and 
Nevirapine
Human 
plasma 
PP 85.0-96.6 UV 7.8 50 
ng/mL
Zorbax 
Extend C18
100
(Rentsch et al., 
2003) 
Efv and 
other 
drugs 
Human 
plasma 
SPE 96-6-97.9 MS 16.3 10 
ng/mL 
LOQ 
Nucleosil 
C18 HD 
1000
(Turner et al., 
2003) 
Efv and 
other 
drugs 
Human 
plasma 
LLE 90.7 UV 24.2 50 
ng/mL
Supelguard 
Discovery 
C8 
200
(Matthews et 
al., 2002) 
Efv and 
other 
drugs 
Human 
plasma 
LLE >89.0 Fluorescence 5 50 
ng/mL
BDS 
Hypersil 
500
(Volosov et al.,  
2002) 
Efv and 
other 
drugs 
Human 
plasma 
PP Not stated MS 4.5 min 
runtime 
10 
ng/mL
Supelco 
LC-18-DB 
80
(Rezk et al., 
2002) 
Efv Human 
plasma 
SPE >99.6 UV 22.5 10 
ng/mL
Eclipse 
XDB C8 
500
(Langmann et 
al., 2001) 
Efv Human 
plasma 
LLE 96.2 ±  3 UV 10.9 25 
ng/mL
Xterra RP 
18 
Not 
stated 
(Sarasa-
Nacenta et al., 
2001) 
Efv Human 
plasma 
SPE 83 UV 6.9 100 
ng/mL
Supelcosil 
LC8 
300
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(Aymard et al., 
2000) 
Efv and 
other 
drugs 
Human 
plasma 
SLE 97.2 ±  2.7 UV 15.2 50 
ng/mL
Symmetry 
C18 
1000
(Proust et al., 
2000) 
Efv and 
other 
drugs 
Human 
plasma 
LLE 83.8 UV 28.6 75 
ng/mL
Licrospher 
100-RP-18 
500
(Veldkamp et 
al., 1999) 
Efv Human 
plasma 
PP 106.4 UV 10.2 10 
ng/mL
Zorbax SB 
C18 
250
(Marzolini et 
al., 2000) 
Efv and 
other 
drugs 
Human 
plasma 
SPE 89.0-98.0 UV 28.7 250 
ng/mL
ChromCart 
filled with 
Nucleosil 
100 
600
 
Table 2.1: Summary of the characteristics of reported extraction and LC detection techniques for the determination Efv from biological samples 
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Reference Analytes Matrix Extraction mode 
Extraction 
recoveries 
(%) 
Detection 
Approx 
retention 
time 
(min)
LOQ/LOD Column 
Sample 
vol. 
(μL) 
                
(Gikas et al., 
2010) 
Rif, 
daptomycin 
and IS 
Rabbit 
plasma 
PP 97.3-102.0 UPLC-UV 2.1 2 μg/mL Acquity 
BEH C18 
25
(Balbão et 
al., 2010) 
Rif Human 
plasma 
Stir bar 
sorptive 
extraction 
75.0-80.0 UV 11 125 ng/mL LiChrocart 
100 RP-8 
200
(de Velde et 
al., 2009) 
dRif, Rif 
and other 
drugs 
Human 
plasma 
PP dRif: 
104.1-
116.9 Rif: 
101.3-
109.4 
MS dRif: 2.3 
Rif: 2.45 
200 ng/mL 
LLOQ 
HyPurity 
Acquastar 
C18 
10
(Fernández-
Torres et al., 
2008) 
Rif Mouse 
plasma 
PP 85.6-96.4 UV ~7.9 1.46 
μg/mL 
LOQ 
Lichrosphere 
100 RP-18 
50
(Song et al., 
2007) 
Rif and 
other drugs 
Human 
serum 
PP 94.8 MS 3.4 50 ng/mL Hydrosphere 
C18 
50
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(Hartkoorn et 
al., 2007) 
Rif Human 
cells 
and 
plasma 
PP Plasma -85-
95 Cells - 
51.73 
MS 1.1 100 ng/mL Betasil 
Phenyl-
Hexyl 
50
(Allanson et 
al., 2007) 
Rif Human  
plasma 
and 
blood 
spots 
SPE Plasma 
84.5  Blood 
spots 65.0 
UV 10.9 Plasma: 
500 ng/mL 
Blood 
spots: 1.5 
μg/mL 
Kromasil 
C18 
450
(Unsalan et 
al., 2005) 
Rif and 
other drugs 
Human 
plasma 
PP 94.6 UV 10.2 700 ng/mL Nova Pak 
C18 
100
( Hemanth 
Kumar et al., 
2004) 
Rif and 
dRif 
Human 
plasma 
and 
urine 
PP dRif: 90.0-
113.0 Rif: 
100.0-
104.0 
UV dRif: 2.9 
Rif:  4..8 
Plasma: 
250 ng/mL 
Urine: 2.5 
μg/mL 
LUNA C18 Plasma: 
200  
Urine: 
2000 
(Calleja et 
al., 2004) 
Rif Rat 
Plasma 
and 
liver 
LLE Liver: 91.0 
Plasma: 
83.0 
UV 4 Plasma: 50 
ng/mL  
Liver: 250 
ng/g 
Ultrabase-
C18 
Plasma: 
100 
Liver: 
0.5g 
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(Panchagnula 
et al., 1999) 
Rif and 
dRif 
Human 
plasma 
and 
urine
LLE Plasma 
dRif:79.1 
Rif: 91.7 
UV dRif: 3.0 
Rif: 6.0 
2 μg/mL Nova Pak 
C18 
100
(Yau Yi Lau 
et al., 1996) 
Rif Human 
plasma 
SPE 97 UV 4.4 50 ng/mL 
LOQ 
Zorbax Rx 
C8 
500
 
Table 2.2: Summary of the characteristics of reported extraction and LC detection techniques for the determination of Rif and dRif from 
biological samples 
 
Reference Analytes Matrix Extraction mode 
Extraction 
recoveries 
(%) 
Detection 
Approx 
retention 
time (min)
LOQ/LOD Column 
Sample 
vol. 
(μL) 
                
(Boffito et 
al., 2002) 
Rif and 
Efv 
Human 
plasma 
LLE Rif: 70 ± 6 
Efv: 98 ± 1 
UV Rif: 4.3  
Efv: 13.1 
50 ng/mL 
LOD 
Phenomenex 
Reverse 
Phase Luna 
200
 
Table 2.3: Summary of the characteristics of reported extraction and LC detection techniques for the simultaneous determination of Efv, Rif and 
dRif from biological samples
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2.2.5.2 Sample extraction/clean-up procedures for rifampicin 
 
Rif has also been successfully isolated from plasma using LLE, PP and SPE. 
From the literature, PP appears to be the most common approach used for the 
extraction of Rif from both plasma (Hartkoorn et al., 2007, Gikas et al., 2010, 
de Velde et al., 2009, Fernández-Torres et al., 2008, Unsalan et al., 2005) and 
serum (Song et al., 2007). Recoveries obtained for Rif using this approach 
were high (84.5% or greater) and required small sample volumes (0.2 mL or 
less).  
Both Unsalan et al., 2005, and Hartkoorn et al., 2007, employed ACN 
for protein precipitation. Unsalan, using 100 μL plasma sample, required a 
very long evaporation step at room temperature for two days. However, 
recoveries were in the range of 92–111%. Hartkoorn used 50 μL of sample and 
achieved 92% recovery of Rif from plasma. Song et al., 2007, used PP for the 
extraction of Rif from serum. Only a small volume of serum (50 µL) was 
required and protein precipitation was achieved using methanol. The recovery 
of Rif in this case was 95%. De Velde et al., 2009, required only 10 μL plasma 
for the precipitation. The most recent PP used for the extraction of Rif was 
Gikas et al., 2010. Rif was extracted from 25 μL rabbit plasma using a mixture 
of ethanol and acetonitrile. Recoveries were high at 97-102% 
Both Panchagnula et al., 1999, and Calleja et al., 2004, used LLE for 
the extraction of Rif from plasma. Both required small sample volumes, with 
relatively high recoveries. Panchagnula used 95 μL of plasma spiked with Rif 
which was extracted with 500 μL of methanol. After centrifugation, 300 μL of 
supernatant was vacuum dried and the residue was reconstituted in 100 μL of 
mobile phase. Recoveries for drug were greater than 90% in plasma. Calleja 
used LLE to extract Rif from rat plasma. Dichloromethane and n-pentane was 
used for the extraction from 100 μL rat plasma. Recoveries averaged at 83% 
for Rif’s extraction from plasma. 
Allanson et al., 2007, and Yau Yi Lau et al., 1996, used SPE to extract 
Rif from plasma. Allanson used Strata-X-CW solid phase extraction cartridges, 
which were firstly washed with methanol and water before loading. Plasma 
was diluted 1:1 with ammonium acetate (25 mM). Interfering substances were 
washed away with ammonium acetate and Rif was eluted with methanolic 
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ammonia. Samples were dried down and reconstituted in 200 μL acetonitrile-
water (1:4, v/v). The recovery of Rif from plasma was 85%.  
Yau Yi Lau used 1 mL of blank human plasma spiked with Rifabutin. C 
8 Bond Elut extraction columns were conditioned with methanol, followed by 
water. The plasma mixture was loaded onto the column and the column was 
washed with water. The analytes were eluted with methanol. Recoveries were 
high at 97%.  
 Balbão et al., 2010,  recently used stir bar sorptive extraction using 200 
μL plasma and dichloromethane to extract Rif. In comparison to the other 
approaches used for the extraction of Rif, the recoveries were low, 75-80%. 
 
2.2.5.3 Sample extraction/clean-up procedures for efavirenz and rifampicin 
simultaneously 
 
Reported methods for the individual extraction of Rif and Efv have been very 
successful. The only reported method for the determination of Rif and Efv 
simultaneously was achieved by Boffito et al., 2002. LLE was used for the 
simultaneous extraction of Rif and Efv from plasma. Extraction was achieved 
using ethyl acetate and n-hexane with a plasma sample volume of 200 μL. The 
recovery of Rif was 70% and Efv was 98%. 
 
2.2.6 Sample separation and detection approaches for efavirenz and 
rifampicin 
 
Various methods of separation and detection have been applied for the 
determination of Efv and Rif as can be seen in Table 2.1 and 2.2. 
 
2.2.6.1  Sample separation and detection approaches for efavirenz  
 
UV is by far the most reported detection approach for the analysis of Efv in the 
literature. In comparison to the MS methods reported for Efv, the sensitivity 
for Efv using UV is quite comparable and at times better with that achieved 
using MS. Dogan-Topal et al., 2007, Choi et al., 2007, and Rezk et al., 2004, 
each achieved extremely good sensitivity using UV to detect Efv.  Dogan-
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Topal achieved a very low limit of quantitation (LOQ) of just 9 ng/mL using 
this form of detection. However, the method required a large sample volume of 
1 mL serum in order to achieve this sensitivity. Also, Efv had a lengthy 
retention time of 11.6 mins. Choi achieved an LOQ of 10 ng/mL, again 
excellent for UV. The sample volume required was low at only 0.2 mL plasma 
but the method suffered from an extremely long retention time of 23.7 mins for 
Efv. Rezk also achieved an LOQ of 10 ng/mL for Efv. Again, sample volume 
was high at 0.55 mL plasma and the retention time of Efv long at 24.9 mins. 
Veldkamp et al., 1999, reported an LOQ of 10 ng/mL with a relatively small 
sample volume of 0.25 mL plasma and a retention time of 10.2 mins for Efv. 
Marzolini et al., 2000, Proust et al., 2000, Aymard et al., 2000 and Notari et 
al., 2006, each used UV for the detection of Efv. However, large sample 
volumes and long elution times for Efv were required in all cases. Notari 
achieved an LOQ of 100 ng/mL, however, 0.6 mL plasma was required and the 
resultant retention time for Efv was 28.4 mins. Aymard required 1 mL plasma 
for the extraction of Efv and a retention time of 15.2 mins resulted for Efv with 
an LOQ of 50 ng/mL. Proust used 0.5 mL plasma and gave a retention time of 
28.6 mins but achieved an LOQ of 75 ng/mL. Marzoloni required 0.6 mL 
plasma which achieved a LOQ of 250 ng/mL but a retention time of 28.7 mins 
resulted. Dailly et al., 2004, suffered from similar problems. Even though an 
LOQ of 100 ng/mL was obtained, a 1 mL plasma volume was required and a 
retention time of 16.1 mins was needed to elute Efv. Lakshmi Sailaja et al., 
2007, achieved a fast retention time of 6.2 mins for Efv and a reasonable LOQ 
of 200 ng/mL but the major disadvantage of this method was that it needed 1 
mL plasma to achieve these results. 
A 50 ng/mL LOQ was obtained by both Weller et al., 2007, and Turner 
et al., 2003, using C8 columns. Both required sample volumes of only 0.2 mL 
plasma however the retention for Efv was relatively long at 15 mins for Weller 
and 24.2 mins for Turner. 
Ramachandran et al., 2006, Kappelhoff et al., 2003, and Veldkamp et 
al., 1999, were quite successful in their determination of Efv using UV. 
Ramachandran achieved an LOQ of 50 ng/mL which required only 0.25 mL 
plasma and retention time was fast at 6.2 mins for Efv. Kappelhoff also 
achieved an LOQ of 50 ng/mL, required a smaller sample volume of just 0.1 
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mL and a short retention time of 7.8 mins. Veldkamp achieved an LOQ of just 
10 ng/mL using just 0.25 mL plasma and Efv eluted at 10.2 mins which is quite 
a good result. Mogatle et al., 2009, and Sarasa-Nacenta et al., 2001, both had 
reasonably short runtimes and small sample volumes. Mogatle required only 
0.1 mL sample volume and achieved an LOQ of 200 ng/mL with a retention 
time of 8 mins for Efv. Sarasa-Nacenta achieved a retention time of 6.9 mins 
for Efv using 0.3 mL plasma which resulted in an LOQ of 100 ng/mL.  
D’Avolio et al., 2010,  describes the most recently used MS method for 
the detection of Efv using a C18 column. The method can detect Efv down to 
31 ng/mL but Efv took 16.9 mins to elute. Martin et al., 2009, described a MS 
method in which Efv was separated using a phenyl column which resulted in 
an extremely short retention time of just 1.9 mins but the method lacked 
sensitivity with an LOQ of just 100 ng/mL. Rentsch et al., 2003, obtained an 
LOQ of 10 ng/mL using MS but again Efv had a high retention time of 16.3 
mins using a C18 column. Volosov et al., 2002, use MS for Efv’s detection and 
achieved an LOQ of 10 ng/mL with a short runtime of just 4.5 mins.  
Matthews et al., 2002, developed a HPLC method with post-column 
photochemical derivatisation and fluorescence detection for the determination 
of Efv and its enantiomer in plasma. Once the drugs had been extracted from 
the plasma matrix they were separated on a YMC-Pack C8 analytical column. 
The LOQ achieved was 50 ng/mL; however, 0.5 mL plasma was required. 
 
2.2.6.2 Sample separation and detection approaches for rifampicin 
 
For the determination of Rif, UV is again the predominant method used in the 
literature. Some of the methods suffer from poor sensitivity including Gikas et 
al., 2010, Fernández-Torres et al., 2008, and Panchagnula et al., 1999. 
Panchagnula used a mobile phase composed of sodium phosphate and 
methanol which, at a flow rate of 1 mL/min had an overall run time of 17 mins 
and eluted Rif at 6 mins. The resultant LOQ was 2 μg/mL which was poor but 
the method only required 0.1 mL plasma for the extraction of Rif.  Fernández-
Torrres achieved an LOQ of 1.46 μg/mL which again was not very low, but 
sample volume was low at only 50 μL. Rif eluted at 7.9 mins. Gikas reported 
the most recent UV method in which μHPLC was used for Rif’s determination. 
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As expected, the elution time for Rif was fast at 2.1 mins, however, the 
sensitivity was poor at 2 μg/mL. On the plus side, only 25 μL rabbit plasma 
was required. 
 Some of the reported UV methods have good sensitivity but suffer from 
a long runtime and/or large sample volumes. Balbão et al., 2010,  using 0.2 mL 
plasma achieved an LOQ of 125 ng/mL with Rif eluting at 11 mins. Allanson 
et al., 2007, achieved an LOQ of 500 ng/mL but the method required 0.45 mL 
plasma. The method was carried out at ambient temperature using a mobile 
phase of ammonium acetate and acetonitrile delivered at 0.7 mL/min on a 
gradient programme over 18 mins with Rif eluting at 10.9 mins. Unsalan et al., 
2003, achieved an LOQ of 700 ng/mL with the method only requiring 0.1 mL 
plasma. Gradient elution was achieved by using potassium dihydrogen 
phosphate and acetonitrile. A flow rate of 0.8 mL/min was used. Overall 
runtime was 20 mins with Rif eluting at 10.2 mins. Calleja et al., 2004,  
achieved separation with a mobile phase composed of water and acetonitrile 
run at a flow-rate of 1 mL/min. LOQ from plasma was good at 0.05 μg /mL 
and Rif eluted at 4 mins.  
 Hartkoorn et al., 2007, Song et al., 2007, and de Velde et al., 2009, 
developed LC-MS methods for the determination of Rif. Sample volumes were 
low, retention times fast, but good sensitivity was difficult to achieve. 
Hartkoorn achieved separation on a Betasil Phenyl-Hexyl column using an 
isocratic mobile phase composed of ammonium acetate and acetonitrile at a 
flow rate of 0.4 mL/min. Mass spectral analysis for Rif was carried out using 
electrospray ionisation (ESI) in the positive ion mode with a capillary 
temperature of 250 °C. The LOQ was found to be 100 ng/mL using only 50 uL 
plasma. Song developed a HPLC/tandem MS method for the determination of 
first-line anti-TB drugs (including Rif) and their major metabolites. Samples 
were analysed using a Hydrosphere C18 column. The mobile phase was a 
gradient of a mixture of methanol and water. Chromatographic separation was 
performed at room temperature for 4 min. Using a Quattro Micro tandem mass 
spectrometer, quantification was achieved by multiple reaction monitoring 
(MRM) in positive ion mode. The LOQ obtained was 50 ng/mL with again 
only 50 μL serum required. DeVelde required only 10 μL plasma for the 
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extraction of Rif, however an LOQ of 200 ng/mL was all that could be 
achieved. 
 
2.2.6.3 Sample separation and detection approaches for efavirenz and 
rifampicin simultaneously 
 
Because both Efv and Rif are used together in HIV/TB applications, it makes 
sense to simultaneously quantitate both drugs. Boffito et al., 2002, developed 
an LC-UV method for the simultaneous determination of Rif and Efv. 
Separation was achieved on a reversed phase Luna 5 µm column. The mobile 
phase consisted of sodium phosphate buffer, acetonitrile and methanol run at a 
flowrate of 1.0 mL/min using a gradient. The UV detector was operated at a 
wavelength of 254 nm. This one reported method for the simultaneous 
determination of Efv and Rif exhibits good sensitivity (LOD 0.05 μg/mL) but 
suffers from a relatively long analysis time (15 mins). See Table 2.3. Boffito, 
however, did not measure Rif’s main metabolite, dRif in the assay they 
developed. It is important to measure Rif as well as dRif because dRif has an 
antimycobacterial activity closely similar to Rif (Hemanth Kumar et al., 2004). 
A method capable of quantifying the metabolism of Rif into its main 
metabolite dRif in the presence of Efv was required. Developing such a method 
was both novel and analytically important. 
Rif (and its metabolite, dRif) and Efv exhibit very different 
physiochemical properties, and so developing a simple, low cost assay to 
detect all three within a clinically relevant concentration range using standard 
chromatography equipment proved extremely challenging. Choice of column, 
mobile phase composition and pH, along with choice of detection and sample 
extraction technique proved vital to the overall success of the assay.  
 
2.3 Experimental 
 
2.3.1 Reagents and materials 
 
HPLC grade acetonitrile (ACN), methanol (MeOH) and water were purchased 
from Sigma-Aldrich. Ammonium acetate, formic acid and acetic acid, all 
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analytical grade, were obtained from Sigma-Aldrich, United Kingdom. Drug-
free sterile filtered human plasma (EDTA k3) was purchased from Europa 
Bioproducts, United Kingdom. Efv and Rif and Rif’s metabolite, dRif were 
purchased from Sequoia Research Products Ltd. United Kingdom. Strata X (33 
μ) SPE cartridges were from Phenomenex, Ireland and Supelco Discovery SPE 
cartridges (Phenyl, C18, 18LT, C8, and CN) were from Sigma Aldrich, United 
Kingdom. Extraction cartridges and plates (SPE, LLE and PP) were purchased 
from Biotage, Sweden. Analytical columns came from Agilent. 
 
2.3.2 Equipment and HPLC assay conditions 
 
The HPLC system consisted of a 1050 series quaternary pump, 1100 series 
autosampler, a diode array detector (DAD) and a 1200 series degasser, all from 
Agilent, United Kingdom. System management and data acquisition were 
performed by the Agilent Chemstation for LC 3D software. Other 
instrumentation employed included a pH meter and electronic mass balance 
both from a Mettler Toledo, USA and a Genevac EZ-2 series personal 
evaporator from Ipswich, United Kingdom. The VacMaster-96 sample 
processing manifold was sourced from Biotage, Sweden.  
 Analytical columns used were Agilent Zorbax SB-C18 (150 x 4.6 mm, 
5 μm), Varian Pursuit C18 (150 x 4.6 mm, 5 μm), Varian Polaris C18 (150 x 
4.6 mm, 5 μm) from Agilent, United Kingdom, and Agilent Zorbax SB Phenyl, 
(150 x 4.6 mm, 5 μm) from Phenomenex, United Kingdom.  The HPLC 
mobile phase consisted of ammonium acetate (pH 4.75, adjusted with 1 M 
acetic acid, 20 mM), ACN and MeOH (40:45:15, v/v/v). A diode array UV 
detector was employed which monitored Efv at 246 nm and Rif and dRif at 
334 nm. The overall runtime was 10 min and the flow rate was 0.8 mL/min at 
ambient temperature.  
 
2.3.3 Preparation of standards 
 
Stock standard solutions of Efv, Rif and dRif were prepared by weighing out 
the powders in a glovebox, dissolving them in ACN to 1 mg/mL concentration 
and storing them in amber vials at 2-4 °C in the dark. Working standards of 
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Efv, Rif and dRif were prepared both in drug-free human plasma and in mobile 
phase (ammonium acetate (pH 4.75, adjusted with 1 M acetic acid, 20 mM), 
ACN and MeOH (40:45:15, v/v/v)) to concentrations over the range 0.1–
20 μg/mL (0.1, 0.5, 1, 5, 10 and 20 μg/mL in plasma which corresponded to 
0.2, 1, 2, 10, 20 and 40 μg/mL in MP) . This range of the standard curve was 
chosen to reflect the plasma concentrations expected in a typical 12 hr 
pharmacokinetic profile post administration of Rif: 0-10 μg/mL (Hartkoorn et 
al., 2007, Yau Yi Lau et al., 1996) Efv: 0-20 μg/mL (Ramachandran et al., 
2006, Mogatle et al., 2009) and both (Boffito et al., 2002). 
A 0.3 mL aliquot of each of the working standards was diluted 1:1 (v:v) 
with a 1% formic acid solution in water. The SPE Evolute Array Wells (25 mg 
ABN, 1 mL) in the 96 well plate sample processing manifold were conditioned 
with 1 mL MeOH and then equilibrated with 1 mL of the 0.1% formic acid 
solution. A 0.6 mL aliquot of the diluted, acidified sample was loaded onto the 
well, washed with 20% MeOH in water and eluted with a water (1 mg/mL 
ascorbic acid)-ACN-MeOH mixture (25:50:25, v/v/v). The samples were 
evaporated to dryness and reconstituted with 150 μL HPLC mobile phase 
(ammonium acetate (pH 4.75, adjusted with 1 M acetic acid, 20 mM), ACN 
and MeOH (40:45:15, v/v/v)). The overall clean-up process resulted in the 
diluted plasma sample being concentrated by a factor of four which equated to 
an overall enrichment factor of two for the neat plasma. The reconstituted 
sample was then transferred to an autosampler vial (with insert) and 20 μL was 
injected into the HPLC system for analysis. 
 
2.3.4 Preparation of patient samples 
 
Blood samples from eleven patients participating in the SPhEAR project were 
obtained by informed consent in the Infectious Disease Department at the 
Mater Hospital, Dublin, Ireland. The methodology of this study was approved 
by the Ethics committee of the Mater Misericordiae Hospital. Bloods samples 
were taken after at least three weeks on therapy to ensure steady state. Patients 
were administered a 600 mg dose of Rif. Samples were drawn at 8 different 
time points over 10 hours. The first sample was taken fasting with a set meal 
provided for all study participants. Blood samples were taken in EDTA 
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preservative which were then centrifuged in a chilled centrifuge and the plasma 
kept frozen at -80 ºC until analysis. A 0.3 mL aliquot of each patient sample 
was extracted using the same procedure described above for the working 
standards. Samples were taken and prepared in duplicate. 
 
2.3.5 Method validation  
 
The fundamental parameters for a bioanalytical method validation are 
accuracy, precision, selectivity, sensitivity and stability. Measurements for 
each analyte in the biological matrix were validated according to FDA 
guidelines (FDA, 2001). 
 
2.4 Results and discussion 
 
2.4.1 Method development 
 
Taking a methodical approach to method development is important. 
Knowledge of the chemistry, structure and solubility of the drugs prior to 
choosing the column, mobile phase and monitoring wavelength was essential. 
The choice of the sample preparation step is also imperative to the success of 
the protocol. It was vital that any methodology developed was better than the 
current state-of-the-art, had novelty, context and application. 
 Assay development for this project was challenging due to the very 
different physiochemical natures of the two drugs (affecting hydrophobicity, 
solubility, acidity) and so designing one fast on-line assay for both drugs was a 
difficult task.  
 
2.4.2 Chromatographic procedure 
 
The heart of a HPLC system is the column. Choosing the right column for this 
assay required consideration of stationary phase chemistry, retention capacity, 
particle size, and column dimensions. Identifying the best stationary phase for 
the separation was a critical step of column selection, and was based on the 
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general chemical principle that “likes dissolves like.” The choice of column 
was challenging due to the widely different polarities of Rif and Efv. A 
separation mechanism employing differences in the chemical structures of 
these analytes was required. As discussed in Chapter 1, in reversed phase 
chromatography, the stationary phase is non-polar and the mobile phase is 
polar. Analytes are attracted to the surface by their non-polar functional 
groups. The most polar analyte elutes from the reversed phase column first 
followed by other analytes in order of decreasing polarity. 
Reversed phase columns, both octadecylsilane (C18) and phenyl, were 
investigated as they work well for water-soluble hydrophobic compounds, see 
Figure 2.2.  
 
Figure 2.2: Reversed phase stationary phases (a) C18 and (b) phenyl 
 
Alkyl phases such as C18 and C8 are best suited for analysing neutral 
compounds with a high ratio of carbon:heteroatoms where the major distinction 
among analytes is their hydrophobicity. C18 is the most popular reversed phase 
in HPLC and so was the stationary phase we chose to primarily investigate. 
An Agilent Zorbax SB-C18 (150 x 4.6 mm, 5 μm) column resulted in 
poor peak shape for Efv, even under different pH conditions, see Figure 2.3, so 
it was deemed unsuitable for the analysis. See Table 2.4.  
(a) (b) 
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Figure 2.3: Chromatogram of a working standard of Efv using an Agilent Zorbax SB-C18 column 
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Table 2.4: Comparison of different mobile phase pH values for Rif and Efv 
using an Agilent Zorbax SB-C18 column  
 
Both Varian Pursuit C18 (150 x 4.6 mm, 5 μm) and Varian Polaris C18 
(150 x 4.6 mm, 5 μm) columns were also trialled. Better results were achieved 
with the Varian Polaris C18 column over the Varian Pursuit C18 column. 
Figure 2.4 shows a chromatogram of a working standard of Rif and Efv using 
the Varian Pursuit C18 column. Good separation was achieved but at the cost 
of a lengthy runtime. Again different pH conditions were tested but they 
yielded no improvement in peak shape or area counts. See Table 2.5. 
 
pH 
Rif  peak 
area 
Efv  peak 
area 
 
3 
4 
5 
 
 
Negligible 
254 
272 
 
591 
603 
598 
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Figure 2.4: Chromatogram of a working standard of Rif and Efv using a Varian pursuit column
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Table 2.5: Comparison of different mobile phase pH’s for Rif and Efv using 
Varian Polaris C18 Column 
 
 The three C18 columns were found to be unsuitable primarily due to the 
large difference in elution time between Efv and Rif. While C18 columns are 
effective for nonpolar analytes, these phases often do not provide the desired 
selectivity for other compounds. In such cases, phenyl columns are the primary 
alternative to alkyl phases and so this column chemistry was also investigated. 
Phenyl columns possess useful selectivity for compounds containing phenyl 
type moieties and so it was postulated that these might be a good alternative to 
C18 for Rif and Efv. The unique selectivity for the phenyl phase is derived 
from an interaction of the pi electrons found in the phenyl groups and is 
therefore useful for the analysis of aromatic-containing compounds.  
An Agilent Zorbax SB Phenyl (150 x 4.6 mm, 5 μm) column was found 
to give the best chromatographic results in terms of good separation and fast 
runtime. Phenyl columns offer unique selectivity from the alkyl phases and are 
generally less retentive than the C18 phase. Figure 2.5 shows the separation of 
both drugs on the Varian Polaris C18 column versus the Agilent Zorbax SB 
Phenyl, column. It was clear that the phenyl column offered a more efficient 
separation with less lag time between both peaks.  
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Figure 2.5: Chromatogram of a working standard of Efv and Rif prepared to 10 
μg/mL in mobile phase comparing (a) the Varian Polaris C18 column and (b) 
the Agilent Zorbax SB Phenyl column 
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 Though choice of column has the greatest effect on resolution, mobile 
phase also effects selectivity and efficiency and is the aspect of 
chromatography over which analysts have the most control. In reverse phase 
chromatography, mobile phase consists of an aqueous buffer and a non-UV 
active water miscible organic solvent. The effect of the organic and aqueous 
phase and the proportions in which they are mixed are discussed in this section. 
Common organic solvents in reverse phase chromatography are methanol and 
acetonitrile. The selection of mobile phase composition and pH in this work 
required extensive optimisation due to the sensitivity of Rif in particular to 
small changes in percentage of organic modifier and pH of the mobile phase. 
As the degree of solubility of the components varies independently in different 
solvents, the choice of organic solvent can affect selectivity and therefore 
resolution. Acetonitrile is a highly polar aprotic solvent, providing adequate 
resolution for many compounds. Due to its ability to form hydrogen bonds, the 
use of methanol as the organic phase can provide significantly different 
selectivity. Selectivity is also greatly affected by amount of aqueous solution in 
the mobile phase, with higher percentages of aqueous phase leading to 
increased retention and frequently to improved selectivity. It was found 
necessary to use a ternary mixture of mobile phase containing water and the 
two organic solvents - ACN and MeOH in order to achieve a fast runtime and 
the sensitivity required. Figure 2.6 shows some of the combinations of water, 
acetonitrile and methanol used. Ascorbic acid was required for the assay and its 
addition is discussed in more detail in section 2.4.4. 
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Figure 2.6: Chromatograms of a 10 μg/mL standard of ascorbic acid (AA), Efv 
and Rif prepared in mobile phase using various mobile phase compositions of 
H2O-ACN-MeOH (a) 35:50:20, v/v/v (b) 45:40:15, v/v/v and c) 40:45:15, 
v/v/v. 
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 In Table 2.6, a comparison of mobile phases investigated are shown 
using ammonium acetate (0.02 M) at ph 4.5 (using acetic acid). The flowrate 
was 1 mL/min. The optimal mixture was found to be H2O-ACN-MeOH; 
40:45:15, v/v/v, as shown in Figure 2.6 (c). Although, at first glance, Figure 
2.6 (a) appears to be the best (fastest) set of conditions, the endogenous plasma 
components coeluted with Rif so it was necessary to move the Rif peak away 
from the solvent front in order to accommodate these early-eluting peaks.  
 
Table 2.6: Comparison of different mobile phase compositions using 
ammonium acetate as buffer 
 
 Both pH and ionic strength of the aqueous portion of mobile phases are 
important parameters in developing analytical methods. The pH of the mobile 
phase can have an important role on the retention of an analyte and can change 
the selectivity of certain analytes. Method development proceeded by 
investigating chromatographic separations firstly at low pH and then at higher 
pH until optimum results were achieved. A thorough pH study revealed that the 
water component of the mobile phase should be 20 mM ammonium acetate, 
adjusted to pH 4.75 with acetic acid for optimal analyte response. See Table 
2.7. 
 
 
Mobile phase 
composition (H2O-
ACN-MeOH) 
Rif Efv 
Retention 
time (min) 
Peak area 
Retention 
time (min) 
Peak area 
 
35:50:15 
40:45:15 
40:35:25 
45:40:15 
 
2.2 
2.8 
3.0 
3.1 
 
800 
816 
708 
721 
 
3.9 
5.3 
5.2 
7.0 
 
1700 
2060 
1626 
1624 
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Table 2.7: Comparison of different mobile phase pH values using ammonium 
acetate as buffer 
 
 Different strengths of ammonium acetate were also looked at using pH 
4.75. Best results were achieved using 0.02 M. See Table 2.8. 
 
 
Table 2.8: Comparison of different ammonium acetate concentrations 
 
 Ammonium phosphate was also investigated using different mobile 
phase compositions (H2O-ACN-MeOH) to see if signal could be improved. See 
Table 2.9. 
 
Mobile phase pH 
Rif Efv 
Retention 
time (min) 
Peak 
area 
Retention 
time (min) 
Peak 
area 
 
4.5 
4.75 
5.0 
5.5 
 
2.9 
2.7 
2.5 
2.8 
 
816 
879 
785 
816 
 
5.5 
5.3 
4.8 
5.3 
 
1549 
1775 
1668 
1860 
Ammonium 
acetate conc. (M) 
Rif Efv 
Retention 
time (min) 
Peak 
area 
Retention 
time (min) 
Peak 
area 
 
0.01 
0.02 
0.04 
0.1 
 
2.5 
2.8 
2.6 
2.7 
 
676 
816 
724 
239 
 
5.0 
5.3 
4.9 
5.0 
 
1540 
2060 
1362 
326 
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Table 2.9: Comparison of different mobile phase compositions using 
ammonium phosphate as buffer 
 
 From the results it can be seen the peak area was slightly higher for Rif 
but significantly lower for Efv. It was decided best to use ammonium acetate as 
buffer mainly due to ease of transfer to a MS method at a later stage.  Flowrate 
was changed from 1 mL/min to 0.8 mL/min which gave higher peak area 
values for both drugs while increasing the retention times slightly. See Table 
2.10.  
 
Table 2.10: Comparison of different flowrates on Rif and Efv 
 
 
 
MP composition 
(H2O-ACN-
MeOH) using 0.01 
M ammonium 
phosphate 
Rif Efv 
Retention 
time (min) 
Peak area 
Retention 
time (min) 
Peak area 
 
30:55:15 
40:45:15 
35:40:25 
 
2.0 
2.4 
2.5 
 
795 
850 
826 
 
2.9 
4.8 
4.1 
 
1646 
1685 
1683 
Flowrate 
(mL/min) 
Rif Efv 
Retention 
time (min) 
Peak 
area 
Retention 
time (min) 
Peak 
area 
 
1.0 
0.8 
 
2.7 
3.1 
 
879 
970 
 
5.3 
6.1 
 
1775 
1934 
 
91 
 
2.4.3 UV detection 
 
As the circulating plasma concentrations of Rif and Efv, when co-administered 
to patients for the treatment of both HIV and TB infection, are high (1-20 
μg/mL) it was decided adoption of UV detection was likely to be sufficient as 
these levels are well within the range that UV can detect. The UV detector is 
also both simple to use and cost effective (employing low price equipment 
which is cheap to maintain and run) (Hartkoorn et al., 2007, Balbão et al., 
2010, Ramachandran et al., 2006, Mogatle et al., 2009, Boffito et al., 2002). 
Hence it is anticipated that adoption of such methodology in areas where there 
are high incidences of HIV infections, but limited laboratory budgets, such as 
sub-Saharan Africa, Eastern Europe and Asia would be more easily achieved.   
The λ max wavelength for Efv was 246 nm and for both Rif and dRif, 
238 nm and 334 nm gave highest absorption. See Figure 2.7. Under the final 
chromatographic conditions, the drugs were well separated with retention 
times for Efv, Rif and dRif of 6.1, 3.1 and 2.7 mins respectively. See Figure 
2.8. 
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Figure 2.7:  UV absorption spectra for Efv, Rif and dRif 
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Figure 2.8: Chromatogram of a working standard of Efv and Rif prepared to 10 μg/mL in mobile phase under the final chromatographic 
conditions  
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 334 nm was chosen as the monitoring wavelength for Rif and dRif as it 
is in a region of the UV spectrum that is typically more selective (nucleic acids 
and proteins absorb strongly up to 280 nm (Lam, 2004))  and also at 334 nm it 
is only slightly less sensitive than the maximum at 238 nm. See Figure 2.9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: Comparison of a 1 μg/mL Rif spiked plasma standard monitored at 
(a) 334 nm and (b) 238 nm  
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 For quantitation of analytes in biological samples, a usual procedure is 
to add an internal standard in the calibration samples and real samples. In this 
work, it was found that the results were sufficiently accurate and robust 
without an internal standard.  
In addition, any routinely available reagent which could act as an 
internal standard could not be identified and given the aim of having a 
reasonably uncomplicated broadly applicable analytical method (e.g. one 
which could be employed with limited infrastructure) the addition of an 
internal standard would increase the complexity of the study. This is in line 
with previous published attempts. 
 
2.4.4 Extraction procedure 
 
In today’s bioanalytical laboratory, reliable, high throughput sample 
preparation techniques are essential. For this work, sample preparation was 
ultimately achieved using the VacMaster-96 sample processing manifold from 
Biotage. The manifold can support SPE, LLE and PP clean-up of samples in 
cartridges and/or well plates. All three extraction approaches were investigated 
in order to find one that could be optimised for extraction of both Efv and Rif 
quickly and efficiently. The three sample extraction methods examined were:  
• supported liquid membrane extraction (SLE), a scaled-down version of 
 liquid liquid extraction (LLE) 
• protein precipitation (PP) 
• solid phase extraction (SPE) 
 
 The SLE plates claim to provide an easier alternative to LLE, with no 
off-line steps (e.g. mixing or centrifuging) required. Problems including 
emulsion formation and separation of liquid layers tend to be eliminated. 
Another big advantage is that the volumes of solvent required are very small. 
SLE uses columns or 96 well plates packed with an inert support material (a 
modified form of diatomaceous earth). When the aqueous sample is applied, it 
spreads over the surface of the support and is absorbed. The analytes remain on 
the surface of the support which forms the phase interface for the extraction. 
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When the organic solvent is applied, analytes are efficiently desorbed and the 
extract is collected. Various extraction solvents were evaluated along with 
different plasma load conditions. Best results in terms of recoveries were 
obtained when plasma was loaded 1:1 with ammonium hydroxide and 
extracted using DCM. See Table 2.11 for all SLE results. 
 
Extraction 
solvent 
 
% Recovery ± % RSD 
1:1; 
plasma: 
1% formic 
acid 
1:1; 
plasma: 
0.1% 
formic acid 
1:1; 
plasma: 
Water 
1:1; 
plasma: 
ammonium 
hydroxide 
 
t-BME 
 
 
DCM 
 
 
Ethyl acetate-
Hexane (80:20, 
v/v) 
 
Ethyl acetate 
 
 
Hexane 
 
 
DCM-APA 
(95:5, v/v) 
 
Rif: 
Efv: 
 
Rif: 
Efv: 
 
Rif: 
Efv: 
 
 
Rif: 
Efv: 
 
Rif: 
Efv: 
 
Rif: 
Efv: 
 
 
<10 
29.6 ± 8.6 
 
15.9 ± 4.0 
41.3 ± 3.6 
 
<10 
49.9 ± 0.9 
 
 
<10 
45.3 ± 2.1 
 
<10 
32.8 ± 3.0 
 
<10 
51.8 ± 5.3 
 
41.4 ± 6.0 
30.6 ± 7.1 
 
62.7 ± 1.9 
72.4 ± 2.8 
 
80.0 ± 3.4 
64.8 ± 1.2 
 
 
60.0 ± 2.7 
53.4 ± 1.8 
 
<10 
15.1 ± 8.3 
 
<10 
51.0 ± 4.8 
 
<10 
26.1 ± 5.6 
 
48.8 ± 4.1 
80.0 ± 2.9 
 
49.9 ± 2.9 
48.9 ± 1.6 
 
 
34.4 ± 9.5 
80.6 ± 5.1 
 
<10  
<10  
 
40.8 ± 2.0 
42.8 ± 3.2 
 
<10 
22.4 ± 5.1 
 
64.1 ± 4.3 
81.4 ± 6.2 
 
34.8 ± 4.1 
49.9 ± 1.5 
 
 
<10 
<10 
 
<10 
14.8 ± 5.3 
 
<10 
50.1 ± 1.5 
 
Table 2.11: Comparison of SLE using different load and extraction solvents for 
a 10 μg/mL standard 
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 PP was carried out in the 96 well format using a ‘solvent first’ 
approach. This claims to eliminate the need for time consuming vortex mixing 
or plate inversion and yield better recoveries when compared with ‘plasma 
first’ methods. PP by filtration in the 96 well format is a high throughput 
alternative to the traditional centrifugation based technique using collection 
plates. The functionalised bottom frit holds up organic precipitation solvent 
while plasma is added, maximising contact time and giving the most efficient 
precipitation effect. No vortex mixing is required. The filtrate does not pass 
into the collection plate until vacuum is applied.  
All three methods gave initial recoveries of greater than 64% for the 
extraction of both Efv and Rif individually at 10 µg/mL, but the extraction 
method which gave the best recoveries for both drugs combined was SPE - see 
Table 2.12. Rif, being highly lipid soluble, is widely distributed in tissues. In 
circulation, 89% of Rif is bound to plasma proteins. Efv is almost completely 
protein bound (> 99%), primarily to albumin. Taking this into consideration, 
the recoveries obtained are very good. 
 
 
 
 
 
 
 
 
 
 
Table 2.12: Comparison of initial sample preparation approaches (n=3) 
 
 Phenomenex Strata X 33 μ, polymeric reversed phase 30 mg/1mL and 
Supelco Discovery SPE, 100 mg/1mL tubes (Phenyl, C18, 18LT, C8, and CN) 
were also investigated. However, high recoveries were not achieved for the 
three drugs combined in comparison to those of the Evolute ABN SPE 
cartridges. The samples were also not as clean and so sensitivity was affected. 
See Table 2.13 for results.  
Sample  
preparation 
approach 
Recovery (%) ± % RSD 
Rif Efv 
 
SLE 
PP 
SPE 
 
64.1 ± 2.0 
76.3 ± 4.1 
65.1 ± 1.1 
 
81.0 ± 2.6 
73.1 ± 5.7 
93.8 ± 0.2 
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Table 2.13: Comparison of recoveries obtained for dRif, Rif and Efv using 
different SPE cartridges (n=2) 
 
 Evolute ABN was the SPE cartridge chosen for this assay.  The 
cartridge sorbent consists of a rugged polystyrene-based polymer 
functionalised with well-defined hydroxyl-functional oligomers which 
simultaneously give very high water wettability but, through the combination 
of non-polar (hydrophobic) and polar (hydrophilic) interactions associated with 
the various functionalities on the column material, allows efficient extraction 
of analytes of wide ranging polarities. See Figure 2.10.  
 
 
 
Figure 2.10: Evolute ABN sSorbent  
SPE 
cartridge 
dRif 
Recovery % 
± % RSD 
Rif   
Recovery % 
± % RSD 
Efv  
Recovery % 
± % RSD 
 
Phenyl 
18 LT 
C8 
CN 
Strata X 
 
69.1 ± 2.4 
0.1 ± 0.0 
0.1 ± 0.0  
71.6 ± 1.5 
90.3 ± 5.5 
 
52.8 ± 5.5 
14.6 ± 28.1 
7.7 ± 40.3 
54.9 ± 9.5 
82.1 ± 5.0 
 
86.5 ± 0.5 
6.0 ± 51.7 
8.9 ± 23.6 
104.6 ± 6.8 
3.8 ± 28.9 
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 These characteristics result in a versatile sorbent for extraction of 
acidic, basic and neutral analytes from biological fluids and other aqueous 
matrices. The stationary phase is packed in a syringe-shaped cartridge or a 96 
well plate, which can be mounted on the extraction manifold. Evolute ABN’s 
optimised pore structure minimises the retention of high molecular weight 
endogenous materials present in complex sample matrices. Efv has a molecular 
weight of 316 g/mol (D’Avolio et al., 2010)  and a pKa of 10.2. Rif has a 
molecular weight of 823 g/mol and an acidic pKa of 1.7 and a basic pKa of 7.9 
(Balbão et al., 2010), it is also very sensitive to light and pH (MSDS 
Rifampicin).  Hence, it was postulated that Efv, Rif and dRif – even with their 
different physiochemical properties - could be extracted by this one sorbent. 
This was borne out experimentally. There are six basic steps in SPE which 
include sample pretreatment, sorbent conditioning, sorbent equilibration, 
sample loading, washing, and analyte elution. During the SPE method 
development each of these steps were investigated.  
As many SPE sorbents are not water-wettable, analytes applied in an 
aqueous sample will not partition onto the sorbent, due to lack of a proper 
phase interface between the dry sorbent surface and the sample. Conditioning 
with a water-miscible organic solvent, methanol for this work, wets the sorbent 
surface and allows the analytes to break through the surface tension of the 
water and move into the sorbent.  
Prior to loading the aqueous sample, the conditioning solvent needed to 
be displaced from the sorbent using an equilibration solvent. The equilibration 
solvent also prepared the sorbent surface to receive the sample. In order that 
the chemistry of the sorbent remained constant throughout the sample loading 
step, the equilibration solvent was similar to the composition of the sample. 
The sorbent was equilibrated with the same buffer as used to dilute the sample.  
Sample pretreatment involved sample dilution and pH adjustment. 
Dilution reduces the viscosity of the aqueous sample, improving 
chromatographic mass transfer, and thus improving the efficiency of the 
extraction. In this work, the plasma sample was diluted 1:1 with an aqueous 
buffer containing formic acid. A comparison of spiked plasma loaded 1:1 with 
0.1% formic acid, 0.01% formic acid and water was evaluated. 1% and 0.1% 
formic acid showed no significant difference between the recoveries observed 
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for dRif and Rif. Loading of samples diluted with water showed a slight 
decrease in the recoveries for both drugs. See Figure 2.11. When Efv was 
loaded with water a cleaner baseline was observed but at the cost of recovery. 
See Figure 2.12. A consideration during the sample load step was the speed 
with which the sample was applied. Care had to be taken to ensure it was slow 
and consistent. Too rapid an application would not allow sufficient time for the 
analytes to partition into the sorbent surface, resulting in analyte breakthrough 
and poor recovery.  
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Figure 2.11: Chromatogram comparing different plasma load conditions for dRif and Rif. 
Blue: 0.1% FA, Red: 0.01% FA Green: water 
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Figure 2.12: Chromatogram comparing different plasma load conditions for Efv. 
Blue: 0.1% FA, Red: 0.01% FA, Green: water 
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The optimum wash solvent needed to be non-polar enough to elute as 
many interferences as possible, but not sufficiently non-polar to elute the 
analytes. This solvent was identified by washing the SPE cartridges starting 
with 100% water, then progressively increasing the proportion of MeOH 
present. Proportions of 10, 20 and 30% MeOH in the wash solvent were 
evaluated. Each wash step was collected and analysed for the presence of the 
drugs. There was a slight loss of recovery when 30% MeOH was employed. 
However, even with an increase in the percentage organic in the wash step 
from 10-30% MeOH, the cleanliness of the baseline was not altered a great 
deal. The wash containing the highest percentage organic but eluted no 
analytes was at 20%.  
For elution, it was required to use the weakest elution solvent that had 
just enough hydrophobicity to give quantitative analyte elution. Such a solvent, 
requiring a ternary mixture of H2O-ACN-MeOH, left behind on the sorbent the 
maximum number of contaminants. Elution of the drugs with mobile phase 
(H2O-ACN-MeOH, 40:45:15, v/v/v) in contrast to H2O-ACN-MeOH, 
25:50:25, v/v/v, significantly affected the recovery of Efv - see Figure 2.13. 
With a higher % aqueous present in the elution solvent, there was a dramatic 
decrease in the integrated areas observed for Efv with elution in mobile phase. 
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Figure 2.13: Comparison of elution with (blue) H2O-ACN-MeOH, 25:50:25 
v/v/v, and (red) mobile phase (H2O-ACN-MeOH, 40:45:15, v/v/v) 
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Initially, 0.5 mL plasma was loaded and reconstituted in 0.25 mL 
mobile phase. As a small plasma volume was an objective for this work, it was 
decided to reduce the amount of plasma loaded to 0.3 mL and reconstitute in 
0.15 mL. On doing so, there was no significant difference in the recoveries 
obtained. See Tables 2.14 and 2.15 for this data.  
 
 
 
 
 
 
 
 
 
 
 
Table 2.14: Comparison of different wash steps loading 0.5 mL plasma and 
reconstituting in 0.25 mL mobile phase 
 
 
 
 
 
 
 
 
 
 
 
Table 2.15: Comparison of different wash steps loading 0.3 mL plasma and 
reconstituting in 0.15 mL mobile phase 
 
 There are safety implications working with material from HIV/TB 
infected patients. Some literature has described the use of heat treatment to 
% MeOH 
wash 
Recovery (%) ± % RSD 
dRif Rif Efv 
10  
20 
30 
96.7 ± 0.5 
96.2 ± 0.9 
97.9 ± 0.3 
 
95.1 ± 0.4 
96.0 ± 0.3 
95.8 ± 0.8 
 
 
71.0 ± 0.8 
73.1 ± 0.3 
72.6 ± 0.3 
 
% MeOH 
wash 
Recovery (%) ± % RSD 
dRif Rif Efv 
10 
20 
30 
97.3 ± 0.4 
96.9 ± 0.1 
99.1 ± 0.1 
96.5 ± 0.1 
96.2 ± 0.2 
97.0 ± 0.4 
 
77.9 ± 0.1 
74.5 ± 0.1 
75.5 ± 0.3 
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inactivate HIV in plasma samples making the samples safer to work with 
(ranges between 56-60 oC and 30-60 mins have been used (Volosov et al., 
2002, Rezk et al., 2004, Sarasa-Nacenta et al., 2001, Marzolini et al., 2000, 
Boffito et al., 2002)) but more recent research has proven that the process of 
heat inactivation significantly and adversely affects the stability of Rif  
(Hartkoorn et al., 2007). When correct health & safety procedures are used, the 
heating process can be eliminated. It was therefore decided not to heat 
inactivate the samples used to validate this assay. The addition of ascorbic acid 
to the elution step of the SPE (1 mg/mL) has been used by some authors to 
prevent the oxidation of Rif to dRif (Allanson et al., 2007, Panchagnula et al., 
1999). In the course of this study, it was found that ascorbic acid had a 
significant impact in maintaining high recoveries for Rif and was hence 
employed in this assay. See Figure 2.14. 
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Figure 2.14: Comparison of 10 μg/mL spiked plasma sample with and without addition of ascorbic acid 
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 A mini stability study indicated that Rif stock solution, when prepared 
in ACN and stored in the fridge, remained stable over time across the entire 
concentration range analysed. See Table 2.16 for a comparison of the same 
concentrations of Rif standard prepared from the ACN stock in mobile phase. 
However, on storing the standards prepared in mobile phase in the fridge and 
analysing them over three days, loss of analyte signal was evident across the 
same concentration range tested. Efv proved stable under the same conditions 
at all concentrations analysed - see again Table 2.16. Stability of Rif varies 
according to pH due to its amphoteric nature. In acidic solutions, Rif undergoes 
hydrolysis to yield 3-formyl-rifamycin and 1-amino 4-methylpiperazine. Under 
alkaline conditions (pH of 7.5 to 9.0) Rif will oxidize if oxygen is present, 
becoming rifampicin-quinone (Alves et al., 2010). Maximum stability of Rif is 
reached in near neutral solutions. As discussed, the addition of ascorbic acid to 
the solution decreases its oxidation (Alves, et al., 2010). Under the slightly 
acidic conditions of the MP (ammonium acetate (pH 4.75, adjusted with 1 M 
acetic acid, 20 mM), ACN and MeOH (40:45:15, v/v/v)), hydrolysis of Rif was 
occurring and hence causing a decrease in its concentration present over the 3 
days. When prepared in the more neutral ACN there was no loss of 
concentration observed for Rif due to it being more stable in near neutral 
solutions. 
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Conc. 
(μg/mL) 
Conc. determined 
Day 1 ± % RSD 
Conc. determined 
Day  3 ± % RSD 
%  drug 
determined after 
day 3  
Rif - prepared in MP
0.5 0.5 ± 3.6 0.2 ± 0.5 41.7 
1 0.9 ± 4.1 0.4 ± 0.8 38.0 
2 2.1 ± 3.5 0.8 ± 1.5 36.2 
5 4.8 ± 2.1 2.1 ± 2.5 43.9 
7 7.4 ± 1.4 3.2 ± 2.1 42.7 
10 9.8 ± 0.5 4.5 ± 3.2 45.7 
Rif - prepared in ACN
0.5 0.5 ± 1.2 0.4 ± 2.1 90.9 
1 0.9 ± 2.7 1.0 ± 0.3 102.9 
2 2.1 ± 2.5 2.1 ± 2.1 101.3 
5 4.8 ± 0.5 4.8 ± 1.1 101.9 
7 7.4 ± 1.1 7.6 ± 1.1 103.0 
10 9.8 ± 1.2 9.9 ± 1.3 100.2 
Efv - prepared in MP
0.5 0.5 ± 4.2 0.5 ± 4.1 94.8 
1 0.8 ± 3.2 0.8 ± 3.9 97.6 
2 2.1 ± 3.2 2.0 ± 1.1 95.3 
5 4.8 ± 4.2 5.0 ± 3.2 103.1 
7 6.8 ± 1.5 7.0 ± 1.1 103.4 
10 9.9 ± 4.5 10.0 ± 1.2 100.5 
Efv - prepared in ACN
0.5 0.5 ± 2.8 0.5 ± 0.9 92.9 
1 1.1 ± 2.1 1.1 ± 2.0 106.7 
2 2.1 ± 1.1 2.0 ± 1.1 96.2 
5 4.8 ± 1.9 5.0 ± 0.3 103.1 
7 7.0 ± 1.0 7.1 ± 2.1 101.5 
10 9.9 ± 1.1 10.0 ± 1.2 100.7 
 
Table 2.16: Comparison of the stability of Rif and Efv when stored in both 
mobile phase and ACN 
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As discussed in Chapter 1, bioanalytical methods, especially in support 
of pharmacokinetic studies, are among the most challenging to develop and 
validate (FDA, 2001). The method developed for this work was no exception. 
Determination of all three drugs simultaneously from such a complex matrix, 
in a simple, rapid and cost effective assay was the key focus of this work. 
Developing such a low cost assay to detect the drugs within a clinically 
relevant concentration range using standard chromatography equipment in 
order to make it applicable to resource-limited settings was a significant 
challenge.  
In summary, an isocratic high performance liquid chromatography 
assay employing solid phase extraction for the simultaneous determination of 
Rif, Efv and dRif from plasma was developed as previously outlined. Using a 
Zorbax SB-Phenyl reversed-phase analytical column with UV detection, good 
separation and detection of the drugs was attained within a fast run time of 10 
min. The method is suitable for selective estimations of Efv, Rif and its 
metabolite dRif in plasma matrix. Various features of the developed method 
include low volumes of plasma required for analysis, simple and fast extraction 
procedure and cost effective chromatographic equipment. This makes the 
method very rapid and economical, especially when a large number of samples 
are to be handled.  
 
2.5 Method validation 
 
A full validation procedure was performed on the method in accordance with 
FDA guidelines (FDA, 2001) including intra-day and inter-day precision, 
accuracy, sensitivity, linearity and range and recovery. Stability following 
freeze-thaw cycles was also investigated. 
 
2.5.1 Accuracy  
 
In order to evaluate the accuracy of the method, six different concentrations of 
Efv, Rif and dRif (0.1, 0.5, 1, 5, 10 and 20 μg/mL) were prepared in plasma 
and analysed in sextuplicate on four consecutive days. The measured amounts 
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were inserted into the equation of the calibration curves and treated as 
unknown concentrations. The calculated concentrations were compared with 
the nominal concentrations. Assay accuracy was expressed as % error i.e. [the 
absolute difference between calculated concentration and spiked concentration] 
/ nominal concentration × 100. 
 The accuracies obtained at the six concentrations examined were all 
acceptable with % error values < 10% - see Table 2.17.  
 
2.5.2 Precision 
 
The precision of Efv, Rif and dRif standards were evaluated by analysing six 
different concentrations of Efv, Rif and dRif (0.1, 0.5, 1, 5, 10 and 20 μg/mL). 
The intra-day precision values were determined by processing each working 
standard concentration in octuplicate on the same day and calculating the 
relative standard deviation (RSD) values. The inter-day precision values were 
determined by processing each working standard concentration in sextuplicate 
for five consecutive days and calculating the RSD values. % RSD was 
expressed as [deviation from the mean]/mean concentration × 100.  Intra- and 
inter-assay precision RSD values were found to be less than 10% in all cases. 
See Table 2.17 for the summarised data.  
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Table 2.17: A summary of the Intra-Day and Inter-Day precision and accuracy 
determinations 
Compound 
INTRA-DAY  (n =8 ) INTER-DAY (n = 6) 
Calculated 
conc. 
(µg/mL) 
Accuracy
(% 
Error) 
Precision 
% RSD 
Calculated 
conc. 
(µg/mL) 
Accuracy 
(% 
Error) 
Precision 
% RSD 
 
dRif 
 
0.1 
0.5 
1.0 
5.1 
9.9 
20.0 
 
10.0 
-6.0 
2.0 
1.4 
1.3 
0.2 
 
0.2 
1.8 
1.7 
7.2 
0.2 
0.3 
 
0.1 
0.5 
1.1 
5.0 
9.9 
20.0 
 
9.0 
4.3 
6.9 
0.8 
0.2 
0.1 
 
0.1 
3.2 
1.0 
0.4 
0.3 
0.8 
 
Rif 
 
0.1 
0.5 
1.1 
4.9 
9.8 
20.1 
 
10.9 
1.7 
6.9 
1.9 
1.6 
0.5 
 
0.8 
3.3 
2.4 
0.6 
0.5 
0.2 
 
0.1 
0.5 
1.1 
4.9 
9.8 
20.1 
 
10.0 
3.5 
6.8 
1.4 
2.1 
0.6 
 
0.9 
1.5 
0.3 
0.3 
0.6 
0.3 
 
Efv 
 
0.1 
0.5 
0.9 
5.0 
9.9 
20.0 
 
8.1 
5.8 
4.7 
0.2 
0.8 
0.2 
 
0.0 
0.8 
1.6 
0.2 
0.1 
0.8 
 
0.1 
0.5 
0.9 
5.1 
10.0 
20.0 
 
9.9 
1.0 
6.3 
0.9 
0.1 
0.0 
 
4.2 
0.9 
1.7 
0.8 
0.5 
0.2 
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2.5.3 Selectivity 
 
For selectivity, six blank plasma samples from different sources were analysed 
and checked for peaks interfering with the detection of the analytes. The assay 
was found to be selective for all drugs analysed. No interfering peaks were 
observed in the extracts of the different blank plasma samples. 
 
2.5.4 Sensitivity 
 
Both the limits of quantitation (LOQ) and detection (LOD) were determined 
for the assay. The LOQ was defined as the lowest concentration that produced 
a peak distinguishable from background noise with a minimum ratio of 10:1. 
LOD was defined as the lowest concentration that produced a peak 
distinguishable from background noise with a minimum ratio of 3:1. The LOQ 
was 0.1 μg/mL for all three drugs. Extracted blank plasma samples did not 
yield any endogenous peaks at the retention times of the drug compounds – see 
Figure 2.15. The LOD was found to be 0.075 μg/mL with % error and RSD 
values less than 15%. 
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Figure 2.15: Chromatograms of extracted drug-free plasma sample 
superimposed on extracted plasma spiked with 100 ng/mL dRif, Rif and Efv. 
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2.5.5 Linearity and range 
 
The calibration curves for Efv, Rif and dRif over the concentration range 0.1 to 
20.0 μg/mL exhibited good linearity with correlation coefficients (R2) for all 
standard curves above 0.99. See Figures 2.16 - 2.18. 
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Figure 2.16: Linearity for dRif plasma standards 
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Figure 2.17: Linearity for Rif plasma standards 
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Figure 2.18: Linearity for Efv plasma standards
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2.5.6 Recovery 
 
As previously discussed, highest recoveries for the drugs in one extraction step 
were obtained with the SPE ABN well plates. Varying concentrations of Efv, 
Rif and dRif (1, 5 and 20 μg/mL) were prepared in drug-free human plasma 
and extracted using the SPE cartridges. The percentage of drug recovered from 
these plasma samples was determined by comparing the calculated 
concentrations following extraction and HPLC assay with the calculated 
concentrations from unextracted samples in MP of the same concentration after 
HPLC assay. Recovery experiments were carried out on three consecutive 
days. Recoveries for plasma samples spiked with 1, 5 and 20 μg/mL of Efv 
were all ≥ 70% (Table 2.18).  
 
 
 
 
 
 
 
 
 
 
 
Table 2.18:  Recovery data for drugs from plasma (n = 3) 
 
2.5.7 Stability 
 
To examine relevant variables around storage and long term stability we 
determined the impact of freeze–thaw cycles on the stability of the drugs in the 
presence of plasma, fresh drug-free plasma samples were spiked with 0.5, 5 
and 20 μg/mL of Efv, Rif and dRif as shown in Table 2.19. Samples 
underwent four freeze-thaw (−20 °C to room temperature) cycles. The drug 
concentrations were then determined in triplicate on three separate occasions 
and compared to plasma samples prepared to the same concentrations that 
were stored at −20 °C and only thawed once immediately prior to analysis. 
Conc. 
(µg/mL) 
Mean % recovery ± % RSD 
dRif Rif Efv 
 
1.00 
5.00 
20.00 
 
 
96.9 ±  0.9 
97.1 ± 0.2 
97.0 ± 0.3 
 
 
94.4 ± 0.7 
94.0 ± 0.1 
93.8 ± 0.2 
 
 
70.0 ± 0.4 
69.4 ± 0.6 
69.8 ± 0.4 
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Long term stability was evaluated using plasma samples spiked with 0.5, 5 and 
20 μg/mL of Efv, Rif and dRif after six months of freezing. This storage time 
was chosen as is does not exceed the time from when samples are first 
collected for the SPhEAR study to the time of last sample analysis. Finally, 
stock solution stability was evaluated by comparing the response obtained 
from standards prepared in mobile phase at three concentrations (0.5, 5 and 20 
μg/mL) left at room temperature for 8 hours to freshly prepared stock 
solutions. 
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Table 2.19: Summary of freeze-thaw stability findings for Rif, dRif and Efv (n = 3) 
Compound Conc. (µg/mL) 
Cycle 1 
% recovery 
 ± % RSD 
Cycle 2 
% recovery 
 ± % RSD 
Cycle 3 
% recovery 
 ± % RSD 
Cycle 4 
% recovery  
± % RSD 
Cycle 5 
% recovery  
± % RSD 
 
dRif 
 
0.5  
5   
20   
 
99.7 ± 0.7 
100.7 ± 2.1 
99.7 ±1.1 
 
98.1 ± 2.5 
100.8 ± 2.0 
99.5 ± 1.2 
 
96.0 ± 0.6 
96.8 ± 0.1 
95.7 ± 1.2 
 
87.6 ± 2.8 
89.5 ± 2.7 
85.3 ± 1.1 
 
85.6 ± 2.1 
90.3 ± 3.2 
83.8 ± 0.5 
 
 
Rif 
 
0.5 
5  
20  
 
100.9 ± 2.0 
99.9 ± 2.9 
99.2 ± 1.1 
 
99.5 ± 0.8 
102.0 ± 2.8 
100.2 ± 1.7 
 
96.1 ± 1.5 
94.3 ± 0.7 
96.7 ± 0.3 
 
88.0 ± 1.2 
90.4 ± 1.0 
90.3 ± 3.1 
 
89.9 ± 1.3 
88.4 ± 2.1 
93.3 ± 1.9 
 
 
Efv 
 
0.5  
5   
20  
 
102.3  ± 1.4 
100.6  ± 1.0 
99.4  ± 0.5 
 
102.0  ± 1.4 
103.5  ± 2.0 
99.1  ± 0.5 
 
99.3  ± 1.4 
100.3  ± 1.3 
96.5  ± 0.1 
 
94.7 ± 0.5 
92.9 ± 0.8 
97.7 ± 0.1 
 
94.0 ± 0.2 
94.8 ± 0.9 
96.9 ± 1.2 
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 The data indicated that three freeze–thaw cycles had little significant 
impact on the Efv, Rif and dRif concentrations measured, which means that 
samples could be repeatedly thawed and re-analysed up to three times if 
required. However, it was noted that the drug quantiation showed increased 
evidence of instability in dRif and Rif on the fourth cycle of the freeze-thaw 
study which suggests that the drugs are less stable after further freeze-thaw 
cycles. Long term (6 months, -80 ºC) storage at the three different 
concentrations showed no significant decline in responses obtained for the 
three drugs. The stability of the three stock solutions prepared in mobile phase 
was also evaluated. Standards (0.5, 5 and 20 μg/mL) left for eight hours at 
room temperature showed no decline in detector response at the three 
concentrations analysed which allowed for daily preparation of daily solutions. 
 The HPLC–UV method was fully validated with inter- and intra-assay 
accuracy and precision falling within the FDA guidelines (FDA, 2001). As 
described in the FDA guideline, quality control samples may not deviate more 
than 15% from the nominal concentration (and 20% for the LLQC), a 
guideline followed and adhered to for this assay.  
 In the literature Calleja et al., 2004,  achieved the lowest LOQ for the 
determination of Rif at just 50 ng/mL, however, this was Rif extracted from rat 
plasma. Balbão et al., 2010,  achieved an LOQ of 125 ng/mL for Rif extracted 
from human plasma, however, the recovery of drug was low at 75-80% and Rif 
had a long retention time of 11 mins. Taking into consideration all aspects of 
the UV method described in this thesis, the method developed and described 
appears to have many advantages over others reported in the literature to date. 
With an LOQ of 100 ng/mL, well below the concentrations found in human PK 
samples, Rif has a usefully short retention time of 3.1 min and a recovery of 
94% from plasma. Also our method is capable of determining Rif’s metabolite 
dRif. In the presence of Efv, this has never been investigated and doing so was 
important in order to determine the extent of Rif’s metabolism to dRif in the 
presence of Efv. There are limited reported methods for the simultaneous 
determination of dRif and Rif, the most successful was Hemanth Kumar et al., 
2004, however, their sensitivity was not as good at 250 ng/mL. Panchagnula et 
al., 1999, also developed a method for the simultaneous determination of dRif 
and Rif. Sample volume was low at only 100 μL, however, the sensitivity 
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obtained was poor at 2 μg/mL. So again, the method described in this thesis is 
the best to date for the simultaneous determination of both Rif and dRif. 
Similar to the LOQ for Rif, dRif’s LOQ was again 100 ng/mL with a recovery 
of 97% from plasma was achieved. 
For Efv, the lowest LOQ obtained for Efv was by Mogatle et al., 2009,  
having achieved 8.96 ng/mL in serum. However, 1 mL sample was needed and 
retention time was 11.6 mins. There are numerous methods reported with 
LOQs of just 10 ng/mL but all suffer from either extremely long elution times 
10.2 – 24.9 min, (Veldkamp et al., 1999, Rezk et al., 2004, Rezk et al., 2002, 
Choi et al., 2007) high sample volumes 0.5 – 1.0 mL (Rezk et al., 2004, Rezk 
et al., 2002, Choi et al., 2007) or both (Rezk et al., 2004, Rezk et al., 2002, 
Choi et al., 2007). The main advantage of the UV method described in this 
thesis in terms of Efv is the short retention time obtained for Efv at 6.1 min, 
which was very challenging in the presence of both dRif and Rif. 
Boffito et al., 2002, developed the only LC-UV method for the 
simultaneous determination of Rif and Efv. This one reported method for the 
simultaneous determination of the two exhibits comparable sensitivity with the 
method we outline herein (LOD 50 ng/mL) but requires gradient elution and 
hence suffers from a relatively long analysis time of 22 mins. The authors also 
did not measure Rif’s main metabolite, dRif. So again, the LC-UV method 
described in this thesis offers excellent sensitivity for each of the drugs, allows 
for the determination of Rif’s metabolite which hasn’t been done before in the 
presence of Efv and the sample volume required is low at only 0.3 mL.  
 
2.6 SPhEAR patient sample results  
 
The blood samples analysed were obtained from eleven patients participating 
in the SPhEAR study. All patients were administered a 600 mg dose of Rif for 
the treatment of TB with Patient B administered both Rif and Efv for the 
simultaneous treatment of HIV and TB. Samples were drawn at eight different 
time points (0, 1, 2, 3, 4, 6, 8 and 10 hrs) over a 10 hour period. See Figure 
2.19 for the chromatograms at 0 and 1 hour post-dosing in Patient A.  
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Figure 2.19:  (a) Overlaid chromatograms from 0 (blue) and 1 hour (red) 
timepoints post-dosing in Patient A being treated with Rif and (b) 
chromatogram from 1 hour timepoint post-dosing in Patient B being treated 
with Efv  
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 The pharmacokinetic profiles for the drugs in each of the patients can 
be seen in Figures 2.20 to 2.31. The results obtained agree with previous levels 
published (Hartkoorn et al., 2007, Boffito et al., 2002). Patient B (HIV 
positive) was administered Efv 10 hours prior to T0 (treatment with Rif). The 
long half-life of Efv generates a gradual decline in the blood concentration over 
time (Ramachandran et al., 2006) and as expected, Efv concentrations showed 
a slight decrease over the same timepoints with concentrations ranging from 3 
to 5 μg/mL (see Figure 2.22). Again, results agree with previous levels 
published (Mogatle et al., 2009, Boffito et al., 2002).   
Rif or dRif were not detected in the plasma of any of the patients pre 
administration of the drug at t=0. Post administration, absorption of Rif into the 
blood stream occurred rapidly. Maximum plasma concentrations (Cmax) of both 
Rif and dRif and the time taken for the drug to reach its highest concentration 
in the blood stream (Tmax) are presented in Table 2.20.  Rif concentrations for 
all patients ranged from up to 19 μg/mL, over the full time period (with levels 
peaking 2-3 hours post administration) and up to 11 μg/mL for dRif. This again 
complies with previous levels published (Hartkoorn et al., 2007, Boffito et al., 
2002). 
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Figure 2.20: Pharmacokinetic profile of Rif and dRif from Patient A participating in the SPhEAR study 
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Patient  B - Rif and dRif
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Figure 2.21: Pharmacokinetic profile of Rif and dRif from Patient B participating in the SPhEAR study  
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Figure2.22: Pharmacokinetic profile of Efv from Patient B participating in the SPhEAR study 
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Patient C
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Figure 2.23: Pharmacokinetic profile of Rif and dRif from Patient C participating in the SPhEAR study 
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Figure 2.24: Pharmacokinetic profile of Rif and dRif from Patient D participating in the SPhEAR study 
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Patient E
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Figure 2.25: Pharmacokinetic profile of Rif and dRif from Patient E participating in the SPhEAR study 
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Patient F
0
5
10
15
20
0 2 4 6 8 10
Time since administration of drug (hr)
R
i
f
 
C
o
n
c
.
 
(
μ
g
/
m
L
)
0
1
2
3
4
5
d
R
i
f
 
C
o
n
c
.
 
(
μ
g
/
m
L
)
Rifampicin
dRifampicin
 
Figure 2.26: Pharmacokinetic profile of Rif and dRif from Patient F participating in the SPhEAR study 
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Figure 2.27: Pharmacokinetic profile of Rif and dRif from Patient G participating in the SPhEAR study 
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Patient H
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Figure 2.28: Pharmacokinetic profile of Rif and dRif from Patient H participating in the SPhEAR study 
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Figure 2.29: Pharmacokinetic profile of Rif and dRif from Patient I participating in the SPhEAR study 
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Patient J
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Figure 2.30: Pharmacokinetic profile of Rif and dRif from Patient J participating in the SPhEAR study 
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Patient  K
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Figure 2.31: Pharmacokinetic profile of Rif and dRif from Patient K participating in the SPhEAR study 
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Patient 
 
dRif Rif 
Cmax (μg/mL) 
± % RSD 
Tmax (hr) 
Cmax (μg/mL) 
± % RSD 
Tmax (hr) 
A 
B* 
C 
D 
E 
F 
G 
H 
I 
J 
K 
3.2 ±  3.1 
3.1 ± 3.2 
3.6 ±  2.8 
2.3 ±  4.3 
1.6 ±  0.5 
3.2 ±  3.1  
1.9 ±  5.3 
11.4 ±  2.6 
3.9 ±  0.5  
3.9 ±  2.6 
2.5 ± 4.0 
2 
3 
2 
2 
3 
3 
3 
2 
3 
4 
3 
15.6 ±  1.9 
5.8 ±  1.7 
13.5 ±  1.5 
11.2 ±  0.9 
8.7 ±  2.3 
11.4 ±  0.9 
6.9 ±  1.4 
18.5 ±  1.1 
12.7 ±  5.5 
10.4 ±  1.9 
11.8 ±  0.8 
1 
2 
2 
2 
3 
1 
2 
2 
2 
4 
2 
 
Table 2.20: Comparison of Patient’s Cmax and Tmax following Rif 
administration 
*Co-administered Efv 
 
 To date, blood samples obtained from the SPhEAR study were of 
patients administered Rif only, with the exception of Patient B who was co-
administered both Rif and Efv. Examination of the Rif and dRif data from all 
patients show that there are interpatient pharmacokinetic differences for this 
drug (as expected from published literature).  
The same dose of Rif in patient B generated the lowest circulating 
blood concentration of drug than in any other patient. As this was the only 
patient who was co administered the drugs, it cannot be certain if this low level 
is due to the presence of Efv in the blood or not.  
Circulating levels of dRif represent a fraction (approximately 20%- 
60%) of the levels of Rif found. Conclusive results cannot be made at this early 
stage with regard to if the pharmacokinetics of Rif are adversely affected when 
a patient is administered both drugs at the same time. 
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2.7 Conclusions  
 
In conclusion, a novel isocratic high performance liquid chromatography 
method for the simultaneous determination of the anti HIV drug, Efv, the anti-
TB drug, Rif and the desacetyl metabolite of Rif in plasma has been developed 
and validated. Using a Zorbax SB-Phenyl reverse-phase analytical column 
with UV detection, the assay employed solid phase extraction which achieved 
good separation and detection of the drugs within a fast run time of 10 min. 
The LOQ was found to be 0.1 μg/mL for each agent.  
The described assay is accurate, precise and fast for the determination 
of these very different drugs in plasma. The easy sample preparation and fast 
separation makes this assay highly suitable for pharmacokinetic studies and 
therapeutic drug monitoring in patients with HIV only, TB only or both 
diseases being treated with Efv and Rif. This new protocol will be used in a 
SPhEAR project which will examine the effects of Efv medication on the 
pharmacokinetics of oral Rif in the treatment of TB in HIV infected patients. 
Analysed to date are blood samples from 11 patients participating in the study. 
Conclusive results with regard to the hypothesis proposed could not be made 
due to lack of patient samples from different patient categories of the project. 
Ten of the eleven patients were administered Rif only, with the exception of 
one who was co-administered both Rif and Efv.  This patient generated the 
lowest circulating blood concentration of drug than in any other patient. 
Results to date show there are interpatient pharmacokinetic differences for this 
drug. Circulating levels of dRif represent a fraction (approximately 20%- 60%) 
of the levels of Rif found. 
This  fast,  low cost and  relatively easy UV‐based assay can accurately 
detect the drug concentrations within a clinically relevant concentration range 
which renders it broadly applicable, especially in third world countries and in 
resource  limited settings where the burden of disease exists. Using standard 
LC‐UV equipment, it has the advantage of being cost effective and easy to use, 
especially when compared to MS which may not be available in laboratories in 
resource limited settings. 
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3.1    Scope of research 
 
The objective of this work was to develop an LC-MS method for the 
simultaneous determination of efavirenz and rifampicin from human plasma. 
As discussed in Chapter 2, appropriate treatment of microbial illness represents 
a significant pharmaceutical challenge.  Nowhere is this more so than in the 
management of HIV infection, where patients often present with concurrent 
tuberculosis infection, thereby necessitating combination drug treatment.  
Examination of the SPhEAR hypothesis necessitated developing a new method 
capable of convenient, rapid and cost effective quantitation of two unrelated 
pharmaceuticals - the antiviral agent efavirenz (Efv) and the anti-TB agent, 
rifampicin (Rif) and this was achieved as outlined in Chapter 2. It was decided 
to further investigate the methodology in order to achieve greater sensitivity 
for the assay. This was achieved using LC-MS analysis. 
 
3.2    Introduction 
The previous chapter described work carried out to develop a LC-UV method 
preceded by SPE for determination of Rif, its metabolite dRif and Efv. It was 
decided to transfer the method to LC-MS in order to increase the sensitivity 
already achieved using the LC-UV method as there are no reported methods in 
the literature for the simultaneous analysis of Rif and Efv using LC-MS. Due to 
time constraints it was decided to focus on the primary drugs Rif and Efv for the 
method development and not optimise for Rif’s metabolite dRif. 
 
3.2.1 Sample extraction/clean-up procedures for efavirenz prior to LC-MS 
analysis 
 
The three main sample extraction techniques employed to extract Efv from 
biological fluids are liquid-liquid extraction (LLE), protein precipitation (PP) 
and solid-phase extraction (SPE). All three approaches have been used prior to 
LC analysis of both drugs as discussed in section 2.2.5. In conjunction with 
LC-MS, all three sample preparation methods have been investigated as shown 
in Tables 3.1 and 3.2. Sample volumes required for PP have been reported as 
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quite low, in the region of 50 – 80 μL ((D’Avolio et al., 2007, Volosov et al., 
2002) and the recoveries obtained were high (93 – 110%). Rentsch et al., 2003, 
describe the one reported SPE method for the extraction of Efv from human 
plasma before LC-MS detection. Recovery for Efv was high in this case (96.6-
96.9%) however, the method required a large sample volume of 1 mL.  Martin 
et al., 2009, used PP and online SPE for the extraction of Efv from human 
plasma. Recovery was good at 75-98%. 
 
3.2.2 Sample extraction/clean-up procedures for rifampicin prior to LC-MS 
analysis 
 
Rif has also been successfully isolated from plasma/serum prior to LC-MS 
detection. From the literature, PP appears to be the most common approach used 
for the extraction of Rif from both plasma (de Velde et al., 2009, Hartkoorn et 
al., 2007) and serum (Song et al., 2007). Recoveries obtained for Rif using this 
approach were high (84.5% or greater) and required relatively small sample 
volumes (0.05 mL or less).  
Hartkoorn et al., 2007, and Song et al., 2007, employed ACN for protein 
precipitation. Hartkoorn used 50 μL of sample and achieved 92% recovery of 
Rif from plasma. Song et al., 2007,  used PP for the extraction of Rif from 
serum. Only a small volume of serum (50 µL) was required and protein 
precipitation was achieved using MeOH. The recovery of Rif in this case was 
95%. De Velde et al., 2009, required just 10 μL plasma for the precipitation of 
both Rif and dRif. 
 There are no reported sample extraction/clean-up procedures for Efv and 
Rif simultaneously. 
 
 
 
 
Table 3.1: Reported extraction and LC-MS detection techniques for Rif from biological samples 
Reference Analytes Matrix Extraction mode 
Extraction 
recoveries (%) Detection 
Approx 
retention 
time (min)
LOQ Column Sample vol. (μL) 
 
(D’Avolio et 
al., 2010) 
 
 
(Martin et 
al., 2009) 
 
 
(D’Avolio  et 
al., 2007) 
 
 
(Rouzes et 
al., 2004) 
 
 
 
(Rentsch  et 
al., 2003) 
 
 
(Volosov et 
al., 2002) 
 
Efv and 
other drug 
 
 
Efv and 
other 
drugs 
 
Efv and 
other 
drugs 
 
Efv and 
other 
drugs 
 
 
Efv and 
other 
drugs 
 
Efv and 
other 
drugs 
 
Dried plasma 
spots on glass 
filter 
 
Human plasma 
 
 
 
Human plasma 
 
 
 
Human 
peripheral blood 
mononuclear 
cells 
 
Human plasma 
 
 
 
Human plasma 
 
n/a 
 
 
 
PP & on-line 
SPE 
 
 
PP 
 
 
 
LLE 
 
 
 
 
SPE 
 
 
 
PP 
 
>85.0 
 
 
 
75-98 
 
 
 
93-110 
 
 
 
88.6 
 
 
 
 
96-6-97.9 
 
 
 
Not stated 
 
 
 
MS 
 
 
 
MS 
 
 
 
MS 
 
 
 
MS 
 
 
 
 
MS 
 
 
 
MS 
 
~16.9 
 
 
 
1.9 
 
 
 
16.7 
 
 
 
8.3 
 
 
 
 
16.3 
 
 
 
4.5 min 
runtime 
 
31.2 ng/mL  
 
 
 
100 ng/mL  
 
 
 
31.2 ng/mL  
 
 
 
2 ng/3 x 10^6 
cells 
 
 
 
10 ng/mL  
 
 
 
10 ng/mL 
 
Atlantis T3 
C18 
 
 
LUNA 
Phenyl 
Hexyl 
 
Atlantis 
dC-18 
 
 
X-Terra 
MS C18 
 
 
 
Nucleosil 
C18 HD 
 
 
Supelco 
LC-18-DB 
 
Not stated 
 
 
 
Not stated 
 
 
 
50 
 
 
 
Not stated 
 
 
 
 
1000 
 
 
 
80 
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Reference Analytes Matrix Extraction mode 
Extraction 
recoveries 
(%)
Detection 
Approx 
retention 
time (min)
LOQ/LOD Column Sample vol. (μL) 
 
(de Velde et 
al., 2009) 
 
 
 
(Song et al., 
2007) 
 
 
 
(Hartkoorn 
et al., 2007) 
 
dRif, Rif 
and other 
drugs 
 
 
Rif and 
other 
drugs 
 
 
Rif 
 
 
 
Human plasma 
 
 
 
 
Human serum 
 
 
 
 
Human cells 
and plasma 
 
 
 
PP 
 
 
 
 
PP 
 
 
 
 
PP 
 
 
 
 
dRif: 104.1-
116.9 
Rif: 101.3-
109.4 
 
94.80 
 
 
 
 
Plasma -85-95 
Cells - 51.73 
 
 
MS 
 
 
 
 
MS 
 
 
 
 
MS 
 
 
 
dRif: 2.3 
Rif: 2.45 
 
 
 
3.4 
 
 
 
 
1.1 
 
 
 
200 ng/mL 
LLOQ 
 
 
 
50 ng/mL 
 
 
 
 
100 ng/mL 
 
 
 
HyPurity 
Acquastar 
C18 
 
 
Hydrosphe
re C18 
 
 
 
Betasil 
Phenyl-
Hexyl 
 
 
10 
 
 
 
50 
 
 
 
 
 
50 
 
 
 
 
Table 3.2: Reported extraction and LC-MS detection techniques for Efv from biological samples 
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3.2.3 Sample separation and MS detection approaches for efavirenz  
 
D’Avolio et al., 2010, and Simiele et al., 2010, described the most recently used 
MS method for the detection of Efv using a C18 column. The method can detect 
Efv down to 31 ng/mL but Efv took 16.9 mins to elute. Martin, et al., 2009, 
described a MS method in which Efv was separated using a phenyl column which 
resulted in an extremely short retention time of just 1.9 mins but the method 
lacked sensitivity with an LOQ of just 100 ng/mL. Rentsch et al., 2003, obtained 
an LOQ of 10 ng/mL using MS but again Efv had a long retention time of 16.3 
mins using a C18 column. Volosov et al,, 2002, used MS for Efv’s detection and 
achieved an excellent LOQ of 10 ng/mL with a short runtime of just 4.5 mins.  
 Matthews et al., 2002, developed a HPLC method with post-column 
photochemical derivatisation and fluorescence detection for the determination of 
Efv and its enantiomer in plasma. Once the drugs had been extracted from the 
plasma matrix they were separated on a YMC-Pack C8 analytical column. The 
LOQ achieved was 50 ng/mL; however, 0.5 mL plasma was required. 
 
3.2.4 Sample separation and MS detection approaches for rifampicin 
 
Hartkoorn et al.,  2007,  Song et al., 2007, and de Velde et al.,  2009, developed 
LC-MS methods for the determination of Rif. Sample volumes are low, retention 
times are fast, but good sensitivity has been difficult to achieve. Hartkoorn 
achieved separation on a betasil phenyl-hexyl column using an isocratic mobile 
phase composed of ammonium acetate and acetonitrile at a flow rate of 
0.4 mL/min. Mass spectral analysis for Rif was carried out using electrospray 
ionisation (ESI) in the positive ion mode with a capillary temperature of 250 °C. 
The LOQ was found to be 100 ng/mL using only 50 μL plasma. Song developed a 
HPLC/tandem MS method for the determination of first-line anti-tuberculosis 
drugs (including Rif) and their major metabolites. Samples were analysed using a 
Hydrosphere C18 column. However, the assay required a gradient with mobile 
phase containing a mixture of methanol and water. Chromatographic separation 
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was performed at room temperature for 4 min. Using a Quattro Micro tandem 
mass spectrometer, quantification was achieved by multiple reaction monitoring 
(MRM) in positive ion mode. The LOQ obtained was 50 ng/mL with again only 
50 μL serum required. De Velde required only 10 μL plasma for the extraction of 
Rif, however an LOQ of 200 ng/mL was all that could be achieved. 
There are no reported LC-MS methods for the simultaneous determination of 
Efv and Rif. 
  
3.3    Experimental 
 
3.3.1 Reagents and materials 
 
MS grade acetonitrile (ACN), methanol (MeOH), water and ammonium acetate 
were purchased from Sigma-Aldrich, United Kingdom. Formic acid and acetic acid 
glacial, analytical grade were obtained from Sigma Aldrich, United Kingdom. 
Drug-free sterile filtered human plasma (EDTA k3) was purchased from Europa 
Bioproducts, United Kingdom. Efv and Rif were purchased from Sequoia Research 
Products Ltd. United Kingdom. SPE extraction cartridges and plates were 
purchased from Biotage, Sweden. 1.1 mL Chromacol vials were purchased from 
Fisher Scientific, Ireland.  
 
3.3.2 Equipment and HPLC assay conditions 
 
The LC-MS system consisting of a 1200 quaternary pump, autosampler and 
degasser and a 6410 QQQ LC/MS, all from Agilent, United Kingdom. System 
management and data acquisition were performed using Agilent Masshunter 
B.01.03 WorkStation Data Acquisition software. Other instrumentation employed 
included a pH meter and electronic mass balance both from a Mettler Toledo, 
USA a Genevac EZ-2 personal evaporator from Ipswich, United Kingdom. The 
VacMaster-96 sample processing manifold was sourced from Biotage, Sweden. 
Chromatographic separation was achieved using an Agilent Zorbax SB Phenyl 
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column, (150 x 4.6 mm, 5 μm). A mixture of ammonium acetate (pH 4.75, 
adjusted with 1 M acetic acid, 20 mM), ACN and MeOH (40:45:15, v/v/v) was 
used as mobile phase, at a flow rate of 0.8 mL/min. The column temperature was 
maintained at 20 °C and the temperature of the autosampler was maintained 4 °C. 
The complete chromatographic run time of each sample was 10 min. Peaks were 
quantified using Agilent Masshunter Software. 
The mass spectrometer was operated using an ESI source in the positive 
ion detection mode. The ionisation temperature was 375 °C, gas flow rate was 
11 L/min and nebuliser pressure was 50 psi. Nitrogen was used as the ionisation 
source gas and ultrapure nitrogen as the collision cell gas. Analysis was performed 
in MRM mode with the following transitions: m/z 823.4 → m/z 791.3 for Rif, m/z 
and m/z 316.1 → m/z 168.0 for Efv with a dwell time of 200 ms. Transitions and 
their optimal detector settings are listed in Table 3.3. The quantifier ions are 
indicated in the table though all transitions were monitored with the qualifier ions 
adding specificity. 
 
Compound 
Precursor
ion 
Optimum 
fragmentor
voltage 
Product 
ion 
Optimum 
collision 
energy 
 
Rif 
 
 
Efv 
 
 
823.4 
 
 
316.1 
 
150 
 
 
100 
 
791.3* 
399.2 
 
272.1 
244.1 
168.0* 
52.9 
 
12.5 
22.5 
 
2.5 
7.5 
22.5 
17.5 
 
Table 3.3: Optimal fragmentor voltages and collision energy settings for Rif and 
Efv 
* Quantifier ion 
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 Quantification was based on the integrated peak area as determined by the 
Masshunter quantification analysis software which quantitates the peak areas of 
the MRM transitions of each analyte. 
 
3.3.3 Preparation of standards 
 
Stock standard solutions of Rif and Efv were prepared by weighing out the 
powders in a glovebox, dissolving them in MS grade ACN to 1 mg/mL 
concentration and storing them in amber vials at 2-4 °C in the dark. Working 
standards of Efv and Rif were prepared both in drug-free human plasma and in 
mobile phase (ammonium acetate (pH 4.75, adjusted with 1 M acetic acid, 20 
mM), ACN and MeOH (40:45:15, v/v/v)) to concentrations over the range 0.01–
20 μg/mL (0.01, 0.1, 1, 2, 10 and 20 μg/mL in plasma which corresponded to 0.02, 
0.2, 2 and 4, 20 and 40 μg/mL in MP) for Efv and 0.001–20 μg/mL (0.001, 0.01, 
0.1, 1, 2, 10 and 20 μg/mL in plasma which corresponded to 0.002, 0.02, 0.2, 2 
and 4, 20 and 40 μg/mL in MP) for Rif. 20 μL was injected into the HPLC system 
for analysis.  
A 0.3 mL aliquot of each of the working standards was diluted 1:1 (v:v) 
with a 1% formic acid solution in water. The SPE Evolute Array Wells (25 mg 
ABN, 1 mL) in the 96 well plate sample processing manifold were conditioned 
with 1 mL MeOH and then equilibrated with 1 mL of the 0.1% formic acid 
solution. A 0.6 mL aliquot of the diluted, acidified sample was loaded onto the 
well, washed with 20% MeOH in water and eluted with a water (1 mg/mL 
ascorbic acid)-ACN-MeOH mixture (25:50:25, v/v/v). The samples were 
evaporated to dryness and reconstituted with 150 μL HPLC mobile phase 
(ammonium acetate (pH 4.75, adjusted with 1 M acetic acid, 20 mM), ACN and 
MeOH (40:45:15, v/v/v)). The overall clean-up process resulted in the diluted 
plasma sample being concentrated by a factor of four which equated to an overall 
enrichment factor of two for the neat plasma. The reconstituted sample was then 
transferred to chromacol vial and 20 μL was injected into the HPLC system for 
analysis. 
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3.3.4 Method Validation  
 
Due to time constraints, the method was only partially validated. Validation 
parameters including sensitivity, linearity, range and recovery were determined for 
the method.  
 
3.4      Results and discussion 
 
3.4.1 Method development 
 
Chapter 2 describes a method capable of extraction, separation and detection of 
Rif, its metabolite dRif and Efv in a single assay utilising UV detection. The 
sensitivity achieved was sufficient for its intended purpose in the SPhEAR project, 
however, there is no method in the literature capable of extracting both Rif and 
Efv simultaneously using LC-MS and so a transfer to an MS-based analysis 
method was proposed in order to achieve greater sensitivity, potentially allowing 
for much smaller sample volumes and less inconvenience for patients having drug 
levels monitored.  
 
3.4.2 Chromatographic procedure 
 
As the optimised chromatographic conditions developed for the LC-UV method 
proved excellent in terms of separation of the drugs, it was decided to keep the 
analytical method in keeping with these conditions and focus method development 
on optimising the MS conditions. Refer to section 2.4.2. 
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Figure 3.1: Chromatogram of a working standard of Efv and Rif prepared to 500 ng/mL in mobile phase 
Efv 
Rif 
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3.4.3 Extraction procedure 
 
There were no changes required for the SPE column or its dimensions in the 
method transfer. The SPE protocol using Evolute ABN cartridges was the same as 
for the LC-UV method discussed in Chapter 2. Refer to section 2.4.4. 
 
3.4.4 MS detection 
 
Briefly discussed in Chapter 1 was the triple quad MS. The MS system utilised for 
this assay consisted of a 6410 QQQ MS from Agilent, United Kingdom. The 
quadrupoles are the first and last sections (MS1 and MS2) of the instrument, with 
a collision cell in the middle section. See Figure 3.2. By creating oscillating 
electric fields, the quadrupole determines the selectivity of the ions trajectory to 
the detector. In the collision cell, ions collide with nitrogen gas atoms to give rise 
to product ions. The fragment ions resulting then proceed to the last quadrupole 
(MS2) where the mass to charge ratio (m/z) is detected. There are various modes in 
which the triple quad MS can operate.  
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MS mode MS1 Collision cell MS2 
MS2 scan 
 
 
 
 
 
Monitor all ions 
SIM 
Select 
m/z 
 
 
 
  
 
Monitor single ion 
Product ion 
scan 
 
Select m/z 
 
 
 
 
 
Product ion scan 
MRM 
 
Select m/z 
 
 
 
 
 
 
Monitor selected 
fragment ion(s) 
 
Figure 3.2: Schematic diagram of mode of action for each quad in the various MS 
scan modes using the Agilent 6410 QQQ MS 
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MS2 Scan  
 
MS2 Scan mode is where the first quadrupole allows all ions unfiltered into the 
collision cell. The collision cell directs the ions to pass unchanged and enter into 
the MS2 where all ions are detected. See Figure 3.2. 
 
SIM  
 
In selected ion monitoring the precursor ion is detected without collision in MS2.  
MS1 filters the ions so that only the ions of a particular m/z ratio are permitted into 
the system.  The detector continues to monitor the same single m/z value over the 
entire scan period, as shown in Figure 3.2. 
 
Product Ion Scan  
 
Product ion scan is used to determine the product ions. The ions enter MS1 where 
only the ions of interested are filtered in and sent to the collision cell. Through 
collision with nitrogen gas, at operator controlled voltages, the precursor ion is 
broken into the product ion(s). In this way it is possible to identify the product 
ions, as shown in Figure 3.2. 
 
MRM 
 
Detection and quantification by MRM mode is undoubtedly the optimum in bio-
analytical methods, as the incoming ion stream is filtered for the specific ion of 
interest.  The specific ion undergoes fragmentation in the collision cell, in the 
presence of an inert gas, in this case pure nitrogen, to yield product ions.  The most 
abundant product ion is used for quantification, while any additional product ions 
detected are used as qualifier ions.  Qualifier ions increase the specificity of the 
analysis. 
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 Using flow injection analysis (FIA) the optimum MRM settings were 
determined for Rif and Efv.  Optimisation was carried out by FIA injecting 250 
ng/mL of the drug, varying each condition sequentially. The use of an injector 
program allowed for the multiple injection of the same compound, from the same 
vial, a defined number of times.  This permits multiple injections to be viewed and 
analysed in one data file, which eliminates the majority of error associated with 
inter-injection variability.  
 The settings of each ion source/spray chamber depend on the mobile phase 
composition, flow rate, and sample identity. The nebuliser pressure, drying gas 
flow, and drying gas temperature are dependent upon the mobile phase 
composition and flow rate. The settings used were set according to the MS 
operation manual for a mobile phase flowrate of 0.8 mL/min. Drying gas 
temperature was set to 375 0C, drying gas flow to 11 L/min and nebuliser pressure 
to 50 psi and with these settings, the following experiments were carried out in 
order to find the best parameters for each drug.   
 
3.4.4.1  Precursor ion determination 
 
The precursor ion is an electrically charged molecular moiety which may 
dissociate to form fragments (Westman-Brinkmalm et al., 2008). These fragments 
may be charged or neutral moieties.  Charged fragments can be detected and used 
to further identify the analyte.  
 Chromatographic conditions were simulated as for the assay developed, a 
flow rate of 0.8 mL/min and ammonium acetate (pH 4.75, adjusted with 1 M 
acetic acid, 20 mM), ACN and MeOH (40:45:15, v:v:v) MP were used while 
optimising the MS conditions. From the autosampler, 10 μL of sample were 
injected into the mass spectrometer by a FIA setup where a TIC scan (discussed in 
Chapter 1) was run in order to establish the predominant precursor ion. The range 
was set from 600 to 850 m/z for Rif and from m/z 200 to 400 for Efv. These ranges 
were chosen as they bracketed the molecular weights of Rif and Efv. Once a 
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prominent peak was seen at the expected m/z value, this was deemed to be the 
precursor ion, Rif had a m/z of 823.4 and Efv had a m/z of 316.1, see Figure 3.3.  
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Figure 3.3: Comparison of (a) background and Rif* and (b) background and Efv* 
(a) 
(b) * 
* 
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3.4.4.2 Fragmentor voltage optimisation 
 
Once the precursor ion had been established, the next step was to determine the 
optimum fragmentation conditions for that precursor ion in order to maximise its 
intensity. The fragmentor voltage (FV) is not actually involved in the 
fragmentation of the precursor ion to the product ion, rather it acts as a filter for 
the MS.  The purpose of the fragmentor voltage is to preferentially maximise the 
throughput of precursor ions into the MS.   
 The mass spectrometer was programmed to perform an MS selected ion 
monitoring (SIM) scan which detects only the selected precursor ion so that the 
optimum fragmentor voltage for that ion could be determined. To increase 
accuracy duplicate injections were performed. These SIM scans were done in 
series where the fragmentor voltage was varied over a range of 20 to 160 V using 
voltage increments of 20 V. See Figure 3.4 and Figure 3.5. The aim was to find the 
highest intensity for the precursor ion as this would maximise sensitivity of the 
assay. Often, more stable molecules will require higher voltages in order to 
fragment in source while more fragile molecules will need less voltage to break 
apart. 150 V achieved optimal results for Rif while 100 V was the best voltage 
setting for Efv. See Table 3.4. The reduction in peak area at higher fragmentor 
voltage is due to the precursor ion being broken down before entering the MS.  
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Figure 3.4: TIC for m/z of 823.4 for Rif in SIM mode with increasing fragmentor voltage 
FV = 20 
FV = 120 FV = 140 FV = 160 FV = 180 
FV = 200 
FV = 100 
FV = 80 
FV = 60 
FV = 40 
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Figure 3.5: TIC for m/z of 316.1 for Efv in SIM mode with increasing fragmentor voltage 
FV = 20 
FV = 40 
FV = 60 FV = 80 
FV = 100 FV = 120 
FV = 140 
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Voltage 
Rif Efv 
Area 
Area 
% 
Area 
Area 
% 
 
20 
 
 
40 
 
 
60 
 
 
80 
 
 
100 
 
 
120 
 
 
140 
 
 
160 
 
 
180 
 
 
200 
 
 
33489 
33262 
 
36809 
37483 
 
39812 
41063 
 
44053 
43590 
 
46167 
46631 
 
49027 
48022 
 
50323 
50389 
 
50537 
49601 
 
50082 
49385 
 
44687 
44396 
 
66.27 
65.82 
 
72.84 
74.17 
 
78.78 
81.25 
 
87.17 
86.25 
 
91.35 
92.27 
 
97.01 
95.02 
 
99.58 
99.71 
 
100.00 
98.15 
 
99.10 
97.72 
 
88.42 
87.85 
 
 
16757 
16711 
 
19477 
19943 
 
22143 
22133 
 
22768 
23613 
 
25003 
24431 
 
22435 
22518 
 
12235 
12367 
 
67.02 
66.84 
 
77.90 
79.76 
 
88.56 
88.52 
 
91.06 
94.44 
 
100.00 
97.71 
 
88.73 
90.06 
 
48.93 
49.46 
 
Table 3.4: Comparison of fragmentation voltages for Rif and Efv on peak area of 
integrated SIM 
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3.4.4.3 Product ion determination 
 
Having established the optimum fragmentor voltage for Rif and Efv, the next step 
involved carrying out a product ion scan in order to identify the product ions of Rif 
and Efv’s precursor ions. The product ions are the ions detected by the detector in 
the third quadrupole of the mass spec, as a result of the fragmentation of 
preselected precursor ions in the collision cells.   
 This was achieved by firstly isolating and then fragmenting the precursor 
ion with varying collision energy values ranging from 0 to 40, using increments of 
10. By exposing the precursor ion to increasing collision energy, fragmentation 
occurred and the product ions were determined As it is very common for 
compounds to readily lose water and or ammonia, it’s important not to choose a 
fragment peak too near to the precursor peak. Choosing the ammonia or water loss 
peaks for the MRM experiment would result in a less than unique transition. 
 Figure 3.6 shows the extracted MS spectrum of the TIC of the product ion 
scan for Rif. Figure 3.6 (A) illustrates Rif’s precursor ion with no collision energy 
applied. Figure 3.6 (B) is with a collision energy setting of 10 V applied.  The 
product ion m/z 791.3 was seen.  A drop in the abundance of the precursor ion was 
also seen, indicating that the m/z 791.3 ion came from m/z 823.4. Figure 3.6 (C) 
showed that a collision energy of 20 V gave a second product ion at m/z 399.2 and 
left little precursor ion. Figure 3.6 (D) with a collision energy of 30 V applied 
showed that a high collision energy completely broke down the precursor ion so 
that it was no longer detectable. The ion with m/z of 791.3 was the most abundant 
ion and so was used for quantification of Rif. 
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Figure 3.6: TIC for the product ion scan of Rif with increasing collision energies 
 
 Figure 3.7 shows the extracted MS spectrum of the TIC of the product ion 
scan for Efv. Figure 3.7 (A) illustrates Efv’s precursor ion with no collision energy 
applied. Figure 3.7 (B) is with a collision energy setting of 10 V applied. Four 
product ions of m/z 272.1, m/z 244.1, m/z 168.0 and m/z 52.9. were seen and left 
little precursor ionindicating these ions came from m/z 318.1. Figure 3.7 (C, D and 
E) of collision energies 20, 30 and 40 V respectively showed that a high collision 
energy completely broke down the precursor ion so that was it was no longer 
detectable. M/z 168.0 was the most abundant ion and so was used for 
quantification of Efv.  
(A)  CE = 0 
(B) CE = 10 
(C) CE = 20 
(D) CE = 30 
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Figure 3.7: TIC for the product ion scan of Efv with increasing collision energies 
 
 
 
 
 
 
(A)  CE = 0 
(E) CE = 40 
(D) CE = 30 
(C) CE = 20 
(B) CE = 10 
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3.4.4.4 MRM transition optimisation 
 
MRM can track many precursor ions and their multiple product ions through the 
MS to provide spectra that are quantifiable. Each transition from precursor ion to 
product ion can have different collision energies. By optimising the MRM 
transition through FIA, the collision energy for each transition was optimised. 
 MRM scans which detected the MS/MS transitions were carried out in 
order to obtain the optimum collision energy (CE) for fragmentation of Rif and 
Efv into their product ions. Duplicate injections were performed to increase 
accuracy. Collision energy was raised in increments of 5 V starting from 0 V so 
that an accurate collision energy could be established. The collision energy that 
gave the most intense peak for the chosen product ion was deemed to be the 
optimum value. Figures 3.8 and Figure 3.9 show the determination of the optimum 
MRM transition setting for Rif and Figures 3.10 through to Figure 3.13 show the 
determination of the optimum MRM transition setting for Efv.  Tables 3.5 and 3.6 
display the results obtained for the optimum MRM transition settings for  both Rif 
and Efv. 
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Figure 3.8: Rif product ion m/z 791.3 with increasing collision energies 
CE = 0 
CE = 20 
CE = 15 CE =1 0 
CE = 5 
CE = 25 
CE = 30 
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Figure 3.9: Rif product ion m/z 399.2 with increasing collision energies 
CE = 0 
CE = 15 
CE = 10 
CE = 5 
CE = 25 CE = 20 
CE = 30 
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Voltage 
791.3 399.2 
Area Area % Area Area % 
 
0 
 
 
5 
 
 
10 
 
 
15 
 
 
20 
 
 
25 
 
 
30 
 
 
 
 
1908 
1907 
 
4744 
4666 
 
9102 
9050 
 
9949 
9829 
 
5715 
5753 
 
1761 
1736 
 
282 
281 
 
 
19.18 
19.17 
 
47.68 
46.90 
 
91.48 
90.96 
 
100.00 
98.80 
 
57.44 
57.82 
 
17.70 
17.45 
 
2.83 
2.82 
 
 
57 
56 
 
142 
145 
 
338 
348 
 
880 
874 
 
1663 
1610 
 
1723 
1737 
 
1133 
1151 
 
3.29 
3.23 
 
8.19 
8.36 
 
19.46 
20.03 
 
50.63 
50.30 
 
95.73 
92.69 
 
99.16 
100.00 
 
62.50 
66.24 
 
 
Table 3.5: Collision energy results for product ions of Rif 
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Figure 3.10: Efv product ion m/z 52.9 with increasing collision energies 
 
CE = 0 
CE = 10 
CE = 15 CE = 20 CE = 25 CE = 30 
CE = 35 CE = 40 
CE = 45 
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Figure 3.11: Efv product ion m/z  168.0 with increasing collision energies 
 
CE = 0 
CE = 15 
CE = 10 
CE = 5 
CE = 30 
CE = 25 CE = 20 
CE = 35 
CE = 40 
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Figure 3.12: Efv product ion m/z  244.1 with increasing collision energies 
 
CE = 0 
CE = 15 
CE = 10 
CE = 5 
CE = 20 
CE = 25 
CE = 30 
CE = 35 
CE = 40 
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Figure 3.13: Efv product ion m/z  272.1 with increasing collision energies 
CE = 20 
CE = 15 
CE = 5 
CE = 10 
CE = 0 
CE = 25 CE = 30 
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 Product ion 
Voltage 
272.1 244.1 168.0 52.9 
Area Area % Area Area % Area Area % Area Area % 
 
0 
 
 
5 
 
 
10 
 
 
15 
 
 
20 
 
 
25 
 
 
30 
 
 
35 
 
425 
441 
 
428 
482 
 
209 
201 
 
53 
42 
 
7 
10 
 
88.17 
91.49 
 
88.80 
100.00 
 
43.42 
41,70 
 
10.98 
8.7 
 
1.45 
2.03 
 
348 
365 
 
593 
629 
 
657 
669 
 
520 
550 
 
362 
265 
 
211 
215 
 
52.08 
54.51 
 
88.70 
94.02 
 
98.21 
100.00 
 
77.78 
82.21 
 
54.11 
54.56 
 
31.57 
32.06 
 
86 
99 
 
210 
211 
 
308 
317 
 
437 
408 
 
491 
481 
 
451 
457 
 
419 
409 
 
341 
303 
 
17.53 
20.12 
 
42.77 
42,97 
 
62.74 
64.56 
 
89.00 
83.11 
 
100.00 
97.97 
 
91.89 
96.79 
 
85.34 
83.27 
 
69.45 
61.68 
 
174 
191 
 
413 
394 
 
568 
576 
 
634 
616 
 
643 
614 
 
598 
575 
 
511 
543 
 
493 
463 
 
27.09 
29.74 
 
64.21 
61.29 
 
88.30 
89.59 
 
98.61 
95.79 
 
100.00 
95.53 
 
93.04 
89.40 
 
79.57 
84.54 
 
76.72 
71.96  
 
Table 3.6: Collision energy results for product ions of Efv 
 
  Table 3.7 displays a summary of the collision energy results obtained for 
product ions of Rif and Efv. 
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Compound Product  ion 
Collision 
energy 
 
Rif: 
 
 
Efv: 
 
 
791.3 
399.2 
 
272.1 
244.1 
168.0 
52.9 
 
12.5 
22.5 
 
2.5 
7.5 
22.5 
17.5 
 
Table 3.7: Summary of collision energy results for product ions of Rif and Efv 
 
 The final MS conditions used in terms of precursor and product ions, 
collision energies and fragmentation voltages are shown in Table 3.8. 
 
Compound Precursor
ion 
Fragmentor
voltage 
Product
ion 
Collision 
energy 
 
Rif 
 
Efv 
 
 
823.4 
 
316.1 
 
150 
 
100 
 
791.3 
 
168.0 
 
12.5 
 
22.5 
 
Table 3.8: Optimum positive mode ESI conditions for Rif and Efv 
 
182 
 
 The signal intensity of Efv in relation to Rif at a concentration of 500 
ng/mL is quite low. On comparing 3 different capillary temperatures, 350 °C 
remained optimal for Rif but on changing from 350 °C to 250 °C, a slight 
improvement was observed for Efv and so 250 °C was used as capillary 
temperature for Efv. See Figure 3.14. 
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Figure 3.14: Comparison of different capillary temperatures for (a) Rif and (b) Efv  
 
 
 
(a) 
350 °C 
250 °C 
300 °C 
350 °C 
300 °C 
250 °C (b) 
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3.5      Method Validation 
 
3.5.1 Sensitivity 
 
LC-MS is inherently more sensitive than LC-UV detection as the technique can 
monitor individual ions whereas; LC-UV is reliant on an entirely different 
detection system. MS detectors combine specificity, selectivity and sensitivity. 
Quantification was based on the mass transitions from precursor to product ion. 
The increased sensitivity of the Agilent Triple Quadrupole MS is in part due to the 
orientation of the ionisation.  The orthogonal orientation of the nebuliser spray to 
the sample capillary reduces the background noise from the samples allowing 
lower LOD and LOQ.  This is because any ions that are uncharged in the source 
do not make it into the MS system.   
 Both the limits of quantitation (LOQ) and detection (LOD) were 
determined for the assay, see Figure 3.15 and Figure 3.16. The LOQ was defined 
as the lowest concentration that produced a peak distinguishable from background 
noise with a minimum ratio of 10:1. An LOQ of 1 ng/mL was obtained for Rif in 
plasma. This is an extremely sensitive result as the literature revealed the lowest 
LOQ for serum spiked with Rif using MS was 50 ng/mL (Song et al., 2007) and in 
plasma 100 ng/mL (Hartkoorn et al.,  2007). Both required a small sample volume 
of 50 μL. 
 An LOQ of 10 ng/mL was obtained for Efv prepared in 0.3 mL plasma. 
Again this is an excellent result and is comparable with the literature which 
reveals the lowest LOQ obtained was 10 ng/mL in plasma (Rentsch et al., 2003, 
Volosov et al., 2002). Rentsch et al. 2003, required a large sample volume of 1 
mL plasma for the analysis and 30 μL of the reconstituted post extracted sample 
was injected for LC-MS analysis. Comparing the analyses by Rentsch with our 
own, the mass of drug on column with their method equated to 300 pg in 
comparison to 200 pg for the assay we describe here. This renders our method 
superior for the analysis of Efv. Volosov et al., 2002, required only 80 μL plasma, 
however, the volume injected for analysis was not specified and so a direct 
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comparison to the method developed here in terms of mass on column could not 
be made. Extracted blank plasma samples did not yield any endogenous peaks at 
the retention times of the drug compounds.  
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Figure 3.15: Chromatogram of a working standard of Rif prepared to 1 ng/mL in plasma 
Rif 
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Figure 3.16: Chromatogram of a working standard of Efv prepared to 10 ng/mL in plasma 
Efv 
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3.5.2 Linearity and range 
 
The calibration curves for Efv and Rif over the concentration range 0.001 - 
20 μg/mL for Rif and 0.01 - 20 μg/mL for Efv exhibited good linearity with 
correlation coefficients (R2) for all standard curves above 0.99. See Figure 3.16 
and Figure 3.17. 
189 
 
 
Figure 3.16: Linearity for Rif plasma standards 
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Figure 3.17: Linearity for Efv plasma standards 
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3.5.3 Recovery 
 
As discussed in Chapter 2, highest recoveries for the drugs in one extraction step 
were obtained with the SPE ABN well plates. And so, the extraction procedure 
remained unchanged. Varying concentrations of Efv, Rif and (0.1, 1 and 10 
μg/mL) were prepared in drug-free human plasma and extracted using the SPE 
cartridges. The percentage of drug recovered from these plasma samples was 
determined by comparing the calculated concentrations following extraction and 
HPLC assay with the calculated concentrations from unextracted samples in MP of 
the same concentration after HPLC assay. Recoveries for plasma samples spiked 
with 0.1, 1 and 10 μg/mL of Efv and Rif were all ≥ 70% (See Table 3.9). This 
correlates with results obtained in Chapter 2. 
 
 
 
 
 
 
 
 
 
 
 
Table 3.9:  Recovery data for drugs from plasma (n = 3) 
 
 
3.6    Conclusions  
 
The LC-UV method described in Chapter 2 was transferred to MS detection using 
similar chromatographic parameters as for the UV method. The sensitivity 
achieved was excellent with an LOQ of just 1 ng/mL for Rif in plasma. As 
Conc. (µg/mL) 
Mean % recovery ± RSD 
Rif Efv 
 
0.1 
1 
10 
 
 
93.1 ± 1.5 
94.0 ± 1.8 
94.8 ± 0.8 
 
 
71.0 ± 2.4 
70.4 ± 1.9 
71.8 ± 2.1 
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discussed, it is far superior to what is available in the scientific literature which 
reveals the lowest LOQ for serum spiked with Rif using MS to be 50 ng/mL (Song 
et al., 2007) and in plasma 100 ng/mL (Hartkoorn et al., 2007). An LOQ of 10 
ng/mL was obtained for Efv prepared in plasma. Again this is an excellent result 
in comparison with what has previously been reported in the  literature which 
reveals the lowest LOQ obtained for Efv was 10 ng/mL in plasma (Rentsch et al., 
2003, Volosov et al., 2002).  
The assay described in this chapter is the first capable of achieving such 
low levels of Rif and Efv from a biological matrix. Furthermore, the fast and easy 
sample treatment by SPE, as well as the short runtime of the assay allows for rapid 
sample processing and analysis. 
Given more time, a decrease in the plasma sample volume would have 
been investigated. There would be major advantages of using finger prick assays 
for blood rather than taking mLs using standard blood collection tubes which 
would allow for more routine analysis.   
Measurements for each analyte in the biological matrix would be validated 
according to FDA guidelines (FDA, 2001) given more time. Validation parameters 
including intra- and inter-day precision, accuracy, sensitivity, linearity and range 
and recovery would be performed on the method. Following a full validation, this 
method would be capable of detecting extremely low levels of both drugs 
simultaneously in aqueous samples which would be useful to pharmaceutical 
companies. It would also be interesting to apply the method to biological samples.  
It would also be advantageous to modify the assay in order to quantify cellular and 
tissue levels of the drugs. 
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Chapter 4 
 
Development of a sensitive assay to extract, separate and 
quantitate scopolamine (anti-motion sickness medication) 
in human serum 
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4.1 Scope of research 
 
The objective of this work was to develop a method for the quantitative and 
sensitive determination of the anti-motion sickness drug, scopolamine, in human 
serum using LC-MS with solid phase extraction. Scopolamine is administered 
as a transdermal patch loaded with 1.5 mg of agent which is gradually released 
over many hours into the circulation, as a result the serum concentration 
resulting from the application of a patch is very low and clearly it would be 
anticipated that half a patch should generate substantially lower circulating drug 
levels, well below the anticipated threshold where UV detection might be 
employed. MS detection was chosen for this work as it is a technique which we 
felt might be sensitive enough to detect the drug at the required concentrations 
(pg/mL range) over time in blood samples. It had been hypothesised at NASA 
that in individuals who appeared adversely affected by the use of a whole 
transdermal patch, if it is halved and then used by the astronaut, that this might 
be just as effective but with a lower severity and incidence of side effects. 
Hence, the rationale for developing this assay was to enable the hypothesis to be 
tested so that, if we generated pilot information a larger more detailed 
evaluation could be conducted. 
 
4.2 Introduction 
 
4.2.1 Motion sickness and its treatment 
 
Motion sickness can occur in response to real or apparent motion. When motion 
sickness occurs in response to real motion, it is often labelled with the related 
vehicle or situation to more specifically identify the ailment, e.g., car sickness, 
air sickness, sea sickness, space sickness, etc. Apparent motion refers to a 
situation in which the individual is stationary, but motion in the visual field 
causes the individual to experience an illusion of motion. Apparent motion can 
occur in rotating drums lined with variously contrasting scenes, in large field of 
view movies that display motion and in computer-generated simulations of real-
world environments. When motion sickness occurs in response to computer-
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generated simulations, it is often referred to as simulator sickness or virtual 
environment sickness. All of these terms are somewhat misleading because 
motion sickness is not really a sickness, but rather a psychophysiological 
response of healthy individuals to real or apparent motion stimulation of 
significant intensity and/or duration and where the orientation information being 
transmitted from the inner ear conflicts with visual and other sensory signals 
arriving concurrently in the brain (Muth, 2006).   
Motion sickness remains a persistent problem for astronauts in 
spaceflight. Motion sickness first appeared as an operational problem in the 
second manned Soviet mission in 1961 and became a significant concern in 
later missions for all nations, especially with increased flight duration. The 
overall incidence of symptoms of motion sickness in the space shuttle program 
has been approximately 70% for astronauts in their first space mission but is 
lower in experienced astronauts. Symptoms of space motion sickness usually 
start to develop within the first several hours in weightlessness. After 72–96 hr, 
most astronauts have either recovered or begin to recover and are able to move 
about freely without eliciting debilitating symptoms. Because the shuttle 
missions are of relatively brief duration, generally 7–14 days, 3 days of 
impaired performance represent a severe negative impact on the mission. 
Symptoms range in severity from drowsiness to nausea and vomiting. Space 
motion sickness is most severe when the body is actively adjusting to 
weightlessness and sickness may reoccur upon landing during readaptation to 
earth gravity (Lackner et al., 2006).   
In motion sickness, a person vomits because conflicting sensory 
information arrives simultaneously in the brain from the inner ear and the eye. 
A group of nerve fibres deep inside the ear helps people keep their balance. It 
is thought that, for some people, the motion of ships, airplanes, trains, 
automobiles, buses and space travel increases the activity of these nerve fibres. 
This increased activity causes the dizziness, nausea, and vomiting of motion 
sickness. People may have one, some, or all of these symptoms. The drugs 
primarily used to treat motion sickness have antihistaminic or anticholinergic 
actions or a combination thereof. In NASA, scopolamine is one of the primary 
drugs used to manage motion sickness symptoms in space.  
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Atropine and scopolamine belong to the alkaloid family. Atropine and 
scopolamine, also referred to as (+)-hyoscyamine and hyoscine, respectively, 
are extracted from plant species belonging to the solanaceae family (Cherkaoui 
et al., 1997). Scopolamine (Scop), is a tropane alkaloid drug (Ceyhan et al., 
2001) (see Figure 4.1) obtained from plants of the family solanaceae, such as 
henbane or jimson weed (datura species) and belladonna. Scop has well known 
pharmacological properties and can be highly toxic due to its powerful anti-
cholinergic properties (Roberge, 2006). Scop acts (1) as a competitive inhibitor 
at postganglionic muscarinic receptor sites of the parasympathetic nervous 
system, and (2) on smooth muscles that respond to acetylcholine but lack 
cholinergic innervation. It has been suggested Scop acts in the central nervous 
system (CNS) by blocking cholinergic transmission from the vestibular nuclei 
to higher centers in the CNS and from the reticular formation to the vomiting 
center. Scop can inhibit the secretion of saliva and sweat, decrease 
gastrointestinal secretions and motility (Beyer et al., 2009), cause drowsiness, 
dilate the pupils, increase heart rate, and depress motor function (Steenkamp et 
al., 2004). 
Although Scop has been employed therapeutically for thousands of 
years, in the 20th century it was purified and its pharmacological actions 
studied extensively. In the past, Scop has been used as a ‘truth’ drug, a mind 
control drug dating back to applications by the Nazis in Germany during World 
War II, and, subsequently, evaluated by the American CIA. As it depresses the 
central nervous system, it has been used as an amnesiac for women in labour, 
producing "Twilight Sleep" (Binotto et al., 2006). Scop has also unfortunately 
become prevalent as a date rape drug as Scop leaves the victim in a state of 
compliancy, where their mind is totally controlled so a recipient can participate 
in the rape and afterwards remember little or nothing at all. The typical 
maximum dosage use for legal/medicinal applications which include control of 
motion sickness and postoperative nausea and vomiting (Roberge, 2006) is 
0.33 milligrams. High doses of 5-7 milligrams can render the victim into a 
zombie-like state as described above and at 10 milligrams can produce coma 
then death.  
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Figure 4.1: Chemical structures of (a) Scop and (b) Atr 
 
Scop can be administered via a transdermal patch, orally, 
subcutaneously, and via ophthalmic and intravenous routes. The transdermal 
patch (worn behind the ear) is the most common form of the drug used in the 
US. However, the following undesirable side effects have been reported while 
taking the patch: dry mouth, as Scop inhibits saliva secretion, drowsiness, 
dizziness and depressed motor function (Sandlin, 2002). In NASA, for patients 
who demonstrate side effects, it has been suggested that using half a 
transdermal patch (cut in half) gives symptom relief while reducing side 
effects. A project to evaluate the efficacy and side effects of standard patch 
versus half patch transdermal Scop in preventing motion sickness induced by 
off-vertical axis rotation (OVAR) was initiated. The hypothesis is that some 
subjects who have undesirable levels of side effects with the full dose will have 
fewer side effects but still have efficacious symptomatic motion sickness 
management with the lower dose. 
(a) 
(b) 
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4.2.2 Physiochemical properties of scopolamine and atropine 
 
Scop is an antimuscarinic agent and has actions that are qualitatively similar to 
those of atropine. Quantitatively, Scop is more potent than atropine in its action 
on the iris, ciliary body and certain secretory (salivary, bronchial and sweat) 
glands, but less potent in its actions on the heart, and intestinal and bronchial 
smooth muscle (Renner et al., 2005).  
Scop is a heterocyclic tropane alkaloid with a molecular weight of 
303.36 g/mol (Steenkamp et al., 2004) and a pKa value of 7.55-7.81 
(Cherkaoui et al., 1997). Scop is lipid soluble (Tullberg, 2007) and therefore 
poorly soluble in water, hence the drug is prepared experimentally in methanol. 
Because of its many exposed functional groups, Scop is readily subject to 
chemical and biological decomposition and is thus stored and administered as a 
hydrated hydro-halogen (typically HCl or HBr) salt for stability.  
Atropine (Atr), like Scop, has a tertiary amine structure (Tullberg, 
2007), the only difference being an additional epoxy group on the tropane ring 
of Scop (Oertel et al., 2001) (See Figure 4.1). Atr has a molecular weight of 
289.37 g/mol (Steenkamp et al., 2004) and a pKa value of 9.85 (Cherkaoui et 
al., 1997). Atr, though less lipid soluble than Scop (Tullberg, 2007), is still 
poorly soluble in water and is also experimentally prepared in methanol. 
 
4.2.3 Sample extraction/clean-up procedures for scopolamine 
 
In order to determine drug concentrations in plasma or serum, it is necessary to 
have an accurate, precise and selective analytical method, requiring a small 
sample volume and with rapid sample processing. The three main sample 
extraction techniques employed to extract drugs from biological fluids tend to 
be liquid-liquid extraction (LLE), protein precipitation (PP) and solid-phase 
extraction (SPE). The characteristics of several of the most accepted Scop 
quantifications methods are summarized below.   
In the main, SPE approaches have been exploited for the extraction of 
Scop from biological matrices such as plasma, serum and urine – see Table 4.1. 
However, many of these methods demonstrate poor Scop recovery.  
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To date, there are no reported PP extraction procedures for Scop from 
biological samples prior to LC analysis.  LLE has been used prior to GC-MS- 
(Oertel et al., 1996) or LC-MS- based quantitation strategies (Xu et al., 1995). 
For example, Xu used dichloromethane to extract l-hyoscyamine and Scop 
from plasma samples. A high recovery resulted for Scop at 93% but the plasma 
sample volume required was high at 1 mL. 
In terms of SPE, Oertel et al., 2002, developed a procedure for the 
extraction of Scop from serum using Atr as an internal standard and employing 
Oasis HLB cartridges. Cartridges were conditioned with methanol of water, 
pushing with air. A sample volume of 0.2 mL serum was required for the 
extraction which was mixed with 0.2 mL phosphate buffer before loading. 
Washing solutions were composed of water and 10% methanol in water. 
Compounds were eluted with methanol. A concentration factor of two resulted 
but the recovery achieved was low at only 51%. 
Chen et al., 2005,  and Beyer et al., 2007, both used SPE for the 
extraction of Scop. Chen used SPE for the extraction of Scop and its 18 
metabolites from rat urine. A 1 mL aliquot of urine samples was loaded onto a 
C18 solid-phase extraction cartridge that was preconditioned with methanol 
and water. The SPE cartridge was then washed with water and the analytes 
eluted with of methanol. In this case, recovery for Scop was satisfactory at 68-
79%. Beyer used mixed mode SPE for the extraction of Scop from plasma. 
Again a high sample volume was required (1 mL) and recovery ranged 
between 67 and 92% for Scop. 
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Reference Analytes Matrix Extraction mode 
Extraction 
recoveries 
(%) 
Detection
Approx 
retention 
time (min) 
LOQ/LOD Column Sample vol. Gradient 
            
(Beyer et 
al., 2007) 
Scop, Atr & 
other drugs 
Plasma Mixed 
mode SPE 
Atr: 51-85 
Scop: 67-92 
MS Atr ~ 5.4 
Scop ~ 4.8 
APCI: 
LLOQ: 
5ng/mL ESI 
LLOQ: 
0.1ng/mL 
C8 1 mL Yes
(Chen et 
al., 2005) 
Scop & its 
18 
metabolites 
Rat 
Urine 
SPE 20 ng/mL: 68 
50 ng/mL: 79
MS 2.9 LOD 5 
ng/mL UV; 
10 μg/mL 
MS; 
Zorbax-
Extend 
RP C18 
1 mL No
(Steenkamp 
et al., 
2004) 
Scop & Atr Viscera  
samples
SPE n/a UV/MS Scop: 20.0 
Atr: 21.6 
Scop: 1 
ng/mL Atr: 
100 pg/mL 
Xterra 
Phenyl 
3g of 
each 
sample 
Yes
(Oertel et 
al., 2002) 
Scop & 
other drugs 
Human 
serum 
SPE Not stated MS Scop: 2.7 LLOQ 50 
pg/mL 
C18 
Purospher 
STAR RP
0.2 mL Yes, dual 
pump 
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(Oertel et 
al., 2001) 
Scop & Atr 
(IS) 
Human 
serum 
& 
micro 
dialysis 
samples
SPE 51 MS Scop: 3.3      
Atr: 3.6 
LLOQ 20 
pg/mL 
C18 
Purospher 
STAR RP
0.2 mL 
serum 
Yes
 
(Xu et al., 
1995) 
 
l-
hyoscyamine 
& Scop (IS) 
 
Plasma 
 
LLE 
 
Scop: 93      
l-
hyoscyamine: 
~110 
 
 
MS 
 
Scop: 0.8 l-
hyoscyamine: 
1.2 
 
l-
hyoscyamine 
20pg/mL 
 
BDS C18 
 
1 mL 
 
No 
 
Table 4.1: Summary of the characteristics of reported extraction and LC detection techniques for the determination of Scop and Atr from 
biological samples 
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4.2.4 Sample separation and detection approaches for scopolamine 
 
There are a number of LC-MS (Auriola et al., 1991, Kursinszki et al., 2005, 
Rancic, et al., 2009, Lund et al., 1978, Lau et al., 1997, Mandal et al., 1991, 
Fliniaux et al., 1993) and LC-UV (Ceyhan et al., 2001, Kursinszki et al., 2005) 
methods in the literature for the analysis of tropane alkaloids in pharmaceutical 
preparations and in plants. GC-MS (Majlát et al., 1982) , CE  (Cherkaoui et al., 
1997, Ye et al., 2001, Mateus et al., 1998, Gao et al., 2005, Bo et al., 2003, 
Eeva et al., 1998, Yuan et al., 2010) and fluorimetry (Pohjola et al., 1994, 
Takahashi et al., 1997) have also been used for the detection of Scop and Atr. 
However, only a limited number of methods for the determination of 
Scop and Atr in biological material have been published (see Table 4.1). Atr 
and Scop have been detected in biological samples using GC–MS techniques 
(Eckert et al., 1981, Oertel et al., 1996, Namera et al., 2002, Bayne et al., 
1975, Deutsch et al., 1990) but the drawback of GC-MS in detecting tropane 
alkaloids is the heat instability of these compounds. Therefore, methods for 
quantitative determination either convert Atr or Scop to their degradation 
product (Eckert et al., 1981) or convert Atr or Scop to less unstable derivatives 
(Namera et al., 2002). 
LC–MS is currently the most common technique employed for the 
detection and quantification of tropane alkaloids as there is little issue with 
stability and sensitivity is excellent (Steenkamp et al., 2004, Xu et al., 1995, 
Oertel et al., 2002, Chen et al., 2005, Beyer et al., 2007). 
UV detection has been employed for Scop, but does not achieve the 
sensitivity required for the levels of the drug found in plasma/serum post patch 
application. As the doses of Scop to be detected are quite low (in the pg/mL 
range), it was decided that MS detection would be necessary in this project to 
give the best chance of being able to achieve adequate sensitivity in blood 
samples. 
Oertel et al. developed two LC-MS methods for the analysis of Scop 
and achieved the best sensitivity for Scop published to date. Oertel et al., 2001 
firstly developed an LC–tandem mass spectrometry for the determination of 
Scop in human serum and microdialysis samples. Even though the retention 
times of the drugs were fast with Scop eluting at 3.3 min, the chromatographic 
205 
 
separation involved a gradient programme which required a 10 min 
equilibration time between runs. The LC–MS/MS system used was an API 
3000 equipped with a turbo ion spray interface which was used in positive ion 
mode. Multiple reaction monitoring (MRM) was performed giving an excellent 
LOQ of 20 pg/mL. 
Oertel et al., 2002, subsequently investigated increasing sample 
throughput in pharmacological studies by using dual-column liquid 
chromatography with tandem MS. The sensitivity achieved using this approach 
was an excellent at 50 pg/mL. They extracted propiverine and its N-oxide, 
talinolol and Scop from serum samples using an automated SPE method. Using 
two C18 Purospher STAR columns, mobile phase gradients were again applied 
and within 4.2 min analytes and matrix were separated, eluting peaks of the first 
column were detected and quantitative LC–MS/MS data were acquired while the 
second column was equilibrated for the next injection. Even though excellent 
sensitivity was achieved, a gradient was required and two columns were needed 
which added complexity to the method. 
Chen et al., 2005, Beyer et al., 2009, and Xu et al. 1995, also developed 
LC-MS methods for Scop.  
Chen et al., 2005, developed a liquid chromatography-tandem mass 
spectrometry method for the analysis of Scop and its eighteen metabolites in rat 
urine. After application of the extraction procedure (see previous section), the 
pre-treated samples were injected into a Zorbax Extend-C18 reversed-phase 
column and detected by an on-line MS/MS system. Mass spectrometric 
detection was carried out in positive ion mode. However, the LOQ achieved was 
poor at 5 ng/mL. 
Beyer et al., 2009, used both APCI and ESI approaches for Scop’s 
detection. APCI resulted in a LOQ of 5 ng/mL and ESI 0.1 ng/mL. Although the 
LOQ using ESI was very low, the method required 1 mL plasma to achieve this 
sensitivity. Scop eluted at 4.8 min but a gradient programme was required for 
the method. 
Xu et al., 1995, developed an LC-MS method whereby Scop was used 
as the internal standard. Using a BDS C18 column, Scop eluted at 0.8 min and 
no gradient was required. Steenkamp et al., 2004, developed an LC-UV-MS 
method for the identification of Atr and Scop. This method allowed the direct 
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coupling of an electrospray (ZMD) mass selective detector to the HPLC 
system. Atr and Scop were well separated from other components and detected 
on the PDA with a LOD of 1 μg/mL and ZMD giving an LOD for Atr of 
10 pg/mL and for Scop of 100 pg/mL. Use of an Xterra Phenyl HPLC column 
with a mobile phase containing ammonium acetate at 0.2 mL/min resulted in 
Scop having an extremely long retention time of 20.0 min and Atr a retention 
time of 21.6 min. 
From the literature, many methods for the determination of Scop suffer 
from having to use a gradient programme or a large sample volume in order to 
achieve their fast runtimes and low sensitivity. In one reported case the use of 
two columns was required which complicates the method. And summarising, 
there is no fast, simple, isocratic method reported which achieves the 
sensitivity required for the analysis of Scop in serum post patch and half patch 
application.  
 
4.3 Experimental 
 
4.3.1 Reagents and materials 
 
MS grade acetonitrile (ACN) methanol (MeOH), water, ammonium formate, 
formic acid, phosphoric acid, scopolamine hydrobromide and atropine were 
obtained from Sigma Aldrich, United Kingdom. SPE extraction cartridges were 
purchased from Waters, Ireland and United States (HLB, WAX, MAX, WCX, 
and MCX) and Supelco (Supelclean LC-18). Scopolamine patches (Transderm 
Scop, scopolamine 1.5 mg from Novartis) were obtained from a local pharmacy. 
Human serum was purchased from Sigma Aldrich. 1.1 mL Chromacol vials 
were purchased from Fisher Scientific, Ireland. Analytical columns used were 
Supelcosil LC-18 (250 x 2.1 mm, 5 μm), Agilent Zorbax SB-CN (100 x 2.1 
mm, 3.5 μm), Agilent Zorbax SB-C18 (50 × 2.1 mm., 3.5 µm), Agilent Zorbax 
SB-Phenyl (150 × 4.6 mm, 5 µm) and Waters Nova-Pak C18 (150 × 3.9 mm, 4 
µm).  
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4.3.2 Equipment and HPLC assay conditions 
 
4.3.2.1 NASA equipment and assay conditions 
 
The LC-MS systems used in NASA, Kennedy Space Centre, consisted of an 
Agilent 1050 series quaternary pump and autosampler, an 1100 degasser and a 
Thermo Finnigan LCQ Deca MS. A T-piece and syringe pump, Agilent KD 
scientific (KDS 100) model were used for direct infusion. System management 
and data acquisition were performed using Empower software.  The SPE 
manifold was from Phenomenex. Other instrumentation included a Mettler 
Toledo pH meter and a Mettler Toledo electronic mass balance. 
Chromatographic separation was achieved using an Agilent Zorbax SB-
CN (150 x 2.1 mm, 5 μm). A mixture of ammonium formate (pH 4 adjusted 
with 1 M formic acid; 2 mM) - MeOH, (30:70, v/v) was used as mobile phase, 
at a flow rate of 0.2 mL/min at ambient temperature. The complete 
chromatographic run time of each sample was 10 min. Peaks were quantified 
using Agilent Masshunter Software. 
The mass spectrometer was operated using an ESI source in the positive 
ion detection mode. Analysis was performed in MRM mode with the following 
transitions: m/z 304.1 → m/z 138.1 for Scop and m/z 290.2 → m/z 124.1 for 
Atr. A collision energy value of 34% was used. Sheath gas and auxiliary gas 
were set to 90% and 10% respectively with a capillary temperature of 270 °C.  
 
4.3.2.2  DCU equipment and assay conditions 
 
Work continued in DCU on a LC-MS system consisting of a 1200 quaternary 
pump, autosampler and degasser and a 6410 QQQ LC/MS, all from Agilent, 
United Kingdom. System management and data acquisition were performed 
using Agilent Masshunter B.01.03 WorkStation Data Acquisition software. 
Other instrumentation employed included a pH meter and electronic mass 
balance both from a Mettler Toledo, USA a Genevac EZ-2 personal evaporator 
from Genevac, Ipswich, United Kingdom and a Cyclone high speed evaporator.  
The SPE manifold was from Phenomenex. 
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Chromatographic separation was achieved using an Agilent Zorbax SB-
Phenyl (150 × 4.6 mm, 5 µm). A mixture of ammonium formate (pH 8 adjusted 
with ammonium hydroxide; 10 mM) - MeOH (10:90, v/v) was used as mobile 
phase, at a flow rate of 0.6 mL/min. The column temperature was maintained at 
20 °C and the temperature of the autosampler was maintained 4 °C. The 
complete chromatographic run time of each sample was 10 min. Peaks were 
quantified using Agilent Masshunter Software. 
The mass spectrometer was operated using an ESI source in the positive 
ion detection mode. The ionisation temperature was 350 °C, gas flow rate was 
11 L/min and nebuliser pressure was 50 psi. Nitrogen was used as the 
ionisation source gas and ultrapure nitrogen as the collision cell gas. Analysis 
was performed in MRM mode with the following transitions: m/z 304.1 → m/z 
138.1 for Scop and m/z 290.2 → m/z 124.1 for Atr with a dwell time of 200 ms. 
Transitions and their optimal detector settings are listed in Table 4.2. The 
quantifier ions are indicated in the table though all transitions were monitored 
with the qualifier ions adding specificity. 
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Compound 
Precursor 
ion 
Optimum 
fragmentor 
voltage 
Product 
ion 
Optimum collision 
energy 
 
Scop 
 
 
Atr 
 
 
304.1 
 
 
290.2 
 
120 
 
 
140 
 
110.1 
121.1 
138.1* 
156.1 
 
124.1* 
93.1 
 
30 
20 
20 
15 
 
22.5 
35 
 
 
Table 4.2: Optimal fragmentor voltages and collision energy settings for Scop 
and Atr  
* Quantifier ion 
 
Quantification was based on the integrated peak area as determined by 
the Masshunter quantification analysis software which quantitates the peak 
areas of the MRM transitions of each analyte. 
 
4.3.3 Preparation of standards 
 
Stock standard solutions of Scop and Atr were prepared by weighing out the 
powders in a glovebox, dissolving them in MeOH to 1 mg/mL concentration 
and storing them at 2 - 4 °C. Working standards of Scop were prepared both in 
drug-free human serum and in mobile phase (MP) (ammonium formate (pH 8, 
adjusted with ammonium hydroxide; 10 mM) - MeOH (10:90, v/v)) to 
concentrations over the range 10–200 pg/mL (10, 20, 50, 100 and 200 pg/mL 
in serum which corresponded to 100, 200, 500, 1000 and 2000 pg/mL in MP).  
This range of the standard curve for Scop was chosen to reflect the serum 
concentrations expected in a typical 72 hr pharmacokinetic profile post 
administration of Scopderm, as the transdermal system is designed to deliver 
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approximately 5 µg/hour over the 72 hours (Bosman et al., 1997, Douma et al., 
1997). The internal standard Atr was prepared in a similar way to Scop. 100 
pg/mL Atr was added to all concentrations of Scop.  
Both spiked serum samples and post extracted spiked serum samples 
were prepared. For the post extracted spiked serum samples, a 500 μL  aliquot 
of diluted blank serum sample diluted 1:1 (v/v) with a 5 mM ammonium 
formate buffer, pH 8 was loaded onto the SPE well, washed with 20% MeOH 
in water and eluted with 0.5 mL 75% MeOH. 50 μL of working standard 
containing Scop and Atr was added to the blank serum extract. For the spiked 
serum samples, a 500 μL aliquot of spiked blank serum sample diluted 1:1 
(v/v) with a 5 mM ammonium formate buffer, pH 8, was loaded onto the SPE 
well, washed with 20% MeOH in water and eluted with 0.5 mL 75% MeOH, 
evaporated to dryness and reconstituted with 50 μL mobile phase. The overall 
clean-up process resulted in the diluted serum sample being concentrated into 
50 μL of MP. 20 μL of the reconstituted sample was injected into the HPLC 
system for analysis. 
 
4.3.4 Preparation of patient samples 
 
Following approval from the Dublin City University Research Ethics 
Committee, (See Appendix A) a study was carried out on 5 volunteers. Blood 
samples were obtained by informed consent in Dublin City University. 
Participants were first administered a whole patch containing 1.5 mg of the drug 
on the back of the ear with subsequent blood collection and observation. Blood 
was drawn over 72 hours at different time points. The blood samples were 
centrifuged in a chilled centrifuge and the serum kept frozen at -80 ºC until 
analysis. A 500 μL aliquot of each patient sample was diluted 1:1 with a 5 mM 
ammonium formate buffer, pH 8 and extracted using the same procedure 
described above for the spiked serum standards. Samples were taken and 
prepared in duplicate. After a wash out of several days half a patch was applied 
and the participant’s serum sampled as previously.  
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4.3.5 Method validation 
 
Validation parameters including intra- and inter-day precision, accuracy, 
sensitivity, linearity and range and recovery were performed on the method. 
Measurements for each analyte in the biological matrix were validated 
according to FDA guidelines (FDA, 2001). 
 
4.4 Results and discussion 
 
Taking a methodical approach to choosing the column, mobile phase and mass 
spectrometer conditions, as well as developing a detailed understanding of the 
chemistry, structure and solubility of the drugs was essential as part of the 
initial development of this part of the work. Optimisation of the sample 
preparation step was also imperative to the likely success of the protocol. 
Given the practical limitations of the existing literature in this field, coupled 
with the practical challenges of employing half patches, it was also vital that 
any methodology developed was better than the current state-of-the-art, had 
novelty, context and application. 
Assay development for this project was challenging due to the fact that 
over a period of three days, the transdermal patch delivers Scop into the blood 
stream in the pg/mL range. The main task was to develop a method capable of 
accurately and reproducible quantitating the anticipated, very low Scop 
concentrations in blood post patch application which would require high 
recoveries from the extraction procedure and excellent sensitivity from the 
detector. 
 
4.4.1 Method development in NASA 
 
4.4.1.1 Chromatographic procedure 
 
Areas focused on for the optimisation of Scop chromatography included choice 
of column, mobile phase composition, buffer concentration and pH. Agilent 
Zorbax SB-CN (100 x 2.1 mm, 3.5 μm) and C18 Supelcosil LC-18 (250 x 2.1 
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mm, 5 μm) columns were investigated using different mobile phase 
compositions and pH. Alkyl-based stationary phases, such as C18, are best 
suited for analysing hydrophobic molecules with a high carbon: heteroatom 
ratio. Cyano-based phases interact strongly with basic, nitrogen-containing and 
halogenated analytes (Kazakevich et al., 2006). See Figure 4.2. 
 
 
 
Figure 4.2: Reversed phase stationary phases (a) C18 and (b) CN  
 
 
 These columns were investigated using different mobile phase 
compositions and pH. The column which gave the best result in terms of peak 
area and shape was the Agilent Zorbax SB-CN. See Fugure 4.3. 
 
(a) (b) 
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Figure 4.3 Chromatograms comparing the separation of Scop and Atr 
using (a) a Supelcosil LC-18 column and (b) an Agilent Zorbax SB-CN column 
 
 The most common solvents used in HPLC/ESI-MS are water, 
methanol, acetonitrile, and mixtures of these. The solvent composition 
(organic/water ratio) is particularly important in the electrospray nebulisation 
and ionisation process, since it determines surface tension of the droplets 
formed and the vaporisation efficiency. Because the surface tension of water is 
much higher than the surface tension of methanol or acetonitrile, the sensitivity 
is reduced when using more than 70 to 80% of aqueous mobile phases. The 
organic/water ratio is more significant when working at high flow rates since 
there is more solvent to be nebulised and vaporised (Chen, 2006). 
With reversed phase stationary phases, retention time is longer for 
molecules which are less polar, while polar molecules elute more readily. By 
adding more water to the mobile phase the retention time generally increases; 
as it makes the affinity of the hydrophobic analyte for the hydrophobic 
stationary phase stronger relative to the now more hydrophilic mobile phase 
(Kazakevich et al., 2006).  Different proportions of methanol-water and 
acetonitrile-water were investigated during the method development stage. 
Poor resolution of Scop and Atr was observed using ammonium formate - 
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MeOH (60:40 v/v) but better results were achieved with ammonium formate - 
MeOH (70:30 v/v).  Also see Figure 4.3 (b). 
The influence of the MP pH is important since this can change the 
hydrophobicity of the analyte. For this reason, a buffering agent was required 
to control the pH (Neue, 2002). Since hyphenated LC-MS instrumentation has 
become more and more popular during the last few years, the standard buffers 
of former times, for example phosphate, have dropped out of favour. The issue 
is that one would like to use volatile mobile phase additives. Phosphates are not 
volatile, and with time will clog the LC-MS interface. This results in 
significant downtime, and more importantly, in a large amount of work to clean 
up the interface again. Therefore,   standard   HPLC methods used with MS 
detection use mobile phase additives that are volatile. Ammonium formate and 
formic acid were chosen for this reason (Neue, 2002). 
Analytical mobile phases of differing pH values (3, 4 and 5) were 
tested. The optimal pH for the LC-MS analysis was at pH 4. The pH 
adjustment was achieved by addition of formic acid. In terms of buffer 
concentration, 2 mM and 5 mM ammonium formate buffers were investigated - 
see Figure 4.4. On comparing the peak areas (response) for Scop using these 
two buffers, it was concluded that the 5 mM buffer solution proved 
considerably better for the peak shape and area of the drug - see Table 4.3. 
 
 Conc. (ng/mL) 
5 mM 
peak area 
2 mM 
peak area 
 
10 
20 
 
2,170,998 
4,184,275 
 
 
2,069,315 
3,800,601 
 
Table .4.3: Comparison of different ammonium formate buffer 
concentrations on peak area of Scop using an Agilent Zorbax SB-CN column 
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Figure 4.4: LC-MS chromatograms comparing ammonium formate buffer 
concentrations for a 10 ng/mL Scop and Atr standard using an Agilent Zorbax 
SB-CN column 
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4.4.1.2 Extraction procedure 
 
Blood contains an innumerable number of compounds that can interfere with 
analyte detection. As the number of interferences increase as the analyte 
concentration decreases, the sample preparation technique becomes an essential 
part of the chromatographic method.   Serum samples contain a significant 
amount of salt and proteins that can precipitate or adsorb on reversed-phase 
packings. The adsorbed protein can easily foul the column, resulting in changes 
in the separation and ultimately clogging the column (Neue, 2002). 
As discussed, there are several sample preparation techniques available 
for the pretreatment of biological samples. Solid phase extraction (SPE) was 
employed for the sample preparation step as the literature shows this to be 
successful and appropriate for the extraction of Scop, yielding good recovery of 
the drug from serum. Two SPE cartridges were investigated - Supelco 
Supelclean LC-18 and Oasis HLB Supelco Supelclean LC-18 is used for 
reversed-phase extraction of nonpolar to moderately polar compounds. The 
Oasis HLB copolymer, with hydrophilic-lipophilic balance can retain both non-
polar and polar compounds.  
Best extraction efficiency results were achieved with the Oasis HLB 
cartridge and hence it was the SPE cartridge of choice for this assay. Oasis HLB 
is a hydrophilic-lipophilic water wettable reversed phase sorbent. It is made 
from a balanced ratio of two monomers, the hydrophilic N-vinylpyrrolidone and 
the lipophillic divinylbenzene. See Figure 4.5 and 4.6. It provides superior 
reversed phase capacity with a special “polar hook” for enhanced retention of 
polar analytes and so is recommended for the extraction of both non-polar and 
polar compounds from biological fluids (Waters, 2010). Taking into 
consideration the structure of Scop, a non-polar tertiary amine, it was an ideal 
extraction sorbent for the drug.  
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Figure 4.5: Oasis HLB sorbent 
 
 
 
 
Figure 4.6: (a) The hydrophilic N-vinylpyrrolidone and (b) the lipophillic 
divinylbenzene of the HLB sorbent 
 
The Oasis cartridge achieved 75% recovery of Scop from serum in 
comparison with 60% for the Supelco cartridge. See Table 4.4. 
 
 
 
Table 4.4: Comparison of recoveries obtained for Scop using different SPE 
cartridges  
 
SPE cartridge type	
Scop recovery (%) 	
± % RSD	
n = 3	
Oasis HLB                 
Supelco Supelclean 
75.1 ± 0.7                  
60.2 ± 2.3 
(a) (b) 
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 As discussed in Chapter 2, there are six basic steps in SPE which 
include sample pretreatment, sorbent conditioning, sorbent equilibration, 
sample loading, washing, and analyte elution. During the SPE method 
development each of these steps were investigated.  
Methanol was again used to condition the sorbent in order to wet the 
sorbent surface and allow the analytes to break through the surface tension of 
the water and move into the sorbent.  
The conditioning solvent needed to be displaced from the sorbent using 
an equilibration solvent, this also prepares the sorbent surface to receive the 
sample. The sorbent was equilibrated with the same buffer as used to dilute the 
sample in order that the chemistry of the sorbent remained constant throughout 
the sample loading step. 
Sample pretreatment involved sample dilution and pH adjustment. As 
discussed, dilution reduces the viscosity of the aqueous sample, improving 
chromatographic mass transfer, and thus improving the efficiency of the 
extraction. In this work, the serum sample was diluted 1:1 with an aqueous 
buffer containing formic acid. The speed with which the sample was applied 
was closely monitored ensuring a slow consistent rate to allow sufficient time 
for the analytes to partition into the sorbent surface. 
The optimum wash solvent needed to be non-polar enough to elute as 
many interferences as possible, but not sufficiently non-polar to elute the 
analytes. The wash solvent was identified by washing the SPE cartridges 
starting with 100% water, then progressively increasing the proportion of 
MeOH present. Proportions of 10, 20 and 30% MeOH in the wash solvent were 
evaluated. Each wash step was collected and analysed for the presence of the 
drugs. There was a slight loss of recovery at 30% and so, the wash containing 
the highest percentage organic but no analytes was at 20%. 
Under the final optimised SPE conditions a 2 mL aliquot of each of the 
working standards was diluted 1:1 (v/v) with a 1% formic acid base solution in 
water. The SPE Oasis HLB (60 mg) cartridges were conditioned with 2 mL 
MeOH and then equilibrated with 2 mL of H2O- buffer solution (50:50 v/v.) A 
4 mL aliquot of the diluted sample was loaded onto the well, washed with 20% 
MeOH in water and eluted with 0.5 mL MeOH. The samples were evaporated 
to dryness and reconstituted with 100 μL MP. The reconstituted sample was 
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then transferred to an autosampler vial (with insert) and 20 μL was injected 
into the HPLC system for analysis. 
The major setback of this optimised SPE method was the high serum 
sample volume at 2 mL. Ideally, a smaller sample volume would be desirable 
but due to the sensitivity achieved from the optimised LC-MS conditions, this 
high volume was required in order to concentrate the sample enough for it to 
reach into the pg/mL range required.  
 
4.4.1.3 Mass spectrometric conditions 
 
As mentioned, Atr and Scop have been detected in biological samples using 
GC–MS techniques (Eckert et al., 1981, Oertel et al., 1996, Namera et al., 
2002, Bayne et al., 1975, Deutsch et al., 1990) but the drawback of GC-MS in 
detecting tropane alkaloids is the heat instability of these compounds (Eckert et 
al., 1981). UV does not achieve the sensitivity required for the levels of the 
drug found in plasma/serum post patch application. As the doses of Scop to be 
detected are quite low (in the pg/mL range), it was decided that MS detection 
would be necessary to achieve adequate sensitivity in blood samples. 
During method development, Scop was identified by directly infusing a 
known concentration into the MS via the t-piece with mobile phase at a flow of 
200 μL/min. Electrospray ionisation (ESI) in the positive ion mode allowed for 
the detection of the protonated precursor (parent) ion m/z 304 – see Figure 4.7. 
This precursor ion was subsequently isolated and subjected to a collision 
energy resulting in two predominant fragment (daughter) ions: m/z 138 and m/z 
156 - Figure 4.7 also. 
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Figure 4.7: The precursor ion and fragment ions of Scop 
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            Following this, Scop was analysed via LC-MS using the multiple 
reaction monitoring (MRM) mode. MRM involves selection of the precursor ion 
and fragmenting it in order to deliver unique product ions that are monitored 
and quantified. MRM was performed on Scop by monitoring the transitions 
between m/z 304 and 138 and between m/z 304 and 156. MRM was performed 
on Atr by monitoring the transition between m/z 290 and 124. This approach 
allowed for sensitive and selective quantitation of Scop. The most important 
parameters affecting the signal quality during ESI/MS operation are heated 
capillary temperature, tube lens offset voltage, capillary voltage and sheath gas 
flow rate and these were all optimised during the development process. 
Optimisation of the sensitivity of Scop detection in the MS detector was 
carried out using both automatic and semi-automatic procedures. The automatic 
procedure adjusts the tube lens offset voltage, capillary voltage, and voltages 
applied to the ion optics until the ion transmission of the analyte is maximised. 
Once this is completed, semi-automatic tuning allows for manual optimisation 
of sheath and auxiliary gas, collision energy and also the capillary temperature 
which needs to be optimised in order to maximise the ion transmission to the 
MS detector. All conditions manually controlled were optimised so as to 
maximise the intensity of the Scop response. Under final conditions within the 
LCQ, capillary temperature was set to 270 °C, collision energy to 34% and 
sheath gas and auxiliary gas to 90% and 10% respectively.  The injection time 
was 800 ms and the number of microscans was three with an isolation width of 
3 amu. 
 
4.4.1.4 Validation 
 
The overall LC-MS method was only partially validated by investigating 
linearity, range, LOD and recovery. Due to time constraints, a full validation 
could not be performed. 
The measured limit of detection (LOD) for Scop in serum was found to 
be 1.0 ng/mL. The calibration curves for Scop over the concentration range 1.0-
15.0 ng/mL in serum exhibited good linearity with correlation coefficients (R2) 
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for all standard curves above 0.99 - see Figure 4.8. The instrument showed 
excellent reproducibility, linearity and signal stability over time. 
223 
 
Scop serum standards
R2 = 0.9964
0
10,000,000
20,000,000
30,000,000
40,000,000
50,000,000
0 3 6 9 12 15
Conc. (ng/mL)
P
e
a
k
 
a
r
e
a
 
Figure 4.8: Linearity for Scop serum standards using an Agilent Zorbax SB-CN column
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            Recovery experiments were performed by spiking known amounts of 
Scop into serum and extracting by SPE. The samples were then analysed using 
the LC-MS method and compared with the results of the standards of Scop 
prepared in diluent which were carried through the same process. Recovery was 
determined in triplicate at concentrations 1, 5 and 10 ng/mL. The extraction 
recovery for Scop averaged 75% at all concentrations prepared. See Figure 4.9. 
SPE showed consistent day-to-day reproducibility of Scop spiked in serum.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: MRM chromatograms of a) extracted serum sample spiked with 10 
ng/mL Scop and b) a working standard of Scop prepared to 10 ng/mL in mobile 
phase using an Agilent Zorbax SB-CN column 
 
              Due to time constraints, further optimisation and validation of the 
method could not be carried out and so a migration of the method was 
proposed in order to continue the research in Ireland. 
 
4.4.2 Method development in DCU 
 
On returning to DCU, it was hoped to continue the above research with a 
method migration to a laboratory within the NICB and validate the method. 
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Work continued using an Agilent LC-MS system consisting of a 1200 
quaternary pump, autosampler and degasser and a 6410 QQQ LC/MS.  
 
4.4.2.1 Chromatographic and extraction procedures 
 
Agilent Zorbax SB-CN column 
 
Under the same chromatographic conditions developed in NASA, a migration 
of the method to the DCU equipment proved unsuccessful. The Agilent Zorbax 
SB-CN (100 × 2.1 mm, 3.5 µm) column previously used was not able to 
achieve separation between the two drugs. The main variable between the two 
methods was the LC-MS instrumentation used. This could have been a possible 
source for differing results obtained upon migrating the methood. Although 
unlikely, there could also have been variability between the chemistries of the 
two cyano columns used. Figure 4.10 displays results using the cyano column 
while varying the % MeOH between 30 and 70%. Buffer used was as before, 5 
mM ammonium formate, pH 4. Using the same flowrate of 0.2 mL/min, 20 µL 
of a Scop and Atr 10 ng/mL mixed standard was injected. As a short runtime 
was desired, a gradient programme was not considered and so, further 
optimisation using this column was not undertaken. 
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Figure 4.10: Comparison of the impact of different % MeOH mobile phase compositions on peak shape and retention for Scop and Atr using an 
Agilent Zorbax SB-CN column
30% MeOH
40% MeOH
50% MeOH
60% MeOH
70% MeOH
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 It was decided to carry out further method development with regards to 
column selection. Structural properties of the analyte molecule play an 
important role in its retention characteristics. In general, an analyte with a 
larger hydrophobic surface area (C-H, C-C, and generally non-polar atomic 
bonds, such as S-S and others) results in a longer retention time because it 
increases the molecule's non-polar surface area, which is non-interacting with 
the water structure. On the other hand, polar groups, such as -OH, -NH2, COO– 
or -NH3+ reduce retention as they are well solvated with water molecules 
(Dong, 2006). Bearing this in mind and the structures of Scop and Atr, it was 
decided to investigate C18, C8 and Phenyl phases in order to find one capable 
of separating the two drugs. 
Zorbax RX-C18 column 
An Agilent Zorbax RX-C18 (narrow bore 150 x 2.1 mm, 5 µ) column was 
firstly investigated under the same chromatographic conditions as for the cyano 
column above. As discussed, with reversed phase stationary phases, retention 
time is longer for molecules which are less polar, while polar molecules elute 
more readily. By adding more water to the mobile phase the retention time was 
increased; thereby making the affinity of the hydrophobic analyte for the 
hydrophobic stationary phase stronger relative to the now more hydrophilic 
mobile phase (Kazakevich et al., 2006). Figure 4.11 displays results using this 
column while varying the % MeOH between 30 and 70%. Buffer used was as 
before, 5 mM ammonium formate, pH 4. Using the same flowrate of 
0.2 mL/min, 20 µL of a Scop and Atr 10 ng/mL mixed standard was injected. 
This column was unable to achieve separation between the two drugs. 
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Figure 4.11: Comparison of the impact of different % MeOH mobile phase compositions on peak shape and retention for Scop and Atr using an 
Agilent Zorbax RX-C18 column
30% MeOH
40% MeOH
50% MeOH
60% MeOH
70% MeOH
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Zorbax Eclipse Rapid Resolution column 
 
The second C18 column investigated was an Agilent Zorbax Eclipse Rapid 
Resolution (50 x 2.1 mm, 3.5 µm) column. Figure 4.12 displays results using 
this column while varying the % MeOH between 30 and 70%. Buffer used was 
as before, 5 mM ammonium formate, pH 4. Using the same flowrate of 
0.2 mL/min, 20 µL of a Scop and Atr 10 ng/mL mixed standard was injected. 
This column was also unable to achieve separation between the two drugs. 
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Figure 4.12: Comparison of the impact of different % MeOH mobile phase compositions on peak shape and retention for Scop and Atr using an 
Agilent Zorbax Eclipse Rapid Resolution column
70% MeOH
60% MeOH
40% MeOH
50% MeOH
30% MeOH
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 Waters Nova-Pak C18 column  
 
The third C18 column investigated was a Waters Nova-Pak C18 (150 × 3.9 
mm, 4 µm). Due to the dimensions of the column, it was decided a higher 
flowrate than 0.2 mL/min was required. Preliminary work was carried out 
using 0.75 mL/min. Areas focused on for the optimisation of the 
chromatography of both drugs – Scop and Atr - included mobile phase 
composition, buffer concentration and pH. Different compositions of MeOH 
were firstly examined, see Figure 4.13. A flowrate of 0.6 mL/min and the same 
20 µL of a Scop and Atr 10ng/mL standard was injected as with the previous 
column investigated. Ammonium formate (pH 4, adjusted with 1 M formic 
acid; 5 mM) - MeOH (10:90, v/v) was chosen for the mobile phase as 
separation of the drugs was achieved with a relatively short runtime.  
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Figure 4.13:  Comparison of the impact of different % MeOH mobile phase 
compositions on peak shape and retention for Scop and Atr  using a Waters 
Nova-Pak C18 column 
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            As discussed in Chapter 1, the selectivity or separation factor of a 
chromatographic system is a measure of the spacing between two given peaks. 
Represented by α, it describes how effectively a chromatographic system can 
separate two compounds (A and B) on the column (Weston et al., 1997). See 
Eqn. 4.1. α is primarily a function of the packing material but can be 
manipulated to some extent by varying the mobile phase and/or temperature. 
 
              α= k 'B / k 'A.                                                          Eqn. 4.1 
 
where k' (the retention/capacity factor) is defined as per Eqn. 4.2. 
 
k'A = t R - tM / tM                                                      Eqn. 4.2 
 
           When calculating the selectivity factor, species A elutes faster than 
species B and so the selectivity factor is always greater than one. The value for 
α can range from 1 (when the retention times of the two compounds are 
identical), to infinity, (if the first component elutes in the void volume). If α is 
approaching 1, then regardless of efficiency or length of time on column, there 
will be no separation (Weston et al., 1997). α was mathematically calculated 
for Scop and Atr using different chromatographic conditions.  
Although 95% MeOH gave higher peak area,  the peaks were broader 
and analysis time long,  see Figure 4.13, and so 90% MeOH was chosen as the 
optimal MP as it offered the best results for both drug peaks with an acceptable 
α value of 1.33 as seen in Table 4.5. 
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% MeOH 
MP 
composition 
t R Scop k'  Scop t R Atr k' Atr α 
85 
90 
95 
3.3 
3.9 
6.3 
1.71 
2.32 
4.25 
3.8 
4.9 
8.4 
2.18 
3.08 
6.0 
1.27 
1.33 
1.41 
 
Table 4.5: Comparison of different % MeOH mobile phase compositions on 
separation factor for Scop and Atr using a Waters Nova-Pak C18 column 
 
          As previously discussed, an important MP factor is the influence of the 
pH since this can change the hydrophobicity of the analyte. A buffering agent 
was hence required in order to control the pH. As ammonium formate and 
formic acid are routinely used in mass spectrometry, it was employed for this 
work.  In order to further optimise the separation, different mobile phase buffer 
concentrations and pHs were looked at.  Ammonium formate (pH 5 adjusted 
with 1 M formic acid) - MeOH (10:90, v/v) at 2, 5, 10 and 20 mM ammonium 
formate buffer concentrations were examined. See Figure 4.14. A 1% formic 
acid - MeOH (10:90, v/v) mobile phase was also investigated, however, from 
Figure 4.15 it can be seen the results obtained were not satisfactory. Separation 
between the peaks was poor and the peak area for Scop was low.  
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Figure 4.14: Comparison of the impact of different ammonium formate 
concentrations (pH 5) on peak shape and retention for Scop and Atr using a 
Waters Nova-Pak C18 column 
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Figure 4.15: Chromatogram of Scop and Atr using 0.1% formic acid as mobile phase using a Waters Nova-Pak C18 column
Scop 
Atr 
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          It was decided to choose 5 mM ammonium formate as buffer for the 
mobile phase. Even though the peak area was slightly lower for both drugs in 
comparison to 2 mM, the retention times of the drugs are much shorter and 
Table 4.6 proves sufficient selectivity was achieved. 
 
Ammonium 
formate conc. 
(mM) 
t R Scop k'  Scop t R Atr  k' Atr α 
2 
5 
10 
20 
6.8 
3.6 
2.7 
2.1 
4.7 
2.0 
1.3 
0.8 
7.4 
4.0 
2.9 
2.2 
5.1 
2.3 
1.4 
0.8 
1.1 
1.2 
1.2 
1.1 
 
Table 4.6: Comparison of different ammonium formate concentrations (pH 5) 
on retention factor for Scop and Atr using a Waters Nova-Pak C18 column 
 
Using the concentration of 5 mM ammonium formate, different pHs 
were examined (3, 4 and 5). pH adjustment was achieved using formic acid. 
From Figure 4.16 it can be seen that pH 4 offered the best compromise 
between good peak shape and adequate separation. Also, the highest peak area 
values were achieved using pH 4. Again sufficient selectivity was achieved as 
seen in Table 4.7. Selectivity achieved using pH 3 and 5 was better than at pH 
4, however, band broadening was evident at these pHs. 
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Figure 4.16: Comparison of the impact of different mobile phase pHs using 5 
mM ammonium formate on peak shape and retention for Scop and Atr using a 
Waters Nova-Pak C18 column 
 
pH 4 
pH 3 
pH 5 
Atr 
Scop 
Scop 
Scop 
Atr 
Atr 
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Mobile     
phase pH 
t R Scop k'  Scop t R Atr k' Atr α 
3 
4 
5 
3.6 
3.6 
3.7 
2.01 
2.00 
2.08 
4.3 
3.9 
4.5 
2.54 
2.25 
2.75 
1.23 
1.13 
1.32 
 
Table 4. 7: Comparison of different mobile phase pHs using 5 mM ammonium 
formate  on retention factor for Scop and Atr using a Waters Nova-Pak C18 
column 
 
 Column temperature was also varied in order to try and improve 
separation between the drugs. Temperatures of 20, 30 and 40 ºC were 
investigated. The change in temperature did not adversely affect the peak areas 
of the drugs and only a small shift in retention time was observed. Hence it was 
decided to maintain temperature at 20 ºC as it is a more convenient, stable and 
achievable temperature to maintain. 
 Four mobile phase flow rates from 0.5 to 0.75 mL/min were tested. The 
results are shown below in Figure 4.17 where it was evident, as might be 
expected, that the slowest flowrate gave the longest retention time and most 
tailing while it was noted that the slowest flowrate also yielded the highest 
peak areas. So a compromise of 0.6 mL/min was chosen as there was less peak 
tailing evident and the peak area obtained was higher than at the faster 
flowrates. 
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Figure 4.17: Comparison of the impact of different flowrates on peak shape 
and retention for Scop and Atr using a Waters Nova-Pak C18 column 
 
A general downfall of the results obtained is the peak tailing associated 
with the Atr peak in particular. There are many sources of peak-tailing, ranging 
from column problems to chemistry problems to instrument problems. The 
most common reasons for peak tailing are extra-column band broadening, 
deterioration of the packed bed, and interaction of the analytes with active sites 
on the packing.  
Also, the separation between both Scop and Atr, although borderline 
acceptable in terms of the α achieved, was not ideal. All areas of the 
chromatographic procedure were investigated in order to further improve this 
separation but to no avail. 
0.7  0.5  
 
0.6  
0.75  
 
0.5  
 
0.6  
 
0.7  0.75  Atr 
 
Scop 
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Under the final Waters Nova-Pak C18 column (150 × 3.9 mm, 4 µm) 
chromatographic conditions a 20 µL injection volume was used. As it is a 4 µm 
particle size column, a higher injection volume is not recommended as it would 
lead to sample overloading and cause peak fronting. A mixture of ammonium 
formate (pH 4 adjusted with 1 M formic acid; 5 mM) - MeOH (10:90, v/v) was 
used as mobile phase, at a flow rate of 0.6 mL/min. The complete 
chromatographic run time of each sample was 10 min, which separated Scop 
and Atr from each other with retention times 5.1 and 6.1 min, respectively. See 
Figure 4.18. The sensitivity achieved for the drugs prepared in mobile phase 
was 100 pg/mL.  
 
 
 
Figure 4.18: Chromatogram of Scop and Atr standard prepared in MP (10 
ng/mL) using a Waters Nova-Pak C18 column 
 
SPE development for use with Waters Nova-Pak C18 column 
 
Solid phase extraction (SPE) was employed for the sample preparation step as 
the literature shows it to be successful and superior for the extraction of Scop 
and Atr, yielding good recoveries of the drug from serum. Five SPE cartridges 
Atr 
Scop 
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were investigated - Oasis HLB, MAX, WAX, MCX and WCX (all 1cc, 30 mg 
cartridges). These are each described briefly below: 
Oasis HLB contains a polymeric water-wettable reversed-phase 
sorbent. This copolymer, with hydrophilic-lipophilic balance can retain both 
non-polar and polar compounds (Waters, 2010). 
Oasis MCX; Mixed-Mode Cation eXchange and Reversed-Phase 
Sorbent is recommended for the extraction of basic compounds. It is synthesised 
from the reversed-phase Oasis HLB polymer and hence features two retention 
mechanisms; cation exchange and reversed-phase. Oasis MAX; Mixed-Mode 
Anion eXchange and Reversed-Phase Sorbent is for the extraction of acidic 
compounds. It too features two retention mechanisms; anion exchange and 
reversed-phase. Both MCX and MAX are water wettable, polymeric sorbents, 
stable from pH 0 to 14. 
Oasis WCX; Weak Cation eXchange is for the extraction of strong 
bases and features cation exchange and reversed phase retention mechanisms. 
Oasis WAX; Weak Anion eXchange is for the extraction of strong acids. Again, 
its retention is mixed-mode, both ion exchange and reversed phase (Waters, 
2010). 
Table 4.8 outlines the SPE conditions used for the SPE Oasis WCX, 
WAX, MAX, WCX and HLB (all 1cc, 30 mg) cartridges. Four replicates for the 
blank serum and four replicates for the spiked serum were used on all 5 
sorbents. 
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Cartridge MCX WAX MAX WCX HLB 
Condition: 1 mL MeOH 1 mL MeOH 1 mL MeOH 1 mL MeOH 1 mL MeOH 
Equil: 1 mL H2O 1 mL H2O 1 mL H2O 1 mL H2O 1 mL H2O 
Load: 
1 mL spiked serum 
/ 1 mL blank 
serum 
1 mL spiked serum 
/ 1 mL blank 
serum 
1 mL spiked serum 
/ 1 mL blank 
serum 
1 mL spiked serum 
/ 1 mL blank 
serum 
1 mL spiked serum 
/ 1 mL blank 
serum 
Wash : 
1 mL 2%  formic 
acid in H2O 
1 mL 2%  formic 
acid in H2O 
1 mL 5% 
ammonium 
hydroxide in H2O 
1 mL 5% 
ammonium 
hydroxide in H2O 
1 mL 5% MeOH 
in H2O 
Eluate 1: 2 x 0.25mL MeOH 2 x 0.25mL MeOH 2 x 0.25mL MeOH 2 x 0.25mL MeOH 2 * 0.25mL MeOH
Eluate 2: 
2 x 0.25 mL 5%  
ammonium 
hydroxide in 
MeOH 
2 x 0.25 mL 5%  
ammonium 
hydroxide in 
MeOH 
2 x 0.25mL  2%  
formic acid in 
MeOH 
2 x 0.25mL  2%  
formic acid in 
MeOH 
 
 
Table 4.8: SPE conditions used for MCX, WAX, MAX, WCX and HLB 
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            For all four ion exchange sorbents, the spiked serum eluate 1’s were 
diluted with 0.5 mL MeOH and the blank serum eluate 1’s diluted with 0.5mL 
recovery standard (100 pg/mL). For MCX, WAX, the spiked serum eluate 2 
was diluted with 0.5 mL 2% formic acid in MeOH and the blank serum eluate 
was diluted with 0.5 mL Recovery standard in 2% formic acid in MeOH (100 
pg/mL). For MAX, WCX, the spiked serum eluate 2 was diluted with 0.5 mL 
MeOH and the blank serum eluate 2 was diluted with 0.5 mL recovery standard 
(100 pg/mL). 
The reconstituted sample was transferred to an autosampler vial and 
20 μL was injected into the LC-MS system for analysis. See Tables 4.9, 4.10, 
4.11 and 4.12 for results. 
 
SPE cartridge type 
Scop recovery (%) 
 ± % RSD 
Atr recovery (%)  
± % RSD 
n = 4 n = 4 
 
HLB 
MAX 
MCX 
WAX 
WCX 
 
89.1 ± 1.1 
85.2 ± 1.4 
0.4 ± 0.3 
4.6 ± 4.3 
131.8 ± 3.9 
 
72.0 ± 1.0 
102.8 ± 1.9 
1.1 ± 9.1 
26.4 ± 2.7 
57.7 ± 1.9 
 
 
Table 4.9: Comparison of SPE approaches loading serum diluted 1:1 with 4% 
phosphoric acid 
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SPE cartridge type 
Scop recovery (%)  
± % RSD 
Atr recovery (%)  
± % RSD 
n = 4 n = 4 
 
HLB 
MAX 
MCX 
WAX 
WCX 
 
 
89.0 ± 0.1 
80.4 ± 1.5 
0.0 ± 0.0 
3.5 ± 5.7 
53.3 ± 0.2 
 
79.2 ± 0.5 
73.9 ± 0.3 
0.0 ± 0.0 
17.2 ± 1.2 
11.8 ± 10.1 
 
Table 4.10: Comparison of SPE approaches loading serum diluted 1:1 with 4% 
ammonium hydroxide 
 
SPE cartridge type 
Scop recovery (%)  
 ± % RSD 
Atr recovery (%)  
 ± % RSD 
n = 4 n = 4 
 
MAX 
MCX 
WAX 
WCX 
 
0.6 ± 5.0 
30.7 ± 0.3 
5.1 ± 0.9 
0.0 ± 0.0 
 
1.3 ± 1.5 
59.5 ± 1.2 
26.4 ± 1.9 
8.5 ± 1.2 
 
 
Table 4.11: Comparison of SPE approaches loading serum diluted 1:1 with 4% 
phosphoric acid (Eluate 2 results) 
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SPE cartridge type 
Scop recovery (%)   
± % RSD 
Atr recovery (%)  
 ± % RSD 
n = 4 n = 4 
 
MAX 
MCX 
WAX 
WCX 
 
0.7 ± 0.9 
1.5 ± 0.5 
3.8 ± 2.6 
0.0 ± 0.0 
 
1.1 ± 0.8 
13.6 ± 2.9 
17.0 ± 0.6 
0.3 ± 1.4 
 
 
Table 4.12: Comparison of SPE approaches loading serum diluted 1:1 with 4% 
ammonium hydroxide (Eluate 2 results) 
 
 Phosphoric acid was used in the SPE load step; however, on MS 
analysis, high column back pressure and a high MS background noise were 
noted (even though the SPE protocol was recommended by Waters.)  After 
analysis of test samples the column lost its ability to function due to extremely 
high background noise and back pressure and so was discarded. As discussed 
with the MP composition, phosphate buffers have dropped out of favor (Neue, 
2002). Phosphates are not volatile, and - with time - clog the LC-MS interface. 
This results in significant downtime, and more importantly, in a large amount 
of work to clean up the interface again (Neue, 2002). 
From these preliminary SPE results as per Tables 4.9 and 4.10, it can be 
seen best results in terms of recovery were achieved with the Oasis HLB 
cartridge. Hence, it was decided the SPE cartridge would be chosen for this 
work.  
Replacing the column with a new one, phosphoric acid was eliminated 
from the extraction procedure in favour of formic acid for the load step. Similar 
recoveries were obtained for Scop using formic acid in the load step with the 
Oasis HLB but significant quantities of Atr eluted with the dead volume as can 
be seen in Figure 4.19. Hence quantitative results were unattainable. 
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Figure 4.19: Chromatogram of an extracted 1ng/mL serum std loaded 1:1 with 1% formic acid using a Waters Nova-Pak C18 column 
Green and Blue: Atr, Red and Black: Scop  
Scop 
Atr Atr in the 
dead volume 
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Furthermore, upon investigating the sensitivity of the analytical protocol, 
an LOQ of 100 pg/mL in serum was obtained for Scop, not low enough for 
determination of the anticipated Scop serum concentrations post patch 
application. This column was hence abandoned as successful results would be 
impossible to attain even if 100% recovery of Scop was achieved via the 
extraction protocol along with no ion suppression. 
 
Agilent Zorbax SB-C18 column  
 
The fourth C18 column investigated was an Agilent Zorbax SB-C18 column 
(50 × 2.1 mm, 3.5 µm). Rapid Resolution columns reduce analysis time while 
maintaining resolution and have the advantage of substantial solvent savings. 
In comparison to the Waters Nova-Pak C18 (150 × 3.9 mm, 4 µm) column, the 
Agilent Zorbax SB-C18 column is much shorter, with a narrower internal 
diameter and smaller particle size. As a starting point, the optimised 
chromatographic conditions from the Waters Nova-Pak C18 column were used. 
Separation between Scop and Atr was achieved but in the injections of 20 and 
10 µL, peak fronting was observed. See Figure 4.20.  Broad peaks or fronting 
indicate sample overload. Fronting occurs when one or more of the compounds 
injected on the column exceeds the capacity of the liquid phase of the column. 
The thinner the liquid phase film, the less of each compound can be retained by 
the column (Neue, 2002). This includes both the injection volume and the 
concentration of each peak in the injection. As a result an injection volume of 
20 µL and 10 µL was too large as a result of the column dimensions and so to 
begin with a smaller injection volume was required. Using a 5 µL injection the 
separation of the two drugs was achieved with a short runtime. 
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Figure 4.20: Comparison of the impact of different injection volumes on peak shape for Scop and Atr using an Agilent Zorbax SB-C18 column
20 µL 
 
10 µL 
 
Scop 
Atr 
Atr 
Scop 
Scop Atr 
5 µL 
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 Increasing the flow rate is the easiest way to decrease the analysis time. 
However, flow rate affects column efficiency, which in turn affects resolution 
and pressure. The flow rate for optimum efficiency is dependent on the particle 
size of the column packing material (Neue, 2002). The main disadvantage of 
increasing flow rate is higher pressure. Elevated pressures will shorten column 
lifetime as well as increase wear on the HPLC system. Increasing flow rate 
above the optimum will also reduce column efficiency and resolution. 
Decreasing the flow rate reduces system wear. However, it also increases 
analysis time. Due to the particle size of this column (3.5 µm), a flowrate of 0.6 
mL/min was not possible as with the Waters Nova-Pak C18 column. A 
flowrate between 0.15 – 0.25 mL/min is recommended using the Zorbax SB-
C18 column. See Figure 4.21 for a comparison of three different flowrates. 0.2 
mL/min was chosen as optimal due to shortest analysis time and highest peak 
areas. 
 
 
251 
 
 
Figure 4.21: Comparison of the impact of different flowrates on peak shape and retention for Scop and Atr using an Agilent Zorbax SB-C18 
column
0.15 mL/min 
 
0.18 mL/min 
 
0.2 mL/min 
 
Atr 
Atr 
Atr 
Scop 
Scop 
Scop 
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 Using this column at a flowrate of 0.2 mL/min, and injection volume 5 
µL, the % MeOH played a significant role on the separation of the two drugs, 
see Figure 4.22. A decrease of % MeOH in the MP consisting of ammonium 
formate (pH 4, adjusted with 1 M formic acid, 5 mM) from 40 to 30% had a 
large impact on the separation of both drugs. The role of the organic modifier is 
to compete against the bonded phase molecule for attraction of the analyte 
molecules. Generally speaking, the higher the organic concentration the 
stronger the mobile phase and the shorter the retention (Jerkovich et al., 2006). 
At 40% MeOH, it proved too strong and the two drugs co-eluted.  
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Figure 4.22: Comparison of the impact of different % MeOH mobile phase compositions on peak shape and retention for Scop  
and Atr using an Agilent Zorbax SB-C18 column
30% MeOH 
40% MeOH 
Scop 
Scop 
Atr 
Atr 
254 
 
            A buffering agent employing ammonium formate was again required in 
order to control the pH. In terms of concentration, 2 mM, 5mM and 10 mM 
ammonium formate buffers were investigated using ammonium formate (pH 4 
adjusted with 1 M formic acid,) - MeOH (70:30, v/v). As the buffer 
concentration increased, the faster the analytes eluted. On comparing the peak 
areas (response) for Scop using these three buffers, it was concluded that the 2 
mM buffer solution proved considerably better for the peak shape and area of 
the drug - see Figure 4.23. 
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Figure 4.23: Comparison of the impact of different ammonium formate concentrations (pH 4) on peak shape and retention for  
Scop and Atr using an Agilent Zorbax SB-C18 column
2 mM 
 
5 mM 
 
10 mM 
 
Scop 
Scop 
Scop 
Atr 
Atr 
Atr 
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 Analytical mobile phases of differing pH values (3, 4 and 5) were tested 
using ammonium formate (2 mM) - MeOH (70:30, v/v). See Figure 4.24. The 
pH adjustment was achieved again by addition of formic acid. As mentioned, 
the pH of the mobile phase is a fundamental parameter in reversed phase 
HPLC that significantly affects the retention of ionisable analytes.  (Neue, 
2002 ). pH reflects the hydrogen ion concentration in solution. Adding acid 
(proton donor), increases the hydrogen ion concentration (lowers pH) of the 
solution. Changing the pH changes the degree of ionisation of molecules in 
solution. It thus affects their polarity, and as a consequence it changes their 
retention times in an HPLC separation. At low pH, the mobile phase protonates 
free silanols on the column and reduces peak tailing. At sufficiently low pH 
basic analytes are protonated and when ionised results in the analyte eluting 
more quickly as can be seen in Figure 4.24. The optimal pH for the LC-MS 
analysis was at pH 5 which resulted in good peak shape and highest peak area. 
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Figure 4.24: Comparison of the impact of different mobile phase pHs using 2 mM ammonium formate on peak shape and retention for Scop and 
Atr using an Agilent Zorbax SB-C18 column
pH 3 
 
pH 4 
 
pH 5 
 
Atr
Atr 
Atr 
Scop 
Scop 
Scop 
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            Under the final chromatographic conditions using an Agilent Zorbax 
SB-C18 (50 × 2.1 mm, 3.5 µm) a 5 µL injection volume was used. A mixture 
of ammonium formate (pH 5 adjusted with 1 M formic acid; 2 mM) - MeOH 
(70:30, v/v) was used as mobile phase, at a flow rate of 0.2 mL/min. The 
complete chromatographic run time of each sample was 5 min, which separated 
Scop and Atr from each other with retention times 2.1 and 3.4 min, 
respectively. However, the sensitivity achieved for the drugs prepared in 
mobile phase was only 200 pg/mL, again likely to be too low for the 
demanding applications of our analyses. 
SPE development for use with Agilent Zorbax SB-C18 column 
 
Using the same SPE conditions as used with the Waters Nova-Pak C18 column 
it was noted problems were again occurring with regards to Atr, this time 
interfering Atr-mimicking endogenous peaks present in the serum blank 
extracted samples. See Figure 4.25. 
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Figure 4.25: Overlay of a 10 ng/mL Scop and Atr standard in MP (grey) 
superimposed on extracted serum blank (green) using an Agilent Zorbax SB-
C18 column 
 
            In the extracted serum blank a peak eluting at Atr’s retention time was 
observed and showed significant intensity and signal/noise ratio. All potential 
sources of contamination were investigated. New Oasis HLB cartridges were 
ordered in along with all new reagents and chemicals. Also suspecting that the 
manifold could be a potential source of carryover, serum was extracted through 
the SPE cartridge without using the manifold. However, there was still a high 
level of Atr-mimicking contaminant detected. 
Biological sample analysis is complicated because the samples contain 
macromolecules and other compounds such as proteins, endogenous and 
exogenous compounds. Materials in the extracted biological matrix can exist in 
much higher concentrations than the analyte. The aim of SPE is to remove as 
many of the unwanted compounds as possible without significant loss of the 
analytes of interest. Unwanted compounds can be present still in higher 
concentrations than the analytes of interest after the first clean-up. LC 
separation further separates analytes of interest from the unwanted compounds. 
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MS/MS offers a third stage of separation through selection of appropriate 
precursor and product ion pairs so that unwanted compounds are not registered 
by the detector. However, those unwanted and MS/MS unseen compounds 
present significant challenges, such as the Atr-mimicking peak in this work. In 
the LC/MS interface, unwanted compounds compete with analytes for 
ionisation and can cause inconsistent matrix effects that are detrimental to 
quantitative LC/MS/MS. If not separated from the analytes, some conjugated 
metabolites break down in the interface so that analyte concentration is 
overestimated.  
Looking at Scop on its own it was noted a significant amount on ion 
suppression was occurring. See Figure 4.26. Displayed is serum blank 
extracted and reconstituted in 1 ng/mL standard of Scop (green) superimposed 
on the pure 1 ng/mL standard (blue) with  the transition m/z 304 to 136 
extracted out.  
 
261 
 
 
Figure 4.26: Serum blank extracted and reconstituted in 1 ng/mL standard of Scop (green) superimposed on the pure 1 ng/mL standard (blue) 
using an Agilent Zorbax SB-C18 column 
Scop 
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 This ion suppression is further proven by Figure 4.27. By overlaying 
the TIC scan of serum blank extracted with a MRM scan of a Scop pure 
standard it can be clearly seen Scop was eluting at the height of the endogenous 
material. As discussed in Chapter 1, the total ion current (TIC) chromatogram 
represents the summed intensity across the entire range of masses being 
detected at every point in the analysis.  
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Figure 4.27: TIC scan of serum blank extracted (black) superimposed on a MRM scan of Scop pure standard (red) using an Agilent Zorbax SB-
C18 column. Note: not to scale 
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            Also in terms of sensitivity, the method was clearly not capable of 
reaching the desired LOQ. Figure 4.28 shows a serum blank extracted and 
reconstituted in MP superimposed on a 100 pg/mL serum standard extracted 
and reconstituted in MP with the transition m/z 304 to 138 extracted out.  
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Figure 4.28: Chromatogram of an extracted serum blank superimposed on an extracted 100 pg/mL serum standard extracted  
using an Agilent Zorbax SB-C18 column
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LLE development for use with Agilent Zorbax SB-C18 column 
 
Due to unsuccessful attempts at optimising SPE conditions for Scop and Atr on 
two different columns, it was decided to investigate an alternative method of 
sample clean up. As discussed, there are several sample preparation techniques 
available for the pretreatment of biological samples. The simplest and fastest 
method for preparing samples is protein precipitation. Protein precipitation is 
most likely to cause ion suppression in ESI, since this method fails to 
sufficiently remove endogenous compounds such as lipids, phospholipids, fatty 
acids, etc. Co-elution of these compounds with the compound of interest 
affects the ESI droplet desolvation process. (Van Eeckhaut et al., 2009). 
Although protein precipitation is quick and easy, it does not result in a very 
clean final extract and so was not investigated. Liquid–liquid extraction (LLE) 
is viewed by some researchers as an efficient means of sample preparation that 
is a cleaner option than protein precipitation (Chambers et al., 2007); we 
therefore decided to investigate LLE as a potential extraction technique for the 
drugs in serum.  
As discussed in Chapter 1, LLE provides sample clean-up whereby 
hydrophobic sample constituents are extracted from aqueous samples with a 
water-immiscible organic phase. Most LLE procedures are based on extraction 
of the target drugs into an organic solvent followed by solvent evaporation, 
reconstitution of residue, and injection into the HPLC system. Inorganic salts 
are normally poorly soluble in the organic solvents used for LLE, and 
consequently they principally remain in the aqueous sample phase. For serum 
samples, proteins may be of concern; however, they are almost insoluble in the 
organic solvents used for LLE and tend to precipitate. Although LLE provides 
excellent sample clean-up for salts and biological macromolecules a broad 
range of other compounds may be co-extracted during LLE.  
LLE optimisation experiments for this work were carried out in a 
similar manner to a previously published LLE extraction procedure carried out 
in DCU (Roche et al., 2009). Similar sample volumes and extraction 
techniques were used.  
Scop is an uncharged tertiary amine. It has a weak basic character with 
a pKa of 7.6 and a reasonable lipid solubility (Renner et al., 2005) which 
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allows for the transdermal absorption of the patch. Most alkaloids are poorly 
soluble in water but readily dissolve in organic solvents, such as diethyl ether 
and dichloromethane. With, acids, alkaloids form salts of various strengths. 
Those salts are usually soluble in water and alcohol and poorly soluble in most 
organic solvents. Exceptions include scopolamine hydrobromide, which is 
soluble in organic solvents.  
To determine the optimum system for liquid–liquid extraction four 
water immiscible volatile organic solvents were tested: ethyl acetate; 
dichloromethane, tert-butyl methyl ether and chlorobutane. The optimised 
conditions for the Agilent Zorbax SB-C18 column (50 × 2.1 mm, 3.5 µm) were 
again used for LLE optimisation work. 
200 μL of blank serum was added to the extraction tube, along with 
100 μL of 1 M ammonium formate pH 8 buffer and 1.7 mL of extraction 
solvent. The extraction tubes were vortexed and mixed on a blood tube mixer 
for 15 min. The samples were centrifuged at 3200 × g for 5 min. 1.1 mL of 
solvent was transferred to conical bottomed glass LC autosampler vials. The 
vials were evaporated to dryness using a Genevac EZ-2 evaporator at ambient 
temperature, without light. The samples were reconstituted in 50 μL of MP 
with 20 μL injected automatically by the autosampler. 1 ng/mL spiked serum 
samples were also prepared and processed in the same manner as the above 
serum blanks samples. Results are shown in Figures 4.29, 4.30, 4.31 and 4.32.  
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Figure 4.29: LC-MS chromatogram, in MRM mode of an extracted serum 
blank sample (blue) and an extracted spiked serum Scop standard (black) and 
Atr (red) superimposed on a pure std of both drugs in MP (green) using 
chlorobutane as extraction solvent 
Scop 
Atr 
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Figure 4.30: LC-MS chromatogram, in MRM mode of an extracted serum 
blank sample (blue) and an extracted spiked serum Scop standard (black) and 
Atr (red) superimposed on a pure std of both drugs in MP (green) using DCM 
as extraction solvent 
Atr 
Scop 
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Figure 4.31: LC-MS chromatogram, in MRM mode of an extracted serum 
blank sample (blue) and an extracted spiked serum Scop standard (red) and Atr 
(black) superimposed on a pure std of both drugs in MP (green) using ethyl 
acetate as extraction solvent 
 
Scop 
Atr 
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Figure 4.32: LC-MS chromatogram, in MRM mode of an extracted serum 
blank sample (blue) and an extracted spiked serum Scop standard (red) and Atr 
(black) superimposed on a pure std of both drugs in MP (green) using tert-
butyl methyl ether as extraction solvent 
Scop 
Atr 
272 
 
 Figure 4.33 shows a chromatogram of a pure standard of Scop and Atr 
in MP extracted through the LLE process. For the pure standards no 
endogenous peaks were observed indicating contaminating peaks were a result 
of the addition of serum to the extraction step. As already mentioned, blood 
contains an innumerable number of compounds that can interfere with analyte 
detection and may contribute to this Atr like peak eluting in the extracted blank 
serum samples.  
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Figure 4.33: LC-MS chromatogram, in MRM mode, of Scop and Atr std in MP brought through the LLE extraction process (no serum) using an 
Agilent Zorbax SB-C18 column
Scop 
Atr 
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            From these results, contamination of the serum stock was suspected. A 
new batch of serum was ordered and brought through the same procedure as 
above. See Figure 4.34. An Atr like peak was again found in the new serum 
blanks extracted through LLE, however, for the new serum stock a single Atr 
like peak was observed in comparison to a split Atr like peak for the old serum 
stock.  
 
275 
 
 
Figure 4.34: LC-MS chromatograms, in MRM mode comparing LLE extracted 
blank serum for old and new serum batches using an Agilent Zorbax SB-C18 
column 
Scop: red, Atr: black 
 
Old stock serum 
New stock serum 
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            The optimum pH of the extraction buffer was also investigated. 
Identical extractions were carried out using dichloromethane (DCM) as the 
solvent system and varying the pH of the extraction buffer. Due to its 
compatibility with mass spectrometry 1 M ammonium formate was selected as 
the aqueous buffer. The aqueous phase was tested across a pH range to 
determine an optimum in combination with DCM extraction solvent. As shown 
in Figure 4.35 the Atr like peak persisted at all pHs and made quantification 
impossible. 
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Figure 4.35: LC-MS chromatograms, in MRM mode, comparing the extraction 
of serum blanks at different pHs using an Agilent Zorbax SB-C18 column 
(Scop: black, Atr: Red) 
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            The optimum extraction buffer pH for Scop was determined to be pH 8 
as this gave greater recovery than the other pHs achieving 89%. Figure 4.36 
shows overlaid chromatograms of both an extracted spiked serum standard and 
extracted blank serum sample at pH 8 and pH 3.5. 
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Figure 4.36: LC-MS chromatogram, in MRM mode, of  extracted spiked serum 
standard superimposed on extracted blank serum sample using an Agilent 
Zorbax SB-C18 column.  
Serum blank: blue, Scop black, Atr: red 
 
pH 8 
pH 3.5 
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            Further LLE optimisation was not carried out as an LOD of only 200 
pg/mL was achieved, see Figure 4.37, again not good enough in terms of 
sensitivity for Scop serum concentrations post patch application.   
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Figure 4.37: LC-MS chromatogram, in MRM mode of  extracted spiked (200 pg/mL) serum standard (black) superimposed on extracted 
serum blank sample (blue) using an Agilent Zorbax SB-C18 column
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Agilent Zorbax RX-C8 column 
 
As C18 columns proved unsuccessful, it was decided to switch column 
chemistries from C18. Octylsilane (C8) is also a popular stationary phase in 
reversed-phase chromatography. It usually provides slightly less retention than 
the more popular C18 (Kazakevich et al., 2006) and because of this, was too 
investigated. See Figure 4.38. 
 
 
Figure 4.38: Reversed phase stationary phases (a) C18 and (b)  C8 
 
 An Agilent Zorbax RX-C8 (narrow bore 150 x 2.1 mm, 5 µm) column 
was investigated. This column was also unable to achieve separation between 
the two drugs under the same chromatographic conditions. Figure 4.39 displays 
results using this column while varying the % MeOH between 40 and 70%. 
Buffer used was as before, 2 mM ammonium formate, pH 5. Using the same 
flowrate of 0.2 mL/min, 20 µL of a Scop and Atr 10 ng/mL mixed standard 
was injected.  
(b) (a) 
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Figure 4.39: Comparison of the impact of different different % MeOH mobile phase compositions on peak shape and retention for Scop and 
Atr using an Agilent Zorbax RX-C8 column
70% MeOH
60% MeOH
50% MeOH
40% MeOH
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Symmetry Shield RP8 column 
 
A Symmetry Shield RP8 (75 x 4.6 mm, 3.5 µm) column was also investigated. 
This column was again unable to achieve separation between the two drugs 
under the same chromatographic conditions. Figure 4.40 displays results using 
this column at 40% MeOH in comparison to 40% MeOH using the above C8 
column. Buffer used was as before, 2 mM ammonium formate, pH 5. Using the 
same flowrate of 0.2 mL/min, 20 µL of a Scop and Atr 10 ng/mL mixed 
standard was injected.  
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Figure 4.40: Comparison of Agilent Zorbax RX-C8 column to Symmetry Shield RP8 at 40% MeOH 
Symmetry Shield RP8
Agilent Zorbax RX-C8 
Scop
Atr
Scop
Atr
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Agilent Zorbax SB-Phenyl column 
 
Following trials on a number of columns it was decided to investigate an 
Agilent Zorbax SB-Phenyl column (150 × 4.6 mm, 5 µm). Steenkamp et al., 
2004,  reports the only other LC-MS method developed for the analysis of 
Scop from a biological matrix using a phenyl column. Their method was used 
to analyse viscera samples whereby Scop and Atr were detected in 
the stomach and its contents, which contained datura seeds. Steenkamp too 
evaluated various HPLC columns including reversed phase C18 in the method 
development but a Waters Xterra Phenyl HPLC column performed the best and 
so, was used by this group. 
As phenyl columns offer unique selectivity from the alkyl phases and 
are generally less retentive than C8 or C18 phases (Kazakevich et al., 2006) it 
was decided this phase would be a good alternative and worth investigating. 
See Figure 4.41. 
 
 
Figure 4.41: Reversed phase phenyl stationary phase 
 
            Figure 4.42 represents the preliminary results achieved using the 
Agilent Zorbax SB-Phenyl column (150 × 4.6 mm, 5 µm). The same flowrate 
of 0.2 mL/min and the same 20 µL of a Scop and Atr 10 ng/mL standard was 
injected as with the previous columns investigated. Separation between Scop 
and Atr was achieved but the retention times of the drugs, even under various 
% MeOH/ammonium formate compositions were too long with a runtime of 25 
minutes required to elute the two drugs. 
.  
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Figure 4.42: Comparison of the impact of different different % MeOH mobile phase compositions on peak shape and retention for Scop and Atr  
using an Agilent Zorbax SB-Phenyl column 
Scop 
Scop 
Scop 
Scop 
Atr 
Atr 
Atr 
Atr 
50% MeOH 
60% MeOH 
70% MeOH 
90% MeOH 
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 As discussed, for quantitation of analytes in biological samples, the 
usual procedure is to add an internal standard in the calibration samples and 
real samples. An internal standard is generally incorporated to correct for 
sample and standard injection volume variations and errors. Since each sample 
and standard contains a constant internal standard amount, the analyte level 
(and its signal) should remain proportional to the internal standard level and the 
analyte concentration is therefore proportional to the ratio of the analyte to 
internal standard signals. Likewise, the sample and standard dilution volume 
can be compensated for by use of an internal standard. Proper selection of an 
internal standard also allows the internal standard to correct for extraction 
efficiency. The internal standard is typically chosen to be similar in structure, 
generally a structural analog to the analyte, so that they have similar partition 
coefficients in liquid extractions and extraction efficiencies in solid phase 
extraction (Grasso et al. 1998). However, use of Atr as an internal standard 
proved both complex and inadequate for this work.  
The optimal internal standard is often regarded as a deuterated or 
carbon-14 analog of the analyte because they have identical chemical 
properties, resulting in identical extraction efficiencies and also identical 
reactivity for derivatisation. Since deuterated analogs chromatographically co-
elute with the analyte, they can only be used with mass-selective detectors 
because mass spectrometers allow for the mass discrimination of the co-eluting 
compounds (Ohannesian et al., Streeter 2002). As with more conventional 
internal standards, deuterated internal standards are used mainly to compensate 
for sample loss during clean up and correct the deviations of injection volumes 
and variability in detector response (Grasso et al. 1998). However, deuterated 
compounds are very expensive and are often not available.  They must also be 
available in absolute purity since any non-deuterated material may confound 
the estimation of the target analyte.  This can be a major limitation for the 
application of such standards in ultrasensitive determinations since any 
contamination by an undeuterated form of the analyte will lead to erroneous 
results. 
 It is recommended in cases where internal standards are not used for 
recovery correction, to use two to three replicate assays on a single sample to 
improve precision (Ohannesian et al., Streeter 2002). Having concluded Atr 
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was extremely problematic in terms SPE quantification and getting a clear 
serum blank baseline it was decided not to proceed with analysis of this drug. 
Also, the high pKa value (10.2) for Atr posed some problems as most 
analytical columns cannot function at pH values higher than nine due to 
degradation of the silica support structure of the reversed phase analytical 
columns.  
With these complexities in mind, it was decided to proceed without an 
internal standard and use three replicates per sample assayed for the remainder 
of the method. Fortunately, it was found that the results were sufficiently 
accurate and robust without the use of an internal standard. 
Due to the wide bore nature of this column, the flow rate was increased 
from 0.2 mL/min to 0.6 mL/min in order to achieve faster analysis time. A flow 
rate reduced below optimum for the particle size can reduce efficiency and 
resolution due to increased band dispersion. 
Figure 4.43 shows the effect of increasing the MP MeOH composition 
from 60-90% using ammonium formate (pH 5, adjusted with 1 M formic acid, 
2 mM) and 0.6 mL/min flowrate again using the same 20 µL injection volume. 
Any decrease from 90% methanol had a massive impact on the sensitivity for 
Scop, with a decrease in both peak height and area observed. 
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Figure 4.43: Comparison of the impact of different different % MeOH mobile phase compositions on peak shape and retention for Scop using an 
Agilent Zorbax SB-Phenyl column 
60% MeOH 
70% MeOH 
80% MeOH 
90% MeOH 
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In order to further optimise Scop’s signal intensity, different mobile 
phase buffer concentrations and pHs were looked at.  Using ammonium 
formate (pH 5 adjusted with 1 M formic acid) - MeOH (10:90, v/v), 2, 5, 10 
and 20 mM ammonium formate buffer concentrations were examined. See 
Figure 4.44. It was decided to choose 10 mM ammonium formate as buffer for 
the mobile phase as it gave the best results in terms of area count in 
comparison to the others investigated. 
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Figure 4.44: Comparison of the impact of different ammonium formate concentrations (pH 5) on peak shape and retention for Scop using an 
Agilent Zorbax SB-Phenyl column 
2 mM 
5 mM 
10 mM 
20 mM 
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 As pH dictates the degree of ionisation of compounds that possess 
ionisable groups, the pH of the mobile phase influences both retention and 
ionisation efficiency in LC-MS. The pH of the mobile phase dictates whether 
analytes are positively or negatively charged, and the overall extent of charge. 
Using ammonium formate (10 mM) - MeOH (10:90, v/v), different pHs were 
then examined (4, 5, 7, 8 and 9). pH adjustment was achieved using formic 
acid and ammonium hydroxide. Although organic acids are the most common 
mobile phase additive for HPLC separations that employ MS detection, it may 
be necessary under certain circumstances to use more neutral conditions, either 
because the analytes are sensitive to acids or do not exhibit optimal resolution 
at low pH. When acids are not suitable, volatile salts, like ammonium formate 
or ammonium acetate, are the additives of choice. At higher pHs, basic 
compounds with pkas greater than 5 (such as Scop with a pKa value of 7.55-
7.81 (Cherkaoui et al., 1997)) become non-charged and the column retains 
them more. At pH > 5 the residual silanols on the silica surface become 
charged and this can lead to stronger interactions with basic compounds and 
increase retention. From Figure 4.45 it can be seen that high pH was needed to 
achieve greater retention of the basic compounds and pH 8 offered the best 
results in terms of peak area.  
Steenkamp et al., 2004, also used basic chromatographic conditions in 
their approach to ensure the maximum retention of basic alkaloids. The phenyl 
column they used, however, could be employed at a pH > 9 and was found to 
be suitable for the chromatography of Atr. A gradient was employed starting 
with 90% water containing 10 mM ammonium acetate, the pH adjusted to 10.5 
with ammonia. Due to the nature of the phenyl column used in our work, a pH 
this basic could not be employed and so was not investigated for further 
optimisation of Atr. 
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Figure 4.45: Comparison of the impact of different mobile phase pHs using 10 mM ammonium formate on peak shape and retention for Scop 
using an Agilent Zorbax SB-Phenyl column 
pH 4 
pH 7 
pH 5
pH 8pH 9  
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 Chromatographic separation was used for validation and analysis of the 
participant’s serum samples was achieved using this Agilent Zorbax SB-Phenyl 
column (150 × 4.6 mm, 5 µm). A mixture of ammonium formate (pH 8 
adjusted with ammonium hydroxide; 10 mM) - MeOH (10:90, v/v) was used as 
mobile phase, at a flow rate of 0.6 mL/min. The column temperature was 
maintained at 20 °C and the temperature of the autosampler was maintained 
4 °C. The complete chromatographic run time of each sample was 10 min, 
which eluted Scop at 4.2 mins. Injection volume was 20 µL. The sensitivity 
achieved for the drugs prepared in mobile phase, 10 pg/mL was the best LOQ 
achieved out of all the columns investigated. As discussed, the solvent 
composition (organic/water ratio) is particularly important in the electrospray 
nebulisation and ionisation process, since it determines surface tension of the 
droplets formed and the vaporisation efficiency. As the surface tension of water 
is much higher than the surface tension of MeOH, the sensitivity is reduced 
when using a high % of aqueous mobile phases. This assay, however, required 
a high % of organic in the MP and may have been a contributing factor to the 
excellent LOQ achieved. It was hence decided to proceed with this column and 
re-optimise SPE conditions.  
4.4.2.2 Extraction procedure  
 
From the results obtained from the Waters Nova-Pak C18 column (150 × 3.9 
mm, 4 µm) and SPE optimisation, it was determined the Oasis HLB cartridges 
gave the best results in terms of Scop SPE recovery in comparison to the four 
ion exchange sorbents. Also, and confirmed by the Agilent Zorbax SB-C18 
column optimisation and SPE results, Atr did not give consistent results in 
terms of recovery, and some form of very similar contaminant was consistently 
found in SPE serum blanks in varying degrees. It was hence decided not to 
proceed with using Atr as internal standard with the Agilent Zorbax SB-Phenyl 
column. With the Agilent Zorbax SB-C18 column, ion suppression played a 
big problem in terms of Scop recovery. Further investigation was therefore 
required in order to obtain the cleanest results possible with the Agilent Zorbax 
SB-Phenyl column. It was decided to carry out an extensive study on the 
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retention of Scop to the Oasis HLB cartridge. Figure 4.46 displays the effect on 
varying the composition of MeOH in the wash step on the retention of Scop to 
the HLB cartridge. It was a crucial step in determining the optimum wash and 
also elution steps for Scop. 
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Figure 4.46: Comparison of different MeOH compositions in the SPE wash step on the retention of Scop 
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As discussed, the optimum wash solvent needed to be non-polar enough 
to elute as many interferences as possible, but not sufficiently non-polar to 
elute the analytes. This solvent was identified by washing the SPE cartridges 
starting with 100% water, then progressively increasing the proportion of 
MeOH present. Proportions of 10 to 100% MeOH in the wash solvent were 
evaluated. Each wash step was collected and analysed for the presence of the 
drugs. See Figure 4.46. There was a slight loss of recovery at 25% MeOH. The 
wash containing the highest percentage organic but no analytes was at 20% and 
provided the cleanest final extract.  
From these results it can be seen, elution with 100% MeOH gave the 
best recovery for Scop in terms of achieving the highest peak area signal. 
However, on introducing serum to the elution step, eluting with 100% MeOH 
was shown to be detrimental to ion suppression results. As previously 
discussed, the SPE elution step requires use of the weakest elution solvent 
which has just enough hydrophobicity to give quantitative analyte elution. 
Eluting with 100% MeOH however, left behind on the sorbent the maximum 
number of contaminants as shown in Figure 4.47. A compromise using 75% 
MeOH proved satisfactory. With a slight decrease in recovery observed as seen 
Figure 4.46, a decrease in the number of contaminants eluting was evident as 
seen in Figure 4.47.   
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Figure 4.47: TIC scan showing differences between eluting with 100% MeOH (green) and 75% MeOH (red) using an Agilent Zorbax SB-
Phenyl column 
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 Figure 4.48 is a representation of where Scop eluted via MRM scan 
with transition m/z 304 to 138 extracted out in comparison to the TIC scan of 
serum blank extracted.  It represents where Scop was eluting in relation to the 
endogenous material from the blank serum extracted.  
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Figure 4.48: Chromatogram of TIC scan of spiked serum sample (red) superimposed on MRM scan of same Scop sample (blue) using an Agilent 
Zorbax SB-Phenyl column.  Note: not to scale 
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            Under the final optimised SPE conditions, Oasis HLB cartridges were 
conditioned with 1 mL MeOH prior to equilibration with 1 mL diluted buffer 
solution with water (1:10, v/v) used in load step (5 mM ammonium formate 
buffer; pH 8). 1 mL buffered serum (0.5 mL serum + 0.5 mL buffer (5 mM 
ammonium formate buffer, pH 8)), was loaded and subsequently washed with 
2 mLs 20% MeOH. The sample was eluted with 0.5 mL 75% MeOH. The vials 
were evaporated to dryness using a Genevac EZ-2 evaporator at ambient 
temperature, without light for ~ 1.5 hours and reconstituted in 0.05 mL MeOH. 
 
4.4.2.3 Mass spectrometric conditions 
 
Mass spectrometry settings for Scop and Atr were optimized by injecting 250 
ng/mL of drug, and by flow injection analysis (FIA) the precursor ion, 
optimum fragmentor voltage, optimum collision energy and product ion was 
determined. As discussed for MRM mode, the fragmentor voltage setting acts 
as a filter allowing the maximum number of precursor ions to enter the system 
in quadrupole one. In the collision cell a voltage is applied and the precursor 
ions are split into their products ions.  This explosion occurs as the products 
ions smash in to the nitrogen ions already present with the energy from the 
voltage applied.  These product ions continue to travel onwards to the third 
quadrupole.  Here, accurate masses of the product ions are detected. 
Each ion source/spray chamber’s settings depend on the mobile phase 
composition, flow rate, and sample identity. The nebuliser pressure, drying gas 
flow, and drying gas temperature are dependent upon the mobile phase 
composition and flow rate. The settings used were set according to the MS 
operation manual for a mobile phase flowrate of 0.6 mL/min. Drying gas 
temperature was set to 375 0C, drying gas flow to 11 L/min and nebuliser 
pressure to 50 psi.  
 
4.4.2.3.1 Precursor ion determination 
 
From the autosampler, 10 µL of sample were injected into the mass 
spectrometer by FIA where a TIC scan was run in order to establish the 
predominant precursor ion. The range was set from m/z 200 to 400 for Scop and 
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from m/z 210 to 350 for Atr. These ranges were chosen as they bracketed the 
molecular weights of Scop and Atr. Once a prominent peak was seen at the 
expected m/z value, this was deemed to be the precursor ion; Scop m/z 304.1 
and Atr m/z 290.2. See Figure 4.49. 
 
 
 
Figure 4.49: Comparison of background and Scop and background and Atr 
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4.4.2.3.2 Fragmentor voltage optimisation 
 
Once the precursor ion had been established the next step was to determine the 
optimum fragmentation conditions for that precursor ion. The mass 
spectrometer was programmed to perform an MS selected ion monitoring (SIM) 
scan which detects only the selected precursor ion so that the optimum 
fragmentor voltage for that ion could be determined. These SIM scans were 
done in series where the fragmentor voltage was varied over a range of 0 to 160 
V. Voltage increments of 20 V were used. 120 V achieved optimal results for 
Scop, with 140 V for Atr. See Table 4.13 
 
 
Voltage 
(V) 
Scop Atr
Area Area % Area Area % 
 
0 
 
 
20 
 
 
40 
 
 
60 
 
 
80 
 
 
100 
 
 
 
374,077 
484,306 
 
868,570 
792,053 
 
961,364 
953,392 
 
1,066,566 
1,049,472 
 
1,154,427 
1,199,793 
 
1,282,118 
1,286,714 
 
 
28.0 
36.3 
 
65.1 
59.4 
 
72.1 
71.5 
 
79.9 
78.7 
 
86.5 
89.9 
 
96.1 
96.4 
 
 
75,207 
111,575 
 
164,944 
161,351 
 
177,633 
174,731 
 
203,193 
196,597 
 
211,708 
221,141 
 
238,428 
241,916 
 
 
27.6 
40.9 
 
60.5 
59.2 
 
65.1 
64.1 
 
74.5 
72.1 
 
77.6 
81.1 
 
87.4 
88.7 
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120 
 
 
140 
 
 
160 
 
1,334,297 
1,276,291 
 
1,217,851 
963,963 
 
940,971 
844,691 
100.0 
95.7 
 
91.3 
72.2 
 
70.5 
63.3 
 
252,353 
250,773 
 
263,927 
272,707 
 
272,675 
269,242 
 
92.5 
92.0 
 
96.8 
100.0 
 
100.0 
98.7 
 
 
Table 4.13: Comparison of fragmentation voltages for Scop and Atr 
 
4.4.2.3.3 Product ion determination 
 
Having established the optimum fragmentor voltage for Scop and Atr, the next 
step involved carrying out a product ion scan in order to identify the product 
ions of Scop’s and Atr’s precursor ions. This was achieved by firstly isolating 
and then fragmenting the precursor ion with varying collision energy values 
ranging from 0 to 50, using increments of 10. The product ions were 
determined by analysing the fragments produced on collision. 
For Scop, this resulted in four predominant product ions: m/z 110.1, m/z 
121.1 m/z 138.1 and m/z 156.1. M/z 138 was the most abundant ion and so was 
used for quantification of Scop; the other 3 ions were monitored for qualitative 
purposes and hence ensuring specificity. According to Chen et al., 2005, the 
most abundant product ion at m/z 138.1 was formed by the loss of tropic acid 
(C9H10O3, 166 Da) and the ion at m/z 156 was produced by the loss of C9H8O2 
(148 Da). See Figure 4.50. For Atr, this resulted in two predominant product 
ions: m/z 124.1 and m/z 93.1. M/z 93.1 was the most abundant ion and so was 
used for quantification of Atr. 
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Figure 4.50: Fragmentation pathway of Scop 
 
4.4.2.3.4 MRM transition optimisations 
 
Repeated multiple reaction monitoring (MRM) scans which detected the 
MS/MS transitions were carried out in order to obtain the optimum collision 
energy for fragmentation of Scop and Atr to their product ions. Collision 
energy was raised in increments of 5 V in this case so that a more accurate 
collision energy could be established. The collision energy that gave the most 
intense peak for the chosen product ion was deemed to be the optimum value. 
See Table 4.14. 
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Compound 
Product 
ion 
Optimum collision 
energy (V) 
 
Scop 
 
 
 
 
Atr 
 
 
110.1 
121.1 
138.1 
156.1 
 
124.1 
93.1 
 
 
30 
20 
20 
15 
 
22.5 
35 
 
Table 4.14: Collision energy results for product ions of Scop and Atr 
            The final MS conditions used in terms of precursor and product ions, 
collision energies and fragmentation voltages are shown in Table 4.15. 
 
Compound 
Precursor 
ion 
Fragmentor 
voltage (V) 
Product 
ion 
Optimum 
collision 
energy 
 
Scop 
Atr 
 
 
304.1 
290.2 
 
120 
140 
 
138 
124.1 
 
20 
22.5 
 
Table 4.15: Optimum positive mode ESI conditions for Scop and Atr 
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4.5 Method validation 
 
A full validation in accordance with the FDA guidelines (FDA, 2001) was 
performed on the previously described method whereby chromatographic 
separation was achieved using an Agilent Zorbax SB-Phenyl (150 × 4.6 mm, 5 
µm). A mixture of ammonium formate (pH 8 adjusted with ammonium 
hydroxide; 10 mM) - MeOH (10:90, v/v) was used as mobile phase, at a flow 
rate of 0.6 mL/min. The column temperature was maintained at 20 °C and the 
temperature of the autosampler was maintained 4 °C. The complete 
chromatographic run time of each sample was 10 min. Peaks were quantified 
using Agilent Masshunter Software. 
The mass spectrometer was operated using an ESI source in the positive 
ion detection mode. The ionisation temperature was 350 °C, gas flow rate was 
11 L/min and nebuliser pressure was 50 psi. Nitrogen was used as the 
ionisation source gas and ultrapure nitrogen as the collision cell gas. Analysis 
was performed in MRM mode with the following transitions: m/z 304.1 → m/z 
138.1 for Scop, with a dwell time of 200 ms.  
Extraction of Scop from serum was achieved using Oasis HLB 
cartridges which were conditioned with 1 mL MeOH prior to equilibration with 
1 mL diluted buffer solution (5 mM ammonium formate buffer; pH 8) with 
water (1:10, v/v)) 1 mL buffered serum (0.5 mL serum + 0.5 mL buffer (5 mM 
ammonium formate buffer, pH 8)), was loaded and subsequently washed with 
2 mLs 20% MeOH. The sample was eluted with 0.5 mL 75% MeOH. The vials 
were evaporated to dryness using a Genevac EZ-2 evaporator at ambient 
temperature, without light for ~ 1.5 hours and reconstituted in 0.05 mL MP. 
The overall LC-MS method was validated for the following 
performance parameters- intra-day and inter-day precision, accuracy, 
sensitivity (LOD and LOQ), linearity and range, recovery and sample stability 
according to the guidelines described by the FDA (FDA, 2001). 
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4.5.1 Accuracy 
 
In order to evaluate the accuracy of the method, five different concentrations of 
Scop (10, 20, 50, 100 and 200 pg/mL) were prepared in serum and analysed in 
triplicate on three consecutive days. The measured amounts were inserted into 
the equation of the calibration curves and treated as unknown concentrations. 
The calculated concentrations were compared with the nominal concentrations. 
Assay accuracy was expressed as % error i.e. [the absolute difference between 
calculated concentration and spiked concentration] / nominal concentration × 
100. The accuracies obtained at the five concentrations examined were all 
acceptable with % error values < 15% - see Table 4.16. These are exceptionally 
good results given the very low concentration of Scop being detected.  
 
4.5.2 Precision 
 
The precision of Scop standards were evaluated by analysing five different 
concentrations of Scop (10, 20, 50, 100 and 200 pg/mL). The intra-day 
precision values were determined by processing each working standard 
concentration in sextuplicate on the same day and calculating the relative 
standard deviation (RSD) values. The inter-day precision values were 
determined by processing each working standard concentration in 
quadruplicate for four consecutive days and calculating the RSD values. % 
RSD was expressed as [deviation from the mean]/mean concentration × 100.  
Intra- and inter-assay precision RSD values were found to be less than 15% in 
all cases which, in accordance to FDA guidelines is the highest value accepted 
(FDA, 2001). See Table 4.16 for the summarised data. Again the results 
obtained, given the levels being detected are very good. 
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Table 4.16: A summary of the Intra-Day and Inter-Day precision and accuracy determinations 
Compound 
INTRA-DAY  (n =4 ) INTER-DAY (n = 3) 
Calculated 
conc. (pg/mL) 
Accuracy 
% Error 
Precision  
% RSD 
Calculated 
conc. (µg/mL) 
Accuracy 
% Error 
Precision 
% RSD 
Scop 
 
10.5 
20.3 
51.1 
99.1 
200.9 
 
10.1 
-6.1 
2.0 
1.4 
4.3 
 
1.2 
1.9 
2.7 
7.2 
2.1 
 
10.1 
20.5 
49.7 
100.0 
199.9 
 
14.0 
-4.3 
6.9 
-1.8 
-2.2 
 
4.1 
4.2 
1.7 
1.4 
0.4 
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4.5.3 Sensitivity and selectivity 
 
Both the limits of quantitation (LOQ) and detection (LOD) were determined 
for the assay. The LOQ was defined as the lowest concentration that produced 
a peak distinguishable from background noise with a minimum ratio of 10:1 
(Shah et al., 1992). LOD was defined as the lowest concentration that produced 
a peak distinguishable from background noise with a minimum ratio of 3:1. 
The limit of quantitation (LOQ) was an exceptional 10 pg/mL for Scop with a 
S/N of 16, the best sensitivity achieved to date for Scop extracted from 
biological matrix. See Figure 4.51. Extracted blank serum samples did not 
yield any endogenous peaks at the retention times of the drug compounds – see 
also Figure 4.51. The LOD was found to be 5 pg/mL with a S/N of 6. These 
values for LOD and LOQ enable pharmacokinetic monitoring of Scop serum 
samples. The signal-to-noise ratio was calculated by the Masshunter qualitative 
analysis software. 
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Figure 4.51: Chromatograms of extracted drug-free serum sample (black) superimposed on extracted serum spiked with 10, 20, 50, 100 and 200 
pg/mL Scop (red) using an Agilent Zorbax SB-Phenyl column 
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Due to the high sensitivity of mass spectrometric detection and the low 
background when quantifying based on the molecular transitions of the ions in 
the collision cell, MRM gave excellent selectivity and the very low LOD and 
LOQs necessary to comfortably quantify Scop post patch (half or full) 
application. 
 
4.5.4 Linearity and range 
 
The calibration curves for Scop were linear over the range of 100–2000 pg/mL 
in mobile phase and recovery from serum was linear over the range 10–200 
pg/mL, see Figure 4.52. The calibration curve was linear with a correlation 
coefficient (R2) value of >0.999.  
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Figure 4.52: Linearity for Scop serum standards using an Agilent Zorbax SB-Phenyl column 
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4.5.5 Recovery 
 
Varying concentrations of Scop (10, 100 and 200 pg/mL) were prepared in 
drug-free human serum and extracted using the SPE cartridges. The percentage 
of drug recovered from these serum samples was determined by comparing the 
calculated concentrations following extraction and HPLC assay with the 
calculated concentrations from post extracted spiked samples in MP of the 
same concentration after HPLC assay. Recoveries for serum samples spiked 
with 10, 100 and 200 pg/mL of Scop were ≥ 73% (Table 4.17).  
There are very few LC-MS methods in the literature for the analysis of 
Scop from biological matrices. The SPE approaches exploited in the literature 
however, demonstrate poor Scop recovery or high sample volume required. 
Oertel et al., 2002, developed a procedure for the extraction of Scop from 
serum employing Oasis HLB cartridges. A sample volume of 0.2 mL serum 
was required for the extraction but the recovery achieved was low at only 51%. 
Beyer et al., 2007, used SPE for the extraction of Scop from plasma. A 
proportionately large sample volume was required (1 mL) and recovery ranged 
between 67 and 92% for Scop. In comparison, the recovery achieved for this 
assay was high at ≥ 73% and sample volume low at 0.5 mL serum required. 
 
Conc. (pg/mL) 
Scop mean % 
recovery ± % RSD 
 
10 
100 
200 
 
73.9 ± 1.6 
76.1 ± 2.0 
74.0 ± 1.1 
 
 
Table 4.17:  Recovery data for Scop in serum (n = 3) 
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4.5.6 Stability 
 
To examine relevant variables around storage and long term stability we 
determined the impact of freeze–thaw cycles on the stability of the drugs in the 
presence of serum, fresh drug-free serum samples were spiked with 10, 100 
and 200 pg/mL of Scop as shown in Table 4.18. Samples underwent three 
freeze-thaw (−20 °C to room temperature) cycles. The drug concentrations 
were then determined in triplicate on three separate occasions and compared to 
serum samples prepared to the same concentrations that were stored at −20 °C 
and only thawed once immediately prior to analysis. Finally, stock solution 
stability was evaluated by comparing the response obtained from standards 
prepared in mobile phase at three concentrations (100, 1000 and 2000 pg/mL) 
left at room temperature for 8 hours to freshly prepared stock solutions. 
 
Compound 
Conc. 
(pg/mL) 
± % RSD 
Cycle 1  
% recovery 
± % RSD 
Cycle 2  
% recovery 
± % RSD 
Cycle 3  
% recovery 
± % RSD 
 
Scop 
 
10 
100 
200 
 
99.7 ± 2.1 
100.7 ± 3.0 
99.7 ± 1.9 
 
98.1 ± 0.5 
100.8 ± 1.8 
99.5 ± 4.0 
 
96.0 ± 3.7 
96.8 ± 2.0 
95.7 ± 0.9 
 
Table 4.18:  Summary of freeze-thaw stability findings for Scop (n = 3) 
The data indicated that three freeze–thaw cycles had little significant 
impact on the Scop concentrations measured, which means that samples could 
be repeatedly thawed and re-analysed up to three times if required. The 
stability of the three stock solutions prepared in mobile phase was also 
evaluated. Standards (100, 1000 and 2000 pg/mL) left for eight hours at room 
temperature showed no decline in detector response at the three concentrations 
analysed which allowed for daily preparation of daily solutions. 
 
 
317 
 
4.5.7 Matrix effects 
 
The impact of matrix effects on the accuracy, precision and robustness of 
bioanalytical methods is of growing concern in the pharmaceutical industry. 
Biological matrices such as plasma, serum and urine have been known to cause 
ion suppression or enhancement effects in mass spectrometric experiments. 
These effects result from co-eluting matrix components that affect the 
ionisation of the target analyte. Endogenous phospholipids are present in high 
concentrations in biological matrices, such as plasma and serum and have been 
implicated in causing ion suppression or enhancement in LC/MS/MS analyses. 
Researchers have described this phenomenon as being due to the effect they 
have on desolvation of the LC effluent droplets in electrospray MS analysis or 
as a result of competition for excess charges on the droplet surface (Chambers 
et al., 2007). The potential impact of ion suppression/enhancement on the 
quantification was assessed by comparison of the results obtained with 
standard dilutions of each drug in methanol (standard solutions) against 
standard dilutions which were added to the eluate of SPE serum blanks (post 
extracted spiked samples) which were then dried and reconstituted in MP. Data 
indicated ~12% ion suppression, which according to FDA guidelines is 
acceptable. See Figure 4.53. This ion suppression could have been reduced 
further by either increasing the proportion of MeOH in the SPE wash step or by 
decreasing the proportion of MeOH in the elution step, both which would have 
been detrimental to the recovery of Scop as outlined previously. Matrix effects 
may also be reduced by simply injecting smaller volumes or diluting the 
sample. However, these solutions clearly influence the sensitivity of the 
method and were therefore not appropriate for this work. Fortunately, 
according to FDA guidelines (FDA, 2001), the value obtained for the % ion 
suppression  is acceptable. 
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Figure 4.53: Chromatogram displaying ion suppression results.  Red: 1ng/ml Scop in MeOH, Black: serum blank reconstituted in the same 
1ng/ml Scop standard in MeOH 
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4.5.8 Patient sample results 
 
Blood samples analysed were obtained from a participant of the pilot study 
discussed in Chapter 5. The participant was administered both the full and half 
Scop patch on different occasions. Samples were drawn at nine different time 
points (0, 3, 6, 7, 8, 9, 24, 48 and 72 hrs) over a 72 hour period. Presented in 
Figure 4.54 are the pharmacokinetic profiles generated from patient A’s serum 
samples following the full and half transdermal Scop patch applications.  
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Figure 4.54: Comparison of pharmacokinetic profiles generated from patient A’s serum samples following half and full transdermal Scop patch 
applications
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 Scop was not detected in serum of the patient pre administration of the 
patch at t=0. On application of the full transderm Scop patch, Scop partitioned 
from the drug saturated adhesive layer into the skin but absorption of Scop into 
the systemic circulation was somewhat slow with effective drug concentrations 
achieved 6-8 hrs post patch application. Maximum serum concentrations (Cmax) 
of 167.5 ± 2.5 pg/mL of the alkaloid were reached at a Tmax, (the time taken for 
the drug to reach its highest concentration in the blood stream) of about 24 hrs.  
As the patch releases Scop continuously over a 72 hr period, constant high 
Scop serum levels were observed, with a slight decline in drug concentration 
observed over time reaching 89.0 ± 4.6 pg/mL at 72 hrs. 
On application of the half transderm Scop patch, the absorption of Scop 
into the systemic circulation was again somewhat slow with effective drug 
concentrations achieved 6-8 hrs post patch application. Maximum serum 
concentrations (Cmax) of 40.8 ± 0.1 pg/mL were reached at a Tmax, of about 48 
hrs.  High Scop serum levels were observed from 9 hrs onward.  
Results of all participants in the Scop pilot study are discussed in more 
detail in chapter 5.  
 
4.6 Conclusions 
 
As discussed, LC–MS is currently the most common technique employed for 
the detection and quantification of tropane alkaloids. From the scientific 
literature read, there is no fast, simple, isocratic method reported which 
achieves the sensitivity required for the analysis of Scop in serum post patch 
and half patch application.  
Oertel et al. developed two LC-MS methods for the analysis of Scop 
and achieved the best sensitivity for Scop published to date giving an LOQ of 
20 pg/mL for Scop in serum (Oertel et al., 2001). Even though the retention 
times for the drugs was fast, the chromatographic separation involved a 
gradient programme which required a 10 min equilibration time between runs 
and the resulting assay demonstrated poor Scop recovery. Oertel el al. 
subsequently investigated increasing sample throughput in pharmacological 
studies by using dual-column liquid chromatography with tandem MS (Oertel 
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et al., 2002). Even though good sensitivity was achieved at 50 pg/mL, a 
gradient was required and two columns were needed which added complexity 
to the method. 
Beyer et al., 2009, used APCI and ESI approaches for Scop’s detection. 
APCI resulted in a LOQ of 5 ng/mL and ESI 0.1 ng/mL. Although the LOQ 
using ESI was low, the method required 1 mL plasma to achieve this sensitivity. 
Scop eluted at 4.8 min but again a gradient programme was requited for the 
method.  
Steenkamp et al., 2004, developed an LC-UV-MS method which 
resulted in an LOD of 100 pg/mL for Scop but suffered from Scop having an 
extremely long retention time of 20.0 min. 
Many methods for the determination of Scop suffer from having to use 
a gradient programme in order to achieve their fast runtimes and low sensitivity, 
however, the assay developed and validated for this work required an isocratic 
elution which resulted in exceptional sensitivity and a short runtime. The assay 
described exhibits the best sensitivity achieved to date for Scop extracted from 
biological matrix. 
In conclusion, a fast, novel and extremely sensitive assay has been 
developed and validated for the determination of Scop in serum using SPE 
coupled to LC–MS/MS. The isocratic elution scheme gives a simple, robust and 
reproducible chromatographic method with an exceptional LOQ of 10 pg/mL 
for Scop. The assay described has been proven accurate and precise for the 
determination of Scop in serum with a recovery of > 73% obtained. The easy 
sample preparation and fast separation makes this assay highly suitable for 
pharmacokinetic studies and therapeutic drug monitoring.  
This method has been applied to a study evaluating the effects of the 
transdermal Scop patch both uncompromised and cut in half. As the assay is 
capable of monitoring serum levels of the drug over time it will also be used in 
the NASA-based motion sickness countermeasures study in order to evaluate 
the effects of the transdermal Scop patch cut in half in preventing motion 
sickness in astronauts induced by off-vertical axis rotation (OVAR). 
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Chapter 5 
 
A pilot comparison of the human pharmacology of a 
half versus full transdermal scopolamine patch 
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5.1    Scope of research  
 
The National Aeronautics and Space Administration (NASA) are currently 
conducting a project entitled ‘Evaluation of countermeasures for motion 
sicknesses’. The purpose of this study is to evaluate the effects of the 
transdermal scopolamine (Scop) patch in preventing motion sickness in 
astronauts induced by off-vertical axis rotation (OVAR). The main question 
being asked is ‘Would cutting a Scop transdermal patch in half reduce the side 
effects associated with the medication while still giving effective protection 
from motion sickness?’  
  It had been hypothesised that if a transdermal patch of Scop is halved 
and only one half then used by the astronaut, that it is just as effective as a full 
patch but with less undesirable side effects. We therefore developed a pilot 
study to examine circulating levels of Scop in five volunteers treated with the 
full patch and a half patch to evaluate this hypothesis and further to consider if 
the patch is compromised by cutting it in half.  
Also the study aimed to compare the severity of side effects induced by 
the transdermal Scop patch both full and in half and correlate these to the levels 
of Scop measured in serum over a 72 hour period.  
 
5.2      Introduction 
 
The skin represents an extraordinarily evolved organ. Not only does it 
physically encapsulate the organism and provide a multifunctional interface 
between us and our surroundings, but it is perpetually engaged in the assembly 
of a highly efficient homeostatic barrier to the outward loss of water. In so 
doing, it furnishes a membrane that is equally adept at limiting molecular 
transport both from and into the body. Overcoming this barrier function then, 
for the purpose of transdermal drug delivery, has been a challenging task for 
the pharmaceutical industry (Naik, et al., 2000). Historically, developments in 
transdermal drug delivery have been incremental, focusing on overcoming 
problems associated with the barrier properties of the skin, reducing skin 
irritation rates and improving the aesthetics associated with passive systems.  
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The efficacy of a transdermal system is primarily dependent upon the 
barrier properties of the skin of the targeted species (Villarino et al., 2006). The 
release of a therapeutic agent from a formulation applied to the skin surface 
and its transport to the systemic circulation is a multistep process which 
involves:  
(a) drug dissolution within and release from the formulation 
(b) partitioning of the agent into the skin’s outermost layer, the stratum 
corneum   
(c) diffusion through the stratum corneum 
(d) partitioning from the stratum corneum into the more aqueous 
epidermal layer 
(e) diffusion through the epidermis and into the upper dermis 
(f) uptake into the local capillary network of the dermis and, 
eventually, the systemic circulation. (Villarino et al., 2006) 
 
 The benefits of transdermal delivery include, not only convenience for 
patients but also increased compliance. Transdermal therapeutic systems allow 
drugs to be delivered in a rate-controlled manner, avoiding first-pass 
metabolism and the fluctuating plasma concentrations which can be 
encountered with some oral medication formulations. In most cases, there are 
fewer side effects than there are with oral delivery of drugs (Musel et al., 
2006). Scop was the first drug marketed as a transdermal therapeutic system. 
Today, numerous drugs have been delivered successfully through transdermal 
patches: Scop, nitroglycerin, nicotine, clonidine, fentanyl, estradiol, 
testosterone, oxybutynin, and, recently, methylphenidate, selegiline, 
rivastigmine and rotigotine (Farahmand et al., 2009). 
 As discussed in Chapter 4, Scop has been shown to be one of the most 
effective agents for prevention of motion sickness. However, due to the short 
half-life of the drug in plasma and dose-dependent adverse effects, the clinical 
use of scopolamine administered orally or parenterally is limited. See Table 5.1 
for a more comprehensive general list of Scop side effects commonly found at 
different doses orally administered (Barratt et al., 2008). 
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Scop dose Effect 
 
0.5 mg 
 
 
 
1 mg 
 
 
 
 
 
2 mg 
 
 
 
 
5 mg 
 
 
 
 
 
 
 
10 mg and above 
 
 
 
slight slowing of cardiac heart rate 
some dryness of mouth  
inhibition of sweating 
 
definite dryness of mouth 
thirst 
acceleration of heart rate sometimes 
preceded by slowing 
mild dilation of pupils 
 
rapid heart rate, palpitation 
marked dryness of mouth 
dilated pupils 
some blurring of near vision 
 
all the above symptoms marked 
difficulty in speaking and 
swallowing 
restlessness and fatigue 
headache, dry hot skin  
difficulty in urination 
 reduced intestinal peristalsis 
 
above symptoms more marked 
pulse rapid and weak 
 iris practically obliterated  
vision very blurred 
skin flushed hot dry and scarlet 
ataxia, restlessness and excitement  
hallucinations and delirium, coma 
 
Table 5.1: Scop dose and effect  
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 To minimise the relatively high incidence of side effects, the 
transdermal dosage form was developed (Renner et al., 2005). Even though 
transdermal Scop has been associated with a lower incidence of side effects 
than orally or parenterally administered Scop, adverse systemic effects have 
still been frequently reported (Nachum et al., 2006). 
Motion sickness is a common affliction of mankind, caused by a 
neurological “disagreement” between visual signals and those generated by the 
balance organ in the inner ear when a person is moving (Gilles, 2007).  Motion 
sickness is very common among astronauts. Space motion sickness and related 
symptoms remain a major limiting factor in space operations where the 
phenomenon can be seriously debilitating. There are several different forms of 
treatment for motion sickness. NASA provide the Scopderm patch for 
astronaut’s treatment of motion sickness.  However, the Administration has 
found that some individuals suffer significant side effects from these patches. 
The most commonly cited negative effects by people using transdermal Scop is 
dryness of the mouth and drowsiness. Temporary blurring of vision and 
dilation (widening) of the pupils has also been reported.  
 
5.2.1 Transdermal scopolamine system 
 
There are various transdermal therapeutic systems available which all use the 
same methodology. Tradenames such as Transderm-Scōp, Transderm-V, and 
Scopoderm are currently available in the market. The transdermal Scop system 
is a film, 0.2 mm thick and 2.5 cm2 in size, made up of four layers. Proceeding 
from the visible surface towards the surface attached to the skin, these layers 
are a backing layer of tan coloured, aluminised, polyester film; a drug reservoir 
of Scop, light mineral oil, and polyisobutylene; a microporous polypropylene 
membrane that controls the rate of delivery of Scop from the system to the 
surface of the skin; and an adhesive formulation of mineral oil, polyisobutylene 
and Scop. A protective peel strip of siliconised polyester, which covers the 
adhesive layer, is removed before the system is used. The inactive components, 
mineral oil (12.4 mg) and polyisobutylene (11.4 mg) are not released from the 
system (Novartis, 2006). See Figure 5.1.  
 
 
 
335
 
Figure 5.1: Diagrammatic representation of the cross section of the transdermal 
Scop patch 
 
 Each transdermal Scop patch contains a reservoir of 1.5 mg of Scop and 
is programmed to deliver in vivo approximately 1.0 mg of Scop at an 
approximately constant rate to the systemic circulation over three days (Renner 
et al., 2005). Patients are instructed to place the patch behind the ear, as the 
permeability of the post auricular skin to Scop is 20 fold higher than other 
areas of the body (Farahmand et al., 2009) for example the skin of the thigh 
(Streisand et al., 1995).  
Upon application, an initial priming dose (140 μg) of Scop is released 
from the adhesive layer to saturate the skin area and to accelerate the 
achievement of steady-state blood levels. The subsequent delivery of Scop to 
the blood is determined by the rate-controlling membrane and is designed to 
produce stable levels in the blood in a therapeutic range at a constant rate of 
approximately 5 μg/hr.  
The literature indicates Scop serum levels of 50 pg/mL are generally 
accepted as affording prophylactic protection against motion sickness (Nachum 
et al., 2001) These levels are attained 6 hours post patch application with a 
steady state of about 100 pg/mL achieved 8-12 hours after application 
(Nachum et al., 2001).  
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5.2.2 Pharmacokinetics of scopolamine 
 
Pharmacokinetics describes how the body affects a specific drug after 
administration The pharmacokinetics of a drug in the body is divided into 
several phases including absorption, distribution, metabolism and excretion. 
This is commonly referred to as the ADME scheme of a drug. Absorption is 
the process of a substance entering the blood circulation. Distribution is the 
dispersion or dissemination of substances throughout the fluids and tissues of 
the body. Metabolism is the irreversible transformation of parent compounds 
into daughter metabolites. Excretion (or elimination) is the elimination of the 
substances from the body. Pharmacokinetic properties of drugs may be affected 
by factors such as the site of administration and the dose of administered drug 
which may affect the absorption rate. The general ADME scheme for 
transdermally formulated Scop is as follows: 
Absorption: As Scop is lipophilic, it is well absorbed percutaneously. 
Following application to the skin behind the ear, circulating blood levels are 
detected within four hours, with peak levels being obtained, on average, within 
24 hours. The average plasma concentration produced is 87 pg/mL for free 
Scop and 354 pg/mL for total Scop (free and conjugates) (Novartis, 2006). 
Distribution: The distribution of Scop is not well characterised. It 
crosses the placenta and the blood brain barrier and may be reversibly bound to 
plasma proteins. 
Metabolism: Although not well characterised, Scop is extensively 
metabolised and conjugated with less than 5% of the total dose appearing 
unchanged in the urine.  As Scop is an ester alkaloid, it is possible that small 
amounts are hydrolysed in the serum giving rise to tropic acid as well as 
scopine or scopoline. Scop glucuronides and sulfates are reported to be the 
main Scop metabolites in man (Stewart, 1979). 
Elimination: The exact elimination pattern of Scop has not been 
determined. Following patch removal, plasma levels decline in a log linear 
fashion with an observed half life of 9.5 hours. Less than 10% of the total dose 
is excreted in the urine as parent and metabolites over 108 hours (Novartis, 
2006). 
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5.2.3 Transdermal scopolamine patch application  
 
The following instructions are given pertaining to patient preparation for Scop 
patch application. After washing the area behind the ear, it is wiped with a 
clean, dry tissue to ensure dryness. The transdermal Scop patch is removed 
from its protective pouch. To expose the adhesive surface of the patch, the 
clear plastic protective strip is peeled off and discarded. The adhesive side is 
placed against the skin. The patch is pressed firmly for 10-20 seconds, ensuring 
the edges adhered to the skin. After patch application behind the ear, hands are 
washed thoroughly in order to avoid contact with the exposed adhesive layer 
and prevent contamination of fingers with Scop. At the end of three days the 
patch is removed and thrown away.  
  
5.2.4 Scopolamine pharmacokinetic studies  
 
The literature contains limited information on transdermal Scop patch 
pharmacokinetics. Most studies on the transdermal Scop patch combine it with 
the oral dose to generate a more immediate effect. Also, the pharmacokinetic 
parameters and therapeutic efficacy of a half transdermal Scop patch have 
never been reported, not to mention a pharmacokinetic study which provides 
some initial correlates with side effects.  
Nachum et al., 2001, conducted a study entitled ‘Scopolamine 
bioavailability in combined oral and transdermal delivery’. Their study 
evaluated the effects of combined transdermal and oral Scop administration on 
the pharmacokinetics of Scop in plasma, on cognitive and psychomotor 
performance, and on the incidence of adverse effects. Plasma levels of Scop 
high enough to prevent seasickness were obtained 0.5 to 2.5 hr after the oral 
administration of Scop as a supplement to the transdermal Scop patch. The 
combination was efficient in achieving therapeutic levels much faster than the 
patch alone, and in maintaining them for a prolonged period of time. These 
results resulted in participants using the combination of a transdermal Scop 
patch and a 0.3-mg tablet of Scop to prevent seasickness. 
 Nachum et al., 2006, also conducted a study entitled: Transdermal 
scopolamine for prevention of motion sickness: clinical pharmacokinetics and 
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therapeutic applications. The transdermal patch attained Scop concentrations of 
50 pg/mL after 6 hours and a steady state of about 100 pg/mL was achieved 8-
12 hours after application. Dry mouth occurred in about 50-60% of test 
subjects and drowsiness in up to 20%. A high % of allergic contact dermatitis 
was observed, affecting 10% of test subjects. No conventional trade name 
could be found in the paper which suggests that it was a developmental patch 
rather than one of the existing formulations. 
 
5.2.4.1 Pharmacokinetics of non-patch scopolamine formulations  
 
Putcha et al., 1989, conducted a trial on the pharmacokinetics and 
bioavailability of Scop in six healthy male subjects receiving 0.4 mg of the 
drug by either oral or intravenous administration. Plasma and urine samples 
were analysed using a radioreceptor binding assay. Mean peak plasma 
concentrations were 2909.8 ± 240.9 pg/mL following IV administration and 
528.6 ± 109.4 pg/mL following oral administration. Elimination half-life of the 
drug was 4.5 ± 1.7 hr. They concluded the variability in absorption and poor 
bioavailability of oral Scop achieved indicated that this route of administration 
may not be reliable or effective. 
Putcha et al., 1996, also investigated the bioavailability of intranasal 
Scop. The bioavailability of Scop in three dosage forms was compared in 12 
healthy non-smoking male volunteers. Subjects received 0.4 mg doses of Scop 
bromide in intravenous (IV), intranasal (IN), or oral (PO) dosage forms on 
three occasions, with at least 2 weeks separating the doses. Plasma Scop 
concentrations were determined using a combined reverse-phase liquid 
chromatography radioreceptor binding assay. They concluded that IN Scop is 
an attractive alternative to IV administration, as indicated by rapid, reliable 
absorption, adequate bioavailability, and relatively low cost. They further 
concluded that measuring salivary flow rate could constitute a satisfactory, 
non-invasive means of evaluating the pharmacodynamics and absorption of 
anticholinergic drugs such as Scop. 
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5.3    Experimental 
 
The LC-MS method developed and validated in Chapter 4 was ideal for 
studying the pharmacokinetics of the transdermal Scop patch in our study, 
firstly because of the complex nature of the blood matrix and secondly the need 
for high sensitivity to observe low concentration and long time point data. 
Standard curves were used for quantitation of the drug in serum samples. The 
samples represented different time points at which bloods were taken post 
patch application. Blank or t=0 samples taken before administration were 
important in determining background and ensuring data integrity with such a 
complex sample matrix. 
All samples were analysed using the assay described in Chapter 4 
which was validated for the determination of Scop in serum. Chromatographic 
separation was achieved using an Agilent Zorbax SB-Phenyl (150 × 4.6 mm, 5 
µm). A mixture of ammonium formate (pH 8, adjusted with ammonium 
hydroxide, 10 mM), MeOH (10:90, v/v) was used as mobile phase, at a flow 
rate of 0.6 mL/min. The complete chromatographic run time of each sample 
was 10 min. Peaks were quantified using Agilent Masshunter Software. 
The mass spectrometer was operated using an ESI source in the positive 
ion detection mode. The ionisation temperature was 350 °C, gas flow rate was 
11 L/min and nebuliser pressure was 50 psi. Analysis was performed in MRM 
mode with the transition m/z 304.1 → m/z 138.1 for Scop; with a dwell time of 
200 ms. Transitions and their optimal detector settings are listed in Table 5.2.  
 
Compound Precursorion 
Optimum 
fragmentor 
Voltage 
Product 
ion 
Optimum 
collision 
energy 
 
Scop 
 
 
304.1 
 
 
120 
 
 
110.1 
121.1 
138.1* 
156.1 
 
30 
20 
20 
15 
 
Table 5.2: Optimal fragmentor voltages and collision energy settings for Scop  
* Quantifier ion 
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The quantifier ion is indicated in the table though all transitions were 
monitored with the qualifier ions adding specificity. Quantification was based 
on the integrated peak area as determined by the Masshunter quantification 
analysis software which quantitates the peak areas of the MRM transitions of 
each analyte. 
 
5.3.1 Preparation of patient samples 
 
Blood samples were obtained by informed consent in Dublin City University. 
Following application of a standard transdermal patch containing 1.5 mg of the 
drug, blood was drawn over 72 hours at different time points. The blood samples 
were centrifuged in a chilled centrifuge and the serum kept frozen at -80 ºC until 
analysis. A 500 μL aliquot of each patient sample was diluted 1:1 with a 5 mM 
ammonium formate buffer, pH 8 and loaded onto the SPE well. The sample was 
washed with 20% MeOH in water, eluted with 0.5 mL 75% MeOH, evaporated 
to dryness and reconstituted with 50 μL mobile phase. Samples were taken and 
prepared in duplicate. 
 
5.3.2 Study Design 
 
Following approval from the Dublin City University Research Ethics 
Committee, (See Appendix A) a study was carried out on five healthy 
volunteers, three males and two females aged between 25 and 28 years. As the 
patch is recommended for application over three days, it was decided to 
conduct blood sampling over this time in order to generate the pharmacokinetic 
profiles. As peak blood levels are obtained 6-9 hours post application, more 
frequent sampling was required around this time. 
On week one of the study, the transdermal Scop full patch was applied 
to two of the patients and half patch to the remaining three patients and worn 
behind the ears over a period of three days. Blood samples were taken at the 
following time points after patch application; T=0 (baseline), 3, 6, 7, 8, 9, 24, 
48 and 72 hours. An intravenous cannula was placed for the 6, 7, 8 and 9 hour 
timepoints. All blood samples were allowed to coagulate for 20 mins, and the 
resultant serum was placed into appropriate vials. Samples were frozen at -80 
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ºC until analysis by the LC-MS method developed for the project. A three 
week washout period in-between patch applications was employed, so 
complete elimination of Scop levels from the patient’s blood was ensured.  
For the second leg of the study, the same volunteers again applied the 
alternative transdermal Scop patch for the three days. Blood was again drawn 
at the same time points as above; time 0, 3, 6, 7, 8, 9, 24, 48, and 72 hrs. All 
blood samples were again allowed to coagulate for 20 mins, and the resultant 
serum will placed into appropriate vials. Samples were frozen at -80 ºC until 
analysis by the LC-MS method described in Chapter 4.  
Pharmacokinetic parameters including the maximum serum concentrations 
of Scop in the blood stream (Cmax) and the time taken for the drug to reach its 
highest concentration in the blood stream (Tmax) were determined by 
visualisation of the graphed data. Also, an estimation of area under the 
concentration-time curve (AUC) was achieved using the trapezoidal method. 
AUC is the most reliable measure of a drug's bioavailability and is directly 
proportional to the total amount of unchanged drug that reaches systemic 
circulation.  
 
5.4  Results and discussion 
 
The trial was conducted with 5 healthy volunteers, 3 males and 2 females aged 
between 25 and 28 years. See Table 5.3 for further details on the 5 patients. 
 
Patient 
Sex  
(M/F) 
Age  
(years) 
Height  
(m) 
Weight 
(kgs) 
A F 25 1.71 62 
B F 27 1.68 63 
C M 28 1.83 88 
D M 25 1.78 75 
E M 25 1.98 77 
 
Table 5.3: Patient summary information 
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Adverse effects of the transdermal Scop patch were assessed throughout the 72 
hour session by individual documentation of symptoms. The serum samples, 
processed from the blood samples were assayed for Scop concentration. The 
average Scop concentrations from the trial are plotted for the evaluation of the 
delivery profile over the 72 hours as outlined below.  
 
5.4.1 Transdermal Scop full vs. half patch results and observations for Patient 
A 
 
Presented in Figure 5.2 are the pharmacokinetic profiles generated from patient 
A’s serum samples following the full and half transdermal Scop patch 
applications. Patient A was a 25 year old healthy female, of average height 
(1.71 m) and weight (62 kgs). 
 Upon application of the transdermal Scop patch, an initial 
priming dose of Scop is released from the adhesive layer to saturate the skin 
area. The subsequent delivery of Scop to the blood is determined by the rate-
controlling membrane and is reported to deliver Scop at a constant rate of 
approximately 5 μg/hr.  
 Scop was not detected in serum of the patient pre administration of the 
patch at t=0. On application of the full transderm Scop patch, Scop partitioned 
from the drug saturated adhesive layer into the skin but absorption of Scop into 
the systemic circulation was somewhat slow with effective drug concentrations 
achieved 6-8 hrs post patch application. Maximum serum concentrations (Cmax) 
of 167.4 ± 1.4 pg/mL of the alkaloid were reached at a Tmax, (the time taken for 
the drug to reach its highest concentration in the blood stream) of about 24 hrs.  
As the patch releases Scop continuously over a 72 hr period, constant high 
Scop serum levels were observed, with a slight decline in drug concentration 
observed over time reaching 89.0 ± 5.2 pg/mL at 72 hrs. 
From the literature it is reported circulating blood levels are detected 
within four hours, with peak levels obtained, on average, within 24 hours. The 
average plasma concentration produced is 87 pg/mL for free Scop (Novartis, 
2006). The results obtained following application of the full transdermal Scop 
patch are in agreement with regards to timing, however, a concentration of 89.0 
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± 5.2 pg/mL is only reached after 72 hrs with much higher levels observed 
between 8 and 48 hrs. 
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Patient A, half vs. full patch
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Figure 5.2: Comparison of pharmacokinetic profiles generated from patient A’s serum samples following half and full transdermal Scop patch 
applications
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Several methods exist for measuring the area under the concentration-
time curve (AUC). For this work, a simple numeric estimation of area was 
achieved using the trapezoidal method. An advantage of this method is that it 
requires only a simple extension of a table of experimental data. Other methods 
involve either greater numeric complexity or fitting of an equation to the 
observations and then calculating the area by integrating the fitted equation 
(Tozer et al., 2006). 
For Patient A, Figure 5.2 is a plot of the concentration against time post 
drug administration. If a perpendicular line is drawn from the concentration at 
3 hrs (12.2 pg/mL) down to the time-axis, then the area bounded between zero 
time and 3 hrs is a trapezoid with an area given the product of the average 
concentration time interval. The average concentration is obtained by adding 
the concentrations at the beginning and end of the time interval and dividing by 
2. Since, in the first interval, the respective concentrations are 0 and 12.2 
pg/mL and the time interval is 3, it follows that: 
 
AUC 0-3 = 
 (0 + 12.2) 
 pg/mL  x   3 hr 
2 
 
 The total AUC over all times is then simply expressed as the sum of the 
individual areas. See Table 5.4. 
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Patient A -Full patch 
Time (hr) 
Conc. 
(pg/mL) 
Time 
interval 
(hr) 
Average 
conc. 
(pg/mL) 
AUC 
 (pg-hr/mL) 
0 0.0 0 / / 
3 12.2 3 6.1 18.4 
6 72.0 3 42.1 126.4 
7 94.2 1 83.1 83.1 
8 134.6 1 114.4 114.4 
9 139.7 1 137.2 137.2 
24 167.5 15 153.6 2303.8 
48 121.0 24 144.2 3461.9 
72 89.0 24 105.0 2520.2 
   Total  
AUC 0-72: 
8765.3 
   
 
Table 5.4: AUC determination for Patient A full Scop patch administration 
 
On application of the half transderm Scop patch, the absorption of Scop 
into the systemic circulation was again somewhat slow with effective drug 
concentrations achieved 6-8 hrs post patch application. Maximum serum 
concentrations (Cmax) of 40.8 ± 0.3 pg/mL were reached at a Tmax, of about 48 
hrs.  High Scop serum levels were observed from 9 hrs onward. See Table 5.5 
for determination of AUC for Patient A post half Scop patch administration. 
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Patient A - Half patch 
Time (hr) 
Conc. 
(pg/mL) 
Time 
interval 
(hr) 
Average 
conc. 
(pg/mL) 
AUC 
 (pg-hr/mL) 
0 0.0 0 / / 
3 11.6 3 5.8 17.5 
6 16.8 3 14.2 42.7 
7 23.3 1 20.1 20.1 
8 25.6 1 24.5 24.5 
9 33.0 1 29.3 29.3 
24 38.5 15 35.8 536.4 
48 40.8 24 39.7 952.0 
72 32.2 24 36.5 875.9 
   Total  
AUC 0-72: 
2498.3 
   
 
Table 5.5: AUC determination for Patient A half Scop patch administration 
 
See Table 5.6 for a comparison of the pharmacokinetic parameters 
determined post full and half Scop patch for Patient A. 
 
Scop dose Cmax (pg/mL)  
± % RSD 
Tmax (hr) AUC 0-72  
(pg-hr/mL) 
 
Full patch 
 
Half patch 
 
167.4 ± 1.4 
 
40.8 ± 0. 3 
 
 
24 
 
48 
 
8765.3 
 
2498.3 
. 
Table 5.6: Comparison of pharmacokinetic data following half and full 
transdermal Scop patch applications for Patient A 
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5.4.1.1 Transdermal Scop full vs. half patch side effects for Patient A 
 
Patient A experienced severe dry mouth and blurred vision (particularly from 
12 to 60 hours) following the full transdermal Scop patch, whereby day to day 
operational performance was seriously hindered. As can be seen in Figure 5.2, 
correlation of these severe adverse effects to higher than expected Scop levels 
over the aforementioned time period is observed. Other adverse effects 
observed by the full transdermal Scop patch on patient A included drowsiness 
and mild itching/redness on application site. These responses resolved on 
cessation of the Scop patch.  
On application of the half transdermal Scop patch, to the same subject, 
the only adverse effect experienced by patient A was mild dry mouth from 9 to 
72 hrs. This again correlates to max Scop levels observed in the serum samples 
over the time range mentioned, see Figure 5.2. 
 
5.4.2 Transdermal Scop full vs. half patch results and observations for 
Patient B 
 
Presented in Figure 5.3 are the pharmacokinetic profiles generated from patient 
B’s serum samples following the full and half transdermal Scop patch 
applications. Patient B was a 27 year old healthy female was average in height 
(1.68 m) and weight (63 kgs).  
 Scop was not detected in serum of the patient pre administration of 
the patch at t=0. On application of the full transderm Scop patch, absorption of 
Scop into the systemic circulation was again somewhat slow with effective 
drug concentrations achieved 6-8 hrs post patch administration. A maximum 
serum concentration (Cmax) of 139.5 ± 0.7 pg/mL was reached at a Tmax of 
about 9 hrs.  Post Cmax, constant high Scop serum levels ranging from that at 24 
hrs (94.5 ± 6.4 pg/mL) to a slight decline at 72 hrs (75.2 ± 3.5 pg/mL) were 
observed. The results obtained following application of the full transdermal 
Scop patch for Patient B are in agreement with levels reported in the literature. 
See Table 5.7 for determination of AUC for Patient B post full Scop patch 
administration.  
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Patient B, half vs. full patch
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Figure 5.3: Comparison of pharmacokinetic profiles generated from patient B’s serum samples following half and full transdermal Scop patch 
applications
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Patient B -Full patch 
Time (hr) 
Conc. 
(pg/mL) 
Time 
interval 
(hr) 
Average 
conc. 
(pg/mL) 
AUC 
 (pg-hr/mL) 
0 0.0 0 / / 
3 50.7 3 25.3 76.0 
6 112.9 3 81.8 245.4 
7 119.7 1 116.3 116.3 
8 130.2 1 125.0 125.0 
9 139.5 1 134.8 134.8 
24 94.5 15 117.0 1754.7 
48 80.6 24 87.6 2101.4 
72 75.2 24 77.9 1869.6 
   Total  
AUC 0-72: 
6423.2 
   
 
Table 5.7: AUC determination for Patient B full Scop patch administration 
 
On application of the half transderm Scop patch, the absorption of Scop 
into the systemic circulation was again somewhat slow with effective drug 
concentrations achieved 6-8 hrs post patch application. Maximum serum 
concentrations (Cmax) of 23.46 ± 4.4 pg/mL were reached at a Tmax, of about 9 
hrs.  Scop serum levels showed a slight decline in concentration from 9 hrs 
onward reaching 11.36 ± 5.9 pg/mL come 72 hrs. See Table 5.8 for 
determination of AUC for Patient B post half Scop patch administration. 
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Patient B - Half patch 
Time (hr) 
Conc. 
(pg/mL) 
Time 
interval 
(hr) 
Average 
conc. 
(pg/mL) 
AUC 
(pg-hr/mL) 
0 0.0 0 / / 
3 5.0 3 2.5 7.5 
6 18.7 3 11.9 35.6 
7 19.0 1 18.8 18.8 
8 22.3 1 20.6 20.6 
9 23.5 1 22.9 22.9 
24 17.7 15 20.6 308.8 
48 16.4 24 17.1 409.8 
72 11.4 24 13.9 333.6 
   Total  
AUC 0-72: 
1157.7 
   
 
Table 5.8: AUC determination for Patient B half Scop patch administration 
 
See Table 5.9 for a comparison of the pharmacokinetic parameters 
determined post full and half Scop patch for Patient B. 
  
Scop dose Cmax (pg/mL) 
 ± % RSD 
Tmax (hr) AUC 0-72  
(pg-hr/mL) 
 
Full patch 
 
Half patch 
 
139.5 ± 0.97 
 
23.5 ± 4.4 
 
 
9 
 
9 
 
 
6423.2 
 
1157.7 
 
 
Table 5.9: Comparison of pharmacokinetic data following half and full 
transdermal Scop patch applications for Patient B 
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5.4.2.1 Transdermal Scop full vs. half patch side effects for Patient B 
 
Patient B experienced moderate dry mouth and slight blurred vision following 
the full transdermal Scop patch, with day-to-day operational performance 
fortunately unhindered. The most notable adverse effect for patient B was 
transient impairment of ocular accommodation, the result of circulating Scop 
blood levels or possibly finger-to-eye Scop contamination during application of 
the patch. This impairment of ocular accommodation has been reported before 
and it was thought to be due to finger to eye contamination (Nachum et al., 
2006). Other effects observed by the full transdermal Scop patch on patient B 
included some drowsiness. These responses became normal on cessation of the 
Scop patch.  
On application of the half transdermal Scop patch, no adverse side 
effects were experienced by patient B This correlates to the low Scop serum 
concentrations observes post half patch application. 
 
5.4.3 Transdermal Scop full vs. half patch results and observations for 
Patient C 
 
Presented in Figure 5.4 are the pharmacokinetic profiles generated from patient 
C’s serum samples following the full and half transdermal Scop patch 
applications. Patient C was a 28 year old healthy male, of height 1.83 m and 
weight 88 kgs. 
 Scop was not detected in serum of the patient pre administration of 
the patch at t=0. On application of the full transderm Scop patch, absorption of 
Scop into the systemic circulation was quite fast with effective drug 
concentrations achieved 3-6 hrs post patch administration. A maximum serum 
concentration (Cmax) of 252.3 ± 1.5 pg/mL of the alkaloid was reached at a Tmax 
of just 7 hrs.  This is extremely high comparatively speaking with the other 
patients. Post Cmax, a rapid decline of the drug serum level was observed 
reaching just 46.0 ± 0.7 pg/mL at 72 hrs and this again was unlike the response 
from the other patients. The results obtained following application of the full 
transdermal Scop patch for Patient C are not in agreement with that published 
in the literature. An initial extremely high concentration of Scop followed by a 
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rapid decrease of the drug concentration was observed and is not typical 
behaviour of the transdermal Scop patch. See Table 5.10 for determination of 
AUC for Patient C post full Scop patch administration. 
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Figure 5.4: Comparison of pharmacokinetic profiles generated from patient C’s serum samples following half and full transdermal Scop patch 
applications 
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Patient C -Full patch 
Time (hr) 
Conc. 
(pg/mL) 
Time 
interval 
(hr) 
Average 
conc. 
(pg/mL) 
AUC 
 (pg-hr/mL) 
0 0.0 0 / / 
3 170.1 3 85.1 255.2 
6 244.2 3 207.1 621.4 
7 252.2 1 248.2 248.2 
8 243.3 1 247.8 247.8 
9 213.0 1 228.2 228.2 
24 95.6 15 154.3 2314.7 
48 69.5 24 82.5 1981.0 
72 46.0 24 57.7 1385.4 
   Total  
AUC 0-72: 
7281.9 
   
 
Table 5.10: AUC determination for Patient C full Scop patch administration 
 
 On application of the half transderm Scop patch, the absorption of 
Scop into the systemic circulation was again somewhat fast with effective drug 
concentrations achieved 3 hrs post patch application. Maximum serum 
concentrations (Cmax) of 49.10 ± 0.2 pg/mL were reached at a Tmax of just 6 hrs.  
Scop serum levels showed a again a steady decline concentration from 6 hrs 
onward reaching 12.6 ± 4.8 pg/mL by 72 hrs. See Table 5.11 for determination 
of AUC for Patient C post half Scop patch administration. 
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Patient C - Half patch 
Time (hr) 
Conc. 
(pg/mL) 
Time 
interval 
(hr) 
Average 
conc. 
(pg/mL) 
Area (pg-
hr/mL) 
0 0.0 0 / / 
3 46.9 3 23.5 70.4 
6 49.1 3 48.0 144.0 
7 43.2 1 46.1 46.1 
8 42.7 1 42.9 42.9 
9 37.9 1 40.3 40.3 
24 20.8 15 29.4 440.6 
48 13.4 24 17.1 411.1 
72 12.6 24 13.0 312.9 
   Total  
AUC 0-72: 
1508.3 
   
 
Table 5.11: AUC determination for Patient C half Scop patch administration 
 
See Table 5.12 for a comparison of the pharmacokinetic parameters 
determined post full and half Scop patch for Patient C. 
 
Scop dose 
Cmax (pg/mL) 
± % RSD 
Tmax (hr) 
AUC 0-72 
(pg-hr/mL) 
 
Full patch 
 
Half patch 
 
252.25 ± 1.5 
 
49.10 ± 0.2 
 
 
7 
 
6 
 
7281.9 
 
1508.3 
 
Table 5.12: Comparison of pharmacokinetic data following half and full 
transdermal Scop patch applications for Patient C 
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5.4.3.1 Transdermal Scop full vs. half patch side effects for Patient C 
 
Patient C experienced moderate to severe dry mouth, dizziness, mild nausea 
and drowsiness following the full transdermal Scop patch, with day to day 
operational performance hindered. As with patient B, transient impairment of 
ocular accommodation was again noted. These responses became normal on 
cessation of the Scop patch. In comparison to all other patients, the most side 
effects were noted with patient C. This again correlates well to the unusually 
high concentrations of Scop determined in the serum samples analysed post 
patch application. 
On application of the half transdermal Scop patch, no adverse side 
effects were experienced by patient C. This correlates to the low Scop serum 
concentrations observes post half patch application. 
 
5.4.4 Transdermal Scop full vs. half patch results and observations for 
Patient D 
 
Presented in Figure 5.5 are the pharmacokinetic profiles generated from patient 
D’s serum samples following the full and half transdermal Scop patch 
applications. Patient D was a 25 year old healthy male of average height (1.78 
m) and weight (75 kgs).  
 Scop was not detected in serum of the patient pre administration of 
the patch at t=0. On application of the full transderm Scop patch, absorption of 
Scop into the systemic circulation was somewhat slow with effective drug 
concentrations achieved 6-8 hrs post patch administration.  A maximum serum 
concentration (Cmax) of 96.7 ± 2.6 pg/mL of the alkaloid was reached at a Tmax 
of 9 hrs.  Post Cmax, constant high Scop serum levels ranging from that at 24 
hrs (73.8 ± 0.8 pg/mL) to a slight decline at 72 hrs (61.6 ± 2.9 pg/mL) were 
observed. The results obtained following application of the full transdermal 
Scop patch for Patient D are in agreement with published results. See Table 
5.13 for determination of AUC for Patient D post full Scop patch 
administration. 
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Patient D, half vs. full patch
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Figure 5.5: Comparison of pharmacokinetic profiles generated from patient D’s serum samples following half and full transdermal Scop patch 
applications 
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Patient D -Full patch 
Time (hr) 
Conc. 
(pg/mL) 
Time 
interval 
(hr) 
Average 
conc. 
(pg/mL) 
AUC 
 (pg-hr/mL) 
0 0.0 0 / / 
3 21.2 3 10.6 31.9 
6 80.2 3 50.7 152.2 
7 91.9 1 86.0 86.0 
8 96.3 1 94.1 94.1 
9 96.7 1 96.5 96.5 
24 73.8 15 85.2 1278.5 
48 73.0 24 73.4 1761.6 
72 61.6 24 67.3 1615.4 
   Total  
AUC 0-72: 
5116.2 
   
 
Table 5.13: AUC determination for Patient D half Scop patch administration 
 
 On application of the half transderm Scop patch, the absorption of 
Scop into the systemic circulation was again somewhat slow with effective 
drug concentrations achieved 8 hrs post patch application. Maximum serum 
concentrations (Cmax) of 22.0 ± 1.2 pg/mL were reached at a Tmax of 9 hrs.  
Scop serum levels showed a again a steady decline concentration from 9 hrs 
onward reaching 10.0 ± 5.6 pg/mL at 72 hrs.  See Table 5.14 for determination 
of AUC for Patient D post half Scop patch administration. 
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Patient D - Half patch 
Time (hr) 
Conc. 
(pg/mL) 
Time 
interval 
(hr) 
Average 
conc. 
(pg/mL) 
AUC 
 (pg-hr/mL) 
0 0.0 0 / / 
3 3.0 3 1.5 4.5 
6 6.7 3 4.8 14.5 
7 8.4 1 7.5 7.5 
8 17.9 1 13.1 13.1 
9 22.0 1 19.9 19.9 
24 16.9 15 19.4 291.6 
48 12.0 24 14.4 346.7 
72 10.0 24 11.0 264.0 
   Total  
AUC 0-72: 
961.9 
   
 
Table 5.14: AUC determination for Patient D half Scop patch administration 
 
See Table 5.15 for a comparison of the pharmacokinetic parameters 
determined post full and half Scop patch for Patient D. 
 
Scop dose Cmax (pg/mL)  
± % RSD 
Tmax (hr) AUC 0-72  
(pg-hr/mL) 
 
Full patch 
 
Half patch 
 
96.7 ± 2.6 
 
22.0 ± 1.4  
 
 
9 
 
9 
 
5116.2 
 
961.9 
. 
Table 5.15: Comparison of pharmacokinetic data following half and full 
transdermal Scop patch applications for Patient D 
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5.4.4.1 Transdermal Scop full vs. half patch side effects for Patient D 
 
Patient D experienced moderate dry mouth and slight blurred vision following 
the full transdermal Scop patch, whereby day to day operational performance 
was unhindered. No other notable side effects were noted. These responses 
became normal on cessation of the Scop patch. Scop serum concentrations 
determined for Patient D were relatively low and so the side effects are fitting 
with the results. 
On application of the half transdermal Scop patch, no adverse side 
effects were experienced by patient D. This correlates to the low Scop serum 
concentrations observes post half patch application. 
 
5.4.5 Transdermal Scop full patch results and observations for Patient E 
 
Presented in Figure 5.6 is the pharmacokinetic profile generated from patient 
E’s serum samples following the full transdermal Scop patch application. 
Patient E was a 25 year old healthy male of height 1.98 m and weight 77 kgs . 
 Scop was not detected in serum of the patient pre administration of 
the patch at t=0. On application of the full transderm Scop patch, absorption of 
Scop into the systemic circulation was slow with effective drug concentrations 
achieved only after 24 hrs post patch administration. A maximum serum 
concentration (Cmax) of 56.5 ± 0.1 pg/mL of the alkaloid was reached after this 
time.  Post Cmax, Scop serum levels ranging from that at 24 hrs to a slight 
decline come 72 hrs (54.9 ± 0.9 pg/mL) were observed. Unlike the other 
patients, no Scop was detected in the 3 hr time point post patch application for 
patient E. 
The results obtained following application of the full transdermal Scop 
patch are for Patient E are much lower in concentration than those published 
with a Cmax  of only 56.5 ± 0.1 pg/mL obtained after 24 hours and maintained 
thereafter. See Table 5.16 for determination of AUC for Patient E post full 
Scop patch administration. 
  Due to unforeseen circumstances unrelated to the study, Patient E 
was unable to continue with the trial and so results for only the full transderm 
Scop patch were obtained.  
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Figure 5.6: Pharmacokinetic profile generated from patient E’s serum samples following full transdermal Scop patch application
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Patient E -Full patch 
Time (hr) 
Conc. 
(pg/mL) 
Time 
interval 
(hr) 
Average 
conc. 
(pg/mL) 
Area (pg-
hr/mL) 
0 0.0 0 / / 
3 0.0 3 0.0 0.0 
6 18.4 3 9.2 27.6 
7 24.4 1 21.4 21.4 
8 30.0 1 27.2 27.2 
9 37.2 1 33.6 33.6 
24 56.5 15 46.8 702.5 
48 53.4 24 54.9 1318.2 
72 54.9 24 54.2 1299.6 
   Total  
AUC 0-72: 
3430.1 
   
 
Table 16: AUC determination for Patient E full Scop patch administration 
 
See Table 5.17 for a summary of the pharmacokinetic parameters 
determined post full transdermal Scop patch for Patient E. 
 
Scop dose Cmax (pg/mL) 
 ± % RSD 
Tmax (hr) AUC 0-72  
(pg-hr/mL) 
 
Full patch 
 
 
56.5 ± 0.1 
 
24 
 
3430.1 
. 
Table 5.17: Pharmacokinetic data following full transdermal Scop patch 
application for Patient E 
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5.4.5.1 Transdermal Scop full patch side effects for Patient E 
 
It is interesting to note Patient E experienced zero side effects following the 
full transdermal Scop patch application. This correlates well to the Scop serum 
concentrations calculated which were lower than in the other patients. Patient E 
was considerably taller (at 1.98 m) than all other patients participating in the 
trial, which could have impacted on the low concentrations obtained due to 
dilution of the circulating blood concentration of Scop. 
 
5.4.6 Comparative analysis of all patient’s results following full and half 
transdermal Scop patch applications 
 
Following the full transdermal Scop patch application, serum concentrations of 
the drug determined indicate large interindividual variations between the 
patients. Scop levels in all five patients, up to 72 hrs post drug administration, 
are presented in Figure 5.7. Considerable differences were found between the 
five patients in particular the first 24 hrs post patch application. Thereafter, 
serum levels of Scop did not differ greatly between the patients.  
 Following the half transdermal Scop patch application, serum 
concentrations of the drug determined also indicated some interindividual 
variations between the patients. Scop levels in all four patients, up to 72 hrs 
post drug administration, are presented in Figure 5.8. Similar profiles to that of 
the corresponding full patch were observed, with again, significant differences 
found in the first 24 hrs post patch application. Thereafter, serum levels of 
Scop did not differ significantly between the patients. 
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Figure 5.7: Comparison of pharmacokinetic profiles generated from Patient’s A-E serum samples following full transdermal Scop patch 
application 
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Patients A - D,  half patch
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Figure 5.8: Comparison of pharmacokinetic profiles generated from Patient’s A-D serum samples following half transdermal Scop patch 
application 
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 As every person's skin absorbs the drug at a different rate, 
interindividual variations in the results obtained were expected. Besides the 
genetic aspects of variations between individuals in absorption and metabolism 
of drugs, ethnicity, age, gender, body weight, compliance, general health and 
skin condition are among the main subject parameters affecting the serum 
concentration profile of transdermally delivered drugs.  
 Although there are significant differences in the general appearance of 
skin and the distribution of hair follicles between males and females, there is 
no convincing evidence to suggest major differences in barrier function. In 
general, bioavailability and protein binding do not appear to be significantly 
affected by gender {{488 Ethel,Tur 1997}}. 
 Variation in results obtained affecting the serum concentration profile 
of the Scop transderm patch could be attributed to patient body weight and 
height, differences in transdermal penetration, absorption and metabolism of 
Scop or variation in serum assay/sampling. Table 5.18 and 5.19 presents a 
summary of the pharmacokinetic parameters determined for all patients. 
 
Patient 
 
Full patch Half patch 
Cmax 
(pg/mL)  
± % RSD 
Tmax (hr) 
Cmax 
(pg/mL)  
± % RSD 
Tmax (hr) 
 
A 
B 
C 
D 
E 
 
167.5 ± 1.5 
139.5 ± 0.7 
252.3 ± 1.5 
96.7 ± 2.6 
56.5 ± 0.0 
24 
9 
7 
9 
24 
40.8 ± 0.2 
23.5 ± 4.4 
49.1 ± 0.2 
22.0 ± 1.2 
n/a 
48 
9 
6 
9 
n/a 
 
Table 5.18: Summary of Patient’s Cmax and Tmax following both full and half 
transdermal Scop patch applications 
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Patient 
Full patch  
AUC 0-72 
 (pg-hr/mL) 
Half patch  
AUC 0-72 
 (pg-hr/mL) 
% AUC present 
in half patch in 
comparison to 
full patch  
 
A 8765.3 2498.3 28.5 
B 6423.2 1157.7 18.0 
C 7281.9 1508.3 20.7 
D 5116.2 691.9 13.5 
E 
 
3430.1 
 
n/a 
 
n/a 
 
 
Table 5.19: Summary of patients AUC data following both full and half 
transdermal Scop patch applications 
 
 From these results it can be seen the levels of Scop present in the half 
transdermal Scop patch vary, with the highest % obtained at ~ 28%. This 
indicates the patch cut in half is not delivering half the drug into the blood 
stream. The variability of the results also indicates the half patch is inconsistent 
in its delivery. Figure 5.9 represents a visual comparison of the AUC data 
following both full and half transdermal Scop patch applications. 
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Figure 5.9: Comparison of AUC data following both full and half transdermal Scop patch applications 
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 Subjective complaints of adverse effects differed significantly between 
the patients particularly following the full transdermal Scop patch application. 
Fortunately no patient was required to terminate the experiment due to the 
adverse effects experienced. Patient E, however, terminated the trial having 
completed the full transdermal Scop patch application due to unforeseen 
circumstances unrelated to the trial.  
The unfavourable effects observed by the full transdermal Scop patch 
included dry mouth, dilated pupils, blurred vision, drowsiness, dizziness and 
mild itching/redness on application site. These responses returned to normal on 
cessation of the Scop patch. Table 5.20 presents a summary of all patient’s 
symptoms and correlating Cmax following the full transdermal Scop patch 
application and Table 5.21 following the half transdermal Scop patch 
application  
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Patient 
Cmax 
(pg/mL)  
± % RSD 
Dry mouth 
Dilated 
pupils 
Blurred 
vision 
Dizziness Nausea Drowsiness
Itching on 
application 
site 
A 167.5 ± 1.5 Y N Y N N Y Y 
B 139.5 ± 0.6 Y Y Y N N N N 
C 252.3 ± 1.5 Y Y N Y Y Y N 
D 96.7 ± 2.6 Y N Y N N N Y 
E 56.5 ± 0.1 N N N N N N N 
 
Table 5.20: Patient’s Cmax and correlating side effects following full transdermal Scop patch application 
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Patient 
Cmax 
(pg/mL)  
± % RSD 
Dry mouth 
Dilated 
pupils 
Blurred 
vision 
Dizziness Nausea Drowsiness
Itching on 
application 
site 
A 40.8 ± 0.25 Y N N N N N N 
B 23.5 ± 4.3 N N N N N N N 
C 49.10 ± 0.2 N N N N N N N 
D 22.0 ± 1.4 Y N N N N N N 
 
Table 5.21: Patient’s Cmax and correlating side effects following half transdermal Scop patch application 
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Patients A and C were more adversely effected following the full 
transdermal Scop patch in comparison to the other patients. From Table 5.18, it 
can be seen the highest Cmax values are associated with these two patients. 
Patient A experienced severe dry mouth and blurred vision whereby day-to-day 
operational performance was seriously hindered. Drowsiness and mild 
itching/redness on application site were also noted. Patient C experienced 
moderate to severe dry mouth, dizziness, mild nausea and drowsiness and 
transient impairment of ocular accommodation with day–to-day operational 
performance also hindered. Patient B, with the third highest Cmax also 
experienced transient impairment of ocular accommodation. Blurred vision and 
dry mouth were also reported. Patient D, with a much lower Cmax than Patients 
A-C, experienced some mild dry mouth and blurred vision and mild 
itching/redness on application site. On the extreme to Patients A and C is 
Patient E who experienced zero side effects following the same application. 
Cmax for Patient E was the lowest obtained of all patients participating in the 
trail. The Scop serum concentrations calculated were much lower than those of 
the other patients and so, this correlated well with Patient E experiencing no 
adverse side effects.  
In the comparative trial using the transdermal Scop half patch, hardly 
any side effects were experienced amongst the patients with just a minimal 
incidence of dryness of the mouth reported by Patient A. 
 
5.5    Conclusions 
 
The ‘Evaluation of countermeasures for motion sicknesses’, project currently 
being conducted in NASA, proposes the idea that cutting a transdermal Scop 
patch in half reduces the side effects associated with the medication while still 
having effective protection from motion sickness.  
In Chapter 4 we developed an analytical protocol capable of supporting 
such a hypothesis and in this chapter a pilot study was instigated in order to 
examine circulating levels of Scop in patients treated with both the full and half 
transdermal Scop patch applications. Following both full and half transdermal 
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patch application, five subjects underwent subsequent blood collection and 
observation for each.  
The study also aimed to compare the severity of side effects induced by 
the transdermal Scop patch both full and in half in correlation to the levels of 
Scop measured in serum over a 72 hour period The study concluded that by 
cutting the transdermal Scop patch in half, Scop levels are far less than half to 
those determined for the full Scop patch. Also, considerable differences in side 
effects between the single-dose and half-dose treatments of the transdermal 
Scop patch applications were observed. Cutting the patch seems to have had a 
disproportionate impact on delivery. As Scop is a reservoir patch whereby 
release is controlled by the polymer film next to the skin, cutting it in half 
could potentially have caused dose dumping of Scop from the reservoir on 
application. Furthermore, cutting it in half might have accelerated the 
dehydration of the medicine soaked reservoir or disrupted the rate-limiting 
membrane delivering the medication. 
 The results attained indicate that by cutting the patch in half, the levels 
of Scop detected are in fact substantially less than half those of the full dose, 
and so the integrity of the drug delivery system and adhesiveness of the patch 
is compromised.  
Using the transdermal Scop full patch, severe side effects were 
observed which hindered operational performance in some of the patients. In 
the comparative trial using the transdermal Scop half patch, hardly any side 
effects were experienced amongst the patients. The literature indicates Scop 
serum levels of 50 pg/mL are generally accepted as affording prophylactic 
protection against motion sickness (Nachum et al., 2001). However, the levels 
attained using the transdermal Scop patch cut in half are lower than this level. 
To date, there is no indication in the literature that a lower dose transdermal 
Scop patch is available. Due to the severe adverse effects reported using the 
full transdermal Scop patch, manufacture of a transdermal Scop patch with a 
lower level of Scop in the a drug reservoir of the patch is highly recommended.  
The NASA-based motion sickness countermeasures study proposes the 
idea that cutting a transdermal Scop patch in half reduces the side effects 
associated with the medication while still having effective protection from 
motion sickness. In this study, it has been demonstrated that cutting the patch 
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in half does significantly reduce the side effects associated with the 
transdermal Scop patch, although the levels associated with this modification 
of the patch are not sufficient to reach the target threshold for suppressing 
motion sickness.  It is, however, highly likely that the levels found would have 
some therapeutic effect and might reduce the severity of motion sickness 
symptoms or give greater resilience to these symptoms without affording full 
protection but also without the marked side effects which can afflict some 
individuals.  
Continuation of the NASA based study should firstly evaluate if the 
low levels of Scop associated with cutting the transdermal Scop patch half 
actually prevent motion sickness in astronauts induced by off-vertical axis 
rotation (OVAR). If the levels are indeed too low to afford prophylactic 
protection against motion sickness, further investigation may warrant the 
manufacture a transdermal Scop patch possessing a lower level of Scop in the 
patch drug reservoir than the transdermal Scop formulations currently 
available.  
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Overall conclusions and future work 
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One of the most difficult tasks faced by the analytical chemist is the clean-up 
and subsequent analysis of biological fluids. Bioanalytical methods developed 
for pharmacological and pharmacokinetic applications are even more 
challenging to develop and validate. This thesis achieved the development of 
novel methods for two very important and strategic investigations and their 
publication will aid the study of these drugs in human blood.  
 
Chapter 2: Simultaneous determination of efavirenz, rifampicin and its main 
metabolite desacetyl rifampicin levels in human plasma 
 
The first project involved the development and validation of an analytical 
protocol enabling the extraction, separation and determination of Efv and Rif 
and its metabolite, dRif, from human plasma. This was achieved using solid 
phase extraction and LC-UV analysis. Most challenging was the fact that Rif 
(and its metabolite, dRif) and Efv exhibit very different physiochemical 
properties, and so, developing this assay proved extremely challenging. The 
LC-UV method developed offers excellent sensitivity for each of the drugs, 
allows for the determination of Rif’s metabolite which had not been done 
previously in the presence of Efv, and the sample volume required is low. The 
easy sample preparation and fast separation makes this assay highly suitable 
for pharmacokinetic studies and therapeutic drug monitoring in patients with 
HIV only, TB only or both diseases being treated with Efv and Rif.  
 This validated protocol was required for the SPhEAR project whereby 
the effects of Efv medication on the pharmacokinetics of oral Rif in the 
treatment of TB in HIV infected patients is currently being investigated. The 
fast, low cost and relatively easy UV-based assay developed can accurately 
detect the drug concentrations within a clinically relevant concentration range 
which renders it broadly applicable, especially in third world countries and in 
resource-limited settings where the burden of disease exists. Using standard 
LC-UV equipment, it has the advantage of being cost effective and easy to use. 
 Drug levels were measurable and significant differences in circulating 
Rif levels were found among the patients. Further work would involve 
completing analysis on all the SPhEAR study samples once all participating 
patients have undergone treatment and subsequent blood draw.  
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To summarise: 
 
• A novel, sensitive isocratic high performance liquid chromatography 
assay employing solid phase extraction for the simultaneous 
determination of Rif, Efv and dRif from plasma was developed and 
validated. 
 
• Various attractive features of the developed method include low 
volumes of plasma required for analysis, simple and fast extraction 
procedure and cost effective chromatographic equipment. This makes 
the method very rapid and economical, especially when a large number 
of samples are to be handled.  
 
• With an LOQ of 100 ng/mL, Rif has a usefully short retention time of 
3.1 min and a recovery of 94% from plasma. Similar to the LOQ for 
Rif, dRif’s LOQ was again 100 ng/mL with a retention time of 2.75 
min and a recovery of 97% from plasma achieved. 
 
• There are limited reported methods for the simultaneous determination 
of dRif and Rif, the most successful achieving a sensitivity of 250 
ng/mL. Our method is the best to date for the simultaneous 
determination of both drugs.  
 
• Our method is capable of determining Rif’s metabolite dRif. In the 
presence of Efv, this has never been investigated. This was important in 
order to determine the extent of Rif’s metabolism to dRif in the 
presence of Efv.  
 
• For Efv, there are numerous methods reported with LOQs of just 10 
ng/mL but all suffer from either extremely long elution times, high 
sample volumes or both. With an LOQ of 100 ng/mL, and a sample 
volume of just 0.3 mL plasma required, Efv has a short retention time 
 
 
381
of 6.1 mins which was very challenging in the presence of both dRif 
and Rif. A recovery of 70 % from plasma was obtained. 
 
• There is only one reported LC-UV method for the simultaneous 
determination of Rif and Efv. It exhibits comparable sensitivity with the 
method we outlined (LOD 50 ng/mL) but requires gradient elution and 
hence suffers from a relatively long analysis time of 22 mins. The 
authors also did not measure Rif’s main metabolite, dRif.  
 
• Given the sensitivity of the method developed and the use of a SPE 
procedure delivering clean samples which had low background and 
excellent recoveries, this method was validated and used to quantitate 
the drug levels of patients participating in the SPhEAR study. 
 
• The drugs can be detected within a clinically relevant concentration 
range using standard chromatography equipment employing UV 
detection which is both simple to use and cost effective (using low price 
equipment which is cheap to maintain and run).  
 
• Adoption of such methodology is easily achievable in areas where there 
are high incidences of HIV infections, but limited laboratory budgets, 
such as sub-Saharan Africa, Eastern Europe and Asia. 
 
Chapter 3: LC-MS determination of efavirenz and rifampicin levels in human 
plasma 
 
It was decided to further investigate the methodology in order to achieve 
greater sensitivity for the assay. This was achieved using LC-MS analysis. The 
developed assay is the first capable of determining Rif and Efv simultaneously 
from a biological matrix using this technique. The sensitivity achieved for Rif 
in plasma is far superior to what is available in the scientific literature and for 
Efv the sensitivity achieved was comparable. Given more time, a decrease in 
the plasma sample volume would have been investigated. There would be 
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major advantages of using finger prick assays for blood rather than taking mLs 
using standard blood collection tubes which would allow for more routine 
analysis.   
 Following a full validation, this method would be capable of detecting 
extremely low levels of both drugs simultaneously in aqueous samples It would 
be interesting to apply the method to biological samples. It would be 
advantageous to modify the assay in order to quantify cellular and tissue levels 
of the drugs. 
 
To summarise: 
• There are currently no reported methods in the literature for the 
simultaneous analysis of Rif and Efv using LC-MS. The LC-UV method 
described in Chapter 2 was transferred to MS detection using similar 
chromatographic parameters as for the UV method.  
 
• The sensitivity achieved was excellent with an LOQ of just 1 ng/mL for 
Rif in plasma. It is far superior to what is available in the scientific 
literature which reveals the lowest LOQ for serum spiked with Rif 
using MS to be 50 ng/mL and in plasma 100 ng/mL.  
 
• An LOQ of 10 ng/mL was obtained for Efv prepared in plasma. Again 
this is an excellent result in comparison with what has previously been 
reported in the literature which reveals the lowest LOQ obtained for 
Efv was 10 ng/mL in plasma. 
 
• The assay described in this chapter is the first capable of achieving 
such low levels of Rif and Efv from a biological matrix. Furthermore, 
the fast and easy sample treatment by SPE, as well as the short runtime 
of the assay allows for rapid sample processing and analysis. 
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Chapter 4: Development of a sensitive assay to extract, separate and determine 
scopolamine (anti-motion sickness medication) in human serum 
 
The third analytical protocol developed and validated was for the determination 
of Scop in serum. This was achieved using solid-phase extraction coupled to 
LC-MS. This developed and validated protocol was required to support a 
project entitled ‘Evaluation of countermeasures for motion sicknesses’ being 
carried out currently in NASA. The purpose of this study is to evaluate the 
effects of the transdermal Scop patch in preventing motion sickness in 
astronauts induced by off-vertical axis rotation. It had been hypothesised that 
cutting a scopolamine transdermal patch in half will reduce the side effects 
associated with the medication while still providing effective protection from 
motion sickness. 
 LC-MS/MS remains one of the most useful tools available for 
bioanalysis and success required understanding the underlying principles of 
both chromatography and MS. The main challenge met here was developing a 
fast, isocratic method capable of determining the extremely low concentrations 
of scopolamine in serum post patch and half patch application. As the 
circulating level of Scop, especially when only half a patch is applied, is very 
low, both the extraction and the analytical methods were pushed to their very 
limits in order to reliably and reproducibly measure the levels of drug 
encountered. The isocratic elution scheme gives a simple, robust and 
reproducible chromatographic method with exceptional sensitivity for Scop. 
The easy sample preparation and fast separation makes this assay highly 
suitable for pharmacokinetic studies and therapeutic drug monitoring. 
 
To summarise:  
 
• A fast, novel and extremely sensitive assay has been developed and 
validated for the determination of Scop in serum using SPE coupled to 
LC–MS/MS. 
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• From the literature, there is no simple, isocratic method reported which 
achieves the sensitivity required for the analysis of Scop in serum post 
patch and half patch application. Methods suffer from having to use a 
gradient programme or a large sample volume in order to achieve their 
fast runtimes and low sensitivity.  
 
• The isocratic elution scheme developed gives a simple, robust and 
reproducible chromatographic method with a short runtime and an 
exceptional LOQ of 10 pg/mL for Scop. Our experimental approach has 
yielded superior levels of sensitivity than those already in the literature 
for Scop extracted from biological matrix. 
 
• The SPE approaches exploited in the literature demonstrate poor Scop 
recovery or high sample volume required. The assay described has been 
proven accurate and precise for the determination of Scop in serum 
with a recovery of 73% obtained.  
 
• This method has been applied to a NASA bases study evaluating the 
effects of the transdermal Scop patch both uncompromised and cut in 
half. 
 
Chapter 5: A pilot comparison of the human pharmacology of a half versus 
full transdermal scopolamine patch  
 
In order to evaluate the NASA based countermeasures for motion sicknesses 
study hypothesis, we developed a pilot study to examine circulating levels of 
Scop in volunteers treated with the full patch and a half patch. It was 
investigated if the patch is compromised by cutting it in half and also to 
compare the severity of side effects induced by the transdermal Scop patch 
both full and in half and correlate these to the levels of Scop measured in 
serum over a 72 hour period. The results attained indicate that by cutting the 
patch in half, the levels of Scop detected are in fact substantially less than half 
those of the full dose, and so the integrity of the drug delivery system and 
adhesiveness of the patch was somewhat compromised. Also, there was a 
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considerable decrease in adverse side effects observed with the half 
transdermal Scop patch application in comparison to the full patch. 
 Continuation of the NASA-based study should firstly evaluate if the 
low levels of Scop associated with cutting the transdermal Scop patch in half 
actually prevent motion sickness in astronauts induced by off-vertical axis 
rotation (OVAR). If the levels are indeed too low to afford prophylactic 
protection against motion sickness, further investigation may warrant the 
manufacture of a transdermal Scop patch possessing a lower level of Scop in 
the patch drug reservoir than the transdermal Scop formulations currently 
available.  
 
To summarise:  
 
• The literature contains limited information on transdermal Scop patch 
pharmacokinetics. Most studies on the transdermal Scop patch combine 
it with the oral dose to generate a more immediate effect.  
 
• The pharmacokinetic parameters and therapeutic efficacy of a half 
transdermal Scop patch have never been reported, not to mention a 
pharmacokinetic study.  
 
• We developed a pilot study to examine circulating levels of Scop in five 
volunteers treated with the full patch and a half patch to evaluate the 
hypothesis that cutting a transdermal Scop patch in half reduces the side 
effects associated with the medication while still having effective 
protection from motion sickness.  
 
• The LC-MS method developed and validated for Scop in serum was 
ideal for studying the pharmacokinetics of the transdermal Scop patch 
in our study due to the need for high sensitivity to observe low 
concentration and long time point data.  
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• The study compared the severity of side effects induced by the 
transdermal Scop patch both full and in half and correlated these to the 
levels of Scop measured in serum over a 72 hour period. Considerable 
differences between the single-dose and half-dose treatments of the 
transdermal Scop patch applications were observed.  
 
• The results attained indicate that by cutting the patch in half, the levels 
of Scop detected are in fact substantially less than half those of the full 
dose, and so the integrity of the drug delivery system and adhesiveness 
of the patch is compromised.  
 
 To conclude, chromatographic methodologies for the analysis of 
different therapeutic drugs in biological matrices under challenging conditions 
representative of the extremes of real world analytical problems were 
developed. This work encountered and overcame problems associated with 
interferences from sample matrices, decomposition products, signal 
perturbations and extremely low levels of drug and metabolites. Successful 
method development was accomplished by means of careful assessment of 
these matrix effects and judicial use of the sample preparation methods coupled 
with suitable chromatography and detection. 
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Appendix A: Ethics review document approved by DCU 
Research Ethics Committee 
 
 
 
 
Dublin City University 
RESEARCH ETHICS COMMITTEE 
 
APPLICATION FOR APPROVAL OF A PROJECT  
INVOLVING HUMAN PARTICIPANTS 
 
Application No. (office use only)  DCUREC/2010/   
 
Period of Approval (office use only) ....../....../...... to
 ....../....../.... 
 
This application form is to be used by researchers seeking ethics approval for 
individual projects and studies. The signed original and an electronic copy of 
your completed application must be submitted to the DCU Research Ethics 
Committee.   
 
NB - The hard copy must be signed by the PI.  The electronic copy should 
consist of one file only, which incorporates all supplementary 
documentation.  The completed application must be proofread and 
spellchecked before submission to the REC.  All sections of the application 
form should be completed.  Applications which do not adhere to these 
requirements will not be accepted for review and will be returned directly 
to the applicant. 
 
Applications must be completed on the form; answers in the form of 
attachments will not be accepted, except where indicated.  No handwritten 
applications will be accepted.  Research must not commence until written 
approval has been received from the Research Ethics Committee. 
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PROJECT TITLE Validation of a method for the analysis of  
Scopolamine (anti-motion sickness medication)  
in human serum for the NASA space research  
programme  
 
 
PRINCIPAL 
INVESTIGATOR(S) 
Dr. Gillian McMahon, Deirdre Fox 
 
 
Please confirm that all supplementary information is included in your 
application (in both signed original and electronic copy). If questionnaire or 
interview questions are submitted in draft form, a copy of the final 
documentation must be submitted for final approval when available. 
 
 INCLUDED NOT 
APPLIC
ABLE 
Bibliography    
Recruitment advertisement    
Plain language statement/Information 
Statement 
   
Informed Consent form    
Evidence of external approvals related to 
the research 
   
Questionnaire 
draft 
 
final 
 
Interview Schedule 
draft 
 
final 
 
Debriefing material     
Other    
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Please note: 
 
1. Any amendments to the original approved proposal must receive prior 
REC approval. 
 
2. As a condition of approval investigators are required to document and 
report immediately to the Secretary of the Research Ethics Committee 
any adverse events, any issues which might negatively impact on the 
conduct of the research and/or any complaint from a participant relating 
to their participation in the study 
 
 
Please submit the signed original, plus the electronic copy of your completed 
application to:  
Ms. Fiona Brennan, Research Officer, Office of the Vice-President for 
Research  
(fiona.brennan@dcu.ie, Ph. 01-7007816) 
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Guidelines to Applicants 
 
1.1 PRINCIPAL INVESTIGATOR(S):  The named Principal Investigator is 
the person with primary responsibility for the research project. Doctoral 
researchers and Research Masters or their supervisors may be listed as 
Principal Investigators, depending on the conventions of the discipline and on 
the individual case. It should be made clear, in subsequent sections of this 
application, who is carrying out the research procedures. In the case of Taught 
Masters and undergraduate student projects the supervisors are Principal 
Investigators. 
 
2.0 PROJECT OUTLINE:  Provide a brief outline of the project, aims, 
methods, duration, funding, profile of participants and proposed interaction 
with them. This description must be in everyday language that is free from 
jargon.  Please explain any technical terms or discipline-specific phrases.  
 
2.1 LAY DESCRIPTION:  Provide a brief outline of the project, including 
what participants will be required to do.  This description must be in everyday 
language which is free from jargon.  Please explain any technical terms or 
discipline-specific phrases. (No more than 300 words). 
 
2.2 AIMS OF AND JUSTIFICATION FOR THE RESEARCH:  State the 
aims and significance of the project (approx. 400 words). Where relevant, state 
the specific hypothesis to be tested. Also please provide a brief description of 
current research, a justification as to why this research should proceed and an 
explanation of any expected benefits to the community. NB – all references 
cited should be listed in an attached bibliography. 
 
2.3 PROPOSED METHOD:  Provide an outline of the proposed method, 
including details of data collection techniques, tasks participants will be asked 
to do, the estimated time commitment involved, and how data will be analysed. 
If the project includes any procedure which is beyond already established and 
accepted techniques please include a description of it.  (No more than 400 
words.) 
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2.4 PARTICIPANT PROFILE:  Provide number, age range and source of 
participants.  Please provide a justification of your proposed sample size.  
Please provide a justification for selecting a specific gender. 
 
2.5 MEANS BY WHICH PARTICIPANTS ARE TO BE RECRUITED:  
Please provide specific details as to how you will be recruiting participants. 
How will people be told you are doing this research? How will they be 
approached and asked if they are willing to participate? If you are mailing to 
or phoning people, please explain how you have obtained their names and 
contact details. This information will need to be included in the plain language 
statement. If a recruitment advertisement is to be used, please ensure you attach 
a copy to this application. 
 
3.3 POTENTIAL RISKS TO PARTICIPANTS AND RISK 
MANAGEMENT PROCEDURES:  Identify, as far as possible, all potential 
risks to participants (physical, psychological, social, legal or economic etc.), 
associated with the proposed research. Please explain what risk management 
procedures will be put in place. 
 
3.6 ADVERSE/UNEXPECTED OUTCOMES:  Please describe what 
measures you have in place in the event that there are any unexpected outcomes 
or adverse effects to participants arising from involvement in the project. 
 
3.7 MONITORING:  Please explain how you propose to monitor the conduct 
of the project (especially where several people are involved in recruiting or 
interviewing, administering procedures) to ensure that it conforms with the 
procedures set out in this application.  In the case of student projects please 
give details of how the supervisor(s) will monitor the conduct of the project. 
 
3.8 SUPPORT FOR PARTICIPANTS:  Depending on risks to participants 
you may need to consider having additional support for participants 
during/after the study.  Consider whether your project would require additional 
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support, e.g., external counselling available to participants.  Please advise 
what support will be available. 
 
4.0 INVESTIGATORS’ QUALIFICATIONS, EXPERIENCE AND 
SKILLS:  List the academic qualifications and outline the experience and 
skills relevant to this project that the researchers and any supporting staff have 
in carrying out the research and in dealing with any emergencies, unexpected 
outcomes, or contingencies that may arise. 
 
5.2 HOW WILL THE ANONYMITY OF THE PARTICIPANTS BE 
RESPECTED?  Please bear in mind that where the sample size is very small, 
it may be impossible to guarantee anonymity/confidentiality of participant 
identity.  Participants involved in such projects need to be advised of this 
limitation. 
 
5.3 LEGAL LIMITATIONS TO DATA CONFIDENTIALITY:  
Participants need to be aware that confidentiality of information provided can 
only be protected within the limitations of the law - i.e., it is possible for data to 
be subject to subpoena, freedom of information claim or mandated reporting by 
some professions. Depending on the research proposal you may need to 
specifically state these limitations.   
 
6.0 DATA/SAMPLE STORAGE, SECURITY AND DISPOSAL: For the 
purpose of this section, “Data” includes that in a raw or processed state (e.g. 
interview audiotape, transcript or analysis).  “Samples” include body fluids or 
tissue samples. 
 
8.0 PLAIN LANGUAGE STATEMENT:  Written information in plain 
language that you will be providing to participants, outlining the phases and 
nature of their involvement in the project and inviting their participation.  
Please note that the language used must reflect the participant age group and 
corresponding comprehension level. 
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9.0 INFORMED CONSENT FORM:  This is a very important document that 
should be addressed by participants to researchers, requiring participants to 
indicate their consent to specific statements, and give their signature. 
 
FOR FURTHER INFORMATION AND NOTES ON THE 
DEVELOPMENT OF PLAIN LANGUAGE STATEMENTS AND 
INFORMED CONSENT FORMS, PLEASE CONSULT THE DCU REC 
WEBSITE: WWW.DCU.IE/RESEARCH/ETHICS 
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1. ADMINISTRATIVE DETAILS 
 
 
THIS 
PROJECT IS: 
 Research Project Funded Consultancy 
(tick as many as 
apply) 
 Practical Class Clinical Trial 
  Student Research 
Project  
(please give details) 
Other  - Please Describe: 
 Resear
chMas
ters 
Taught Masters 
 PhD Undergraduate 
 
Project 
Start Date: 
April 2010 Project End 
date: 
  June 2010 
 
1.1 INVESTIGATOR CONTACT DETAILS (see Guidelines) 
 
PRINCIPAL INVESTIGATOR(S):  
 
TITL
E 
SURNAME FIRST NAME PHONE FAX EMAIL 
Dr. McMahon Gillian 01 700 
8351 
n/a gillian.mcmahon@d
cu.ie 
Ms Fox Deirdre 01 700 
8351 
n/a deirdre.fox4@mail.
dcu.ie 
 
OTHER INVESTIGATORS: 
 
TITL SURNAME FIRST NAME PHONE FAX EMAIL 
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E 
Dr. Levine Lanfang (321) 
861-
2931 
n/a lanfang.h.levine@na
sa.gov 
                                    
                                    
                                    
 
FACULTY/DEPARTMENT/SCH
OOL/ CENTRE: 
(NB – if Nursing, please note all 
students including PhD’s must 
attach the letter from the Nursing 
Ethics Advisory Committee to this 
application) 
 
School of Chemical Sciences 
 
 
1.2 WILL THE RESEARCH BE UNDERTAKEN ON-SITE AT 
DUBLIN CITY UNIVERSITY? 
 
YES  NO (If NO, give details of off-campus location.) 
      
 
1.3 IS THIS PROTOCOL BEING SUBMITTED TO ANOTHER 
ETHICS COMMITTEE, OR HAS IT BEEN PREVIOUSLY 
SUBMITTED TO AN ETHICS COMMITTEE?) 
 
YES  NO (If YES, please provide details and copies of 
approval(s) received etc.)   
 
 
DECLARATION BY INVESTIGATORS 
The information contained herein is, to the best of my knowledge and belief, 
accurate.  I have read the University’s current research ethics guidelines, and 
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accept responsibility for the conduct of the procedures set out in the attached 
application in accordance with the guidelines, the University’s policy on 
Conflict of Interest and any other condition laid down by the Dublin City 
University Research Ethics Committee or its Sub-Committees.  I have attempted 
to identify all risks related to the research that may arise in conducting this 
research and acknowledge my obligations and the rights of the participants. 
 
If there any affiliation or financial interest for researcher(s) in this research or 
its outcomes or any other circumstances which might represent a perceived, 
potential or actual conflict of interest this should be declared in accordance 
with Dublin City University policy on Conflicts of Interest.  
 
I and my co-investigators or supporting staff have the appropriate 
qualifications, experience and facilities to conduct the research set out in the 
attached application and to deal with any emergencies and contingencies 
related to the research that may arise. 
 
Signature(s): 
 
Principal investigator(s):  ____________________________ 
 
 
Print name(s) in block letters: __________________________ 
 
 
Date:________________________ 
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2. PROJECT OUTLINE  
 
2.1 LAY DESCRIPTION (see Guidelines) 
   
Scopolamine is one of the substances used by NASA to combat motion sickness 
in space. The Scopolamine patch, an over the counter medication, is the most 
common form of the drug in the US. However, undesirable side effects have 
been reported. It had been hypothesised at NASA that if a transdermal patch of 
scopolamine is halved and then used by the astronaut, that it is just as effective 
as a full patch but with less undesirable side effects. In NASA, I developed and 
optimised a method for the determination of scopolamine in blood in order to 
evaluate if the levels of the half patch are indeed half of the Scopolamine level in 
full patch. However, the method was only semi-validated due to time restraints. 
On return to DCU, I was able to transfer the assay to a similar instrument here so 
that I could complete the work I had initially set out to do. Healthy volunteers 
will be asked to wear the full patch for 3 days orthe patch cut in half for 3 days 
with blood drawn at different time points which will subsequently be assayed for 
scopolamine concentration. 
 
 
2.2 AIMS OF AND JUSTIFICATION FOR THE RESEARCH (see 
Guidelines) 
 
 This research is collaboration with NASA, Kennedy Space Centre, 
Florida where Dr. Daniel Woodard is conducting a project entitled ‘Evaluation 
of countermeasures for motion sicknesses’. The purpose of this study is to 
evaluate the effects of the transdermal scopolamine patch in preventing motion 
sickness in astronauts induced by off-vertical axis rotation (OVAR). The main 
question being asked is ‘Would cutting a scopolamine transdermal patch in half 
reduce the side effects associated with the medication while still having 
effective protection from motion sickness?’  
 
By the oral route, scopolamine is effective within 0.5 h for a period of 6 
h. Because of its short half-life in plasma and dose-dependent adverse effects, 
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the clinical use of scopolamine administered orally or parenterally is limited. To 
minimize the relatively high incidence of side effects, the transdermal dosage 
form has been developed. The Transderm Scop (transdermal scopolamine) 
system is a circular flat patch designed for continuous release of scopolamine 
following application to an area of intact skin on the head, behind the ear. Each 
system contains 1.5 mg of scopolamine base. The recommended dosage is a 
single patch applied at least 6-8 hours before the anti-motion sickness effect is 
required. After 72 hours, the patch should be removed and a new one applied 
behind the opposite ear. Therapeutic Scopolamine plasma levels are obtained 
very slowly, 6 to 8 h post patch application. 
 
The literature contains limited information on Scopolamine patch 
pharmacokinetic information. Most studies on the Scopolamine transdermal 
patch combine it with the oral dose so as protection from motion sickness is 
effective immediately. Also, the Scopolamine patch cut in half to prevent 
motion sickness has never been reported, not to mention a pharmacokinetic 
study on it. The levels of Scopolamine post patch application are quite low at 
~100ng/mL, and with the patch cut in half, levels would be lower again. This 
study would conclude if the integrity of the patch is compromised by cutting it 
in half. Methods previously published are not sensitive enough to achieve this 
goal.  
 
Developed and optimised in NASA, Florida, is a novel reversed phase 
High Performance Liquid Chromatography assay with Mass Spectrometry 
detection and solid phase extraction for the determination of scopolamine. 
However, it was not fully validated due to time constraints. Following a 
technology transfer of the method here in DCU, completion of the validation is 
now planned. Real patient samples will be required for the validation section 
and also a pharmacokinetic study on the patch cut in half could be performed 
given approval from the REC as it has never been done before. The LC-MS 
method I’ve developed is extremely sensitive (Limit of Quantitation 10pg/mL) 
and achieving the anticipated levels of Scopolamine in blood post patch 
application and post half patch application should be well within the capability 
of the method.  
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Some studies have been conducted: 
 
Lakshmi Putcha et al. [1] conducted a trial on the pharmacokinetics and 
bioavailability of scopolamine in six healthy male subjects receiving 0.4 mg of 
the drug by either oral or intravenous administration.  
 
Lakshmi Putcha  et al. [2] compared the bioavailability of scopolamine 
in three dosage forms in 12 healthy non-smoking male volunteers. Subjects 
received 0.4-mg doses of scopolamine bromide in intravenous (IV), intranasal 
(IN), or oral (PO) dosage forms on three occasions, with at least 2 weeks 
separating the doses. Saliva volume and flow rate and percent suppression of 
control flow rate were determined from each sample. Absorption after IN and 
PO scopolamine administration was rapid; plasma concentrations [1680 (IN) 
and 164 pg/mL (PO)] peaked within 1 h of dosing [0.37 (IN) and 0.78 h (PO)], 
respectively. IN and IV scopolamine suppressed salivary flow rate to similar 
extents (95% and 99.7%), respectively. Times to reach maximum effect were 
1.05 and 0.27 h after IN and IV dosage, respectively.  
          Nachum et al. [3] headed a study entitled: Transdermal scopolamine for 
prevention of motion sickness: clinical pharmacokinetics and therapeutic 
applications. The protective plasma concentration of scopolamine is estimated 
to be 50 pg/mL. TTS-S attains that concentration after 6 hours; a steady state of 
about 100 pg/mL is achieved 8-12 hours after application. Dry mouth occurred 
in about 50-60% of subjects, drowsiness in up to 20%, and allergic contact 
dermatitis in 10%.  
Nachum et al. [4] also conducted a study entitled : Scopolamine 
bioavailability in combined oral and transdermal delivery  which  investigated 
the pharmacokinetics of scopolamine after patch application in combination 
with oral tablets, 0.6 mg, 0.3 mg, or placebo.Subjects were 25 healthy, male 
naval-crew volunteers, , aged 18 to 20 years, randomly divided into three 
groups: group 1 (n = 9), TTS-S patch + 0.6 mg of scopolamine per os (p.o.); 
group 2 (n = 8), TTS-S patch + 0.3 mg of scopolamine p.o.; and group 3 (n = 
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8), TTS-S patch + placebo tablet. Subjects were drug free for at least 72 h 
before the study. They were required to refrain from strenuous physical activity 
during the study.Blood samples were collected before treatment and 0.5, 1, 1.5, 
2.5, 3.5, 6, 8, and 22 h post-treatment, and were analysed for scopolamine 
levels. 
 
2.3 PROPOSED METHOD (see Guidelines) 
  
It has been agreed with Dr. Donal O Gorman in the School of Health and 
Human Performance that blood sampling will be conducted by experienced 
personnel in the School of Health and Human Performance. 
 
As the patch is recommended for application over 3 days, it was decided to 
conduct blood sampling over this time in order to generate the pharmacokinetic 
profile. Peak blood levels are obtained 6-8 hours post application, hence more 
frequent sampling is required around this time. 
 
The study will be conducted over 2 weeks. On week 1 (Monday, 9am) the 
Scopolamine transdermal full patch will be randomly applied to 10 of the  
participants and half patch to the remaining 10 participants and worn over a 
period of 3 days. Blood will be drawn at different time points; time 0, 3, 6, 7, 8, 
9, 24, 48, and 72 hrs. 
 
5 days will be left in-between the patch applications to ensure complete 
elimination of Scopolamine levels from the participant’s blood. 
 
On week 2 (Tuesday, 9am), the same volunteers will again apply the 
Scopolamine transdermal patch (either half or full, depending on what was 
previously worn) for a period of 3 days. Blood will be drawn at the same time 
points as above; time 0, 3, 6, 7, 8, 9, 24, 48, and 72 hrs. 
 
Healthy participants are required to wear the patch continuously over the three 
days and not to subject themselves to any strenuous activity. As there are so 
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many time point samples required participants are asked to eat and drink as 
normal. Participants are asked to note any side effects observed. 
 
All blood samples will be allowed to coagulate for 20 mins, and the resultant 
serum will be placed into appropriate vials. Samples will be frozen at -20ºC 
until analysis by the LC-MS method developed for the project.. 
 
2.4 PARTICIPANT PROFILE (see Guidelines) 
A total of 20 healthy adult participants aged 18-60 years of age will be 
recruited for this study. As this is a validation study, the sample number was 
based on existing studies that have been completed. The following studies, 
included in the reference list, studied between 6-25 participants.  
Lakshmi Putcha  et al. [2] used 12 participants for their trial while Nachum et 
al. [4] used 25 and Lakshmi Putcha et al. [1] used 6. 
     	
2.5 MEANS BY WHICH PARTICIPANTS ARE TO BE RECRUITED 
(see Guidelines) 
 Participants will be informed of this study through a circulating email to 
DCU staff and students.  
 
Email: 
Apologies to whom this does not concern. 
 
The School of Chemical Sciences is currently undertaking a study to validate 
the measurement of Scopolamine in blood. Scopolamine comes in the form of 
an over-the-counter patch that prevents motion sickness. The aim of our study 
is to determine if half the patch would result in an adequate circulating level of 
Scopolamine. This research is in collaboration with NASA, Kennedy Space 
Centre, Florida.  We are looking for volunteers to conduct two trials separated 
by one week. In one trial you will be asked to wear the Scopolamine patch for 3 
days and the other trial is identical but only half the patch is worn. A blood 
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sample to determine the level of Scopolamine in circulation will be taken at a 
number of time points over each of the 3-day trials (0, 3, 6, 7, 8, 9, 24, 48, and 
72 hrs post patch application). 
 
If you would like to hear more about this study, please contact Deirdre Fox at 
deirdre.fox4@mail.dcu.ie or 01-7008351 
 
 
2.6 PLEASE EXPLAIN WHEN, HOW, WHERE, AND TO WHOM 
RESULTS WILL BE DISSEMINATED, INCLUDING WHETHER 
PARTICIPANTS WILL BE PROVIDED WITH ANY 
INFORMATION AS TO THE FINDINGS OR OUTCOMES OF THE 
PROJECT? 
 
All participants will be given a report of their results, and also the results of the 
group averages. Results will be compiled as part of a PhD thesis and will 
hopefully be presented at conferences and published in the scientific literature. 
 
 
2.7 OTHER APPROVALS REQUIRED Has permission to gain access to 
another location, organisation etc. been obtained?  Copies of letters of 
approval to be provided when available. 
  
 YES  NO  NOT APPLICABLE 
 
 (If YES, please specify from whom and attach a copy.  If NO, please 
explain when this will be obtained.) 
      
 
2.8 HAS A SIMILAR PROPOSAL BEEN PREVIOUSLY APPROVED 
BY THE REC? 
 
 YES  NO 
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(If YES, please state both the REC Application Number and Project 
Title) 
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3. RISK AND RISK MANAGEMENT 
 
3.1 ARE THE RISKS TO SUBJECTS AND/OR RESEARCHERS 
ASSOCIATED WITH YOUR PROJECT GREATER THAN 
THOSE ENCOUNTERED IN EVERYDAY LIFE? 
 
YES  NO If YES, this proposal will be subject to full REC 
review 
If NO, this proposal may be processed by 
expedited administrative review 
 
3.2 DOES THE RESEARCH INVOLVE: 
 YES N
O 
• use of a questionnaire? (attach copy)?  
• interviews (attach interview questions)?  
• observation of participants without their knowledge?  
• participant observation (provide details in section 
2)? 
 
• audio- or video-taping interviewees or events?  
• access to personal and/or confidential data 
(including student, patient or client data) without the 
participant’s specific consent? 
 
• administration of any stimuli, tasks, investigations 
or procedures which may be experienced by 
participants as physically or mentally painful, 
stressful or unpleasant during or after the research 
process? 
 
• performance of any acts which might diminish the 
self-esteem of participants or cause them to 
experience embarrassment, regret or depression? 
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• investigation of participants involved in illegal 
activities? 
 
• procedures that involve deception of participants?  
• administration of any substance or agent?  
• use of non-treatment of placebo control conditions?  
• collection of body tissues or fluid samples?  
• collection and/or testing of DNA samples?  
• participation in a clinical trial?  
• administration of ionising radiation to participants?   
 
3.3 POTENTIAL RISKS TO PARTICIPANTS AND RISK 
MANAGEMENT PROCEDURES (see Guidelines) 
 
Scopolamine transdermal patch is an over the counter medication, and as the 
levels of the drug being released into the drug stream is low, side effects should 
be minimal. If side effects occur the patch can be removed at any time. 
The following are some of the side effects that are known to be associated with 
this medicine. Just because a side effect is stated here does not mean that all 
people using this medicine will experience that or any side effect. 
Dry mouth, Drowsiness, Blurred vision, Irritation of skin at patch 
application site, Irritation of the eyelids, Dizziness, Dilated pupils, 
Restlessness, Confusion, Hallucinations, Difficulty passing urine, 
Headache, nausea, vomiting and disturbance of balance after removing 
the patch.  
As some people are prone to drowsiness and dizziness while taking the patch, 
participants are not recommended to drive while taking the patch (half and full). 
 
3.4 ARE THERE LIKELY TO BE ANY BENEFITS (DIRECT OR 
INDIRECT) TO PARTICIPANTS FROM THIS RESEARCH? 
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 YES  NO (If YES, provide details.)      
 
3.5 ARE THERE ANY SPECIFIC RISKS TO RESEARCHERS? (e.g. 
risk of infection or where research is undertaken at an off-campus 
location) 
  
 YES  NO (If YES, please describe.)      
 
3.6 ADVERSE/UNEXPECTED OUTCOMES (see Guidelines) 
 If side effects occur, which will be minimal, patch can be removed at 
any time. 
 
3.7 MONITORING (see Guidelines) 
Regular check in’s with personnel drawing blood, contact with 
participants (phone and email) with updates regarding timings of blood 
draws etc) 
 
3.8 SUPPORT FOR PARTICIPANTS (see Guidelines) 
 
Additional support for the subjects will not be required for this trial. 
 
3.9 DO YOU PROPOSE TO OFFER PAYMENTS OR INCENTIVES 
TO PARTICIPANTS? 
 
 YES  NO (If YES, please provide further details.)      
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4. INVESTIGATORS’ QUALIFICATIONS, EXPERIENCE AND 
SKILLS (Approx. 200 words – see Guidelines) 
 
Dr. Gillian McMahon: 
 
Role in proposed project: Overseeing the project and acting as a direct 
supervisor  
 
• BSc in Analytical Science from Dublin City University, Ireland, 1992.  
• PhD, The Royal College of Surgeons in Ireland/DCU, 1998. 
• Postdoctoral research fellow in The National Centre for Sensor Research 
(NCSR) at Dublin City University 
• Group research manager for the Chemical Sensors Group in the NCSR 
• Currently: lecturer in the School of Chemical Sciences.  
 
Deirdre Fox: 
 
Role in proposed project: Responsible for doing analysis of blood samples 
 
• BSc Analytical Chemistry with Quality Assurance, Cork Institute of 
Technology (CIT). 2006 
• Currently: Third year of PhD entitled ‘The evaluation of novel phases 
and approaches to selectively extract and analyse different drugs in 
human blood and other biological matrices’.  
 
Dr. Lanfang Levine 
 
Role in proposed project: Involved in the initial development of the 
methodology and is providing collaborative support for this project 
 
• Ph.D. Agricultural Science, Chemistry of Forest Products (1990), 
Nagoya University, Nagoya, Japan  
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• M.S. Organic Chemistry (1985), Guangzhou Institute of Chemistry, 
Academia Sinica, Guangzhou, China  
• B.S Chemical Engineering (1982), The South China Institute of 
Technology, Guangzhou, China  
• Currently: Senior Research Chemist & Analytical Chemistry Discipline 
Coordinator in Dynamac Corporation 
Kennedy Space Centre, Florida. 
 
 
 
5. CONFIDENTIALITY/ANONYMITY 
 
5.1 WILL THE IDENTITY OF THE PARTICIPANTS BE 
PROTECTED? 
 
 YES  NO (If NO, please explain) 
      
 
IF YOU ANSWERED YES TO 5.1, PLEASE ANSWER THE 
FOLLOWING QUESTIONS: 
 
5.2 HOW WILL THE ANONYMITY OF THE PARTICIPANTS BE 
RESPECTED? (see Guidelines) 
 
All participants will be assigned a random identification number by me. Their 
name will not be associated with any blood tubes or documentation thereafter.  
All information will be stored in a password protected computer and all written 
documentation will be held within a locked filing cabinet.  
 
 
5.3 LEGAL LIMITATIONS TO DATA CONFIDENTIALITY: (Have 
you included appropriate information in the plain language statement 
and consent form?  See Guidelines) 
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YES  NO (If NO, please advise how participants will be 
advised.) 
      
 
 
 
6 DATA/SAMPLE STORAGE, SECURITY AND DISPOSAL (see 
Guidelines) 
 
 
6.1 HOW WILL THE DATA/SAMPLES BE STORED? (The REC 
recommends that all data be stored on campus) 
 
Stored at DCU      
Stored at another site     (Please explain 
where and for what purpose) 
      
 
6.2 WHO WILL HAVE ACCESS TO DATA/SAMPLES? 
 
Access by named researchers only      
   
Access by people other than named researcher(s)  (Please explain 
who and for what purpose)  
Other  :     (Please explain) 
       
 
6.3 IF DATA/SAMPLES ARE TO BE DISPOSED OF, PLEASE 
EXPLAIN HOW, WHEN AND BY WHOM THIS WILL BE 
DONE? 
 I will be responsible for disposal of bio hazardous waste post analysis. 
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FUNDING 
 
 
7.1 HOW IS THIS WORK BEING FUNDED? 
 IRCSET 
 
7.2 PROJECT GRANT NUMBER (If relevant and/or known) 
 Not known 
 
7.3 DOES THE PROJECT REQUIRE APPROVAL BEFORE 
CONSIDERATION FOR FUNDING BY A GRANTING BODY?  
 
 YES  NO  
 
 
7.4 HOW WILL PARTICIPANTS BE INFORMED OF THE SOURCE 
OF THE FUNDING? 
In plain language statement and Consent form 
 
7.5 DO ANY OF THE RESEARCHERS, SUPERVISORS OR 
FUNDERS OF THIS PROJECT HAVE A PERSONAL, 
FINANCIAL OR COMMERCIAL INTEREST IN ITS OUTCOME 
THAT MIGHT COMPROMISE THE INDEPENDENCE AND 
INTEGRITY OF THE RESEARCH, OR BIAS THE CONDUCT 
OR RESULTS OF THE RESEARCH, OR UNDULY DELAY OR 
OTHERWISE AFFECT THEIR PUBLICATION? 
 
YE
S 
 NO (If Yes, please specify how 
this conflict of interest will 
be addressed.) 
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8. PLAIN LANGUAGE STATEMENT (Approx. 400 words – see 
Guidelines) 
 
Research Study title: Validation of a method for the analysis of Scopolamine 
(anti-motion sickness medication) in human serum for the NASA space 
research programme 
 
Principal Investigators: Dr. Gillian McMahon (gillian.mcmahon@dcu.ie ) 
Deirdre Fox (Deirdre.fox4@mail.dcu.ie) 
 
Department: School of Chemical Sciences, Dublin City University, Dublin 9 
 
Purpose: The purpose of this study is to evaluate whether cutting a 
Scopolamine patch in half is delivering half of the anticipated Scopolamine or if 
the patch is compromised by cutting it in half. 
 
Scopolamine is one of the substances used by NASA to combat motion 
sickness in space. The Scopolamine patch, an over the counter medication, is 
the most common form of the drug in the US. However, undesirable side effects 
have been reported. It had been hypothesised at NASA that if a transdermal 
patch of scopolamine is halved and then used by the astronaut, that it is just as 
successful as a full patch but that the side effects are much reduced. In NASA, 
developed and optimised is a method for the determination of scopolamine in 
order to evaluate if the levels of the half patch are indeed half of the 
Scopolamine level in full patch. However, the method was only semi-validated 
due to time restraints. The method developed in NASA was transferred to a 
similar instrument here so that completion of the work could be achieved.  
 
The Scopolamine patch is a circular flat patch designed for continuous 
release of scopolamine over a period of 3 days, following application to the skin 
behind the ear. The main side effects reported while taking the patch are dry 
mouth, drowsiness and dizziness. 
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By conducting a study over a two week period, you will be asked to take 
either the full/ half patch on the first week, leaving 5 days before taking the 
full/half patch the following week. Blood draw times are 0, 3, 6, 7, 8, 9, 24, 48, 
and 72 hrs post patch application. 
 
Post analysis of the blood, it will be concluded whether cutting the patch 
in half is delivering half amounts of Scopolamine in comparison to the full 
patch, into the blood or if the patch is indeed compromised by cutting it in half. 
A pharmacokinetic study will be carried out on the patch; both full and cut in 
half as it has never been done before.  
 
This PhD research project is funded by IRCSET. 
 
 You will be assigned a random identification number by me. Your name 
will not be associated with any blood tubes or documentation thereafter.  All 
information will be stored in a password protected computer and all written 
documentation will be held within a locked filing cabinet.  
 
 You may withdraw from the research study at any time point. There will be no 
penalty for withdrawing before all time point samples have been drawn. 
Confidentiality of information provided can only be protected within the 
limitations of the law - i.e., it is possible for data to be subject to subpoena, 
freedom of information claim or mandated reporting by some professions.  
 
 If you have concerns about this study and wish to contact an 
independent person, please contact: The Secretary, Dublin City University 
Research Ethics Committee, c/o Office of the Vice-President for Research, 
Dublin City University, Dublin 9. Tel 01-7008000 
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9. INFORMED CONSENT FORM (Approx. 300 words – see 
Guidelines) 
 
Research Study title: Validation of a method for the analysis of Scopolamine 
(anti-motion sickness medication) in human serum for the NASA space 
research programme 
 
Principal Investigators: Dr. Gillian McMahon, Deirdre Fox, Dr. Lanfang 
Levine 
 
Department: School of Chemical Sciences, Dublin City University, Dublin 9 
 
Purpose of Research: In NASA, Kennedy Space Centre, Florida, Dr. 
Daniel Woodard is conducting a project entitled ‘Evaluation of 
countermeasures for motion sicknesses’. The purpose of this study is to 
evaluate the effects of the transdermal scopolamine patch in preventing motion 
sickness in astronauts induced by off-vertical axis rotation (OVAR). The main 
question being asked is ‘Would cutting a scopolamine transdermal patch in half 
reduce the side effects associated with the medication while still having 
effective protection from motion sickness?’ My role is to determine if the 
Scopolamine patch is compromised by cutting it in half. This study would also 
provide sufficient samples for pharmacokinetic profiling of the Scopolamine, 
both full and cut in half. This PhD research project is funded by IRCSET. 
 
I understand I will be asked to take the full Scopolamine patch, applied 
behind my ear, for 3 days, give blood at 9 different time points (0, 3, 6, 7, 8, 9, 
24, 48, and 72 hrs post patch application) and repeat this entire process 5 days 
later with the Scopolamine patch cut in half. 
 
I understand associated side effects with taking the Scopolamine patch are: 
Dry mouth, Drowsiness, Blurred vision, Irritation of skin at patch application 
site, Irritation of the eyelids, Dizziness, Dilated pupils, Restlessness, Confusion, 
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Hallucinations, Difficulty passing urine, Headache, nausea, vomiting and 
disturbance of balance after removing the patch.  
As some people are prone to drowsiness while taking the patch, I have been 
advised not to drive for the duration of days taking the patch. 
 
Please complete the following: (Circle yes or no for each question) 
I have read the plain language statement?    Yes/No 
I understand the information provided?    Yes/No 
I have had an opportunity to ask questions and discuss this study? Yes/No 
I have received satisfactory answers to all my questions?  Yes/No 
 
I understand I will be assigned a random identification number for this study 
and that my name will not be associated with any blood tubes or documentation 
associated. 
 
I understand that I may withdraw from the research study at any time point. 
There will be no penalty for withdrawing before all time course samples have 
been drawn. 
 
I have read and understand the information in this form. My questions and 
concerns have been answered by the researchers, and I have a copy of this 
consent form. Therefore I consent to take part in this research project 
 
Participants Signature: ____________________________________ 
 
Name in Block Capitals: ____________________________________ 
 
Witness:  ____________________________________ 
 
Date:   _____________________________________ 
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Appendix B: Blood sampling protocol for scopolamine pilot 
study 
 
 
Standard template for ethical justification for blood sampling associated 
with human studies conducted within DCU. 
Version 1 September 2006 
Completion instructions: 
This document is intended to prompt responses to a number of standard 
questions which generally need to be answered to justify the sampling of blood 
associated with human studies. 
The document is not meant to be an exhaustive exploration of the justification 
for such sampling and in specific situations, additional information may be 
required/ requested.   
Answers are expected to be brief but should also be informative.  See a sample 
completed form at the end.   
Queries should be directed to the Secretary of the Research Ethics Committee 
in the OVPR office.  
 
1) Briefly explain why blood sampling is required 
 
 
 
 
 
2) Outline the analytes, components or general applications to be 
investigated in subject blood  (now and any future studies) 
 
 
 
 
 
 
The transdermal patch releases Scopolamine into the blood stream, my 
research involves evaluating the patch, both un compromised and cut in half. 
Scopolamine from transdermal patch 
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3) Are any alternatives available to substitute the venous sampling of 
blood?  yes/no.   
 
  
 
 
 
 
4) Will sampling require cannulation or direct vein puncture? yes/no 
 
5) Outline the minimum volume of original subject blood (i.e. not serum or 
plasma) required to  measure the required components.   
 
  
 
 
 
 
6) Are steps being taken in the protocol to minimise the volume of blood 
samples being taken?   yes/no 
  
 
  
 
 
7) Are steps included to minimise the number of blood samples/vein 
puncture being taken?  yes/no 
 
 
 
 
 
8) Anticipated sampling methodology 
 
Yes – saliva and urine. However this study is in order to complete validation 
using serum blood samples. 
3 mL 
Smallest blood collection tube 
Cannula inserted for first 6 time points (between 0 and 9 hours post patch 
application) 
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Volume of blood to be taken per sample 
 
3 mL 
Maximum number of samples to be taken per “sitting” 
 
1 
Maximum number of samples taken per day 
 
6  
Maximum number of samples to be taken over the course 
of the full study (if long duration study indicate the 
amount taken in an active 1 month period) 
 
9 per trial 
Maximum anticipate number of vein puncture episodes 4 per trial 
Total volume of blood that will be taken from subject.  
 
27 mL per 
trial 
 
9) I certify that:-  
• all persons sampling blood in this study are certified to do so through 
the school/unit where this work is being conducted  
• that all those manipulating the resultant samples are fully trained in the 
safe practice of handling blood  
• all persons handling this blood have received appropriate information 
according to current vaccination policy. 
 
 
Signature of Study PI       Date 
 
 
An original signed copy must accompany electronic submissions.  
Alternatively, a PDF or other scanned version with a signature may be 
submitted 
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Appendix C:  Publications 
 
FOX, D., O’CONNOR, R., MALLON, P. and MCMAHON, G., 2011. 
Simultaneous determination of efavirenz, rifampicin and its metabolite 
desacetyl rifampicin levels in human plasma. Journal of pharmaceutical and 
biomedical analysis, 56(4), pp. 785-791.  
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Appendix D: Oral and poster presentations 
 
The work carried out for the duration of this thesis was presented in both poster 
form and oral presentations at various scientific conferences and meetings: 
 
Oral Presentations 
 
  An oral presentation was presented to Kennedy Space Centre personnel 
on 13th Apr, 2009. The presentation was held at the Kennedy Space 
Centre, Florida.  
Title: Development of an analytical protocol to extract, separate and 
determine the anti-motion sickness drug scopolamine in human serum 
 Authors: Fox D, Levine L, McMahon G.  
 
 An oral presentation was presented at the FAS closing ceremony on 15th 
Apr, 2009. The ceremony was held at the Kennedy Space Centre, 
Florida.  
Title: Development of an analytical protocol to extract, separate and 
determine the anti-motion sickness drug scopolamine in human serum 
 Authors: Fox D, Levine L, McMahon G.  
 
An oral presentation was presented on 04th April, 2010 to Dr. Patrick 
Mallon and all coordinating staff involved in the SPhEAR project. The 
presentation was held at Mater Misericordiae University Hospital, 
Dublin. 
Title: Development of an analytical protocol to extract, separate and 
determine rifampicin (anti-TB medication) and efavirenz (anti- HIV 
medication) in blood samples of co- infected patients for SPhEAR 
programme 
 Authors: Fox D, O’Connor R, Mallon P, McMahon G  
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 An oral presentation was presented at the Irish Universities Chemistry 
Research Colloquium (IUCRC) on 02nd July, 2010. The Colloquium 
was held at Queens University, Belfast.  
Title: Development of an analytical protocol to extract, separate and 
determine efavirenz (anti-HIV medication) and rifampicin (anti-TB 
medication) in co-infected patients  
 Authors: Fox D, O’Connor R, Mallon P, McMahon G  
 
Poster Presentations 
 
A poster was presented at the HTC, ExTech 10 conference held in 
Bruges, Belgium on Jan 28th to Feb 1st, 2008. 
The poster title was: “Development of an analytical protocol to extract, 
separate and determine rifampicin (anti-TB medication) and efavirenz 
(anti-HIV medication) in co-infected patients. 
 Authors: Fox D, O’Connor R, Mallon P, McMahon G.  
 
A poster was presented at the Infectious Diseases Society of Ireland 
(IDSI), Inaugural Annual Scientific Meeting, Dublin 2 on 11-13th June, 
2008. 
Title: Development of an analytical protocol to extract, separate and 
determine rifampicin (anti-TB medication) and efavirenz (anti-HIV 
medication) in co-infected patients. 
 Authors: Fox D, O’Connor R, Mallon P, McMahon G. 
 
A poster was presented at the Analytical Research Forum (ARF) on 21- 
23rd July, 2008. The ARF was held at the University of Hull, UK. 
Title: Development of an analytical protocol to extract, separate and 
determine rifampicin (anti-TB medication) and efavirenz (anti-HIV 
medication) in co-infected patients. 
 Authors: Fox D, O’Connor R, Mallon P, McMahon G. 
 
A poster was presented at the Analytical Research Forum (ARF) on 21- 
23rd July, 2009. The ARF was held at the University of Kent, UK. 
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Title: Development of an analytical protocol to extract, separate and 
determine the anti-motion sickness drug scopolamine in human serum 
 Authors: Fox D, Levine L, McMahon G. 
 
A poster was presented at the International Symposium on 
Chromatography (ISC) on 13- 16th Sept, 2010. The ISC was held at the 
Valencia Conference Centre, Spain. 
Title: Development of a low cost, analytical process to extract, separate 
and determine efavirenz and rifampicin plasma concentrations in 
HIV/TB co-infected patients 
 Authors: Fox D, O’Connor R, Mallon P, McMahon G. 
 
A poster was presented at the tenth International Congress on Drug 
Therapy in HIV infection 07-11th Nov, 2010. The HIV10 conference 
was held in Glasgow, UK. 
Title: Development of a low cost, analytical process to extract, separate 
and determine efavirenz and rifampicin plasma concentrations in 
HIV/TB co-infected patients 
 Authors: Fox D, O’Connor R, Mallon P, McMahon G. 
 
 
Scientific conferences prove a great way to network with fellow scientists and 
to explore what research is being conducted in similar fields of work.  
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Appendix E: Training received 
 
 
Throughout this research masters degree I received both formal and in-house 
training on a variety of analytical instruments. I was also trained on my 
teaching skills. 
 
• In house LC-UV training was given by my supervisor Dr. McMahon in 
Oct 2007 at Dublin City University. This was conducted in order to 
familiarise myself with the basic running and operation of the LC-UV 
instrument and also the Chemstation software. 
 
• I was trained on LC-MS instrumentation in Kennedy Space Centre, Oct 
2008, by my mentor Dr. Levine. This training was designed to show the 
basic running, operation and maintenance of LC-MS. 
 
• A course was attended in the National Centre for Sensor Research, 
Dublin City University where the basic principles of operation of a MS 
were explained and a demonstration performed on MS operation. This 
two-day course was given by Dr. Maurice Burke. 
 
• While at the HTC, Ex-Tech 10 (Jan 28th until Feb1st) conference in 
Brugge, Belgium I attended a short course entitled ‘Modern Sample 
Preparation’. I found the course extremely helpful and beneficial as it 
was particularly relevant to the analytical research I was working on 
throughout my project. 
 
• Official training on LC-MS instrumentation in the National Institute for 
Cellular Biotechnology was given by Dr. Sandra Roche in Oct 2009. 
This training gave me a good understanding of the operation and 
maintenance of the LC-MS used for this thesis. 
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Appendix F: Relevant experience gained 
 
 
In Dublin City University, research students are obligated to partake in 
demonstrating duties. These duties involved overseeing a number of 
undergraduate students conducting practical experiments in scientific 
laboratories. 
 
During my time in Dublin City University I have already taught: 
 
• First year Science students between Oct and Mar 2007-2008. This was a 
lab based practical course on the basic techniques used in Chemistry. I 
had to supervise 12 students, each week with a different experiment.  I 
had to grade weekly reports. 
 
• Third year Analytical Science students between Oct and Dec 2009. This 
was a lab based practical course in the analysis of organic and inorganic 
species. I was supervising 2 experiments: High Performance Liquid 
Chromatography and Spectroscopy. I had to grade weekly reports 
submitted by the students.  
 
I attended various safety courses, lone working training and seminars and talks 
given by guest and visiting lecturers who came to DCU to talk on chemistry and 
biology topics. 
 
 
 
